,Rank,NCT Number,Title,Acronym,Status,Study Results,Conditions,Interventions,Outcome Measures,Sponsor/Collaborators,Gender,Age,Phases,Enrollment,Funded Bys,Study Type,Study Designs,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents,URL
0,1,NCT05003960,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Autism,,Recruiting,No Results Available,Autism,Biological: AlloRx,Safety (adverse events)|Efficacy: Autism Treatment Evaluation Checklist (ATEC),The Foundation for Orthopaedics and Regenerative Medicine,All,"Child, Adult, Older Adult",Phase 1,15.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SC-8-ATG-8-02,2021-09-01,2025-09-01,2025-09-01,2021-08-13,,2021-08-13,"Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,https://ClinicalTrials.gov/show/NCT05003960
1,2,NCT02649959,An Open Label Study of CM-AT for the Treatment of Children With Autism,,"Active, not recruiting",No Results Available,Autism,Drug: CM-AT,Aberrant Behavioral Checklist: Subscale of Irritability / Agitation (ABC-I) at fecal chymotrypsin (FCT) levels less than or equal to 12.6|Aberrant Behavior Checklist: Subscale of Lethargy / Social Withdrawal (ABC-L) at fecal chymotrypsin (FCT) levels less than or equal to 12.6,Curemark,All,3 Years to 17 Years   (Child),Phase 3,405.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,00104/Open Label-Autism,2015-10-01,2021-12-01,2022-06-01,2016-01-08,,2021-01-26,"Southwest Autism Research & Resource Center (S.A.R.R.C.), Phoenix, Arizona, United States|University of Arizona, Pediatrics Multidisciplinary Research Unit, Tucson, Arizona, United States|Arkansas Children'S Hosp. Research Institute (A.C.H.R.I.), Little Rock, Arkansas, United States|N.R.C. Research Institute, Orange, California, United States|M.I.N.D. Institute (Univ.of California, Davis), Sacramento, California, United States|University of California (U.C.S.F.), San Francisco, California, United States|IMMUNOe Research Centers, Centennial, Colorado, United States|Yale Child Study Center, New Haven, Connecticut, United States|Segal Institute For Clinical Research, North Miami, Florida, United States|Advent Health -Lake Mary Pediatrics, Orange City, Florida, United States|A.P.G. Research, Orlando, Florida, United States|Research Institute of Deaconess Clinic, Newburgh, Indiana, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|L.S.U. Health Sciences Center, Shreveport, Louisiana, United States|Detroit Clinical Research Center, P.C., Bingham Farms, Michigan, United States|Children'S Specialized Hospital, Egg Harbor Township, New Jersey, United States|Barbara Enright, Toms River, New Jersey, United States|Clinical Research Center of Nj, Voorhees, New Jersey, United States|Lovelace Scientific Resources, Albuquerque, New Mexico, United States|Montefiore Med.Cneter, Autism & Obsessive Compulsive Spectrum Program, Bronx, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Duke Center For Autism and Brain Development, Durham, North Carolina, United States|Cleveland Clinic Autism Center, Cleveland, Ohio, United States|Omega Medical Research, Warwick, Rhode Island, United States|Carolina Clinical Trials, Inc., Charleston, South Carolina, United States|Vanderbilt Universtiy Med.Center-Treatment&Research Inst. For Asd, Nashville, Tennessee, United States|University of Texas, Houston-Behavioral & Biomedical Sciences, Houston, Texas, United States|Focus Center of Clinical Research, Clinton, Utah, United States|University of Virginia, Dept. of Psychiatry and Neurobehavioral Sciences, Charlottesville, Virginia, United States|Neuroscience, Inc, Herndon, Virginia, United States|Carilion Clinic-Virginia Tech, Carilion School of Medicine, Roanoke, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02649959
2,3,NCT02410902,A Trial of CM-AT in Children With Autism With All Levels of FCT (The Blum Study),,Completed,No Results Available,Autism,Drug: CM-AT|Drug: PLACEBO,Primary outcome measurements to determine efficacy of treatment with CM-AT versus placebo for changes in the Aberrant Behavior Checklist subscale for Irritability / Agitation (ABC-I) between baseline and Week 12/Termination visit|Secondary Outcome measurements of changes in the Aberrant Behavior Checklist Checklist subscale for Lethargy / Social Withdrawal (ABC-L) between baseline and Week 12/Termination visit,Curemark,All,3 Years to 8 Years   (Child),Phase 3,335.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",00103,2015-05-01,2017-12-22,2017-12-22,2015-04-08,,2021-04-30,"Southwest Autism Research & Resource Center (S.A.R.R.C.), Phoenix, Arizona, United States|University of Arizona, Pediatrics Multidisciplinary Research Unit, Tucson, Arizona, United States|Arkansas Children'S Hosp. Research Institute (A.C.H.R.I.), Little Rock, Arkansas, United States|N.R.C. Research Institute, Orange, California, United States|M.I.N.D. Institute (Univ.of California, Davis), Sacramento, California, United States|University of California (U.C.S.F.), San Francisco, California, United States|IMMUNOe RESEARCH CENTERS, Centennial, Colorado, United States|Yale Child Study Center, New Haven, Connecticut, United States|Segal Institute For Clinical Research, North Miami, Florida, United States|Florida Hospital Medical Group-Lake Mary Pediatrics, Orange City, Florida, United States|Kaley Kildahl, Orlando, Florida, United States|Research Institute of Deaconess Clinic, Evansville, Indiana, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|L.S.U. Health Sciences Center, Shreveport, Louisiana, United States|Detroit Clinical Research Center, P.C., Bingham Farms, Michigan, United States|Children'S Specialized Hospital, Egg Harbor Township, New Jersey, United States|Children'S Specialized Hospital, Toms River, New Jersey, United States|Clinical Research Center of Nj, Voorhees, New Jersey, United States|Lovelace Scientific Resources, Albuquerque, New Mexico, United States|Montefiore Med.Center, Autism & Obsessive Compulsive Spectrum Prog., Bronx, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Duke Center For Autism and Brain Development, Durham, North Carolina, United States|Cleveland Clinic, Center For Autism Research, Cleveland, Ohio, United States|Omega Medical Research, Warwick, Rhode Island, United States|Carolina Clinical Trials, Inc., Charleston, South Carolina, United States|Vanderbilt University Med.Center -Treatment & Research Inst. For Asd, Nashville, Tennessee, United States|University of Texas, Houston Dept. of Psychiatry and Behavioral Sciences, Houston, Texas, United States|Ericksen Research & Development, Clinton, Utah, United States|University of Virginia, Dept. of Psychiatry and Neurobehavioral Sciences, Charlottesville, Virginia, United States|Neuroscience, Inc., Herndon, Virginia, United States|Carilion Clinic-Virginia Tech, Carilion School of Medicine, Roanoke, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02410902
7,8,NCT01098383,Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders,,Unknown status,No Results Available,Autism,"Drug: Acetyl-Choline Esterase Inhibitors and Choline supplements|Drug: Indistinguishable placebo tablets, matching both donepezil and choline",Core autistic symptoms (ATEC)|Side effects and adverse events questionnaire|Linguistic performance (CELF-4)|Adaptive functioning (Vineland-II)|Comorbid behaviors (CSI-4 questionnaire)|Executive functions (BRIEF questionnaire),Sheba Medical Center|The Israeli Society of Clinical Pediatrics (HIPAK),All,"10 Years to 18 Years   (Child, Adult)",Phase 4,84.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SHEBA-09-7151-LG-CTIL,2010-03-01,2017-12-01,2017-12-01,2010-04-02,,2016-10-14,"Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel",,https://ClinicalTrials.gov/show/NCT01098383
8,9,NCT01836562,A Clinical Trial to Study the Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Autism,BMCA,Unknown status,No Results Available,Autism,Biological: STEM CELL THERAPY,Improvement in childhood autism rating scale|Improvement in perfusion of brain with PET scan report,"Chaitanya Hospital, Pune",All,"3 Years to 70 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,100.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,00105,2014-09-01,2016-06-01,2016-06-01,2013-04-22,,2014-09-17,"Chaitanya Hospital, Pune, Maharashtra, India",,https://ClinicalTrials.gov/show/NCT01836562
10,11,NCT00881452,A Trial of CM-AT in Children With Autism,CM-AT,Completed,No Results Available,Autism,Drug: CM-AT|Drug: Placebo,Evidence of changes in behavior scales associated with the core symptoms of autism|Other key measures of behavior and quality of life associated with autism,Curemark,All,3 Years to 8 Years   (Child),Phase 3,182.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",00101,2009-05-01,2011-06-01,2011-09-01,2009-04-15,,2018-04-19,"Southwest Autism Research and Resource Center, Phoenix, Arizona, United States|University of California, Davis, M.I.N.D. Institute, Sacramento, California, United States|University of California, San Francisco, San Francisco, California, United States|Neuropsychiatric Research Center of Orange County, Santa Ana, California, United States|Lake Mary Pediatrics, Orange City, Florida, United States|Institute for Behavioral Medicine, Smyrna, Georgia, United States|Alexian Brothers Center for Psychiatric Research, Hoffman Estates, Illinois, United States|Louisiana State University Health Science Center, Shreveport, Louisiana, United States|Saint Peters University Hospital, New Brunswick, New Jersey, United States|Mount Sinai School of Medicine, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|Oklahoma University Child Study Center, Oklahoma City, Oklahoma, United States|Cyn3rgy Research, Gresham, Oregon, United States|Hershey Medical Center, Hershey, Pennsylvania, United States|Drexel University, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Texas, Houston, Houston, Texas, United States|Westside Medical, Clinton, Utah, United States",,https://ClinicalTrials.gov/show/NCT00881452
11,12,NCT00912691,A Trial of CM-AT in Children With Autism- Open Label Extension Study,CM-AT,Completed,No Results Available,Autism,Drug: CM-AT,Evidence of changes in behavior scales associated with the core symptoms of autism|Other key measures of behavior and quality of life associated with autism,Curemark,All,9 Years to 12 Years   (Child),Phase 3,165.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,00102/Autism,2010-01-01,2016-02-01,2016-02-01,2009-06-03,,2019-03-01,"Southwest Autism Research and Resource Center, Phoenix, Arizona, United States|University of California, Davis, M.I.N.D. Institute, Sacramento, California, United States|University of California, San Francisco, San Francisco, California, United States|Neuropsychiatric Research Center of Orange County, Santa Ana, California, United States|Lake Mary Pediatrics, Orange City, Florida, United States|Institute for Behavioral Medicine, Smyrna, Georgia, United States|Alexian Brothers Center for Psychiatric Research, Hoffman Estates, Illinois, United States|Louisiana State University, Shreveport, Louisiana, United States|Saint Peter's University Hospital, New Brunswick, New Jersey, United States|Mount Sinai School of Medicine, Manhattan, New York, United States|University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|Oklahoma State University, Child Study Center, Oklahoma City, Oklahoma, United States|Cyn3rgy Research Center, Gresham, Oregon, United States|Hershey Medical Center, Hershey, Pennsylvania, United States|Drexel University, Philadelphia, Pennsylvania, United States|Universtiy of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Texas, Houston, Houston, Texas, United States|Ericksen Research & Development, Clinton, Utah, United States",,https://ClinicalTrials.gov/show/NCT00912691
12,13,NCT03786744,Allogenic Cord Blood Transfusion in Patients With Autism,,Completed,Has Results,Autism Spectrum Disorder|Autism,Biological: ASD CB-MNC injection.|Other: Standard therapy.,A Number of Participants With Non-serious and Serious Adverse Events 24 Hrs Post-transfusion|Autism Treatment Evaluation Checklist (ATEC).|Cytokine Analysis.|Immune Status as Determined by Percentage of Peripheral Blood Cells|Immune Status as Determined by Absolute Cell Count of Peripheral Blood Cells,"State-Financed Health Facility ""Samara Regional Medical Center Dinasty""",All,3 Years to 15 Years   (Child),Phase 1|Phase 2,20.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12112018,2018-10-12,2019-10-12,2019-12-12,2018-12-26,2020-11-19,2020-11-19,"Medical Centre Dinasty, Samara, Russian Federation","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03786744/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03786744
17,18,NCT01911442,Lurasidone Pediatric Autism Study,,Completed,Has Results,Autism,Drug: Lurasidone 20 mg daily|Drug: Lurasidone|Drug: Placebo,Change in Aberrant Behavior Checklist (ABC) Irritability Subscale Score at Week 6|Change From Baseline in Clinical Global Impression-Severity (CGI-S) at Week 6|Change From Baseline in Aberrant Behavior Checklist (ABC) Hyperactivity Subscale Score at Week 6|Change From Baseline in Children's Yale-Brown Obsessive Compulsive Scales (CY-BOCS) Modified for Pervasive Developmental Disorders (PDDs)|Change From Baseline in the Caregiver Strain Questionnaire (CGSQ)|Proportion of Subjects Who Have CGI-I Score of 1 (Very Much Improved) or 2 (Much Improved) at Week 6|Proportion of Subjects Who Have at Least 25% Reduction From Baseline to Week 6 in the ABC Irritability Subscale Score.,Sunovion,All,6 Years to 17 Years   (Child),Phase 3,150.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D1050325,2013-08-01,2014-11-01,2014-11-01,2013-07-30,2016-02-25,2016-02-25,"Harmonex Neuroscience Research, Dothan, Alabama, United States|Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|Newport Beach Clinical Research Associates, Newport Beach, California, United States|University of California San Francisco Medical Center, San Francisco, California, United States|Florida Clinical Research Center, LLC, Bradenton, Florida, United States|Sarkis Clinical Trials - Parent, Gainesville, Florida, United States|Palm Springs Research Institute Inc, Hialeah, Florida, United States|Florida Clinical Research Center, LLC, Maitland, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|University of South Florida, Saint Petersburg, Florida, United States|Medical Research Group of Central Florida, Sanford, Florida, United States|University of South Florida, Tampa, Florida, United States|Institute for Behavioral Medicine, LLC, Smyrna, Georgia, United States|Capstone Clinical Research, Inc., Libertyville, Illinois, United States|Baber Research Group, Naperville, Illinois, United States|University of Kentucky, Lexington, Kentucky, United States|Lake Charles Clinical Trials, LLC, Lake Charles, Louisiana, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|NeuroScientific Insights, Rockville, Maryland, United States|Neurobehaviorial Medicine Group, PLLC, Bloomfield Hills, Michigan, United States|Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas, Nevada, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|Childrens Specialized Hospital, Toms River, New Jersey, United States|Montefiore Medical Center PRIME, Bronx, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Chapel Hill Neurology, Chapel Hill, North Carolina, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|The Ohio State University Nisonger Center, Columbus, Ohio, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Cyn3rgy Research & Development, Gresham, Oregon, United States|Suburban Research Associates, Media, Pennsylvania, United States|Segal Institute for Clinical Research, Charleston, South Carolina, United States|Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States|Family Psychiatry of The Woodlands, P.A., The Woodlands, Texas, United States|Ericksen Research & Development, LLC, Clinton, Utah, United States|CRI Lifetree, Salt Lake City, Utah, United States|University of Virginia, Charlottesville, Virginia, United States|Neuroscience, Inc., Herndon, Virginia, United States|Carilion Clinic, Roanake, Virginia, United States|Pacific Institute of Medical Sciences, Bothell, Washington, United States",,https://ClinicalTrials.gov/show/NCT01911442
23,24,NCT04766177,Role of Bumetanide in Treatment of Autism,,Recruiting,No Results Available,Autism,Drug: Bumetanide|Drug: Placebo,Number of patients with improved CARS score,Sherief Abd-Elsalam|Tanta University,All,3 Years to 12 Years   (Child),Phase 3,80.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",autism,2021-01-01,2030-12-01,2030-12-01,2021-02-23,,2021-02-23,"Sherief Abd-Elsalam, Tanta, Egypt",,https://ClinicalTrials.gov/show/NCT04766177
31,32,NCT01343511,Safety and Efficacy of Stem Cell Therapy in Patients With Autism,,Completed,No Results Available,Autism,Biological: human cord blood mononuclear cells|Biological: human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells,Childhood Autism Rating Scale，CARS|Clinical Global Impression Scale，CGI|Aberrant Behavior Checklist，ABC|Adverse Event and Serious Adverse Event,"Shenzhen Beike Bio-Technology Co., Ltd.|Shandong Jiaotong Hospital|Association for the Handicapped Of Jinan",All,3 Years to 12 Years   (Child),Phase 1|Phase 2,37.0,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BKCR-AUTISM-1.0(2009),2009-03-01,2010-06-01,2011-05-01,2011-04-28,,2011-10-14,"Shandong Jiaotong Hospital, Jinan, Shandong, China",,https://ClinicalTrials.gov/show/NCT01343511
32,33,NCT02192749,Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy for Autism,,Completed,No Results Available,Autism,Biological: Umbilical cord mesenchymal stem cells,Number of participants with adverse events|Number of participants with a change in disability as measured by the Autism Treatment Evaluation Checklist (ATEC)|Number of participants with a change in disability as measured by the Childhood Autism Rating Scale (CARS)|Change from baseline macrophage-derived chemokine (MDC)|Change from baseline thymus and activation-regulated chemokine (TARC),Translational Biosciences,All,6 Years to 16 Years   (Child),Phase 1|Phase 2,20.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TBS-UCMSC-ASD001,2014-07-01,2017-08-01,2017-08-01,2014-07-17,,2017-10-13,"Stem Cell Institute, Panama City, Panama",,https://ClinicalTrials.gov/show/NCT02192749
34,35,NCT02111551,Phase I Nicotinic Agonist Treatment Trial for Autism,,Terminated,No Results Available,Autism,Drug: DMXB-A 150 mg|Other: placebo|Drug: DMXB-A 75 mg,Difference between drug and placebo on theTotal Scale Score on the repeatable Battery for the Assessment of neuropsychological Status at 2 hours after administration|Difference between drug and placebo on the CPT at 30 minutes after administration|Difference between the P50 auditory evoked potential test/conditioning ratio 1 hour after administration|Difference between placebo and drug on the Social Responsiveness scale 2 hours after administration,"University of Colorado, Denver",All,18 Years to 50 Years   (Adult),Phase 1,2.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",14-0614,2015-06-01,2016-05-01,2016-05-01,2014-04-11,,2016-06-16,"University of Colorado Denver, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT02111551
38,39,NCT02627508,Pilot Trial of Pregnenolone in Autism,,Recruiting,No Results Available,Autism Spectrum Disorder|Autism,Drug: Pregnenolone|Drug: Placebo,"Change from baseline in parent rated Aberrant Behavior Checklist Irritability (ABC-I) score during treatment|Change from baseline in parent rated Aberrant Behavior Checklist (ABC) scores during treatment|Change from baseline in parent rated Sensory Profile Questionnaire (SPQ) scores during treatment|Change from baseline in Vineland Adaptive Behavior Scales Second Edition (VABS-II)|Change from baseline in Clinical Global Impression (CGI) scores during treatment|Change from baseline in levels of pregnenolone and its related neurosteroids in peripheral blood|Change from baseline on the Autism Diagnostic Observation Schedule (ADOS)|Change from baseline in laboratory based eye-gaze measures|Change from baseline in laboratory based electroencephalography (EEG) measures|Change from baseline in laboratory clinical lab values including complete metabolic panel, complete blood count with differential, cholesterol panel and routine urinalysis.|Change from baseline in parent rated Social Responsiveness Scale (SRS) scores during treatment|Change from baseline on the Dosage Record Treatment Emergent Symptom Scale (DOTES) scores during treatment",Stanford University|Simons Foundation,All,"14 Years to 25 Years   (Child, Adult)",Phase 2,40.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IRB-34762,2016-01-29,2023-04-01,2023-04-01,2015-12-11,,2021-05-03,"Stanford University School of Medicine, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT02627508
40,41,NCT00498173,Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism,,Completed,Has Results,Autism,Drug: Atomoxetine|Drug: Placebo,"ADHD Rating Scale (ADHDRS)-Home Version Total Score (Randomized Phase)|ADHD Rating Scale (ADHDRS)-Home Version Inattention and Hyperactivity Scores (Randomized Phase)|Aberrant Behavior Checklist (ABC) (Randomized Phase)|Social Responsiveness Scale (SRS) (Randomized Phase)|Vineland Adaptive Behavior Scales (VABS) Composite Score (Randomized Phase)|Pediatric Quality of Life Inventory (Randomized Phase)|Pediatric Anxiety Rating Scale, 5-Item Total (Randomized Phase)|Odds of Clinical Global Impression-Improvement Scale, Very Much or Much Improved (1 or 2) (Randomized Phase)|Change in ADHD Rating Scale (ADHDRS)-Home Version Total Score (Open-label Trial)|Change in ADHD Rating Scale (ADHDRS)-Home Version Inattention and Hyperactivity Scores (Open-label Trial)|Change in Aberrant Behavior Checklist (ABC) (Open-label Trial)|Change in Social Responsiveness Scale (SRS) (Open-label Trial)|Change in Vineland Adaptive Behavior Scales (VABS) Composite Score (Open-label Trial)|Change in Pediatric Quality of Life Inventory (Open-label Trial)|Change in Pediatric Anxiety Rating Scale, 5-item Total (Open-label Trial)",Massachusetts General Hospital|National Institute of Mental Health (NIMH),All,5 Years to 15 Years   (Child),Phase 3,60.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",R01MH077600|DDTR B2-NDA,2007-07-01,2015-10-01,2015-10-01,2007-07-09,2017-08-14,2017-08-14,"Christian Sarkine Autism Treatment Center at Riley Hospital for Children, Indianapolis, Indiana, United States|Lurie Center - MassGeneral Hospital, Lexington, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00498173
42,43,NCT03887754,Therapeutic Issues for Autism,,Completed,No Results Available,Autism Spectrum Disorder,Drug: Risperidone|Device: hyperbaric oxygen therapy|Drug: Non specific Multivitamin,"Childhood Autism Rating Scale version 2 (CARS2)measured after one year and after two years to compare the effect of hyperbaric oxygen therapy, Risperidone, both of them and the placebo effect",Minia University,All,5 Years to 7 Years   (Child),Phase 2,80.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,Autism Spectrum Disorder,2016-01-01,2018-01-01,2018-12-01,2019-03-25,,2019-03-25,,,https://ClinicalTrials.gov/show/NCT03887754
44,45,NCT02947048,Safety of L1-79 in Autism,,Completed,No Results Available,Autism,Drug: L1-79|Drug: Placebo,Adverse event frequency|Change from baseline in CGI|Change from Baseline in Vineland Adaptive Behavior Scales - 2nd Edition|Change from Baseline in the Autism Diagnostic Observation Schedule (ADOS)|Change from baseline in Aberrant Behavior Checklist - Community|Change from baseline in the Social Responsiveness Scale - 2nd edition (SRS-2)|Changes from baseline in the Repetitive Behavior Scale - Revised (RBS-R).|Plasma concentrations of L1-79,F Peter Halas|Yamo Pharmaceuticals LLC,Male,"13 Years to 21 Years   (Child, Adult)",Phase 2,42.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HT 02-121,2016-10-01,2017-12-01,2018-02-01,2016-10-27,,2020-02-10,"Eric Bartky MD, Bartky Health Care Center, Livingston, New Jersey, United States|F. Peter Halas MD, Sea Girt Pediatrics, Sea Girt, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT02947048
46,47,NCT00549562,Study of Paliperidone ER in Adolescents and Young Adults With Autism,,Completed,Has Results,Autism,Drug: Paliperidone ER,The Clinical Global Impression-Improvement(CGI-I)|The Aberrant Behavior Checklist|The Children's Yale-Brown Obsessive Compulsive Scale Modified for Pervasive Developmental Disorders|The Social Responsiveness Scale|The Vineland Adaptive Behavior Scales (VABS) - Maladaptive Behavior Domain,"Indiana University School of Medicine|Ortho-McNeil Janssen Scientific Affairs, LLC|Indiana University",All,"12 Years to 21 Years   (Child, Adult)",Phase 3,25.0,Other|Industry,Interventional,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0709-24|R076477-AUT-4002,2007-11-01,2010-09-01,2010-09-01,2007-10-26,2017-05-16,2017-05-16,"Riley Child & Adolescent Psychiatry Clinic- Riley Hospital, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT00549562
48,49,NCT00252603,Galantamine Versus Placebo in Childhood Autism,,Completed,No Results Available,Autism|Childhood Autism,Drug: Galantamine,Autism Diagnostic Observation Schedule-Generic (ADOS-G)- Change from Baseline to Final Visit|Clinical Global Impression Improvement (CGI)- Change from Baseline to Final Visit|Aberrant Behavior Checklist (ABC) (hyperactivity/irritability sections)- Change from Baseline to Final Visit|Vineland Adaptive Behavior Scale- Change from Baseline to Final Visit|MacArthur Communicative Development Inventory (MCDI)- Change from Baseline to Final Visit|Conners' Parent Rating Scale-Revised: Long form (CPRS-R:L)- Change from Baseline to Final Visit,"University of Medicine and Dentistry of New Jersey|National Alliance for Autism Research|Rutgers, The State University of New Jersey",All,5 Years to 17 Years   (Child),Phase 3,20.0,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,4682,2004-04-01,,2007-04-01,2005-11-11,,2007-01-29,"UMDNJ Robert Wood Johnson Medical School - Dept of Psychiatry, Piscataway, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00252603
54,55,NCT03179787,Post-Marketing Surveillance Study of Aripiprazole in Patients With Autism,,Completed,Has Results,Autism,Drug: Aripiprazole oral product,Mean Changes of Aberrant Behavior Checklist-Japanese Version (ABC-J) Irritability Subscale Scores From Baseline.,"Otsuka Pharmaceutical Co., Ltd.",All,6 Years to 17 Years   (Child),,528.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,031-101-00116,2017-04-01,2020-03-17,2020-07-06,2017-06-07,2021-09-16,2021-09-16,"Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT03179787/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT03179787/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03179787
56,57,NCT00166621,Early Pharmacotherapy Aimed at Neuroplasticity in Autism : Safety and Efficacy,,Completed,No Results Available,Autism,Drug: Buspirone,"Safety will be measured by obtaining clinical laboratory tests, vital signs and evaluating probably or definitely related adverse events.|Population pharmacokinetics will be conducted to measure plasma concentrations in relation to the drug responses to buspirone.|The primary efficacy outcome will be the overall severity score from the Clinical Global Impressions assessment obtained from two raters, (parent and examiner)|Comparisons of allele, and genotype frequencies between responders and non-responders will be done for each polymorphism using Fisher's exact test to best predict response to buspirone.","Chugani, Diane C.",All,2 Years to 6 Years   (Child),Phase 1|Phase 2,20.0,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,PPRU 10659s,2004-03-01,,2005-08-01,2005-09-14,,2011-07-20,"PET Center/Children's Hospital of Michigan, Detroit, Michigan, United States",,https://ClinicalTrials.gov/show/NCT00166621
67,68,NCT01944046,Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors,SOARS-B,Completed,Has Results,Autism Spectrum Disorders,Drug: Double blind phase Placebo Nasal Spray|Drug: double Blind Oxytocin Nasal Spray|Drug: Open Label intranasal oxytocin,"Change in Aberrant Behavior Checklist-Modified Social Withdrawal Subscale ABC-mSW, a Measure of Social Reciprocity|Change in Sociability Factor (SF)|Change in Social Responsiveness Scale-2 (SRS-2) Social Motivation Subscale Score|Change in Stanford Binet-5th Edition (SB-5) IQ Score",Linmarie Sikich|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Duke University,All,3 Years to 17 Years   (Child),Phase 2,290.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Pro00063950|1U01HD073984|13-0593,2014-08-01,2017-11-30,2017-11-30,2013-09-17,2021-01-05,2021-06-18,"Lurie Center for Autism, Massachusetts General Hospital, Boston, Massachusetts, United States|Mount Sinai School of Medicine, New York, New York, United States|Center for Autism and the Developing Brain, White Plains, New York, United States|Duke Center for Autism and Brain Development, Durham, North Carolina, United States|Duke University , Genetics Center, Durham, North Carolina, United States|Vanderbilt University, Nashville, Tennessee, United States|Seattle Children's Hospital Research Institute, Seattle, Washington, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT01944046/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01944046
75,76,NCT04031755,A Proof-of-Concept Study of Minocycline in Autism,,Completed,No Results Available,Autism Spectrum Disorder|Autism,Drug: Minocycline|Drug: Placebos,Subject weight will be compared pre- and post-treatment in the drug versus placebo conditions|Aberrant Behavior will be evaluated pre- and post-treatment in the drug versus placebo conditions|Incidence of liver toxicity will be evaluated in the pre- and post-treatment setting in the drug versus placebo conditions,"Children's Hospital Medical Center, Cincinnati",All,"12 Years to 22 Years   (Child, Adult)",Phase 1,53.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CIN001 - Minocycline in ASD,2019-04-19,2020-10-30,2020-10-30,2019-07-24,,2020-12-08,"Thompson Center for Autism & Neurodevelopmental Disorders - University of Missouri, Columbia, Missouri, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Center for Autism and Developmental Disorders - University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT04031755
80,81,NCT01780883,Melatonin Dose-effect Relation in Childhood Autism,MELADOSE,Completed,No Results Available,Childhood Autism,Drug: melatonin|Drug: Placebo,Severity of autistic disorder|Severity of autistic impairments|Sleep problems|Excretion of the urinary metabolite of melatonin,"Rennes University Hospital|Centre Hospitalier Guillaume Régnier, RENNES",Male,6 Years to 8 Years   (Child),Phase 2,34.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ANSM A91245-56,2013-02-01,2013-07-01,2013-09-01,2013-01-31,,2013-09-05,"Service de Psychiatrie de l'Enfant et de l'Adolescent - Hôpital de la Pitié-Salpêtrière, Paris, France|Centre Hospitalier Spécialisé Henri Laborit, Poitiers, France|Service de Psychothérapie de l'Enfant et de l'Adolescent - Hôpital Robert Debré, Reims, France|Pôle de Psychiatrie de l'Enfant et de l'Adolescent - Centre Hospitalier Guillaume Régnier, Rennes, France",,https://ClinicalTrials.gov/show/NCT01780883
81,82,NCT02140112,Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo in Autism Spectrum Disorder,,Terminated,No Results Available,Autism,Biological: Trichuris suis ova|Other: Placebo,Change from Baseline in Aberrant Behavior Checklist - Irritability (ABC-I) at 16 weeks,"Coronado Biosciences, Inc.",All,5 Years to 17 Years   (Child),Phase 2,23.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CNDO 201-101,2014-05-01,2015-04-01,2015-04-01,2014-05-16,,2015-11-04,"Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States|Baber Research Group, Naperville, Illinois, United States|Montefiore Medical Center Dept. of Psychiatry, Child Annex, Bronx, New York, United States|Red Oak Psychiatry, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02140112
82,83,NCT00490802,Intranasal Oxytocin in the Treatment of Autism,,Completed,Has Results,Autism,Drug: Oxytocin|Drug: Placebo,"Clinical Global Impressions Scale - Improvement - Social|Repetitive Behavior Scale - Revised|Diagnostic Analysis of Nonverbal Accuracy, Paralanguage Test|Yale-Brown Obsessive-Compulsive Scale|Social Responsiveness Scale","Evdokia Anagnostou|Icahn School of Medicine at Mount Sinai|Anagnostou, Evdokia, M.D.",All,18 Years to 60 Years   (Adult),Phase 2,19.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",06-0230 0001 02 PS,2006-06-01,2011-09-01,2012-04-01,2007-06-25,2014-11-05,2015-10-23,"Mount Sinai School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00490802
84,85,NCT04623398,Effect of Lithium in Patients With Autism Spectrum Disorder and Phelan-McDermid Syndrome (SHANK3 Haploinsufficiency),Lisphem,Not yet recruiting,No Results Available,Autism Spectrum Disorder,Drug: Lithium Carbonate|Drug: Placebo,Score social responsiveness scale|score of autism diagnosis observation scale|Score of attention deficit hyperactivity disorder|score of child's sleep disorder rating scale|Score of Dunn Sensory Profile|Score of Aberrant Behavior checklist scale|score of global functioning|Score of Vineland Adaptive Behavior Composite|Score of surrounding constraints|score of Columbia Suicide Severity Rating Scale,Assistance Publique - Hôpitaux de Paris,All,"7 Years to 18 Years   (Child, Adult)",Phase 3,22.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",P160914,2021-09-01,2023-09-01,2023-09-01,2020-11-10,,2021-09-16,"Hôpital Robert Debré, Paris, France",,https://ClinicalTrials.gov/show/NCT04623398
85,86,NCT01999894,Open-label Study of Safety and Tolerability of Memantine in Children With Autism,,Completed,Has Results,Autism|Pediatric Autism,Drug: Memantine HCl,Number of Patients Who Experienced a Treatment-emergent Adverse Event (TEAE),Forest Laboratories|Merz Pharmaceuticals GmbH,All,"6 Years to 18 Years   (Child, Adult)",Phase 2,102.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MEM-MD-67,2009-11-01,2013-02-01,2013-02-01,2013-12-03,2014-03-18,2014-03-18,"Forest Investigative Site 005, Phoenix, Arizona, United States|Forest Investigative Site 003, Sacramento, California, United States|Forest Investigative Site 021, San Francisco, California, United States|Forest Investigative Site 026, Santa Ana, California, United States|Forest Investigative Site 020, Santa Ana, California, United States|Forest Investigative Site 002, Stanford, California, United States|Forest Investigative Site 024, Jacksonville Beach, Florida, United States|Forest Investigative Site 007, St. Petersburg, Florida, United States|Forest Investigative Site 014, Hoffman Estates, Illinois, United States|Forest Investigative Site 023, Naperville, Illinois, United States|Forest Investigative Site 010, Indianapolis, Indiana, United States|Forest Investigative Site 025, Cambridge, Massachusetts, United States|Forest Investigative Site 011, Toms River, New Jersey, United States|Forest Investigative Site 006, Voorhees, New Jersey, United States|Forest Investigative Site 017, Manhasset, New York, United States|Forest Investigative Site 013, Cleveland, Ohio, United States|Forest Investigative Site 015, Cleveland, Ohio, United States|Forest Investigative Site 001, Columbus, Ohio, United States|Forest Investigative Site 019, Oklahoma, Oklahoma, United States",,https://ClinicalTrials.gov/show/NCT01999894
89,90,NCT00211796,Divalproex Sodium ER in Adult Autism,,Completed,No Results Available,Autism,Drug: Divalproex Sodium ER,the Clinical Global Improvement and Severity scales (CGI-I and CGI-S)|Overt Aggression Scale-Modified (OAS M)|Affective Lability Scale (ALS).|Global Assessment of Functioning Scale (GAF)|Aggression Questionnaire (AQ)|the Hamilton Depression (Ham-D) Scale|Yale Brown Obsessive Compulsion Scale (YBOCS)|Compulsion sub-scale|Aberrant Behavior Checklist (ABC)|Barratt Impulsiveness Scale|Version11 (BIS-11).,Montefiore Medical Center,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,10.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GCO#04-1106,2005-04-01,2007-04-01,2007-04-01,2005-09-21,,2018-05-31,"Mount Sinai School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00211796
91,92,NCT00872898,"Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism",,Completed,Has Results,Autism,Drug: Memantine - Extended Release (ER)|Drug: Placebo,Extent of Absorption of Memantine (Part One)|Change in Total Raw Score of Social Responsiveness Scale|Core Autism Treatment Scale-Improvement: Total Score|Core Autism Treatment Scale-Improvement: Social Interaction|Core Autism Treatment Scale-Improvement: Communication|Change in Children's Communication Checklist-2 (CCC-2) - Speech Subscale|Change in Children's Communication Checklist-2 (CCC-2) - Syntax Subscale|Change in Children's Communication Checklist-2 (CCC-2) - Semantics Subscale|Change in Children's Communication Checklist-2 (CCC-2) - Coherence Subscale|Change in Children's Communication Checklist-2 (CCC-2) - Initiation Subscale|Change in Children's Communication Checklist-2 (CCC-2) - Scripted Language Subscale|Change in Children's Communication Checklist-2 (CCC-2) - Context Subscale|Change in Children's Communication Checklist-2 (CCC-2) - Nonverbal Communication Subscale|Change in Children's Communication Checklist-2 (CCC-2) - Social Relations Subscale|Change in Children's Communication Checklist-2 (CCC-2) - Interests Subscale,Forest Laboratories|Merz Pharmaceuticals GmbH,All,"6 Years to 18 Years   (Child, Adult)",Phase 2,124.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MEM-MD-57A,2009-04-01,2012-08-01,,2009-03-31,2014-01-14,2014-01-14,"Forest Investigative Site, Phoenix, Arizona, United States|Forest Investigative Site, Sacramento, California, United States|Forest Investigative Site, San Francisco, California, United States|Forest Investigative Site, Santa Ana, California, United States|Forest Investigative Site, Stanford, California, United States|Forest Investigative Site, Jacksonville Beach, Florida, United States|Forest Investigative Site, St Petersburg, Florida, United States|Forest Investigative Site, Hoffman Estates, Illinois, United States|Forest Investigative site, Naperville, Illinois, United States|Forest Investigative Site, Indianapolis, Indiana, United States|Forest Investigative Site, Cambridge, Massachusetts, United States|Forest Investigative Site, Toms River, New Jersey, United States|Forest Investigative Site, Voorhees, New Jersey, United States|Forest Investigative Site, Manhasset, New York, United States|Forest Investigative Site, Cleveland, Ohio, United States|Forest Investigative Site, Columbus, Ohio, United States|Forest Investigative Site, Oklahoma City, Oklahoma, United States",,https://ClinicalTrials.gov/show/NCT00872898
93,94,NCT00873834,Fluoxetine Essay in Children With Autism,FAIR,Withdrawn,No Results Available,Autism,Drug: fluoxetine|Drug: placebo,"Subscores of Autism Diagnostic Interview (ADI-R)at each visit of the protocol (LECOUTER et RUTTER, 1989)|Sides effect scale (FSEC)|Aberrant Behavior Checklist (Aman et al., 1985)|Clinical Global Impressions (CGI) severity and improvement (NIMH.1985)",Assistance Publique - Hôpitaux de Paris,All,5 Years to 12 Years   (Child),Phase 2,0.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",P030901|AOM 98082,2009-09-01,2010-11-01,2011-11-01,2009-04-02,,2012-01-10,,,https://ClinicalTrials.gov/show/NCT00873834
95,96,NCT04517799,Trial of Cannabidiol to Treat Severe Behavior Problems in Children With Autism,,Recruiting,No Results Available,Autism|Autism Spectrum Disorder,Drug: Epidiolex|Drug: placebo oral solution,"Total Score on Repetitive Behavior Scale-Revised (RBS-R)|Total Score on Child Behavior Checklist (CBCL)|Autism Diagnostic Observation Scale- 2 (ADOS-2)|Total Score on Aberrant Behavior Checklist (ABC)|Total Score on Self Harm Inventory|Total Score on Social Responsiveness Scale|Total Score on Peabody Picture Vocabulary test (PPVT-4)|Total Score on Expressive One Word Picture Vocabulary test, Fourth Edition (EOWPVT-4)|Total Score on Children's Sleep Habits Questionnaire (CSHQ)","University of California, San Diego|Wholistic Research and Education Foundation",Male,7 Years to 14 Years   (Child),Phase 2|Phase 3,30.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",181455,2020-06-01,2022-02-28,2022-12-31,2020-08-18,,2021-09-05,"University of California, San Diego, La Jolla, California, United States",,https://ClinicalTrials.gov/show/NCT04517799
97,98,NCT00208559,Ziprasidone in Children With Autism: A Pilot Study,,Completed,No Results Available,Autism,Drug: Ziprasidone,Clinical Global Impressions|Children's Psychiatric Rating Scale,Drexel University College of Medicine|Drexel University,All,"12 Years to 18 Years   (Child, Adult)",Phase 2,15.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,00936,2002-02-01,2005-06-01,2006-08-01,2005-09-21,,2010-06-17,"Drexel University College of Medicine at Friends Hospital, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00208559
102,103,NCT02090829,Intranasal Oxytocin and Learning in Autism,,Withdrawn,No Results Available,Autism Spectrum Disorders,Drug: Syntocinon (synthetic oxytocin)|Other: Placebo,"Change from Baseline to Post-testing on the The Part/Whole Identity Test|Change from Baseline to Post-testing on the Reading the Mind in the Eyes Task|Change from Baseline to Post-testing on measures of social attention, reward/motivation, perception and cognition",University of Minnesota|Children's Hospital of Philadelphia,Male,12 Years to 17 Years   (Child),Phase 2,0.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",1402M48250,2014-03-01,2018-03-01,2018-03-01,2014-03-18,,2019-11-01,"Center for Neurobehavioral Development, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02090829
104,105,NCT01630811,Nuedexta for the Treatment of Adults With Autism,Nuedexta,Completed,Has Results,Autism,Drug: Nuedexta|Other: Placebo,Change in Maladaptive Behaviors|Primary Safety Endpoints|Change in Aggressive Behavior,Sutter Health,All,18 Years to 60 Years   (Adult),Phase 2,13.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CHKI-Nued0911,2012-01-24,2015-12-15,2015-12-15,2012-06-28,2017-12-08,2017-12-08,"Sutter Pediatric Neurology, Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT01630811
106,107,NCT01474993,Sulforaphane-rich Broccoli Sprout Extract for Autism,,Completed,Has Results,Autism,Drug: Sulforaphane-rich Broccoli Sprout Extract|Drug: Placebo,"Change From Screening/Baseline in Social Responsiveness Scale (SRS) at 4 Weeks, 10 Weeks, 18 Weeks and 22 Weeks|Change From Screening/Baseline in Aberrant Behavior Checklist (ABC) at 4 Weeks, 10 Weeks, 18 Weeks and 22 Weeks|Ohio Autism Clinical Global Impression Scale - Severity (OACIS-S) Scale at 4 Weeks, 10 Weeks, 18 Weeks and 22 Weeks|Ohio Autism Clinical Impressions Scale - Improvement (OACIS-I) (or CGI-I Scores) Scores at 4 Weeks, 10 Weeks, 18 Weeks and 22 Weeks|Liver Function Tests [Serum Glutamic Oxaloacetic Transaminase (SGOT) and Serum Glutamic Pyruvic Transaminase (SGPT)] at 4 Weeks, 18 Weeks and 22 Weeks|Renal Function Tests (Serum Creatinine) at 4 Weeks, 18 Weeks and 22 Weeks|Thyroid Stimulating Hormone (TSH) at 4 Weeks, 18 Weeks and 22 Weeks|Red Blood Cell (RBC) Count at 4 Weeks, 18 Weeks and 22 Weeks|White Blood Cell (WBC) Count at 4 Weeks, 18 Weeks and 22 Weeks|Platelet Count at 4 Weeks, 18 Weeks and 22 Weeks|Change From Screening and Baseline in Urinary Isoprostane F2α-VI Levels at 24 Hours After First Dose, at 4 Weeks, 10 Weeks, 18 Weeks and 22 Weeks|Change From the Screening Visit in Heat Shock Protein Gene Expression (Relative Maximum Gene Expression) at 24 Hours After First Dose, 18 Weeks and 22 Weeks","Andrew Zimmerman|Johns Hopkins University|University of Massachusetts, Worcester",Male,"13 Years to 30 Years   (Child, Adult)",Phase 2,44.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2011P002221,2011-12-01,2013-11-01,2013-11-01,2011-11-18,2014-11-24,2018-09-12,"Lurie Center for Autism, MassGeneral Hospital for Children, Lexington, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01474993
107,108,NCT00211757,Divalproex Sodium vs. Placebo in Childhood/Adolescent Autism,,Completed,Has Results,Autism,Drug: Divalproex sodium|Drug: Placebo,Number of Participants Reporting Improvement on the Clinical Global Impression|Change in Aberrant Behaviors as Measured by the Aberrant Behavior Checklist Scores,Montefiore Medical Center|National Institute of Neurological Disorders and Stroke (NINDS),All,5 Years to 17 Years   (Child),Phase 2,27.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01-0294|1R21NS043979,2002-09-01,2008-07-01,2008-07-01,2005-09-21,2018-12-06,2018-12-06,"Mount Sinai School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00211757
108,109,NCT00584701,Pharmacogenomics in Autism Treatment,PG,Completed,Has Results,Autism,Drug: Risperidone,Percent Change of ABC - Irritability Subscale Score|Exon Expression Positively or Negatively Correlated With Percentage Improvement in ABC-I,"University of California, San Francisco|Janssen, LP|National Institute of Mental Health (NIMH)",All,"4 Years to 18 Years   (Child, Adult)",Phase 2|Phase 3,49.0,Other|Industry|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,200715817-1|R21MH080026,2008-01-01,2009-05-01,2009-05-01,2008-01-02,2012-07-24,2012-07-24,"UC San Francisco, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT00584701
111,112,NCT01638819,Autologous Cord Blood Stem Cells for Autism,,Completed,Has Results,Autism,Biological: Autologous Cord Blood Stem Cells|Biological: Placebo,"Change in Language (Total Standard Score, Range 40 - 160)|Change in Behavior/Learning (Standard Score, Range 40 - 160 for Each Subtest)|Change in Knowledge and Fluid Reasoning (Scaled Score, Range 1-19 for Each Subtest)",Sutter Health,All,2 Years to 7 Years   (Child),Phase 2,30.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CB2011Chez,2012-08-01,2015-12-01,2016-12-01,2012-07-12,2018-08-20,2018-08-20,"Sutter Pediatric Neurology, Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT01638819
113,114,NCT00655174,Fluvoxamine and Sertraline in Childhood Autism - Does SSRI Therapy Improve Behaviour and/or Mood?,,Completed,No Results Available,Autism,Drug: fluvoxamine|Drug: sertraline|Drug: Placebo,The severity of the autistic child's behaviour or condition (assessed by parents)|Weight and vital signs|Blood count and liver function studies,The Hospital for Sick Children,All,3 Years to 10 Years   (Child),Phase 3,108.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",0019990290,1999-06-01,2006-09-01,2007-01-01,2008-04-09,,2008-04-09,"The Hospital for Sick Children, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00655174
114,115,NCT01624194,Intranasal Oxytocin Treatment for Social Deficits in Children With Autism,,Completed,Has Results,Autism,Drug: Oxytocin nasal spray|Drug: Placebo,"Change From Baseline in Parent Rated Social Responsiveness Scale (SRS) Scores During Treatment.|Number of Participants With Side Effects Assessed Using Parent Rated Dosage Record Treatment Emergent Symptom Scale (DOTES) Scores During Treatment|Change From Baseline in Height.|Clinical Global Impression-Improvement (CGI-I) Score at Week 4|Parent Rated Aberrant Behavior Checklist (ABC) Irritability Scores at Baseline and Week 4|Change From Baseline in Parent Rated Spence Children's Anxiety Scale (SCAS) During Treatment.|Change From Baseline in Vineland Adaptive Behavior Scales, Second Edition - Social and Communication Subscales During Treatment.|Change From Baseline in Laboratory Based Facial Emotion Recognition Abilities During Treatment.|Change From Baseline in Laboratory Based Eye-gaze to Social Cues During Treatment.|Change From Baseline in Reading the Mind in the Eyes Test, Child Version (RMET-child) Scores During Treatment.|Change From Baseline in Laboratory Based Social Mimicry Abilities During Treatment.|Change From Baseline in Developmental NEuroPSYchological Assessment (NEPSY-II) Affect Recognition Scores During Treatment.|Change From Baseline in Plasma Oxytocin Levels During Treatment.|Change From Baseline in Parent Rated Repetitive Behavior Scale- Revised (RBS-R) Scores During Treatment.|Change From Baseline in Weight|Change From Baseline in Heart Rate|Change From Baseline in Blood Pressure",Stanford University,All,6 Years to 12 Years   (Child),Phase 2,54.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SU-12132011-8827,2012-06-01,2016-05-01,2016-05-01,2012-06-20,2018-06-06,2019-07-15,"Stanford University School of Medicine, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT01624194
115,116,NCT00208533,Aripiprazole in Children With Autism: A Pilot Study,,Completed,No Results Available,Autism,Drug: Aripiprazole,Clinical Global Impressions,Drexel University College of Medicine|Drexel University,All,"12 Years to 18 Years   (Child, Adult)",Phase 2,11.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,02841,2004-02-01,2011-11-16,2011-11-16,2005-09-21,,2018-07-30,"Drexel University College of Medicine at Friends Hospital, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00208533
122,123,NCT03033784,Autism Oxytocin Brain Project,,Completed,Has Results,Autism|Autism Spectrum Disorder,Drug: 8 International Units (IU) of Oxytocin|Drug: 24IU of Oxytocin|Drug: 48IU of Oxytocin|Drug: Placebo,Resting State Functional Connectivity (rsFC) Salience Network (Anterior Cingulate Cortex (ACC) and Insula Versus Visual Cortex)|Blood Oxygen Level Dependent (BOLD) Activity in Response to Social Cues|Percent Change in Blood Oxygen Level Dependent (BOLD) Activity During Ball-Game Task|Oxytocin Plasma Concentration|Rate of Smiling During Global Clinical Interview|Milliseconds of Visual Fixation|Social Learning Test (SLT) Reaction Time,Emory University|National Institute of Mental Health (NIMH),Male,18 Years to 45 Years   (Adult),Phase 2,51.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",IRB00093455|P50MH100023,2017-05-10,2018-10-03,2018-10-03,2017-01-27,2021-01-12,2021-01-12,"Emory University, Atlanta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT03033784/Prot_SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT03033784/ICF_002.pdf",https://ClinicalTrials.gov/show/NCT03033784
124,125,NCT02871349,Trial of Propranolol in Children and Youth With Autism Spectrum Disorder and Predictors of Response,,Completed,No Results Available,Autism Spectrum Disorder,Drug: Propranolol|Drug: Placebo|Device: Magnetic Resonance Imaging (MRI),Change in General Social Outcomes Measure (GSOM) Assessment|Change in Social Responsiveness Scale (SRS-2)|Change in score on Anagrams test|Change in Semantic fluency test results|Change Clinical Global Impression surveys|Change in Autism Impact Measure (AIM)|Change in Clinical Evaluation of Language Fundamentals (CELF-5) assessment|Change in Vineland Adaptive Behavior Scales (VABS-2) assessment|Change in score on Aberrant Behavior Checklist (ABC)|Change in gastrointestinal symptomology,University of Missouri-Columbia|United States Department of Defense,All,"7 Years to 24 Years   (Child, Adult)",Early Phase 1,69.0,Other|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2005213,2016-08-01,2020-08-01,2020-08-01,2016-08-18,,2020-10-08,"Thompson Center for Autism & Neurodevelopmental Disorders, Columbia, Missouri, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02871349/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT02871349
125,126,NCT04484077,hCT-MSC Infusion in Adults With Autism Spectrum Disorder,AIMs,Not yet recruiting,No Results Available,Autism Spectrum Disorder|Autism,Biological: hCT-MSC,"Incidence of infusion reactions|Incidence of product-related infections|Evidence of formation of anti-HLA antibodies|Incidence of graft vs. host disease|Incidence of unexpected adverse events, by severity and relation to study|The Vineland Adaptive Behavior Scale Interview, 3rd Edition, Comprehensive interview form|Social Responsiveness Scale, Second Edition (SRS-2)|Social Withdrawal Subscale of the Aberrant Behavior Checklist, Community Edition (ABC-C)|Repetitive Behavior Scale Revised - parent/guardian questionnaire|Pediatric Quality of Life Inventory General Core Scales|Pediatric Quality of Life Inventory Family Impact Measure|Pediatric Quality of Life Inventory General Core Scales - Adult Version","Joanne Kurtzberg, MD|The Marcus Foundation|Duke University",All,18 Years to 35 Years   (Adult),Phase 1,12.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PRO00104691,2021-09-01,2023-03-01,2023-03-01,2020-07-23,,2021-06-29,"Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04484077
131,132,NCT03866668,A Study of Esomeprazole in Children With Autism,,Suspended,No Results Available,Autism|Autism Spectrum Disorder,Drug: Esomeprazole,"Change from Baseline on the Social Responsiveness Scale, 2nd Edition (SRS-2)|Change from Baseline on the Aberrant Behavior Checklist, 2nd Edition (ABC-2)",Stanford University|SPARK (Stanford University),All,2 Years to 6 Years   (Child),Phase 2,25.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB-44589,2019-05-29,2022-12-01,2022-12-01,2019-03-07,,2021-05-04,"Stanford University School of Medicine, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT03866668
137,138,NCT01040221,Trichuris Suis Ova in Autism Spectrum Disorders,TSO,Completed,No Results Available,Autism,Drug: Trichuris Suis Ova,Yale-Brown Obsessive Compulsive Scale (YBOCS): to measure repetitive behaviors|Aberrant Behavior Checklist (ABC): to measure aggression and irritability|Clinical Global Impression - Improvement (CGI-I): to measure global functioning|Repetitive Behavior Scale-Revised.,Montefiore Medical Center|Simons Foundation,All,18 Years to 35 Years   (Adult),Phase 1,10.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",11-11-384,2012-11-01,2014-06-01,2014-07-01,2009-12-29,,2018-04-03,"Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT01040221
140,141,NCT02586935,Tideglusib vs. Placebo in the Treatment of Adolescents With Autism Spectrum Disorders,TIDE,Completed,No Results Available,Autism Spectrum Disorders,Drug: Tideglusib|Other: Placebo,Effect of tideglusib vs. placebo on measures of social engagement/withdrawal|Efficacy of tideglusib vs. placebo on measures of repetitive behaviours|Efficacy of tideglusib vs. placebo on measures of social function|Safety and tolerability of tideglusib in adolescents with ASD|Pharmacokinetic (PK) parameters in this age group,"Evdokia Anagnostou|Holland Bloorview Kids Rehabilitation Hospital|McMaster University|University of Western Ontario, Canada|Unity Health Toronto|University of Toronto|Anagnostou, Evdokia, M.D.",All,12 Years to 17 Years   (Child),Phase 2,83.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TIDE-06-2015,2016-02-10,2018-02-25,2018-02-25,2015-10-27,,2018-05-31,"McMaster University, Offord Centre for Child Studies, Hamilton, Ontario, Canada|University of Western Ontario, Lawson Health Research Institute, London, Ontario, Canada|Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02586935
145,146,NCT01912378,Triadic Interactions of Families With Autism and Oxytocin,TAO,Withdrawn,No Results Available,Autism Disorder,Drug: Oxytocin|Drug: Placebo nasal spray,Parental social behavior|Child and Parent Physiological Synchrony|Child social behavior,"University of California, San Francisco",All,"7 Years to 60 Years   (Child, Adult)",Phase 1,0.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",TAO,2013-08-01,2015-05-01,2015-05-01,2013-07-31,,2019-01-16,"University of California, San Francisco, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT01912378
155,156,NCT02094651,Treatment of Children With Autism Spectrum Disorders and Epileptiform EEG With Divalproex Sodium,,Withdrawn,No Results Available,Autism,Drug: divalproex sodium|Other: Placebo,effect of drug vs placebo on reduction in epileptiform EEG discharges in children with ASD|behavior changes in drug vs placebo.,Boston Children's Hospital|University of Louisville,All,4 Years to 10 Years   (Child),Phase 2,0.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",P00005744,2014-04-01,2016-10-01,2016-10-01,2014-03-24,,2016-10-21,"University of Louisville, Louisville, Kentucky, United States|Boston Childrens Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02094651
160,161,NCT03771560,Folinic Acid in Autism,,Completed,Has Results,Autism Spectrum Disorder,Drug: folinic acid,Aberrant Behavior Checklist (ABC) - Parent Reported Change|Aberrant Behavior Checklist (ABC) - Teacher Reported Change|Social Responsiveness Scale (SRS) - Parent Reported Change|Social Responsiveness Scale (SRS) - Teacher Reported Change|Pediatric Quality of Life (PedsQL) - Parent Reported Change,"University of California, San Francisco",All,"5 Years to 25 Years   (Child, Adult)",Phase 2|Phase 3,18.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Folinic acid,2018-02-15,2018-06-30,2018-06-30,2018-12-11,2019-12-03,2019-12-03,"University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT03771560/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03771560
162,163,NCT00467753,Oxcarbazepine Versus Placebo in Childhood Autism,,Completed,Has Results,Autism,Drug: Oxcarbazepine|Other: Placebo/sugar pill,Vineland Adaptive Behavior Scales|Aberrant Behavior Checklist|Autism Diagnostic Observation Schedule|Clinical Global Impression Improvement (CGI-AD),"University of Medicine and Dentistry of New Jersey|National Alliance for Research on Schizophrenia and Depression|Rutgers, The State University of New Jersey",All,5 Years to 17 Years   (Child),Not Applicable,5.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",0220055339,2006-04-01,2011-12-01,2011-12-01,2007-05-01,2013-12-16,2021-01-13,"Child and Adolescent Psychiatry at the University Behavioral Healthcare Building, UMDNJ-RWJMS, Piscataway, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00467753
163,164,NCT03202303,Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD),,Recruiting,No Results Available,Autism Spectrum Disorder,Drug: Cannabidivarin|Drug: Matched Placebo,Aberrant Behavior Checklist-Irritability Subscale (ABC-I)|Repetitive Behavior Scale-Revised (RBS-R)|Aberrant Behavior Checklist-Social Withdrawal Subscale (ABC-SW)|Pediatric Quality of Life Inventory (PedsQL) Family Impact Module|Vineland Adaptive Behavior Scale-3 (Vineland 3)|Clinical Global Impressions-Improvement (CGI-I)|Montefiore Einstein Rigidity Scale-Revised (MERS-R),Montefiore Medical Center|United States Department of Defense|GW Pharmaceuticals Ltd.,All,"5 Years to 18 Years   (Child, Adult)",Phase 2,100.0,Other|U.S. Fed|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2017-8538|AR160104|G32379,2019-04-12,2021-10-06,2021-10-06,2017-06-28,,2021-08-05,"Montefiore Medical Center, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT03202303
167,168,NCT01945957,Brain Imaging of Intranasal Oxytocin Treatment in Autism,,Completed,No Results Available,Autism Spectrum Disorders,Drug: Oxytocin,Aim 1a. fMRI Activation Analysis/Connectivity|Aim 1b. Proportion of Time Attending to Social Stimuli (Eye Tracking)|Plasma Oxytocin (OT) levels in aim 1b. and 2b.|Salivary Oxytocin (OT) levels for all aims.|SRS-Social Responsiveness Scale|Pervasive Developmental Disorders Behavior Inventory-Screening Version (PDDBI-SV)|ABC-lethargy/social withdrawal subscale,"University of North Carolina, Chapel Hill|Duke University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"6 Years to 18 Years   (Child, Adult)",Phase 1,33.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other",12-2622|U54HD079124-01,2014-09-01,2017-01-01,2017-01-01,2013-09-19,,2017-04-25,"The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01945957
174,175,NCT01064973,An Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders,,Terminated,No Results Available,Autism Spectrum Disorders,Drug: arbaclofen,Irritability subscale of the Aberrant Behavior Checklist,"Seaside Therapeutics, Inc.",All,6 Years to 17 Years   (Child),Phase 2,32.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,22007,2010-02-01,2012-12-01,2012-12-01,2010-02-09,,2012-12-20,"Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|University of California-Los Angeles Neuropsychiatric Institute, Los Angeles, California, United States|Yale Child Study Center, New Haven, Connecticut, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|University of North Carolina Neurosciences Hospital, Chapel Hill, North Carolina, United States|Vanderbilt Kennedy Center, Nashville, Tennessee, United States|Red Oaks Psychiatry Associates, P.A., Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01064973
176,177,NCT04089579,hCT-MSC in Children With Autism Spectrum Disorder,IMPACT,Recruiting,No Results Available,Autism|Autism Spectrum Disorder,Biological: Cord Tissue Mesenchymal Stromal Cells|Other: Placebo Infusion,Change on the Socialization and Communication Subscale Standard Scores on the Vineland Behavior Scales|Change in VABS-3 Socialization Standard Score|Change in VABS-3 Communication Standard Score|Change in CGI-Severity score|CGI-Intervention score|Change in the Pediatric Quality of Life Scale,"Joanne Kurtzberg, MD|The Marcus Foundation|Duke University",All,4 Years to 11 Years   (Child),Phase 2,164.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Pro00102894,2020-10-12,2022-10-01,2023-05-01,2019-09-13,,2021-03-18,"Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04089579
177,178,NCT00065962,Secretin for the Treatment of Autism,,Completed,No Results Available,Autism,"Drug: secretin, synthetic porcine|Drug: secretin, biologically derived porcine",,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute on Deafness and Other Communication Disorders (NIDCD),All,3 Years to 12 Years   (Child),Phase 3,85.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Treatment,5P01HD035465|NICHD-23|57-937|Supplement CRC99-3|3P01HD035468,1999-06-01,,2000-05-01,2003-08-05,,2005-06-24,"Children's Hospital, Denver, Colorado, United States|Center on Human Development and Disability, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00065962
186,187,NCT04644003,"Safety, Tolerability and Pharmacokinetics Study of STP1 in a Subgroup of Patients With Autism Spectrum Disorder",,Recruiting,No Results Available,Autism Spectrum Disorder,Drug: STP1|Drug: Placebo,Safety and Tolerability|Plasma concentration of STP1 (PK),Stalicla SA,All,18 Years to 40 Years   (Adult),Phase 1,16.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",STP1-C004,2020-12-07,2021-11-30,2021-12-31,2020-11-25,,2021-06-18,"Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04644003
199,200,NCT02007447,Oxytocin in Adolescents With Autism Spectrum Disorders,OXYASD,Terminated,No Results Available,Autism Spectrum Disorder,Drug: OCYTOCINA - SPRAY NASAL,SOCIAL SKILLS|REPETITIVE BEHAVIOR,University of Sao Paulo General Hospital,Male,"12 Years to 18 Years   (Child, Adult)",Phase 2|Phase 3,30.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CAAE 10922213.7.0000.0068,2015-06-01,2015-08-01,2018-05-04,2013-12-10,,2019-10-28,"Institute os Psychiatry, Clinical Hospital at São Paulo, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT02007447
200,201,NCT00183404,Long-Term Olanzapine Treatment in Children With Autism,,Completed,No Results Available,Autism,Drug: Olanzapine,Children's Psychiatric Rating Scale|Aberrant Behavior Checklist|Clinical Global Impressions|Treatment Emergent Symptoms Scale|Olanzapine Untoward Effects Checklist|Abnormal Involuntary Movement Scale|Neurological Rating Scale,Drexel University|National Institute of Mental Health (NIMH),All,3 Years to 12 Years   (Child),Phase 2|Phase 3,32.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R01MH073524|DDTR B2-NDA,2004-09-01,2011-07-01,2011-10-01,2005-09-16,,2014-08-15,"Drexel University College of Medicine at Friends Hospital, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00183404
209,210,NCT04278898,Targeting the Neurobiology of Restricted and Repetitive Behaviors in Children With Autism Using N-acetylcysteine,,Recruiting,No Results Available,Autism Spectrum Disorder,Drug: N-Acetylcysteine,Change in glutamatergic neurometabolites (Glx) measured by proton spectroscopy Magnetic Resonance Imaging (MRI)|Change in Gamma band amplitude and synchronization measured by electroencephalography,Stanford University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),All,3 Years to 12 Years   (Child),Phase 2,24.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IRB-54931,2021-02-12,2022-08-01,2023-01-01,2020-02-20,,2021-08-12,"Stanford University School of Medicine, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT04278898
210,211,NCT03117530,Measuring Brain Inflammation in Autism,,Suspended,No Results Available,Autism Spectrum Disorder,Drug: Minocycline,Evaluate differences in CNS microglial activation in adults with ASD versus healthy volunteers via in vivo CNS binding of [11C]-DAA1106|Evaluate the effect of 12-weeks of minocycline exposure on CNS microglial activation in adults with ASD by measuring change in [11C]-DAA1106 binding pre- and post- treatment|Effect of minocycline exposure on cognition across seven cognitive domains before and after low dose intervention and regular dose intervention as measured by MCCB (MATRICS Consensus Cognitive Battery) subdomain scores|Effect of minocycline exposure on self-rated anxiety and emotion regulation as measured by ADAMS (Anxiety and Depression Mood Scale)|Effect of minocycline exposure on peripheral inflammatory cytokine profiles as measured by DNA and RNA expression in blood samples,"University of California, Los Angeles",Male,18 Years to 35 Years   (Adult),Phase 1,30.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16-001784,2017-04-11,2022-12-01,2022-12-01,2017-04-18,,2020-08-10,"UCLA, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT03117530
213,214,NCT03204786,Intranasal Vasopressin Treatment in Children With Autism,,Recruiting,No Results Available,Autism|Autism Spectrum Disorder|ASD,Drug: Vasopressin (USP) Injectable Solution [Vasostrict]|Drug: Placebo,"Change from baseline in parent rated Social Responsiveness Scale, Second Edition Total Scores (SRS-2) total scores during treatment.|Change from baseline in Clinical Global Impression (CGI) scores during treatment.|Change from baseline on Reading the Mind in the Eyes Test (RMET) during treatment.|Change from baseline on the Facial Emotion Recognition Test during treatment.|Change from baseline in parent rated Repetitive Behavior Scale Revised (RBS-R) scores during treatment.|Change from baseline in parent rated Spence Children's Anxiety Scale (SCAS) during treatment.|Change from baseline on electrocardiogram (EKG) (P Duration, PR Interval, QRS Interval, QT Interval) during treatment.|Change from baseline on clinical labs (Sodium, Potassium, Chloride) during treatment.|Change from baseline on blood pressure (systolic and diastolic) during treatment.|Change from baseline on the Dosage Record Treatment Emergent Symptom Scale (DOTES) during treatment.|Change from baseline in Overt Aggression Scale (OAS) during treatment.|Baseline vasopressin concentration predicting primary and secondary behavioral outcome measures.",Stanford University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),All,6 Years to 17 Years   (Child),Phase 2|Phase 3,100.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IRB-39972|1R01HD091972,2018-02-20,2024-04-01,2024-07-01,2017-07-02,,2021-10-05,"Stanford University, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT03204786
214,215,NCT03597477,Procedure Sedation With Dexmedetomidine in Children With Autism Spectrum Disorders During Magnetic Resonance Imaging,,Completed,No Results Available,Autism Spectrum Disorder,Drug: Dexmedetomidine,The 50% and 95% effective doses of intranasal dexmedetomidine|sedation induction time|Wake -up time,Guangzhou Women and Children's Medical Center,All,2 Years to 12 Years   (Child),,136.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Intranasal dexmedetomidine,2018-07-16,2020-09-17,2020-09-18,2018-07-24,,2021-02-25,"Guangzhou Women and Children Medical Center, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT03597477
219,220,NCT00811083,Dimercaptosuccinic Acid (DMSA) Treatment of Children With Autism and Heavy Metal Toxicity,,Completed,No Results Available,Autism,Drug: DMSA - dimercaptosuccinic acid,"Determine the effect of DMSA therapy on the symptoms of autism|Determine the safety of DMSA therapy by pre/post assessment of complete blood count, standard chem panel including liver/kidney function, and excretion of essential minerals|Determine if the initial severity of autism correlates with the excretion of toxic metals",Southwest College of Naturopathic Medicine,All,3 Years to 8 Years   (Child),Phase 1|Phase 2,80.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",DMSA,2005-05-01,2007-04-01,2007-04-01,2008-12-18,,2008-12-18,"Southwest College of Naturopathic Medicine, Tempe, Arizona, United States",,https://ClinicalTrials.gov/show/NCT00811083
220,221,NCT01881737,A Study of Pregnenolone in the Treatment of Individuals With Autism,,Completed,Has Results,Autistic Disorder,Drug: Pregnenolone,"Number of Participants With Adverse Events According to Dosage Record and Treatment Emergent Symptom (DOTES) as Assessed at All Follow-up Visits (2, 4, 6, 8, 10, 12, and 16 Weeks)|Social Responsiveness Scale (SRS) Total Score|Sensory Profile Questionnaire Total Score|Vineland Adaptive Behavior Scale|Repetitive Behavior Scale|Pregnenolone Level in Peripheral Blood as Measured at Baseline and After 12 Weeks",Stanford University,All,18 Years to 45 Years   (Adult),Phase 2,15.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SU-08092011-8246,2011-07-01,2013-09-01,2013-09-01,2013-06-20,2017-03-29,2017-03-29,"Stanford University School of Medicine, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT01881737
222,223,NCT01372449,A Multi-site Double-blind Placebo-controlled Trial of Memantine Versus Placebo in Children With Autism (MEM),,Completed,No Results Available,Autism Spectrum Disorder,Drug: Memantine|Drug: Placebo,Developmental Neuropsychological Assessment (NEPSY) Apraxia and Repetition of Nonsense Words Subtests|Expressive Vocabulary Test (EVT)|Vineland Adaptive Behavior Scale - Revised|Safety Monitoring Uniform Research Form,"Evdokia Anagnostou|Icahn School of Medicine at Mount Sinai|Rush University Medical Center|Nationwide Children's Hospital|Anagnostou, Evdokia, M.D.",All,6 Years to 12 Years   (Child),Phase 2,23.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",111576,2011-12-01,2015-10-01,2015-10-01,2011-06-14,,2017-03-20,"Rush University Medical Center, Chicago, Illinois, United States|Mount Sinai School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01372449
227,228,NCT01171937,Risperidone Treatment In Children With Autism Spectrum Disorder And High Levels Of Repetitive Behavior,ProjectV,Completed,No Results Available,Autism,Drug: Risperidone|Drug: Placebo,Aberrant Behavior Checklist,"University of California, Los Angeles|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,8 Years to 16 Years   (Child),Phase 2,41.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-06-033|P50HD055784,2008-09-01,2016-09-01,2016-12-01,2010-07-29,,2017-05-03,"UCLA, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT01171937
232,233,NCT00263796,An fMRI Study of the Effect of Intravenous Oxytocin vs. Placebo on Response Inhibition and Face Processing in Autism,,Completed,No Results Available,Autism,Drug: Oxytocin|Drug: Placebo,Change in BOLD with oxytocin infusion,"Anagnostou, Evdokia, M.D.",All,18 Years to 50 Years   (Adult),Phase 1,16.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",GCO # 04-0749 (2),2006-03-01,2010-10-01,2012-09-01,2005-12-09,,2014-04-30,"Mount Sinai School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00263796
238,239,NCT02940574,Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders,,Completed,Has Results,Autism Spectrum Disorders,Drug: Syntocinon (Oxytocin)|Other: Placebo (Physiological water (solution of sodium chloride (NaCl) in water)),"Change From Baseline in Brain Activity During Task (Task-based fMRI) After a Single Dose of Nasal Spray|Change From Baseline in Brain Activity During Task (Task-based fMRI) After 4 Weeks of Nasal Spray|Change From Baseline in Brain Activity During Task (Task-based fMRI) After 8 Weeks, Including 4 Weeks Without Nasal Spray|Change From Baseline in Brain Activity During Task (Task-based fMRI) After 52 Weeks, Including 48 Weeks Without Nasal Spray|Change From Baseline in Brain Connectivity During Rest (Resting-state fMRI) After a Single Dose of Nasal Spray|Change From Baseline in Brain Connectivity During Rest (Resting-state fMRI) After 4 Weeks of Nasal Spray|Change From Baseline in Brain Connectivity During Rest (Resting-state fMRI) After 8 Weeks, Including 4 Weeks Without Nasal Spray|Change From Baseline in Brain Connectivity During Rest (Resting-state fMRI) After 52 Weeks, Including 48 Weeks Without Nasal Spray|Change From Baseline in Performance on the Emotion Recognition Task (Accuracy/Reaction Time) After a Single Dose of Nasal Spray|Change From Baseline in Performance on the Emotion Recognition Task (Accuracy/ Reaction Time) After 4 Weeks of Nasal Spray|Change From Baseline in Performance on the Emotion Recognition Task (Accuracy/ Reaction Time) After 8 Weeks (Including 4 Weeks Without Nasal Spray)|Change From Baseline in Performance on the Emotion Recognition Task (Accuracy/ Reaction Time) After 52 Weeks (Including 48 Weeks Without Nasal Spray)|Change From Baseline in Informant-based/ Self-report Scores on Questionnaires Assessing Attachment, Social Functioning, Quality of Life and Mood After 4 Weeks of Nasal Spray|Change From Baseline in Informant-based/ Self-report Scores on Questionnaires Assessing Attachment, Social Functioning, Quality of Life and Mood After 8 Weeks, Including 4 Weeks Without Nasal Spray|Change From Baseline in Informant-based/ Self-report Scores on Questionnaires Assessing Attachment, Social Functioning, Quality of Life and Mood After 52 Weeks, Including 48 Weeks Without Nasal Spray|Change From Baseline in Scores on Questionnaire Assessing Mood After a Single Dose of Nasal Spray",KU Leuven|The Branco Weiss Fellowship|Research Foundation Flanders,Male,18 Years to 40 Years   (Adult),Phase 4,40.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",S56327|2014-000586-45,2015-04-01,2016-12-01,2019-12-01,2016-10-21,2020-02-13,2021-02-10,,,https://ClinicalTrials.gov/show/NCT02940574
245,246,NCT04294290,Open Label Phase I hCT-MSC in Toddlers With Autism Spectrum Disorder,TACT,Recruiting,No Results Available,Autism Spectrum Disorder,Biological: hCT-MSC infusion,Safety of hCT-MSC infusion as measured by incidence of infusion reactions|Safety of hCT-MSC infusion as measured by severity of infusion reactions|Safety of hCT-MSC infusion as measured by incidence of product-related infections|Safety of hCT-MSC infusion as measured by severity of product-related infections|Safety of hCT-MSC infusion as measured by evidence of alloimmunization via anit-HLA antibodies|Safety of hCT-MSC infusion as measured by incidence of graft vs. host disease|Safety of hCT-MSC infusion as measured by severity of graft vs. host disease|Safety of hCT-MSC infusion as measured by incidence of unexpected adverse events|Safety of hCT-MSC infusion as measured by severity of unexpected adverse events|Change in PDD Behavior Inventory Autism Composite Score (PDDBI)|Change in mean of the Socialization Subscale and Communication Subscale standard scores on the Vineland Adaptive Behavior Scales (VABS-3)|Change in Clinical Global Impression Scale (CGI)|Change in Communicative Development Inventories (CDI-2)|Change in attention abilities as assess via eye-tracking|Change in brain activity as measured by EEG,Duke University|The Marcus Foundation,All,18 Months to 48 Months   (Child),Phase 1,12.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00104460,2021-02-24,2022-12-01,2022-12-01,2020-03-04,,2021-03-19,"Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04294290
247,248,NCT01887132,A Trial of the Drug Donepezil for Sleep Enhancement and Behavioral Change in Children With Autism,,Terminated,Has Results,Autism Spectrum Disorders,Drug: Donepezil|Drug: Placebo,"Nonverbal Developmental Quotient (NVDQ)|REM Percentage at Baseline, 6, 12 and 18 Months",National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC),All,24 Months to 50 Months   (Child),Phase 2,5.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,130164|13-M-0164,2013-06-01,2015-12-01,2015-12-01,2013-06-26,2017-09-25,2017-09-25,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01887132
249,250,NCT01908205,Intranasal Oxytocin for the Treatment of Children and Adolescents With Autism Spectrum Disorders (ASD),OXY-R,Completed,Has Results,Autism Spectrum Disorder,Drug: Intranasal Oxytocin|Drug: Placebo,Efficacy of Intranasal Oxytocin vs. Placebo on Measures of Social Function|Efficacy of Intranasal Oxytocin vs. Placebo on Measures of Social Cognition|Number of Participant Considered Social Responders|Efficacy of Intranasal Oxytocin vs. Placebo on Measures of Repetitive Behaviors|Efficacy of Intranasal Oxytocin vs. Placebo on Measures of Anxiety|Efficacy of Intranasal Oxytocin vs. Placebo on Measures of Quality of Life|Number of Participant Considered Overall Responders|Safety and Tolerability of Intranasal Oxytocin in Children and Adolescents With ASD,"Evdokia Anagnostou|United States Department of Defense|Anagnostou, Evdokia, M.D.",All,10 Years to 17 Years   (Child),Phase 2,60.0,Other|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",OXY-R07-2013,2013-09-01,2015-09-01,2016-03-01,2013-07-25,2020-11-16,2020-11-16,"University of Minnesota, Minneapolis, Minnesota, United States|Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01908205
250,251,NCT02627131,Autologous Bone Marrow Stem Cell Therapy for Autism,,Completed,No Results Available,Autistic Disorder,Biological: Autologous Bone Marrow Mononuclear Cells,Change in Total Score of Childhood Autism Rating Scale (CARS)|Number of adverse events,Vinmec Healthcare System,All,3 Years to 16 Years   (Child),Phase 2,24.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TBG 003,2014-04-01,2015-12-01,2015-12-01,2015-12-10,,2015-12-10,"Vinmec International Hospital, Hanoi, Vietnam",,https://ClinicalTrials.gov/show/NCT02627131
252,253,NCT03538431,Improving Driving in Young People With Autism Spectrum Disorders,,Completed,Has Results,Autism Spectrum Disorder,Drug: Buspirone,Driving Performance - Measured by Mean Off-Road Glance Duration|Heart Rate,Massachusetts General Hospital|Massachusetts Institute of Technology,All,18 Years to 24 Years   (Adult),Phase 4,26.0,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,2018-P-000900,2018-10-31,2019-12-16,2019-12-16,2018-05-29,2021-03-18,2021-03-18,"Massachusetts General Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT03538431/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03538431
256,257,NCT02508259,"University of California, San Diego (UCSD) Suramin Autism Treatment-1 (SAT1) Trial",SAT1,Completed,Has Results,Autism Spectrum Disorders,Drug: Suramin|Drug: Saline,"Autism Diagnostic Observation Schedule, 2nd Edition (ADOS2)|Expressive Language|Aberrant Behavior Checklist (ABC)|Autism Treatment Evaluation Checklist (ATEC)|The Clinical Global Impression - Improvement Scale (CGI-I)|Repetitive Behavior Questionnaire","University of California, San Diego",Male,4 Years to 17 Years   (Child),Phase 1|Phase 2,10.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",15-0134,2015-05-01,2016-03-01,2016-04-01,2015-07-24,2019-07-16,2019-07-16,"University of California, San Diego School of Medicine, La Jolla, California, United States",,https://ClinicalTrials.gov/show/NCT02508259
258,259,NCT01417026,Intranasal Oxytocin and Learning in Autism,,Completed,Has Results,Autism Spectrum Disorders,Drug: Intranasal Oxytocin (Trade name: Syntocinon),"Change From Baseline to Post-testing (After Max. 12 Days) on the Part/Whole Identity Test (LFI Skills Battery)|Change From Baseline to Post-testing (After Max. 12 Days) on the Reading the Mind in the Eyes Test (Child Version)|Changes From Baseline to Post-testing (After Max. 12 Days) on the ""Happy Faces"" Measure of Social Attention",Robert Schultz|Children's Hospital of Philadelphia,Male,12 Years to 17 Years   (Child),Phase 2,36.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",11-008241,2011-09-01,2015-04-01,2015-04-01,2011-08-16,2017-03-30,2017-03-30,"The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01417026
263,264,NCT02811627,Predicting Treatment Response to Memantine in Autism Using Magnetic Resonance Spectroscopy,,Completed,No Results Available,Autism Spectrum Disorder,Drug: Memantine|Device: Magnetic Resonance Imaging,Clinical Global Impressions - Improvement|Social Responsiveness Scale (SRS)|General Social Outcomes Measure (GSOM)|Aberrant Behavior Checklist (ABC)|Test of Language Competence,University of Missouri-Columbia,All,"16 Years and older   (Child, Adult, Older Adult)",Early Phase 1,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,2004983HS,2016-06-01,2021-04-01,2021-04-01,2016-06-23,,2021-04-14,"University of Missouri, Columbia, Missouri, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT02811627/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02811627
266,267,NCT04878718,Vancomycin and Fecal Microbiota Transplant in a Single Patient With Autism Spectrum Disorder,,Available,No Results Available,Autism Spectrum Disorder|Autism,Biological: Fecal Microbiota Transplant; Vancomycin,,ProgenaBiome|Topelia Therpeutics,All,"2 Years and older   (Child, Adult, Older Adult)",,,Other,Expanded Access:Individual Patients,,19343,,,,2021-05-07,,2021-09-05,"Ventura Clinical Trials, Ventura, California, United States",,https://ClinicalTrials.gov/show/NCT04878718
268,269,NCT03640156,Modulating Socially Adaptive Mirror System Functioning in Autism by Oxytocin,,Completed,No Results Available,Autism Spectrum Disorder,Drug: Oxytocin|Other: Placebo,Change from baseline in socially adaptive mirroring as measured by TMS|Change from baseline in mirroring of others' actions as measured by TMS|Change from baseline in corticospinal excitability as measured by TMS|Change from baseline in total fixation duration towards the eye region of the model.,KU Leuven,Male,18 Years to 35 Years   (Adult),Phase 3,25.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",S56327c,2018-07-26,2019-12-19,2019-12-19,2018-08-21,,2020-02-05,"Katholieke Universiteit Leuven, Leuven, Belgium",,https://ClinicalTrials.gov/show/NCT03640156
276,277,NCT02493426,Single Dose Intranasal Oxytocin and Cognitive Effects in Autism,,"Active, not recruiting",No Results Available,Autism Spectrum Disorders,Drug: Intranasal Oxytocin|Drug: Placebo,Social Cognition Tasks|Cognitive Rigidity Tasks|Brain Body Physiology measures,University of Minnesota,All,"5 Years to 40 Years   (Child, Adult)",Phase 2,30.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",INOT Challenge,2014-05-01,2020-12-31,2020-12-31,2015-07-09,,2020-01-09,"Center for Neurobehavioral Development, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02493426
280,281,NCT00467818,Omega 3 Fatty Acids in the Treatment of Children With Autism Spectrum Disorders,,Completed,Has Results,Autism,Drug: Omega 3 fatty acids|Other: Placebo,Clinical Global Impression Scale(CGI)- Improvement|Aberrant Behavior Checklist (ABC)|Vineland Adaptive Behavior Scale|Overt Aggression Scale-Modified|Parental Stress Index,"University of Medicine and Dentistry of New Jersey|National Center for Complementary and Integrative Health (NCCIH)|Rutgers, The State University of New Jersey",All,5 Years to 17 Years   (Child),Not Applicable,17.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",0220060238|5R21AT002927,2007-01-01,2010-12-01,2010-12-01,2007-05-01,2020-12-16,2021-01-26,"University Behavioral Health Care Building, UMDNJ-RWJMS, Piscataway, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00467818
281,282,NCT04630847,Familial Fecal Microbiota Transplant for the Treatment of Subjects With Autism Spectrum Disorders,,Not yet recruiting,No Results Available,Autism|Autism Spectrum Disorder,Biological: Fecal Microbiota Transplant,Adverse Events|Serious Adverse Events|ATEC|CARS-2|QoLA|SRS-II|Shannon Diversity Index,ProgenaBiome|Ventura Clinical Trials,All,"2 Years and older   (Child, Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,VCT-1,2021-12-01,2024-06-01,2024-12-01,2020-11-16,,2021-09-05,"ProgenaBiome, Ventura, California, United States",,https://ClinicalTrials.gov/show/NCT04630847
282,283,NCT03434366,Intranasal Ketamine With Dexmedetomidine for the Treatment of Children With Autism Spectrum Disorder,,Recruiting,No Results Available,Autism Spectrum Disorder,Drug: ketamine and dexmedetomidine|Drug: ketamine|Drug: Saline,Autism Diagnostic Interview Revised (ADI-R)|Autism Diagnostic Observation Schedule (ADOS)|autism behavior checklist (ABC)|magnetic resonance spectroscopy(MRS)|Childhood Autism Rating Scale (CARS),Guangzhou Women and Children's Medical Center,All,2 Years to 15 Years   (Child),Phase 2,50.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",intranasal ketamine,2018-01-20,2023-12-30,2023-12-30,2018-02-15,,2020-05-26,"Guangzhou Women and Children Medical Center, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT03434366
285,286,NCT01970345,A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder,,Recruiting,No Results Available,Autism Spectrum Disorder,Drug: IGF-1|Drug: Placebo/saline,Aberrant Behavior Checklist - Social Withdrawal Subscale|Social|Language|Repetitive Behavior|Overall Functional Outcomes|Caregiver Strain,Icahn School of Medicine at Mount Sinai|Autism Science Foundation,All,5 Years to 12 Years   (Child),Phase 2,10.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GCO 13-1206,2014-05-01,2022-05-01,2022-05-01,2013-10-28,,2021-07-15,"Icahn School of Medicine at Mount Sinai, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01970345
290,291,NCT00036244,Synthetic Human Secretin in Children With Autism,,Completed,No Results Available,Autism,Drug: RG1068 (Synthetic Human Secretin),,Repligen Corporation,All,32 Months to 59 Months   (Child),Phase 3,,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,RG1068-04,2002-04-01,,2004-01-01,2002-05-09,,2005-08-05,"Southwest Autism Research Center, Phoenix, Arizona, United States|UCLA Pediatric Neurology, Los Angeles, California, United States|Children's Hospital and Research Center at Oakland, Oakland, California, United States|1st Allergy & Clinical Research Center, Centennial, Colorado, United States|Alachua Family Psychiatry, Gainesville, Florida, United States|Miami Children's Hospital, Miami, Florida, United States|Riley Children's Hospital, Indianapolis, Indiana, United States|The Clinical Trials Center:A Division of Children's Hospital, Metairie, Louisiana, United States|Hardy Healthcare Associates, Hingham, Massachusetts, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|University of Medicine and Dentistry of New Jersey, Newark, New Jersey, United States|Schneider Children's Hospital, New Hyde Park, New York, United States|The Ohio State University, Columbus, Ohio, United States|Children's Biomedical Center of Utah, Sandy, Utah, United States|Puget Sound Neurology, Edmonds, Washington, United States",,https://ClinicalTrials.gov/show/NCT00036244
291,292,NCT02353130,Cortical Metrics Assessment Outcome Measure Development in Autism With Memantine Treatment,,Withdrawn,No Results Available,Autism Spectrum Disorders,Drug: Memantine-XR,cortical metrics (a mathematical plot of tactile responsivity in 3 dimensions)|Clinical Global Impressions - Improvement Score.|PDD-BI SV change 0-8|ABC-SW subscale score 0-8,"University of North Carolina, Chapel Hill",Male,8 Years to 12 Years   (Child),,0.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,14-1996,2015-07-01,2015-12-01,2015-12-01,2015-02-02,,2017-05-08,,,https://ClinicalTrials.gov/show/NCT02353130
303,304,NCT05063656,Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin,,Not yet recruiting,No Results Available,Autism Spectrum Disorder,Drug: Gabapentin,Right Anterior Insula GABA level,"David Cochran|Eagles Autism Foundation|University of Massachusetts, Worcester",All,13 Years to 17 Years   (Child),Phase 4,40.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Gabapentin ASD Trial,2021-11-01,2023-11-01,2023-11-01,2021-10-01,,2021-10-01,"University of Massachusetts Medical School, Worcester, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT05063656
304,305,NCT00036231,Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction,,Terminated,No Results Available,Autism,Drug: RG1068 (Synthetic Human Secretin),,Repligen Corporation,All,32 Months to 59 Months   (Child),Phase 3,,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,RG1068-03,2002-04-01,,,2002-05-09,,2005-11-21,,,https://ClinicalTrials.gov/show/NCT00036231
305,306,NCT05067582,"A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder",,Not yet recruiting,No Results Available,Autism Spectrum Disorder|Autism,Drug: L1-79,"Vineland Adaptive Behavior Scale, Third Edition (Vineland-3), Average of the Growth Scale Value (GSV) score of the three Socialization Subdomains (combined)|Brief Observation of Social Communication Change (BOSCC)|Clinical Global Impression of Severity of Illness (CGI-S) weighted for socialization|Clinical Global Impression of Change (CGI-C) weighted for socialization|Percent of subjects showing a statistically significant improvement in GSV on 2 of the Socialization Subdomains|Caregiver Global Impression of Change of 3 Most Bothersome Symptoms of ASD (CGI-3P)|Social Responsiveness Scale, Second Edition (SRS-2) Social-Communication and Interaction - DSM-5 Composite T-score|Social Responsiveness Scale, Second Edition (SRS-2) Total T-score|Social Responsiveness Scale, Second Edition (SRS-2) Social Motivation T-score|Vineland-3 Socialization Domain, Standard Score|Parent-rated Anxiety Scale for ASD (PRAS-ASD)|Child's Sleep Habits Questionnaire (CSHQ)",Yamo Pharmaceuticals LLC,All,"12 Years to 21 Years   (Child, Adult)",Phase 2,50.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Y202,2021-10-01,2023-02-01,2023-03-01,2021-10-05,,2021-10-05,,,https://ClinicalTrials.gov/show/NCT05067582
307,308,NCT01962870,The Role of Vasopressin in the Social Deficits of Autism,,Completed,Has Results,Autism Spectrum Disorders,Drug: Vasopressin|Drug: Placebo,"Change From Baseline in Parent Rated Social Responsiveness Scale, 2nd Edition (SRS-2) T-Score After Treatment.|Change From Baseline in Clinical Global Impression (CGI) Severity, Social and Communication Scores During Treatment.|Change From Baseline in Reading the Mind in the Eyes Test, Child Version (RMET-child) Scores During Treatment.|Change From Baseline in Laboratory Based Facial Emotion Recognition Abilities During Treatment.|Change From Baseline in Parent Rated Repetitive Behavior Scale Revised (RBS-R) Scores During Treatment.|Change From Baseline in Parent Rated Spence Children's Anxiety Scale (SCAS) During Treatment.|Number of Participants With Side Effects Assessed Using Parent Rated Dosage Record Treatment Emergent Symptom Scale (DOTES) Scores During Treatment|Change From Baseline on the Overt Aggression Scale (OAS) During Treatment.|Change From Baseline in Heart Rate After Treatment.|Change From Baseline in Parent Rated Aberrant Behavior Checklist (ABC) Scores During Treatment.|Change From Baseline in Parent Rated Pediatric Quality of Life (PedQL) Inventory Scores During Treatment.|Change From Baseline in Parent Rated Vineland Adaptive Behavior Scales Second Edition (VABS-II) - Social and Communication Subscales During Treatment.|Change From Baseline in Clinical Chemistry Labs (NA+, K+, Cl-) During Treatment.|Change From Baseline in Laboratory Based Eye-gaze to Social Cues During Treatment.|Change From Baseline in Laboratory Based Social Mimicry Abilities During Treatment.|Change From Baseline in Blood Pressure After Treatment|Change From Baseline in Body Weight After Treatment.|Change From Baseline in Body Temperature After Treatment|Change From Baseline in the Awareness of Social Inference Test Revised (TASIT-R) Scores During Treatment.|Change From Baseline in a Developmental Neuropsychological Assessment, Second Edition. (NEPSY-II) Affect Recognition Scores During Treatment.|Change From Baseline in Plasma Vasopressin Levels During Treatment.",Stanford University|National Institute of Mental Health (NIMH),All,6 Years to 12 Years   (Child),Phase 2,68.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",IRB-26034|R21MH100387-01,2013-12-01,2017-05-30,2017-05-30,2013-10-14,2019-05-24,2019-05-24,"Stanford University School of Medicine; Psychiatry and Behavioral Sciences, Stanford, California, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT01962870/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT01962870/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT01962870
320,321,NCT01288716,Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders,,Completed,No Results Available,Autism Spectrum Disorders,Drug: Arbaclofen,Aberrant Behavior Checklist-Social Withdrawal Subscale,"Seaside Therapeutics, Inc.",All,"5 Years to 21 Years   (Child, Adult)",Phase 2,150.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",209AS208,2011-05-01,2012-08-01,2012-09-01,2011-02-02,,2013-07-31,"Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|University of California-Los Angeles Neuropsychiatric Institute, Los Angeles, California, United States|University of California-Davis, M.I.N.D. Institute, Sacramento, California, United States|Pharmax Research Clinic, Miami, Florida, United States|Lake Mary Pediatrics, Orange City, Florida, United States|Institute for Behavioral Medicine, Smyrna, Georgia, United States|Institute for Juvenile Research, Chicago, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|Boston Children's Hospital, Boston, Massachusetts, United States|University of Massachusetts, Worcester, Massachusetts, United States|University of Missouri, Thompson Research Center for Autism & Neurodevelpmental Disorders, Columbia, Missouri, United States|Seaver Autism Center, Mount Sinai Medical Center, New York, New York, United States|University of North Carolina Neurosciences Hospital, Chapel Hill, North Carolina, United States|Akron Children's Hospital, Akron, Ohio, United States|Cutting Edge Research, Oklahoma City, Oklahoma, United States|Summit Research Network, Portland, Oregon, United States|Suburban Research Associates, Media, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University of Tennessee Medical Group, LeBonheur Children's Hospital, Memphis, Tennessee, United States|Vanderbilt Kennedy Center, Nashville, Tennessee, United States|Red Oaks Psychiatry Associates, P.A., Houston, Texas, United States|Road Runner Research, San Antonio, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01288716
321,322,NCT04655326,Probiotic Therapy for Children and Adults With Autism Spectrum Disorder,,Recruiting,No Results Available,Autism Spectrum Disorder,Biological: Flore,Parent Global Impressions of Autism|Social Responsiveness Scale|Gastrointestinal Symptom Rating Scale,Arizona State University|Sun Genomics,All,"30 Months to 75 Years   (Child, Adult, Older Adult)",Early Phase 1,1000.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STUDY00012299,2020-10-15,2022-10-15,2023-03-15,2020-12-07,,2020-12-07,"Arizona State University, Tempe, Arizona, United States",,https://ClinicalTrials.gov/show/NCT04655326
334,335,NCT02611921,Study of Intranasal Ketamine for Social Impairment in Autism Spectrum Disorder,,Completed,No Results Available,Autism Spectrum Disorder,Drug: Ketamine|Drug: Placebo,Change in Social Withdrawal subscale score of the Aberrant Behavior Checklist (ABC)|Change in the Clinician-rated CGI Improvement scale (CGI-I),"Children's Hospital Medical Center, Cincinnati|Roivant Sciences, Inc.|Cures Within Reach",All,"12 Years to 30 Years   (Child, Adult)",Phase 1,21.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2015-2494,2015-12-22,2018-05-07,2018-05-07,2015-11-23,,2018-10-12,"Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02611921
340,341,NCT02212275,Cortical Metrics in Intervention Trials With Autism Spectrum Disorders,,Withdrawn,No Results Available,Autism Spectrum Disorders,Drug: Dextromethophan,"The difference in the Cortical Metric before and after acute exposure to dextromethorphan (DXM)|Change in the cortical metric|The Cortical Metric|Aberrant Behavior Checklist (ABC) Total Score|Pervasive Developmental Disorders Behavior Inventory - Screening Version Score (PDDBI-SV) Social Deficit Score|Social Responsiveness Scale, Version 2 Total Score (SRS)",Duke University|North Carolina Translational and Clinical Sciences Institute,Male,8 Years to 12 Years   (Child),Phase 2|Phase 3,0.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label),Pro00065239|14-1141,2015-08-01,2016-07-01,2016-07-01,2014-08-08,,2016-08-25,"University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States|Duke Center for Autism and Brain Development, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02212275
350,351,NCT01333072,Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART),BAART,Completed,Has Results,Autistic Disorder,Drug: Aripiprazole|Drug: Risperidone,Changes in the Irritability Subscale of the Larger ABC (Abberent Behavior Checklist) That Occur From Baseline to 10 Weeks,Medical University of South Carolina,All,6 Years to 17 Years   (Child),Phase 4,80.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",R01HD062550-01A1,2011-07-01,2015-08-01,2015-08-01,2011-04-11,2018-09-26,2018-09-26,"Medical University of South Carolina, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT01333072
358,359,NCT03678129,GABA Pathways in Autism Spectrum Disorder (ASD),,Unknown status,No Results Available,Autism Spectrum Disorder,Drug: AZD7325_10|Drug: AZD7325_20|Drug: Placebo,Neurochemical response to GABAergic stimulation.|Functional connectivity measures using resting state functional magnetic resonance imaging.|Brain oscillations under sensory stimulation,King's College London,All,18 Years to 60 Years   (Adult),Not Applicable,100.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",REC 18/WM/0208,2018-12-07,2020-02-15,2021-09-14,2018-09-19,,2019-02-26,"King's College London, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT03678129
360,361,NCT02550912,A Study Evaluating the Effect of Vitamin D on Clinical Outcome in Autistic Children,,Completed,No Results Available,Autism,Drug: Vitamin D3|Other: Placebo,Effect of vitamin D on changes in behavioral measures (Childhood autism rating scale)|Effect of vitamin D on changes in behavioral measures (autism treatment evaluation checklist)|Effect of vitamin D on calcium level|Effect of vitamin D on phosphorous level|Effect of vitamin D on alkaline phosphatase level|Effect of vitamin D on parathyroid hormone level|Effect of vitamin D on liver function test (alanine transaminase and aspartate transaminase)|Effect of vitamin D on kidney function test (Blood urea nitrogen and serum creatinine),Ain Shams University,All,2 Years to 15 Years   (Child),Phase 2,42.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PhD(NO.18),2015-08-01,2016-02-01,2016-03-01,2015-09-16,,2016-07-12,"Faculty of Pharmacy AinShams University, Cairo, Egypt",,https://ClinicalTrials.gov/show/NCT02550912
362,363,NCT03466671,A Trial of TTA-121 on Autism Spectrum Disorder,,"Active, not recruiting",No Results Available,Autism Spectrum Disorder,Drug: TTA-121,Efficacy on autism spectrum social core symptom assessed by social reciprocity score on the Autism Diagnostic Observation Schedule module 4|Efficacy on autism spectrum core symptom assessed by communication score on the Autism Diagnostic Observation Schedule module 4|Efficacy on autism spectrum core symptom assessed by repetitive and restricted behavior score on the Autism Diagnostic Observation Schedule module 4|Efficacy on autism spectrum core symptom assessed by revised algorithm score of social affect on the Autism Diagnostic Observation Schedule module 4|Efficacy on autism spectrum core symptom assessed by revised algorithm of repetitive and restricted behavior score on the Autism Diagnostic Observation Schedule module 4|Efficacy assessed by Clinical Global Impression-Improvement|Efficacy assessed by Clinical Global Impression-Severity|Efficacy assessed by Global Assessment of Functioning|Efficacy assessed by gaze fixation time on social region|Efficacy assessed by quantitative analysis of facial expression,Hamamatsu University|Japan Agency for Medical Research and Development,Male,18 Years to 54 Years   (Adult),Phase 2,144.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",UMIN000031412,2018-02-27,2020-03-16,2020-03-30,2018-03-15,,2019-12-20,"Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan",,https://ClinicalTrials.gov/show/NCT03466671
367,368,NCT04520685,CASCADE: CAnnabidiol Study in Children With Autism Spectrum DisordEr,CASCADE,Recruiting,No Results Available,Autism Spectrum Disorder,Drug: Oral cannabidiol 100mg/mL|Drug: Placebo,"Aberrant Behavior Checklist- 2nd Edition (ABC-2): Irritability subscale raw score|Aberrant Behavior Checklist- 2nd Edition (ABC-2): Lethargy/Social Withdrawal subscale|Aberrant Behavior Checklist- 2nd Edition (ABC-2): Stereotypic Behavior subscale|Aberrant Behavior Checklist- 2nd Edition (ABC-2): Inappropriate Speech subscale|Aberrant Behavior Checklist- 2nd Edition (ABC-2): Hyperactivity/Noncompliance subscale|Anxiety, Depression, and Mood Scale (ADAMS): Total Score|Anxiety, Depression, and Mood Scale (ADAMS): General Anxiety subscale|Anxiety, Depression, and Mood Scale (ADAMS): Social Avoidance subscale|Social Responsiveness Scale - 2nd Edition (SRS-2): total T-score|Ohio Autism Clinical Impressions Scale - Severity (OACIS-S) scale|Ohio Autism Clinical Impressions Scale - Improvement (OACIS-I) scale|Autism Screening Instrument for Educational Planning - 3rd Edition (ASIEP - 3): Interaction Assessment Autism Interaction Score|Repetitive Behavior Scale - Revised (RBS-R)|Brief Rating Inventory of Executive Functioning - 2nd edition (BRIEF-2): Global Executive Functioning Score|Brief Rating Inventory of Executive Functioning - 2nd edition (BRIEF-2): ADHD score|Brief Rating Inventory of Executive Functioning - 2nd edition (BRIEF-2): Index scores|Sleep Clinical Global Impressions - Severity Scale (Sleep CGI-S)|Sleep Clinical Global Impressions - Improvement Scale (Sleep CGI-I)|Autism Family Experience Questionnaire (AFEQ)|NIH Toolbox Scales: Satisfaction with Social Roles and Activities - Short Form 4a|NIH Toolbox Scales: Life Satisfaction - Short Form 8b|NIH Toolbox Scales: Positive Affect - Short Form 4a|Pediatric Quality of Life Inventory (PedsQL) - Core Scale|Pediatric Quality of Life Inventory (PedsQL) - Cognitive Functioning Scale","University of Colorado, Denver",All,5 Years to 17 Years   (Child),Phase 2,70.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",19-2168,2021-11-30,2023-06-01,2023-06-01,2020-08-20,,2021-07-23,"Children's Hospital Colorado, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT04520685
369,370,NCT01788072,INtranasal OXyTocin for the Treatment of Autism Spectrum Disorders,INOXT,Completed,No Results Available,Autism Spectrum Disorder,Drug: Intranasal Oxytocin|Drug: Placebo,Efficacy of intranasal oxytocin vs. placebo on social function in adults with ASD|Efficacy of intranasal oxytocin vs. placebo on a continuous measure of social cognition in adults with ASD|Efficacy of intranasal oxytocin vs. placebo on a continuous measure of social function in adults with ASD|Efficacy of intranasal oxytocin vs. placebo on a continuous measure of social responsiveness in adults with ASD|Safety and tolerability of intranasal oxytocin in adults with ASD|Efficacy of intranasal oxytocin vs. placebo on quality of life|Efficacy of intranasal oxytocin vs. placebo on anxiety,"Evdokia Anagnostou|Holland Bloorview Kids Rehabilitation Hospital|McMaster University|Unity Health Toronto|Anagnostou, Evdokia, M.D.",All,18 Years to 45 Years   (Adult),Phase 2,70.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",INOXT-10-2013,2014-06-01,2017-08-01,2017-10-01,2013-02-11,,2018-01-25,"St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01788072
375,376,NCT03849456,Safety and Tolerability of Cannabidivarin (CBDV) in Children and Young Adults With Autism Spectrum Disorder,,Terminated,No Results Available,Autism Spectrum Disorder,Drug: GWP42006,"Number of Participants Who Experienced Severe Treatment-Emergent Adverse Events (TEAEs)|Change from Baseline in Children's Communication Checklist-2 (CCC-2)|Change from Baseline in Social Responsiveness Scale-2 (SRS-2)|Change from Baseline in Vineland Adaptive Behavior Scales, 3rd Edition (Vineland-3)|Change from Baseline in National Institutes of Health (NIH) Toolbox Cognition Battery|Change from Baseline in Repetitive Behavioral Scale - Revised (RBS-R)|Change from Baseline in Children's Sleep Habits Questionnaire (CSHQ)|Change from Baseline in Aberrant Behavior Checklist (ABC)|Clinical Global Impressions-Improvement (CGI-Improvement)",GW Research Ltd,All,"4 Years to 18 Years   (Child, Adult)",Phase 2,1.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GWND18089,2020-01-07,2020-05-26,2020-05-26,2019-02-21,,2021-05-27,"Clinical Trial Site, Louisville, Kentucky, United States|Clinical Trial Site, Lexington, Massachusetts, United States|Clinical Trial Site, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03849456
376,377,NCT04745026,Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder,,Recruiting,No Results Available,Autism Spectrum Disorder,Drug: GWP42003-P|Drug: Placebo,Change from Screening in Aberrant Behavior Checklist (ABC) Subscale Scores|Change from Day 1 in Vineland Adaptive Behavior Scales-3 (VABS-3) Scores|Change from Day 29 in Clinical Global Impression Improvement (CGI-I) Scores|Change from Screening in Clinical Global Impression Severity (CGI-S) Scores|Number of Participants with Severe Treatment-emergent Adverse Events|Number of Participants with Clinically Significant Clinical Laboratory Parameter Values|Number of Participants with Clinically Significant Vital Sign Values|Number of Participants with Clinically Significant Physical Examination Procedure Findings|Number of Participants with Clinically Significant 12-lead Electrocardiogram Findings|Number of Participants with a Positive Response to Questions Regarding Suicidal Behavior Using the Columbia-Suicide Severity Rating Scale (C-SSRS),GW Research Ltd,All,6 Years to 17 Years   (Child),Phase 2,160.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GWND19189|2020-002819-21,2021-05-04,2023-02-28,2023-03-30,2021-02-09,,2021-06-11,"Clinical Trial Site, Scottsdale, Arizona, United States|Clinical Trial Site, Orlando, Florida, United States|Clinical Trial Site, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT04745026
378,379,NCT03835117,Effect of a Wide Spectrum Nutritional Supplement on Mitochondrial Function in Children With Autism Spectrum Disorder,,Recruiting,No Results Available,Autism Spectrum Disorder,Drug: Wide-spectrum nutritional supplement|Other: Placebo,Change in mitochondrial activity in study patients|Change in the Childhood Autism Rating Scale (CARS) score|Change in the Clinical Global Impression scale (CGI) score|Change in the Children's Yale-Brown Obsessive Compulsive Scale modified for Autism Spectrum Disorder (CYBOCS-ASD) score|Change in the Aberrant Behavior Checklist (ABC) scores|Change in the Parent-rated Anxiety Scale for ASD (PRAS-ASD) score|Change in the Caregiver Strain Questionnaire (CGSQ) score|Change in the Vineland III Caregiver score|Evaluate intervention safety|Evaluate intervention effect on cellular regulatory pathways known to be implicated in ASD|Examine the change in attention to social stimuli|Examine the change in cognitive ability,Phoenix Children's Hospital,All,2 Years to 17 Years   (Child),Phase 2,50.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MITO,2020-02-01,2022-04-01,2022-04-01,2019-02-08,,2021-03-15,"Phoenix Children's Hospital, Phoenix, Arizona, United States",,https://ClinicalTrials.gov/show/NCT03835117
380,381,NCT03537950,Shifting Brain Excitation-Inhibition Balance in Autism Spectrum Disorder,,Unknown status,No Results Available,Autism Spectrum Disorder,Drug: PLC|Drug: CBD|Drug: CBDV,Brain biochemistry response to pharmacological stimulation|Measurement of low frequency brain activity using resting state fMRI|Measurement of brain functional connectivity using resting state fMRI,King's College London,Male,18 Years to 50 Years   (Adult),Not Applicable,38.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",HR15-162744,2016-08-22,2017-02-16,2019-04-27,2018-05-25,,2018-05-25,"King's College London, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT03537950
385,386,NCT02385799,A Trial of Sertraline in Young Children With Autism Spectrum Disorder,Sert2,Completed,Has Results,Autism Spectrum Disorder,Drug: Sertraline Liquid Placebo|Drug: Sertraline,"Change in Mullen Scales of Early Learning - Expressive Language Raw Score|Change in Mullen Scales of Early Learning - Combined Age Equivalent Score|Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) Adaptive Behavior Composite Standard Score|Preschool Anxiety Scale-Revised - Total Score|Preschool Language Scale-Fifth Edition - Total Language Raw Score|Sensory Processing Measure-Preschool - Social Participation Raw Score|Clinical Global Impression Scale-Severity (CGI-S)|Clinical Global Impression Scale-Improvement (CGI-I)|Visual Analog Scale - Language/Communication Score","Randi J. Hagerman, MD|Health Resources and Services Administration (HRSA)|University of California, Davis",All,24 Months to 72 Months   (Child),Phase 2,58.0,Other|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",663866,2015-04-01,2018-07-01,2018-07-01,2015-03-11,2019-05-09,2019-10-22,"UC Davis MIND Institute, Sacramento, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02385799/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02385799
389,390,NCT00996931,Efficacy and Safety of Lenalidomide for Treatment of Autistic Spectrum Disorders,,Completed,Has Results,Autism,Drug: lenalidomide,Change in TNF-alpha Levels|Change in Childhood Autism Rating Scale (CARS)Value From Baseline to 6 Weeks,Sutter Medical Foundation,Male,6 Years to 16 Years   (Child),Phase 2,6.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RV-ASD-CHEZ-0329,2009-02-01,2009-12-01,2009-12-01,2009-10-16,2013-05-29,2013-05-29,,,https://ClinicalTrials.gov/show/NCT00996931
390,391,NCT01039792,Trial of Methyl B12 on Behavioral and Metabolic Measures in Children With Autism,B12,Completed,Has Results,Autistic Disorder,Drug: Methyl B12|Dietary Supplement: Placebo,Clinical Global Impression-Improvement (CGI-I),"University of California, San Francisco|University of California, Davis|Arkansas Children's Hospital Research Institute",All,3 Years to 7 Years   (Child),Phase 2|Phase 3,57.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",Autism Speaks 3031,2010-01-01,2013-10-01,2013-11-01,2009-12-25,2017-02-24,2017-02-24,"UCSF, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT01039792
391,392,NCT04049578,"A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Balovaptan in Children With Autism Spectrum Disorder",,Terminated,Has Results,Autism Spectrum Disorder,Drug: Balovaptan,"Area Under the Curve at Steady State (AUCss) of Balovaptan|Plasma Concentration of Balovaptan|Plasma Concentration of M2 Metabolite, as Applicable|Plasma Concentation of M3 Metabolite|Plasma Concentration Ratio of M2 to Balovaptan, as Applicable|Plasma Concentration Ratio of M3 to Balovaptan|Number of Participants With Adverse Events",Hoffmann-La Roche,All,2 Years to 4 Years   (Child),Phase 1,2.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,WP40877,2019-12-19,2020-04-23,2020-05-06,2019-08-08,2020-10-14,2020-10-14,"Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|Richmond Behavioral Associates, Staten Island, New York, United States|University Hospitals Cleveland Medical Center; Division of Child and Adolescent Psychiatry, Cleveland, Ohio, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Red Oak Psychiatry Associates, PA, Houston, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT04049578/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04049578
392,393,NCT03594552,Modulation of the Brain Excitatory/Inhibitory (E/I) Balance in Autism Spectrum Disorder (ASD),,Unknown status,No Results Available,Autism Spectrum Disorder,Drug: Arbaclofen_15|Drug: Arbaclofen_30|Drug: Placebo,Neurochemical response to GABAergic stimulation.|Functional connectivity measures using resting state functional magnetic resonance imaging.|Brain oscillations under sensory stimulation,King's College London,All,18 Years to 60 Years   (Adult),Not Applicable,100.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",HR16-17 4081,2018-02-01,2019-09-30,2020-02-02,2018-07-20,,2018-07-20,"King's College London, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT03594552
398,399,NCT03589898,Study of Neuroimaging Biomarkers of Social Cognition Deficits in Adolescents (Age 13-17) With Autism Spectrum Disorder and Effects of Gabapentin,,Recruiting,No Results Available,Autism Spectrum Disorder,Drug: Gabapentin,Cortical GABA in Anterior Cingulate Cortex|Cortical GABA in Right Anterior Insula|Cortical Glx in Anterior Cingulate Cortex|Cortical Glx in Right Anterior Insula,"University of Massachusetts, Worcester|National Institute of Mental Health (NIMH)|Johns Hopkins University",All,13 Years to 17 Years   (Child),Early Phase 1,42.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,H00012656|1K23MH113008-01A1,2017-09-14,2022-08-31,2022-08-31,2018-07-18,,2021-09-23,"University of Massachusetts Medical School, Worcester, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03589898
403,404,NCT03156153,A Study of Bumetanide for the Treatment of Autism Spectrum Disorders,,Completed,No Results Available,Autism Spectrum Disorder,Drug: Bumetanide|Drug: Placebo,Childhood Autism Rating Scale(CARS)|Clinical Global Impressions Scale (CGI)|Social Responsiveness Scale (SRS)|Autism Diagnostic Observation Schedule (ADOS)|Short Sensory Profile Report|Symbolic Play Test|Chinese Communicative Development Inventory,"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Shanghai Jiao Tong University School of Medicine",All,3 Years to 6 Years   (Child),Phase 2,120.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",XH-16-048,2017-05-24,2019-07-08,2019-07-10,2017-05-17,,2021-03-01,"Xinhua Hospital, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT03156153
406,407,NCT01706523,Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders,,Terminated,No Results Available,Autism Spectrum Disorders,Drug: STX209 (arbaclofen),Safety and tolerability of STX209|Aberrant Behavior Checklist,"Seaside Therapeutics, Inc.",All,"5 Years to 21 Years   (Child, Adult)",Phase 3,165.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,209AS209,2011-11-01,2013-07-01,2013-07-01,2012-10-15,,2013-07-31,"Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|University of California-Los Angeles Neuropsychiatric Institute, Los Angeles, California, United States|UCDavis M.I.N.D Insitute, Sacramento, California, United States|Pharmax Research Clinic, Miami, Florida, United States|Lake Mary Pediatrics, Orange City, Florida, United States|Institute for Behavioral Medicine, Smyrna, Georgia, United States|Institute for Juvenile Research, Chicago, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|Boston Children's Hospital, Boston, Massachusetts, United States|University of Massachusetts, Worcester, Massachusetts, United States|University of Missouri, Thompson Research Center for Autism & Neurodevelopmental Disorders, Columbia, Missouri, United States|Seaver Autism Center, Mount Sinai Medical Center, New York, New York, United States|NYS Institute for Basic Research in Developmental Disabilities, Staten Island, New York, United States|UNC Chapel Hill Department of Psychiatry, Chapel Hill, North Carolina, United States|Akron Children's Hospital, Akron, Ohio, United States|Cutting Edge Research, Oklahoma City, Oklahoma, United States|Summit Research Network, Portland, Oregon, United States|Suburban Research Associates, Media, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University of Tennessee Medical Group, LeBonheur Children's Hospital, Memphis, Tennessee, United States|Vanderbilt Kennedy Center, Nashville, Tennessee, United States|Red Oaks Psychiatry Associates, P.A., Houston, Texas, United States|Road Runner Research, San Antonio, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01706523
407,408,NCT03504917,A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension,,Terminated,Has Results,Autism Spectrum Disorder,Drug: Balovaptan|Drug: Placebo,"Change From Baseline at Week 24 on the Vineland Adaptive Behavior Scales (Vineland-II) Two-domain Composite (2DC) Score.|Change From Baseline at Week 12 on the Vineland-II 2DC Score|Change From Baseline at Weeks 12 and 24 in the Pediatric Quality of Life (PedsQL) Inventory Generic Core Scales, Version 4.0, on Summary and Total Scores|Change From Baseline at Weeks 12 and 24 in the Vineland-II Adaptive Behavior Composite Standard Score|Change From Baseline at Week 12 and 24 on the Vineland-II Socialization Domain Standard Score|Change From Baseline at Weeks 12 and 24 on the Vineland-II Communication Domain Standard Score|Change From Baseline at Weeks 12 and 24 on the Vineland-II Daily Living Skills Domain Standard Score|Change From Baseline in Severity of Clinical Impressions as Measured by Clinical Global Impression-Severity (CGI-S)|Improvements in Clinical Impressions, as Measured by Clinical Global Impression-Improvement (CGI-I)|Change From Baseline at Weeks 12 and 24 in the Hamilton Anxiety Rating Scale (HAM-A) Total and Domain Scores|Proportion of Subjects With a >=6-point Improvement in Vineland-II 2DC Score|Percentage of Participants With Adverse Events",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,322.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WN39434,2018-08-08,2020-03-04,2020-07-01,2018-04-20,2021-05-07,2021-09-23,"Harmonex Neuroscience Research, Dothan, Alabama, United States|Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|Woodland Research Northwest, LLC, Rogers, Arkansas, United States|University of California , Los Angeles (UCLA); Child, Adolescent Psychiatry, Los Angeles, California, United States|PCSD Feighner Research, San Diego, California, United States|University of California at San Francisco, San Francisco, California, United States|MCB Clinical Research Centers, Colorado Springs, Colorado, United States|Yale University / Yale-New Haven Hospital, New Haven, Connecticut, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|APG- Advanced Psychiatric Group, Orlando, Florida, United States|IMIC Inc., Palmetto Bay, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Uni of Chicago; Centre For Advanced Medicine, Chicago, Illinois, United States|Lake Charles Clinical Trials, LLC, Lake Charles, Louisiana, United States|The Johns Hopkins Hospital, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota, United States|Millennium Psychiatric Associates, LLC, Saint Louis, Missouri, United States|Hapworth Research Inc., New York, New York, United States|Center for Autism and the Developing Brain, New York, New York, United States|Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|University Hospitals, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|UPMC Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center; Department of Psychiatry, Nashville, Tennessee, United States|BioBehavioral Research of Austin, PC, Austin, Texas, United States|Red Oak Psychiatry Associates, PA, Houston, Texas, United States|Aspen Clinical Research, Orem, Utah, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Seattle Children's Hospital, Seattle, Washington, United States|Okanagan Clinical Trials, Kelowna, British Columbia, Canada|Holland Bloorview Kids Rehabilitation Hospital; Autism Research Centre, East York, Ontario, Canada|University of Western Ontario, London, Ontario, Canada|McGill University Health Centre - Glen Site, Montreal, Quebec, Canada|Hopital Charles Perrens; Centre de Ressources Autisme Aquitaine, Bordeaux, France|Hospices Civils de Lyon; Centre d'Investigation Clinique Pédiatrique, LYON Cedex, France|Centre hospitalier du Rouvray; CRAHN Centre de Ressources Autisme Haute-Normandie, Sotteville Les Rouen, France|ASST di Pavia; Dip. di Scienze del Sistema Nervoso e del Comportamento, Pavia, Lombardia, Italy|AUSL di Piacenza; Psichiatria di Collegamento, Piacenza, Lombardia, Italy|ASL TO2; Centro Pilota Regione Piemonte - Dip. Salute Mentale, Torino, Piemonte, Italy|A.O.U. Policlinico - V. Emanuele - P.O. Gaspare Rodolico; Dip. Terapia integrata disturbi resistenti, Catania, Sicilia, Italy|Hospital Mutua de Terrassa; Departamento de Psiquiatria, Terrassa, Barcelona, Spain|Hospital Universitari Vall d'Hebron; Sevicio de Psiquiatría, Barcelona, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Psiquiatria del niño y del adolescente, Madrid, Spain|Hospital Universitario Rio Hortega; Departamento de Psiquiatria, Valladolid, Spain|Western General Hospital; Wellcome Trust CRF, Edinburgh, United Kingdom|Queen Elizabeth University Hospital; Clinical Research Facility, Glasgow, United Kingdom|Kings College Hospital; Kings Clinical Research Facility, London, United Kingdom|RE:Cognition Health; RE:Cognition Health, London, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT03504917/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03504917
409,410,NCT01366885,Vitamin D to Prevent Autism in Newborn Siblings,,Completed,Has Results,Autistic Disorder,Drug: Vitamin D3,Number of Children Who Developed Autism|Number of Mothers Who Developed Side Effects From Vitamin D,Oregon Health and Science University,Female,20 Years to 44 Years   (Adult),Phase 2,20.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,OHSU-AS-11-1-11,2008-02-01,2016-02-01,2016-02-01,2011-06-06,2016-06-14,2016-06-14,"Evergreen Center, Oregon City, Oregon, United States",,https://ClinicalTrials.gov/show/NCT01366885
412,413,NCT02561481,Sulforaphane Treatment of Children With Autism Spectrum Disorder (ASD),,Completed,Has Results,Autism Spectrum Disorder,Drug: Sulforaphane|Drug: Placebo,"Change in Ohio Autism Clinical Impressions Scale - Improvement (OACIS-I) Average Score From Baseline|OACIS-I Response Rate on Aberrant Behaviors Subscale|OACIS-I Response Rate on Social Communication Subscale|Change in Total Aberrant Behavior Checklist Score From Baseline|Change in Total SRS-2 Score From Baseline|Dithiocarbamate Plasma Concentration Detected by Cyclocondensation at Each Visit|Comparison of Free Reduced Glutathione (GSH), Total GSH, Oxidized Glutathione (GSSG) at Week 0 and 15|Free GSH:GSSG and Total GSH:GSSG Ratios at Week 15","University of Massachusetts, Worcester|Congressionally Directed Medical Research Programs|Johns Hopkins University",All,3 Years to 12 Years   (Child),Phase 1|Phase 2,60.0,Other|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",H00007832|AR140087,2015-12-01,2018-12-01,2020-01-01,2015-09-28,2020-11-25,2020-12-17,"University of Massachusetts Medical School, Worcester, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT02561481/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT02561481/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02561481
416,417,NCT00609531,Functional MRI Evaluation of the Effect of Citalopram in Autism Spectrum Disorders,,Completed,No Results Available,Autism Spectrum Disorders,Drug: Citalopram|Drug: Placebo,Functional Magnetic Resonance Imaging|Clinicians Global Improvement Scale|Childrens Yale-Brown Obsessive Compulsive Scale,"University of North Carolina, Chapel Hill|National Institute of Mental Health (NIMH)",All,"10 Years to 55 Years   (Child, Adult)",Phase 1,12.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)",04-0975|NIH/NCRR K12 RR023248|The Dana Foundation|K23MH081285,2007-01-01,2009-08-01,2009-08-01,2008-02-07,,2012-10-08,"UNC-Chapel Hill, Chapel Hill, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00609531
420,421,NCT03664232,"A Study to Investigate the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Participants With Autism Spectrum Disorder",Envision,Recruiting,No Results Available,Autism Spectrum Disorder,Drug: JNJ-42165279|Drug: Placebo,Change from Baseline in the Autism Behavior Inventory (ABI) Core Domain Score to Day 85|Change from Baseline in ABI Social Communication Domain Score to Day 85|Change from Baseline in ABI Repetitive/Restrictive Behavior (RRB) Domain Score to Day 85|Change from Baseline in the ABI Mood and Anxiety Domain Score to Day 85|Change from Baseline in the ABI Challenging Behavior Domain Score|Change from Baseline in the ABI Self-Regulation Domain Score|Change from Baseline in the Aberrant Behavior Checklist (ABC) Subscales|Change from Baseline in the Autism Behavior Inventory-Short Form (ABI-S) Scale Domains|Change from Baseline in the Autism Behavior Inventory-Clinician Interview (ABI-C) Domains|Change from Baseline in the Clinical Global Impression-Severity (CGI-S) Scale Score|Change from Baseline in the Repetitive Behavior Scale - Revised (RBS-R) Scale Score|Change from Baseline in the Zarit Burden Interview (ZBI) Scale Score|Change from Baseline in the Child Adolescent Symptom Inventory - Anxiety (CASI-Anx) Scale Score|Change from Baseline in the Social Responsiveness Scale 2 (SRS-2) Score|Change from Baseline in the Caregiver Global Impression of Severity (Caregiver GI-S)|Caregiver Assessment of Treatment Score|Self Global Impression of Improvement (Self GI-I) Score|Clinical Global Impression-Improvement (CGI-I),"Janssen Research & Development, LLC",All,"13 Years to 35 Years   (Child, Adult)",Phase 2,80.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CR108275|42165279AUT2001,2018-11-07,2022-03-28,2022-06-24,2018-09-10,,2021-09-20,"Harmonex Neuroscience Research, Dothan, Alabama, United States|Southwest Autism Research and Resource Center, Phoenix, Arizona, United States|NRC Research Institute, Orange, California, United States|APG Research, LLC, Orlando, Florida, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Sheppard Pratt Health System, Baltimore, Maryland, United States|New York Presbyterian Hospital, New York, New York, United States|Nathan Kline Institute, Orangeburg, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|BioBehavioral Research of Austin, PC, Austin, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT03664232
421,422,NCT02551380,Folinic Acid in Children With Autism Spectrum Disorders,EFFET,Unknown status,No Results Available,Autism Spectrum Disorder,Drug: FOLINORAL|Other: Placebo,Evaluation of severity of autistic symptoms with standardized scale ADOS (Autism Diagnosis Observation Scale)|Evaluation of the reduction of autistic symptom perceived by parents with a heteroevaluation scale : SRS (social responsiveness scale)|evaluate the constancy of auto antibodies anti-FRα,"Central Hospital, Nancy, France",All,3 Years to 10 Years   (Child),Phase 2,40.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,2015-000955-25,2015-10-01,2018-01-01,2018-01-01,2015-09-16,,2017-04-07,"CHU Nancy-Hopital Brabois Enfants, Vandoeuvre les Nancy, France",,https://ClinicalTrials.gov/show/NCT02551380
430,431,NCT01028820,FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders,AripfMRI,Completed,Has Results,Autism Spectrum Disorder,Drug: Aripiprazole,Baseline and Week 8scores on Children's Yale-Brown Obsessive Compulsive Scale - Pervasive Developmental Disorder Version|Total Repetitive Behavior Scale - Revised (RBS_R),"University of North Carolina, Chapel Hill|Duke University|National Institute of Mental Health (NIMH)",All,"10 Years to 55 Years   (Child, Adult)",Phase 4,13.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,090795|K23MH081285,2009-08-01,2011-01-01,2011-01-01,2009-12-09,2014-03-11,2014-03-11,"University of North Carolina, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01028820
433,434,NCT02487082,Pilot Study of Sleep Therapy and Biomarkers in Children With Autism Spectrum Disorders,,Terminated,No Results Available,Autism Spectrum Disorder,Drug: Melatonin and Donepezil|Other: Placebo,Lethargy/Social Withdrawal|Stereotypic Behavior|Sleep quality|Clinician Global improvement|Parent Global improvement,Stony Brook University,All,4 Years to 17 Years   (Child),Phase 2,12.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",65708,2015-06-01,2020-12-31,2021-01-29,2015-07-01,,2021-04-28,"Stony Brook University, Stony Brook, New York, United States",,https://ClinicalTrials.gov/show/NCT02487082
434,435,NCT01308749,A Study of Oxytocin in Children and Adolescents With Autistic Disorder,Oxytocin,Completed,Has Results,Autism,Drug: Oxytocin|Drug: Placebo,Number of Participants Who Could Tolerate Twice Daily Oxytocin|Change in Mean Plasma Oxytocin Level During Period 1 - Double Blind Phase|Change in Mean Weight|Change in Mean Total Social Social Responsiveness Scale (SRS) T-score|Change in Mean Autism Diagnostic Observation Schedule (ADOS) Total Score|Change in Mean Aberrant Behavior Checklist (ABC)-Social Withdrawal Subscale Score Over Both Periods|Change in Mean Pervasive Developmental Disorder Behavior Inventory - Screening Version (PDDBI-SV) Total Score Over Both Periods|Change in Mean Systolic Blood Pressure During Period 1|Mean Change in Prolactin Levels Over Period 1|Mean Change in Temperature During Period 1,"University of North Carolina, Chapel Hill|Autism Speaks",All,3 Years to 17 Years   (Child),Phase 2,25.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",11-0493,2011-03-01,2013-04-01,2013-04-01,2011-03-04,2017-07-17,2017-07-17,"University of North Carolina Chapel Hill, Chapel Hill, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01308749
447,448,NCT04895215,AB-2004 in Treatment of Adolescents With Irritability Associated With Autism Spectrum Disorder (ASD),,Recruiting,No Results Available,Autism Spectrum Disorder (ASD),Drug: AB-2004|Drug: Placebo,The mean change in the ABC-I score (Irritability) from Baseline to Week 8 for AB-2004 High Dose|The mean change in the ABC-I score (Irritability) from Baseline to Week 8 for AB-2004 Low Dose|The mean change in the Clinical Global Impression-Severity (CGI-S) from Baseline to Week 8 for AB-2004 High Dose and AB-2004 Low Dose|Number of participants who reported treatment emergent adverse events (TEAEs),"Axial Therapeutics, Inc.",All,13 Years to 17 Years   (Child),Phase 2,195.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",AXL-2004-002,2021-08-02,2022-12-01,2023-06-01,2021-05-20,,2021-08-20,"Axial Therapeutics, Woburn, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04895215
449,450,NCT02901431,A Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Participants With Autism Spectrum Disorder (ASD),,Terminated,Has Results,Autism Spectrum Disorder,Drug: Placebo|Drug: RO5285119,"Change From Baseline in Vineland™-II Adaptive Behavior Scale Two Domain Composite (2DC) Score at Week 24 for Balovaptan (R05285119) 10 mg Equivalent Compared to Placebo|Change From Baseline in Vineland™-II Composite Standard Score After 12 Weeks and 24 Weeks of Treatment for Balovaptan (R05285119) 10 mg Equivalent Compared to Placebo|Change From Baseline in Vineland™-II Adaptive Behavior Scale Communication, Socialization, and Daily Living Skills Domain Standard Scores at Weeks 12 and 24 for Balovaptan (R05285119) 10 mg Equivalent Compared to Placebo|Proportion of Subjects With >=6 Points Improvement in the Vineland-II 2DC Score for Balovaptan (R05285119) 10 mg Equivalent Compared to Placebo|Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Score at Weeks 12 and 24 for Balovaptan (R05285119) 10 mg Equivalent Compared to Placebo|Change From Baseline in Ohio Autism Clinical Impressions Scale-Severity (OACIS-S) Score at Weeks 12 and 24 for Balovaptan (R05285119) 10 mg Equivalent Compared to Placebo|Clinical Global Impressions- Improvement (CGI-I) Score at Weeks 12 and 24 for Balovaptan (R05285119) 10 mg Equivalent Compared to Placebo|Ohio Autism Clinical Impressions Scale- Improvement (OACIS-I) Score at Weeks 12 and 24 for Balovaptan (R05285119) 10 mg Equivalent Compared to Placebo|Change From Baseline in Patient-Reported Pediatric Quality of Life (PedsQL) v4.0 Generic Core Scale After 12 Weeks and 24 Weeks of Treatment for Balovaptan (R05285119) 10 mg Equivalent Compared to Placebo|Change From Baseline in Vineland-II Composite Standard Score in Adolescents and Children Independently at Weeks 12 and 24 for Balovaptan (R05285119) 10 mg Equivalent Compared to Placebo|Change From Baseline in Vineland-II Adaptive Behavior Scale 2DC Score at Week 12 for Balovaptan (R05285119) 10 mg Equivalent Compared to Placebo|Percentage of Participants With Adverse Events for Treatment With Balovaptan",Hoffmann-La Roche,All,5 Years to 17 Years   (Child),Phase 2,339.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP30153,2016-11-21,2020-04-15,2020-06-30,2016-09-15,2021-02-08,2021-02-08,"Harmonex Neuroscience Research, Dothan, Alabama, United States|Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|NRC Research Institute, Orange, California, United States|PCSD Feighner Research, San Diego, California, United States|University of California at San Francisco, San Francisco, California, United States|Children's Hospital of Colorado, Aurora, Colorado, United States|DBA IMMUNOe Int'l Res Center, Centennial, Colorado, United States|Yale University / Yale-New Haven Hospital, New Haven, Connecticut, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|Segal trials, North Miami, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|APG- Advanced Psychiatric Group, Orlando, Florida, United States|USF Rothman Center, Saint Petersburg, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Capstone Clinical Research, Libertyville, Illinois, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Boston Childrens Hospital, Boston, Massachusetts, United States|Massachusetts General Hospital; Lurie Center for Autism, Lexington, Massachusetts, United States|UMASS Medical School, Worcester, Massachusetts, United States|University of Minnesota; Clin. Neuro Research Unit, Minneapolis, Minnesota, United States|St. Charles Psychiatric Associates, Saint Charles, Missouri, United States|Midwest Childrens Health Research Institute, Lincoln, Nebraska, United States|Albert Einstein College of Medicine, Bronx, New York, United States|Center for Autism and the Developing Brain, New York, New York, United States|Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States|University of Rochester, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|DUKE SCHOOL OF MEDICINE;Duke Center for Autism and Brain Development, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|University Hospitals, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Suburban Research Associates, Media, Pennsylvania, United States|Children's Hospital of Philadelphia;Allergy/Immunology Department, Philadelphia, Pennsylvania, United States|UPMC Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|BioBehavioral Research of Austin, PC, Austin, Texas, United States|Relaro Medical Trials, Dallas, Texas, United States|Red Oak Psychiatry Associates, PA, Houston, Texas, United States|Road Runner Research, San Antonio, Texas, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Pacific Institute of Medical Sciences, Bothell, Washington, United States|Core Clinical Research, Everett, Washington, United States|Seattle Children's Research Institute; Psychiatry and Behavioral Medicine, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT02901431/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT02901431/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02901431
452,453,NCT02176317,Autologous Umbilical Cord Blood Infusion for Children With Autism Spectrum Disorder (ASD),,Completed,No Results Available,Autism Spectrum Disorder,Biological: Autologous Umbilical Cord Blood,Number of participants with non-serious and serious adverse events.|The primary efficacy measure will be change in the Vineland Adaptive Behavior Scale- II,"Duke University|The Marcus Foundation|PerkinElmer, Inc.",All,24 Months to 72 Months   (Child),Phase 1,25.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00052449,2014-06-01,2015-12-01,2015-12-01,2014-06-27,,2019-12-03,"Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02176317
456,457,NCT05013164,Role of Folinic Acid in Improving the Adaptive Skills and Language Impairment in Children With Autism Spectrum Disorder,,Completed,No Results Available,Autism Spectrum Disorder,Drug: Folinic Acid,To determine the role of folinic acid in improving the speech and adaptive skills among children with autism spectrum disorders|To dertermine improvement of stereotype movements and hyperactivity in children with autism spectrum disorders,Nishtar Medical University,All,3 Years to 14 Years   (Child),Phase 2,44.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ICHMultan,2020-10-01,2021-03-30,2021-03-30,2021-08-19,,2021-08-24,"Children's Hospital and Institute of Child Health, Multan, Punjab, Pakistan",,https://ClinicalTrials.gov/show/NCT05013164
462,463,NCT02081027,Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders,,Completed,No Results Available,Autism Spectrum Disorders,Drug: Riluzole|Other: placebo,Clinical Global Impression-Improvement|Aberrant Behavior Checklist- Irritability,"Children's Hospital Medical Center, Cincinnati",All,"12 Years to 25 Years   (Child, Adult)",Early Phase 1,8.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science",CIN001- Riluzole in Autism,2013-09-19,2015-04-01,2015-05-01,2014-03-07,,2021-01-14,"Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02081027
466,467,NCT00846547,Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders,,Completed,Has Results,Autism Spectrum Disorders,Drug: Arbaclofen,"Irritability Subscale of the Aberrant Behavior Checklist, Community Version","Seaside Therapeutics, Inc.",All,6 Years to 17 Years   (Child),Phase 2,32.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,22003,2009-02-01,2010-06-01,2010-09-01,2009-02-18,2013-06-14,2013-06-14,"Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|University of California-Los Angeles Neuropsychiatric Institute, Los Angeles, California, United States|Yale Child Study Center, New Haven, Connecticut, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|University of North Carolina Neurosciences Hospital, Chapel Hill, North Carolina, United States|Vanderbilt Kennedy Center, Nashville, Tennessee, United States|Red Oaks Psychiatry Associates, PA, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00846547
468,469,NCT02414503,Effects of Intranasal Administration of a Single Dose of Oxytocin Using a Novel Device in Adults With Autism Spectrum Disorder,,Completed,No Results Available,Autism Spectrum Disorder,Drug: 8IU intranasal oxytocin|Drug: 24IU intranasal oxytocin|Drug: Placebo|Device: OptiNose Breath Powered Bi,Performance on an emotion sensitivity test|Performance on a facial emotion morphing task|Performance on the reading the mind in the eyes test|Performance on an emotional dot probe task|Heart rate variability|Eyetracking,OptiNose AS|Oslo University Hospital|University of Oslo,Male,18 Years to 35 Years   (Adult),Phase 1|Phase 2,17.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",SMR-2728|2014-005452-26,2015-04-01,2016-02-01,2016-02-01,2015-04-10,,2016-09-27,"NORMENT, KG Jebsen Centre for Psychosis Research - TOP Study, Oslo, Norway",,https://ClinicalTrials.gov/show/NCT02414503
469,470,NCT04258839,Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148,,Enrolling by invitation,No Results Available,Irritability Associated With Autism Spectrum Disorder,Drug: Brexpiprazole,Adverse Events|Aberrant Behavior Checklist (ABC-I)|Clinical Global Impression (CGI-S),"Otsuka Pharmaceutical Development & Commercialization, Inc.|H. Lundbeck A/S",All,5 Years to 17 Years   (Child),Phase 3,100.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,331-201-00191,2020-01-17,2022-08-20,2022-08-20,2020-02-06,,2020-05-28,"For additional information regarding sites, Princeton, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT04258839
470,471,NCT02255565,Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study,,Completed,Has Results,ADHD|Autism,Drug: Very Low Dose Quillivant XR|Drug: Low Dose Quillivant XR|Drug: Moderate Dose Quillivant XR,ADHD Rating Scale - IV|Clinical Global Impressions-ADHD - Severity|Clinical Global Impression - Improvement (CGI-I),Seattle Children's Hospital|Pfizer,All,5 Years to 16 Years   (Child),Phase 4,36.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,WI185890,2014-09-01,2016-09-01,2016-10-01,2014-10-02,2017-06-05,2017-08-01,"Seattle Children's Hospital, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT02255565
471,472,NCT04174365,Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder,Anchor,Recruiting,No Results Available,Irritability Associated With Autism Spectrum Disorder (ASD),Drug: Brexpiprazole|Drug: Placebo,The mean change from baseline to Week 8 in the Aberrant Behavior Checklist- Irritability subscale score (ABC-I)|The mean change from baseline to Week 8 in the Clinical Global Impression- Severity of Illness Scale (CGI-S) score pertaining to irritability,"Otsuka Pharmaceutical Development & Commercialization, Inc.|H. Lundbeck A/S",All,5 Years to 17 Years   (Child),Phase 3,130.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",331-201-00148,2019-10-30,2022-02-23,2022-02-23,2019-11-22,,2020-05-28,"For additional information regarding sites, Princeton, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT04174365
472,473,NCT02226458,An Exploratory Open Label Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum Disorder,Autism,Withdrawn,No Results Available,Autism Spectrum Disorder,Drug: EPI-743,Primary Efficacy|Secondary Endpoint|Safety Endpoint,Edison Pharmaceuticals Inc,All,3 Years to 14 Years   (Child),Phase 2,0.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EPI743-14-025,2014-10-01,2015-11-01,2016-01-01,2014-08-27,,2015-03-10,,,https://ClinicalTrials.gov/show/NCT02226458
474,475,NCT00468130,Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children,Abilify,Completed,No Results Available,Autism,Drug: Aripiprazole|Drug: Placebos,Clinical Global Impression Improvement (CGI-AD)|Aberrant Behavior Checklist,"University of Medicine and Dentistry of New Jersey|Rutgers, The State University of New Jersey",All,5 Years to 17 Years   (Child),Not Applicable,15.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",0220055441,2006-05-01,2009-11-01,2009-11-01,2007-05-02,,2021-03-02,"Department of Child and Adolescent Psychiatry, University Behavioral Health Care Building, Piscataway, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00468130
475,476,NCT02069977,Study to Evaluate the Efficacy and Safety of Aripiprazole,,Unknown status,No Results Available,Autism,Drug: Aripiprazole,"irritability subscale of the aberrant behavior checklist|Change from baseline in ABC-subscale of lethargy/social withdrawal, stereotypic behavior, hyperactivity, inappropriate speech|Change of CGI-S, CGI-I from baseline|Change of Behavioral problems from baseline|Change of Adaptive Skills from baseline|Change of Parental stress from baseline",Yoo-Sook Joung|Korea Otsuka International Asia Arab|Samsung Medical Center,All,6 Years to 17 Years   (Child),Phase 4,79.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,031OTC1301,2014-02-01,2016-02-01,2016-02-01,2014-02-24,,2014-03-11,"Inje University Ilsan Paik Hospital, Ilsan, Gyeonggi-do, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Medical City, Pasig, Philippines|Philippine Children's Medical Center, Quezon City, Philippines|Siriraj Hospital Mahidol University, Bangkok, Thailand",,https://ClinicalTrials.gov/show/NCT02069977
477,478,NCT01966679,Targeting GABA-A for the Treatment of Social Disability in Young Adults With Autism Spectrum Disorders: A Phase II Proof of Mechanism Trial,FAST-AS,Completed,No Results Available,Autism Spectrum Disorder,Drug: AZD7325|Drug: Placebo,EEG,"University of California, Los Angeles",All,18 Years to 35 Years   (Adult),Phase 2,40.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HHS-NIH-DA-12-241,2013-10-01,2015-07-01,2015-07-01,2013-10-21,,2015-10-22,"UCLA, Los Angeles, California, United States|Emory University, Atlanta, Georgia, United States|Seattle Children's Research Institute, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01966679
478,479,NCT01914939,"A Randomized, Controlled Trial of Intranasal Oxytocin as an Adjunct to Behavioral Therapy for Autism Spectrum Disorder",,Completed,No Results Available,Autism Spectrum Disorders,Drug: Oxytocin|Behavioral: Social Skills focused CBT|Behavioral: Stress management/relaxation training|Drug: placebo drug,Changes in the Autism Diagnostic Observation Schedule (ADOS)|Clinical Global Impression Scale (CGI)|Social Responsiveness Scale (SRS)|Reading the Mind in the Eyes Test (RMET)|Social Ball Tossing Task,Massachusetts General Hospital|Massachusetts Institute of Technology,Male,18 Years to 40 Years   (Adult),Phase 2,92.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",W81XWH-12-1-0543|Clinical Trial Award,2014-04-01,2017-11-01,2017-11-01,2013-08-02,,2020-01-27,"Massachusetts General Hospital, Boston, Massachusetts, United States|Massachusetts Institute of Technology Martinos Imaging Center, Cambridge, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01914939
480,481,NCT04299464,"A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)",,Recruiting,No Results Available,Autism Spectrum Disorder (ASD),Drug: Placebo|Drug: RO7017773,"Change from Baseline to Week 12 in the Adaptive Behavior Composite score of the Vineland Adaptive Behavior Scales, Third Edition (Vineland-3)|Percentage of Participants with Adverse Events (AEs)|Percentage of Participants with Serious Adverse Events (SAEs)|Percentage of Participants Discontinuing Treatment due to AEs|Change from Baseline Over Time in Suicide Risk Using the Columbia-Suicide-Severity Rating Scale (C-SSRS)|Change from Baseline to Week 12 in Behavior/Symptoms as Measured by all Domains of the Repetitive Behavior Scale-Revised (RBS-R)|Change from Baseline to Week 12 on the Vineland-3 Socialization Domain|Change from baseline to Week 12 on the Vineland-3 Communication domains",Hoffmann-La Roche,All,"15 Years to 45 Years   (Child, Adult)",Phase 2,105.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BP41316|2019-003524-20,2021-03-31,2023-09-30,2023-09-30,2020-03-06,,2021-10-07,"Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|University of California at San Francisco, San Francisco, California, United States|MCB Clinical Research Centers, Colorado Springs, Colorado, United States|Yale University / Yale-New Haven Hospital, New Haven, Connecticut, United States|Research Centers of America, LLC, Oakland Park, Florida, United States|APG- Advanced Psychiatric Group, Orlando, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Capstone Clinical Research, Libertyville, Illinois, United States|Lake Charles Clinical Trials, LLC, Lake Charles, Louisiana, United States|Massachusetts General Hospital; Lurie Center for Autism, Lexington, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Montefiore Medical Center, Bronx, New York, United States|Nathan Kline Institute, Orangeburg, New York, United States|University Hospitals, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|UPMC Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States|Vanderbilt Medical Center, Nashville, Tennessee, United States|BioBehavioral Research of Austin, PC, Austin, Texas, United States|Relaro Medical Trials, Dallas, Texas, United States|Red Oak Psychiatry Associates, PA, Houston, Texas, United States|Road Runner Research, San Antonio, Texas, United States|Core Clinical Research, Kirkland, Washington, United States|Okanagan Clinical Trials, Kelowna, British Columbia, Canada|Janeway Childrens Health; and Rehabilitation Centre, St. John's, Newfoundland and Labrador, Canada|Holland Bloorview Kids Rehabilitation Hospital; Autism Research Centre, East York, Ontario, Canada|London Health Sciences Centre; Victoria Hospital, London, Ontario, Canada|AOU Policlinico Tor Vergata, Università Roma Tor Vergata, Roma, Lazio, Italy|Ist. G. Gaslini; UOC Neuropsichiatria Infantile, Genova, Liguria, Italy|Istituto Scientifico Medea; U.O Psicopatologia età evolutiva, Bosisio Parini (LC), Lombardia, Italy|ASST di Pavia; Dip. di Scienze del Sistema Nervoso e del Comportamento, Pavia, Lombardia, Italy|A.O.U. Policlinico - V. Emanuele - P.O. Gaspare Rodolico; Dip. Terapia integrata disturbi resistenti, Catania, Sicilia, Italy|IRCCS Fondazione Stella Maris; U.O. Complessa NPI 3 - Psichiatria dello sviluppo, Calambrone (PI), Toscana, Italy|Hospital Santa Caterina; Servicio de Psiquiatría, Salt, Girona, Spain|IGAIN (Instituto Global de Atención Integral al Neurodesarrollo), Barcelona, Spain|Hospital Universitari Vall d'Hebron; Sevicio de Psiquiatría, Barcelona, Spain|Hospital Universitario Infanta Leonor; Servicio de Psiquiatría, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT04299464
482,483,NCT03183674,Oxytocin in Spectrum Autism Disorders,OxytocinASD,Completed,No Results Available,Autistic Disorder,Drug: Oxytocin|Other: placebo,Eye tracking|Nepsy,University of Sao Paulo General Hospital,All,3 Years to 16 Years   (Child),Phase 1,80.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",10922213.7.0000.0068-2,2016-07-15,2017-07-20,2018-05-15,2017-06-12,,2019-10-28,"Instituto de Psiquiatria, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT03183674
487,488,NCT01793441,A Study of RG7314 to Investigate Efficacy and Safety in Individuals With Autism Spectrum Disorders (ASD),,Completed,No Results Available,Autism Spectrum Disorder,Drug: Placebo|Drug: RG7314,"Change From Baseline in Social Communication Deficits as Measured by Social Responsiveness Scale 2 (SRS-2)|Percentage of Participants with Suicidality, as Measured by the Columbia-Suicide Severity Rating Scale (C-SSRS)|Percentage of Participants With Adverse Events|Change From Baseline in Behavior/Symptoms as Measured by Aberrant Behavior Checklist (ABC)|Change From Baseline in Behavior/Symptoms as Measured by Repetitive Behavior Scale-Revised (RBS-R)|Change From Baseline in Behavior/Symptoms as Measured by Anxiety, Depression and Mood Scale (ADAMS)|Measure: Change From Baseline in Behavior/Symptoms as Measured by State-Trait Anxiety Inventory (STAI)|Change From Baseline in Clinical Global Impressions as Measured by Clinical Global Impressions Improvement (CGI-I) Scale|Change From Baseline in Adaptive Functioning and Skills as Measured by Vineland-II Adaptive Behavior Scale (VABS)|Plasma Concentration of RG7314|Plasma Concentration of RG7314 Metabolite M3|Area Under the Plasma Concentration Versus Time Curve From Time Zero to Last Measurable Concentration (AUClast) of RG7314|AUClast of RG7314 Metabolite M3|Maximum Observed Plasma Concentration (Cmax) of RG7314|Cmax of RG7314 Metabolite M3|Percentage of Participants With Clinical Response, Defined as At Least 25% Improvement in the SRS-2 Score With a CGI-I Score of 1 or 2",Hoffmann-La Roche,Male,18 Years to 45 Years   (Adult),Phase 2,223.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP28420|2012-005597-55,2013-09-01,2016-09-01,2016-09-01,2013-02-15,,2017-02-03,"Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|Phoenix, Arizona, United States|University of California Davis, Sacramento, California, United States|Sacramento, California, United States|PCSD Feighner Research, San Diego, California, United States|San Diego, California, United States|University of California at San Francisco, San Francisco, California, United States|San Francisco, California, United States|Santa Ana, California, United States|Stanford, California, United States|DBA IMMUNOe Int'l Res Center, Centennial, Colorado, United States|Centennial, Colorado, United States|Yale University; Yale Child Study Center, New Haven, Connecticut, United States|New Haven, Connecticut, United States|Neurology offices of south florida, Delray Beach, Florida, United States|Delray Beach, Florida, United States|Research Centers of America, LLC, Oakland Park, Florida, United States|Oakland Park, Florida, United States|Compass Research, Orlando, Florida, United States|Orlando, Florida, United States|Emory University School of Medicine; Department of Human Genetics & Pediatrics, Decatur, Georgia, United States|Decatur, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Chicago, Illinois, United States|The Kennedy Krieger Institute, Baltimore, Maryland, United States|Baltimore, Maryland, United States|Neuroscientific Insights, Rockville, Maryland, United States|Rockville, Maryland, United States|Massachusetts General Hospital, Lexington, Massachusetts, United States|Lexington, Massachusetts, United States|University of Minnesota; Clin. Neuro Research Unit, Minneapolis, Minnesota, United States|Minneapolis, Minnesota, United States|Montefiore Medical Center; Departments of Psychiatry & Biobehavioral Science, Bronx, New York, United States|Bronx, New York, United States|Mount Sinai School of Medicine; Seaver Autism Center, New York, New York, United States|New York, New York, United States|Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States|Orangeburg, New York, United States|DUKE SCHOOL OF MEDICINE;Duke Center for Autism and Brain Development, Durham, North Carolina, United States|Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|University Hospitals, Cleveland, Ohio, United States|Cleveland, Ohio, United States|UPMC Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Vanderbilt Medical Center, Nashville, Tennessee, United States|Nashville, Tennessee, United States|Road Runner Research, San Antonio, Texas, United States|San Antonio, Texas, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Bellevue, Washington, United States|Pacific Institute of Medical Sciences, Bothell, Washington, United States|Bothell, Washington, United States|Seattle Children's Research Institute, Seattle, Washington, United States|Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01793441
489,490,NCT01972074,Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder,,Completed,Has Results,Autism Spectrum Disorder,Drug: Memantine|Other: Placebo,Treatment Responder,Massachusetts General Hospital|Mclean Hospital,All,8 Years to 17 Years   (Child),Phase 3,84.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2013-P-001826,2015-02-17,2018-05-07,2018-05-07,2013-10-30,2019-09-11,2019-09-11,"Massachusetts General Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT01972074/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01972074
490,491,NCT04099381,Safety and Efficacy of the Transfusion of UCB in Patients With an ASD Depending on the Degree of HLA Compatibility.,ASD-HLA2019,Recruiting,No Results Available,Autism Spectrum Disorder|Autism,Biological: ASD CB-MNC infusion low level HLA compatibility.|Biological: ASD CB-MNC infusion high level HLA compatibility.|Other: Standard therapy.,Number of participants with non-serious and serious adverse events.|The Childhood Autism Rating Scale (CARS2).|Autism Treatment Evaluation Checklist (ATEC).|Evaluation of the survival of donor cells in the host body without immune responses|The correlation of the concentration of T-regulatory cells (CD4/CD25/FoxP3) in the sample of umbilical cord blood and the treatment effectiveness degree|The correlation of the concentration of T-regulatory cells (CD4/CD25/FoxP3) in the patient depending on the severity of the disease.|The correlation of the concentration of CD34+ cells in the cord blood sample and the treatment effectiveness degree,"State-Financed Health Facility ""Samara Regional Medical Center Dinasty""|INBIO, LLC",All,3 Years to 14 Years   (Child),Phase 1|Phase 2,150.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ASD-HLA2019,2019-08-10,2021-12-26,2022-05-26,2019-09-23,,2020-03-02,"Medical Centre Dinasty, Samara, Russian Federation",,https://ClinicalTrials.gov/show/NCT04099381
492,493,NCT01337687,Intranasal Oxytocin for the Treatment of Autism Spectrum Disorders,INOT,Completed,Has Results,Autism Spectrum Disorders,Drug: Intranasal Oxytocin|Drug: Placebo,Number of Participants With Improvement on the Clinical Global Impression-Improvement (CGI-I) Scale|Change in Obsessive- Compulsive Behavior Based on Yale Brown Obsessive Compulsive Scale (YBOCS)|Change in Repetitive Behavior Based Repetitive Behavior Scale - Revised (RBS-R)|Change in Facial Emotion Recognition Based on Diagnostic Analysis of Nonverbal Accuracy - 2 (DANVA-2),Montefiore Medical Center|National Alliance for Research on Schizophrenia and Depression,All,18 Years to 55 Years   (Adult),Not Applicable,19.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",09-10-303,2009-10-01,2013-12-01,2013-12-01,2011-04-19,2020-02-27,2020-02-27,"Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT01337687
499,500,NCT03008889,A Feasibility Study of N-acetylcysteine for Self-injurious Behavior in Children With Autism Spectrum Disorder,NAC,Completed,Has Results,Autism Spectrum Disorder,Drug: N-acetylcysteine|Drug: Placebo,Percentage of Participants Randomized|Attrition Rate|Study Medication Compliance|Successful Collection of Outcome Measures|Parent Satisfaction Rating|Positive Predictive Value of Screening Method of Classifying Self-injurious Behavior (SIB) by Type.|Aberrant Behavior Checklist Irritability Subscale Score at Baseline and 9 Weeks Post-intervention|Number of Self-Injurious Behavior Events|Change in Clinical Global Impression (CGI-I) Scale at 9 Weeks Post-intervention|Change in Biomarkers and Possible Mechanisms of Action of NAC in Children With ASD.,Emory University,All,5 Years to 12 Years   (Child),Phase 2,8.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IRB00088115,2018-07-05,2019-09-12,2019-09-12,2017-01-04,2020-12-16,2021-01-26,"Marcus Autism Center, Atlanta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT03008889/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03008889
500,501,NCT02839915,Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder,,Recruiting,No Results Available,Autism Spectrum Disorder,Drug: Folinic Acid|Other: Placebo,Change in Clinical Evaluation of Language Fundamentals 4 (CELF-4) Score.|Change in Clinical Evaluation of Language Fundamentals Preschool (CELF-P) score|Change in Clinician Global Impression for Improvement (CGI-I) Score,Phoenix Children's Hospital|Emory University|Harvard University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Aprofol,All,5 Years to 12 Years   (Child),Phase 2,134.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IRB00089662|R01HD088528,2020-08-13,2023-07-01,2024-07-01,2016-07-21,,2021-08-24,"Phoenix Children's Hospital, Phoenix, Arizona, United States|Children's Healtcare of Atlanta, Atlanta, Georgia, United States|Harvard University, Lexington, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02839915
501,502,NCT04270708,Intranasal Dexmedetomidine vs Oral Triclofos Sodium for EEG in Children With Autism,,Not yet recruiting,No Results Available,Autistic Disorder,Drug: Dexmedetomidine|Drug: Triclofos 100 MG/ML,"Maximal Sedation Depth|Technician satisfaction from sedation|Neurologist satisfaction from EEG motion artifact|Compliance with IN vs Oral Delivery|Resistance to drug administration (1-10 scale)|Achieving sedation following single dose|Achieving sedation following rescue dose|Sedation onset, duration and recovery periods|Adverse Events",Rabin Medical Center,All,"3 Years to 19 Years   (Child, Adult)",Phase 4,200.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care",0090-20-RMC,2020-03-01,2022-03-01,2022-08-01,2020-02-17,,2020-02-17,,,https://ClinicalTrials.gov/show/NCT04270708
503,504,NCT00936182,Study of Fluconazole in Children With Autism Spectrum Disorder,,Unknown status,No Results Available,Autism Spectrum Disorder,Drug: Fluconazole,PDD Behavior Inventory,The Center for Autism and Related Disorders|The International Child Development Resource Center|Thoughtful House,All,3 Years to 10 Years   (Child),Not Applicable,50.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C0901,2009-07-01,2010-07-01,2011-07-01,2009-07-09,,2009-07-09,"Center for Autism and Related Disorders, Tarzana, California, United States|International Child Development Resource Center, Melbourne, Florida, United States|Thoughtful House, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT00936182
504,505,NCT01333865,A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders,,Completed,Has Results,Autism Spectrum Disorders,Drug: Memantine,Number of Participants With Reduction in ASD Symptom Severity as Defined by the Social Responsiveness Scale (SRS)|Number of Participants With Reduction in ASD Symptom Severity as Defined by the NIMH Clinical Global Impression for Pervasive Developmental Disorders (CGI-PDD) Improvement Score,Massachusetts General Hospital,All,18 Years to 50 Years   (Adult),Phase 4,25.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2010-P-000016,2010-01-01,2014-07-01,2014-07-01,2011-04-12,2014-10-06,2016-03-24,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01333865
507,508,NCT01093768,Brain Imaging Study of Adults With Autism Spectrum Disorders,,Completed,No Results Available,Autism Spectrum Disorders,Drug: Oxytocin|Drug: Vasopressin,Changes in brain activations|Performance scores and reaction time on behavioral tasks,National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC),All,18 Years to 40 Years   (Adult),Phase 1,38.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Diagnostic,100068|10-M-0068,2010-02-19,2013-04-11,2013-04-11,2010-03-26,,2019-12-17,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01093768
509,510,NCT03715153,Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.,,"Active, not recruiting",No Results Available,Autism Spectrum Disorder (ASD),Drug: BUMETANIDE/S95008|Drug: PLACEBO,"Childhood Autism Rating Scale, Second Edition (CARS2) total raw score|Social Responsiveness Scale, Second Edition (SRS-2) total raw score|Clinical Global Impression - Global Improvement (CGI-I) score|Vineland Adaptative Behaviour Scale II (VABS II)|Adverse Event and Pediatric Adverse Event Rating Scale (PAERS)|Abnormalities in 12-leads electrocardiogram (ECG) parameters|Renal ultrasound|Columbia-Suicide severity scale Children's version (C-SSRS-C)|Acceptability and palatability questionnaires|Paediatric Quality of Life Inventory (PedsQL) questionnaire","Institut de Recherches Internationales Servier|ADIR, a Servier Group company|Servier",All,2 Years to 6 Years   (Child),Phase 3,211.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CL3-95008-002|2017-004420-30,2018-10-04,2021-06-15,2022-09-20,2018-10-23,,2021-01-20,"Richmond Behavioral Associates, Staten Island, New York, United States|Liverpool Hospital, Liverpool, Australia|The Royal Children's Hospital Melbourne, Parkville, Australia|Trial Tech em Pesquisas com Medicamentos Ltda, Curitiba, Brazil|Hospital Universitário Walter Cantídio-Universidade Federal do Ceará, Fortaleza, Brazil|Clínica Neurológica e Neurocirúrgica de Joinville, Joinville, Brazil|Hospital São Vicente de Paulo, Passo Fundo, Brazil|Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo, Brazil|Faculdade de Medicina da Universidade de São Paulo - Departamento de psiquiatra, São Paulo, Brazil|University hospital of Ostrava, Department of Psychiatry, Poruba, Ostrava, Czechia|University Hospital Brno, Department of Child Neurology, Brno, Czechia|Institute of Neuropsychiatric Care, Department of Child Psychiatry, Praha, Czechia|GSC CHU-LENVAL Centre ressource autisme, Nice, Alpes-Maritimes, France|Hôpitaux Universitaires de Strasbourg Service de Psychiatrie de l'Enfant et de l'Adolescent, Strasbourg, Alsace-Champagne-Ardenne-Lorraine, France|Centre d'Investigation Clinique de Lyon, Bron, Auvergne Rhone Alpes, France|Hôpital Le Vinatier CRA Rhône-Alpes, Bat 211, Bron Cedex, Auvergne-Rhône-Alpes, France|Hôpital Robert Debré Service de Psychiatrie de l'enfant et de l'adolescent, Paris, Ile De France, France|CHU Rouen, Rouen, Normandie, France|Centre Hospitalier du Rouvray Centre de Ressources pour l'Autisme, Sotteville-lès-Rouen, Normandie, France|Hôpital des Enfants-Pellegrin, Bordeaux, Nouvelle Aquitaine, France|Centre Hospitalier Charles Perrens CRA Aquitaine, Bordeaux, Nouvelle-Aquitaine, France|Vadaskert Korhaz es Szakambulancia, Budapest, Hungary|Servus Salvus Kft., Budapest, Hungary|Magyar Református Egyház Bethesda Gyermekkórháza, Budapest, Hungary|Bekes Megyei Kozponti Korhaz Gyermek es ifjusagpszichiatriai osztaly, Gyula, Hungary|Szegedi Tudományegyetem Szent-Gyorgy Albert Klinikai Kozpont Gyermekgyógyászati Klinika Gyermek es Ifjusagpszichiátriai o, Szeged, Hungary|Neuro Riabilitazione/Psicopatologia dell'età evolutiva Istituto Scientifico Medea - Bosisio Parini, Bosisio Parini, Lombardia, Italy|U.O. di Neuropsichiatria Infantile Fondazione Istituto Neurologico Nazionale Casimiro Mondino Istituto di Ricovero e Cura a Carattere Scientifico, Pavia, Lombardia, Italy|Clinica di Neuropsichiatria dell'Infanzia e dell'Adolescenza Ospedale Pediatrico-Microcitemico, Cagliari, Sardegna, Italy|Programma Interdipartimentale ""Autismo 0-90"" A.O.U. Policlinico ""Gaetano Martino"", Messina, Sicilia, Italy|U.O.C. Psichiatria dello Sviluppo IRCCS Fondazione Stella Maris, Calambrone, Toscana, Italy|U.O. di Neuropsichiatria Infantile Azienda Ospedaliera Universitaria Senese, Siena, Toscana, Italy|""Niepubliczny Zakład Opieki Zdrowotnej Gdańskie Centrum Zdrowia Sp. z o.o., Gdansk, Poland|Centrum Badań Klinicznych PI-House sp. z o.o, Gdansk, Poland|NAVICULA Centrum Diagnozy i Terapii Autyzmu w Łodzi, Lodz, Poland|Fundacja SYNAPSIS ul., Warszawa, Poland|Samodzielny Publiczny Dziecięcy Szpital Kliniczny w Warszawie Oddział Kliniczny Psychiatrii Wieku Rozwojowego, Warszawa, Poland|Centro Hospitalar e Universitario de Coimbra Hospital Pediatrico, Coimbra, Portugal|National Institute of Children Diseases, Department of Child Psychiatry, Bratislava, Slovakia|EPAMED, s.r.o., Košice, Slovakia|Hospita Mutua de Terrassa, Terrassa, Barcelona, Spain|Policlinica Guipuzcoa, San Sebastian, Guipuzcoa, Spain|Hospital Puerta de Hierro, Majadahonda, Madrid, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Niño Jesus, Madrid, Spain|Hospital Universitario Gregorio Marañon, Madrid, Spain|Colchester Hospital, Colchester, United Kingdom|ReCognition Health, London, United Kingdom|The Winnicott Centre 195-197 Hathersage Road, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT03715153
510,511,NCT03514784,Combination Probiotic: BB-12 With LGG (Different Doses) in Treating Children With Autism Spectrum Disorder,,Recruiting,No Results Available,Autism Spectrum Disorder|Gastrointestinal Symptoms,Drug: BB-12 with LGG (Higher Dose)|Drug: Placebo|Drug: BB-12 with LGG (Lower Dose),Effects of BB-12+LGG at different doses on adverse events (safety)|Effects of BB-12+LGG at different doses on irritability and maladaptive behaviors with Aberrant Behavior Checklist (ABC)|Effects of BB-12+LGG at different doses on irritability and maladaptive behaviors measured with the Social Responsiveness Scale-2,"The University of Texas Health Science Center, Houston|Texas Higher Education Coordinating Board|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,4 Years to 16 Years   (Child),Phase 1|Phase 2,70.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",HSC-MS-17-0995|R01HD095158-02,2016-05-01,2025-09-01,2025-09-01,2018-05-02,,2020-11-17,"UTHealth, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03514784
518,519,NCT02947880,Evaluation of the Efficiency of Treatment by BUMETANIDE on Autistic Children With a Known Ethiology,BUMAUTEP,Withdrawn,No Results Available,Autistic Disorder,Drug: Bumetanide|Drug: Placebo,Change (evolution) between day 0 and day 99 of the result of the scale CARS (Childhood Autism Rating Scale).|CARS (Childhood Autism Rating Scale) between D0 and D99 and between D99 and D190 which will be describe by etiology,"University Hospital, Limoges",All,5 Years to 17 Years   (Child),Phase 2,0.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",I14039,2016-12-01,2019-12-01,2020-06-01,2016-10-28,,2021-06-02,,,https://ClinicalTrials.gov/show/NCT02947880
519,520,NCT01813318,Study of Acamprosate in Autism,,Completed,No Results Available,Autistic Disorder,Drug: Acamprosate|Drug: Placebo,"Change from baseline to week 10 on the Social WIthdrawal subscale of ABC|Change Clinical Global Impression- Improvement|Change in ABC subscales: Irritability, Stereotypy, Hyperactivity, and Inappropriate Speech from baseline to week 10","Children's Hospital Medical Center, Cincinnati|Autism Speaks",All,5 Years to 17 Years   (Child),Phase 1,36.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",CIN001-Acamprosate in Autism,2013-07-02,2017-09-07,2017-09-07,2013-03-18,,2021-02-03,"Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01813318
522,523,NCT00409747,Minocycline to Treat Childhood Regressive Autism,,Completed,Has Results,Autism|Minocycline|Regressive Autism,Drug: Minocycline,"z Score|Clinical Global Impressions Scale-Severity (CGI). (Connors & Barkley, 1985)",National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC),All,3 Years to 12 Years   (Child),Phase 4,11.0,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,070024|07-M-0024,2006-11-01,2010-06-01,2011-04-01,2006-12-11,2015-12-11,2015-12-11,"Childrens National Medical Center, Washington, District of Columbia, United States|National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00409747
523,524,NCT04382885,Cariprazine Pediatric ASD PK Study,,Recruiting,No Results Available,Autism Spectrum Disorder,Drug: Cariprazine,Incidence of Adverse Events (AEs)|Incidence of Serious Adverse Events (SAEs)|Incidence of AEs leading to discontinuation|Percentage of participants with potentially clinically significant values in clinical laboratory assessments|Percentage of participants with potentially clinically significant values in vital signs assessments|Percentage of participants with potentially clinically significant values in ECG assessments|Percentage of participants who have suicidal ideation or suicidal behaviors in C-SSRS assessments|Percentage of participants with treatment-emergent parkinsonism in SAS assessments|Percentage of participants with treatment-emergent akathisia in BARS assessments|Percentage of participants with potentially clinically significant values in ocular examination parameters|Pharmacokinetics: Maximum plasma concentrations (Cmax) of cariprazine and its metabolites DCAR and DDCAR on Days 1 and 42|Pharmacokinetics: Time of maximum plasma concentrations (Tmax) of cariprazine and its metabolites DCAR and DDCAR on Days 1 and 42|Pharmacokinetics: Area under the plasma concentration-time curve during the dosing interval (AUC0-tau) of cariprazine and its metabolites DCAR and DDCAR on Days 1 and 42|Pharmacokinetics: Terminal elimination half-life (T1/2) of cariprazine and its metabolites DCAR and DDCAR|Pharmacokinetics: Minimum plasma concentrations (Cmin) during the dosing interval of cariprazine and its metabolites DCAR and DDCAR on Day 42|Pharmacokinetics: Average plasma concentrations (Cavg) during the dosing interval of cariprazine and its metabolites DCAR and DDCAR on Day 42|Pharmacokinetics: Apparent total clearance of cariprazine from plasma (CL/F) on Day 42|Pharmacokinetics: Volume of distribution during the terminal elimination phase (Vz/F) of cariprazine,Allergan,All,5 Years to 17 Years   (Child),Phase 1,24.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2000-103-009,2020-06-26,2021-09-30,2021-09-30,2020-05-11,,2021-07-29,"Neuropsychiatric Research Center of Orange County /ID# 233663, Orange, California, United States|Atlanta Center for Medical Research /ID# 233576, Atlanta, Georgia, United States|iResearch Atlanta, LLC /ID# 233614, Decatur, Georgia, United States",,https://ClinicalTrials.gov/show/NCT04382885
524,525,NCT00695136,The Effect of Donepezil (Aricept(Registered Trademark)) on REM Sleep in Children With Autism,,Completed,Has Results,Autism|Cognition Disorder,Drug: Donepezil hydrochloride|Behavioral: Increase REM sleep percentage,Change in Percentage of Time That Subjects With Autism Spend in REM Sleep.,National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC),All,2 Years to 10 Years   (Child),Phase 1|Phase 2,17.0,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label),080154|08-M-0154,2008-06-01,2011-01-01,2011-01-01,2008-06-11,2013-04-24,2013-04-24,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00695136
529,530,NCT00889538,"Study of Glutathione, Vitamin C and Cysteine in Children With Autism and Severe Behavior Problems",,Completed,No Results Available,Autism|Severe Behavior Disorder,"Drug: placebo|Drug: glutathione|Drug: glutathione, vit C and NAC","Improvement in both developmental skills and behavior with either glutathione or glutathione, Vitamin C and N-acetylcysteine therapy as compared to placebo therapy. Subjects will also be monitored using clinical and laboratory safety parameters.|Response to glutathione (changes in behavior) will correlate with the glutathione level (GSH) and GSH:GSSG ratio",University of Louisville|Cumberland Pharmaceuticals|Norton Healthcare,All,5 Years to 16 Years   (Child),Not Applicable,24.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Glutathione-KCPCRU-01,2009-04-01,2012-09-01,2012-09-01,2009-04-29,,2016-12-07,"KCPCRU, Louisville, Kentucky, United States",,https://ClinicalTrials.gov/show/NCT00889538
532,533,NCT04725383,Amitriptyline for Repetitive Behaviors in Autism Spectrum Disorders,,Not yet recruiting,No Results Available,Autism Spectrum Disorder|Repetitive Compulsive Behavior,Drug: amitriptyline,Clinical Global Impressions scale-Improvement of Much Improved (2) or Very Much Improved (1)|Child Yale Brown Obsessive Compulsive Scale- Pervasive Developmental Disorders (CYBOCS-PDD)|Repetitive Behavior Scale-revised,"University of Missouri, Kansas City",All,6 Years to 17 Years   (Child),Phase 3,30.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2015984|17-055,2021-06-01,2024-06-01,2024-12-20,2021-01-26,,2021-05-11,,,https://ClinicalTrials.gov/show/NCT04725383
536,537,NCT01248130,Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders,,Terminated,Has Results,Autism Spectrum Disorder (ASD),Drug: Omega-3 Fatty Acid,Change in Social Responsiveness Scale (SRS) Total Raw Score|Change in NIMH Clinical Global Impression Scale for Pervasive Developmental Disorders (CGI-PDD) Improvement Scores,Massachusetts General Hospital,All,6 Years to 17 Years   (Child),Phase 2,7.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2009-P-001593,2009-11-01,2013-04-01,2013-04-01,2010-11-25,2014-09-22,2017-11-06,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01248130
538,539,NCT00005014,Treatment of Autism in Children and Adolescents,,Completed,No Results Available,Autistic Disorder,Drug: Risperidone,,National Institute of Mental Health (NIMH),All,5 Years to 17 Years   (Child),Phase 3,101.0,NIH,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Treatment,N01 MH70001|N01 MH70009|N01 MH80011|N01 MH70010|DSIR CT,1997-10-01,,2001-02-01,2000-04-03,,2014-04-17,"UCLA, Los Angeles, California, United States|Yale Univ, New Haven, Connecticut, United States|Indiana Univ / Riley Hosp for Children, Indianapolis, Indiana, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|Ohio State Univ, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00005014
541,542,NCT00515320,Study of Fluoxetine in Autism,SOFIA,Completed,No Results Available,Autistic Disorder,Drug: Fluoxetine|Drug: Placebo,"The percentage change from baseline to the endpoint visit for the CYBOCS-PDD score.|The time and dose related course of therapeutic effects|The inter-relationship between these effects in the context of global clinical changes.|The indirect effects on patient caregivers of the dose regime in these subjects compared to placebo during treatment.|Safety measures will be physical examination, vital signs, EKG/ECG & clinical laboratory tests.",Neuropharm|Autism Speaks,All,5 Years to 17 Years   (Child),Phase 3,158.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NPL-2008-4-AUTUS-004,2007-08-01,2009-01-01,2009-01-01,2007-08-13,,2012-04-27,"Southwest Autism Research and Resource Centre, Phoenix, Arizona, United States|University of California Davis, Sacramento, California, United States|University of Florida, Department of Psychiatry, Gainesville, Florida, United States|Institute for Behavioral Medicine, Smyrna, Georgia, United States|University of Illinois, Chicago, Illinois, United States|AMR-Baber Research Inc., Naperville, Illinois, United States|Harvard Medical School, Medford, Massachusetts, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|Center for Psychiatry and Behavioral Medicine, Las Vegas, Nevada, United States|CRCNJ, Voorhees, New Jersey, United States|Long Island Jewish Hospital, Bethpage, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|Western Psychiatric Institute and Clinic/ Merck Child Outpatient Clinic, Pittsburgh, Pennsylvania, United States|Red Oak Psychiatry Associates, Houston, Texas, United States|Seattle Children's Hosptial University of Washington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00515320
547,548,NCT00004486,Randomized Study of Fluoxetine in Children and Adolescents With Autism,,Completed,No Results Available,Autism,Drug: fluoxetine,,Icahn School of Medicine at Mount Sinai|FDA Office of Orphan Products Development,All,5 Years to 17 Years   (Child),Not Applicable,45.0,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,199/14266|MTS-FDR001520|MTS-GCO-96-713,1998-09-01,,2002-12-01,1999-10-19,,2015-03-25,"Albert Einstein College of Medicine, Bronx, New York, United States|New York University Medical Center, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00004486
548,549,NCT00576732,A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder,,Completed,Has Results,Autistic Disorder|Autism,Drug: Placebo|Drug: Risperidone high dose|Drug: Risperidone low dose,Change in Aberrant Behavior Checklist Irritability (ABC-I) Subscale|Number of Participants Who Had at Least 25% Improvement in ABC-I|Change in Clinical Global Impression Severity (CGI-S)|Number of Participants Who Had Clinical Global Impression Change Ratings of Much or Very Much Improved.|Change in Fasting Glucose (mg/dL) at 6 Weeks|Change in Insulin Resistance (IR) at 6 Weeks|Change in Fasting Glucose (mg/dL) at 6 Months|Change in Insulin Resistance (IR) at 6 Months,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",All,5 Years to 17 Years   (Child),Phase 4,96.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CR014740|RISAUT4002,2007-12-01,2009-09-01,2010-03-01,2007-12-19,2010-09-28,2014-05-09,"Dothan, Alabama, United States|Phoenix, Arizona, United States|Sacramento, California, United States|Santa Ana, California, United States|Boca Raton, Florida, United States|Miami, Florida, United States|Smyrna, Georgia, United States|Hoffman Estates, Illinois, United States|Naperville, Illinois, United States|Lake Charles, Louisiana, United States|Bronx, New York, United States|Manhasset, New York, United States|New York, New York, United States|Staten Island, New York, United States|Columbus, Ohio, United States|Oklahoma City, Oklahoma, United States|Philadelphia, Pennsylvania, United States|Houston, Texas, United States|Fairfax, Virginia, United States|Portsmouth, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00576732
550,551,NCT01183221,The Effects of Oxytocin on Complex Social Cognition in Autism Spectrum Disorders,,Completed,Has Results,Autism|ASD,Drug: Syntocinon|Drug: Placebo,Empathic Accuracy Performance|Fmri BOLD Response During Empathic Accuracy Task,Alexander Kolevzon|Icahn School of Medicine at Mount Sinai,All,18 Years to 45 Years   (Adult),Phase 2,30.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",GCO 09-0857,2010-06-18,2014-04-25,2014-04-25,2010-08-17,2021-04-15,2021-04-15,"Mount Sinai School of Medicine - Seaver Autism Center for Research and Treatment, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01183221
555,556,NCT01395953,Double-blind Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders,,Withdrawn,No Results Available,Autism Spectrum Disorder (ASD),Drug: Buspirone|Drug: Placebo,Reduction in Pediatric Anxiety Rating Scale (PARS) Score|Clinical Global Impression-Anxiety (CGI-Anxiety) Improvement Score,Massachusetts General Hospital,All,6 Years to 17 Years   (Child),Phase 2,0.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2011-P-000703,2011-11-01,2013-07-01,2013-07-01,2011-07-18,,2021-07-09,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01395953
556,557,NCT00850070,Sapropterin as a Treatment for Autistic Disorder,,Completed,Has Results,Autistic Disorder,Drug: sapropterin|Drug: Placebo,"Clinical Global Impression -- Improvement (CGI-I) Scale|Clinical Global Impression -- Severity (CGI-S) Scale|Preschool Language Scale-Fourth Edition (PLS-4). Assesses Expressive and Receptive Language Skills in Ages Birth Through 6 Years, 11 Months.|Vineland Adaptive Behavior Scale-II.|Children's Yale Brown Obsessive Compulsive Scale (C-YBOCS)|Connor's Preschool ADHD Questionnaire|Adverse Events Scale|Aberrant Behavior Checklist (ABC) - Inappropriate Speech|Social Responsiveness Scale (SRS)|Parent Global Assessment (PGA) Scale",The Children's Health Council|BioMarin Pharmaceutical,All,3 Years to 6 Years   (Child),Phase 2,46.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CHC-0901,2009-03-01,2011-08-01,2011-10-01,2009-02-24,2014-02-28,2018-05-01,"The Children's Health Council, Palo Alto, California, United States",,https://ClinicalTrials.gov/show/NCT00850070
557,558,NCT02504554,Beneficial Bacteria Treatment for Autism,BBT,Completed,Has Results,Gastrointestinal Problems|Autism Spectrum Disorders,"Drug: oral Vancomycin|Drug: MoviPrep|Drug: Prilosec|Biological: human fecal material; processed, frozen administered orally|Biological: human fecal material; processed, frozen; administered orally and rectally",Gastrointestinal Symptom Responsiveness Scale (GSRS)|Parent Global Impressions-Revised (PGI-R)|Blood Safety Markers (Assessment of Blood Chemistry Panel and Complete Blood Count)|Childhood Autism Rating Scale (CARS)|Social Responsiveness Scale (SRS)|Short Sensory Profile|Vineland Adaptive Behavior Scale (VABS)|Daily Stool Record (DSR),Arizona State University|Northern Arizona University|University of Arizona|University of Minnesota,All,7 Years to 17 Years   (Child),Phase 1|Phase 2,18.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STUDY00001053,2014-07-01,2016-04-01,2016-04-01,2015-07-22,2019-12-18,2019-12-18,,,https://ClinicalTrials.gov/show/NCT02504554
560,561,NCT00057408,A Controlled Study of Olanzapine in Children With Autism,,Completed,No Results Available,Autistic Disorder,Drug: olanzapine (Zyprexa)|Drug: Placebo,Children's Psychiatric Rating Scale|Clinical Global Impressions|Aberant Behavior Checklist|Treatment Emergent Symptoms Scale|Olanzapine Untoward Effects Checklist|Abnormal Involuntary Movement Scale|Neurological Rating Scale,FDA Office of Orphan Products Development|National Institute of Mental Health (NIMH),All,3 Years to 12 Years   (Child),Phase 2,78.0,U.S. Fed|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2190,2003-05-01,,2005-09-01,2003-04-02,,2015-03-25,"Drexel University College of Medicine c/o Friends Hospital, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00057408
561,562,NCT00873509,Buspirone in the Treatment of 2-6 Year Old Children With Autistic Disorder,B-ACE,Completed,No Results Available,Autistic Disorder,Drug: Buspirone|Drug: Placebo,"To evaluate the effects of twice-daily oral buspirone on core features of autism in autistic children 2-6 years measuring the change from baseline in ADOS (Autism Diagnostic Observation Schedule) Composite Total scores compared to placebo at 6 months.|To evaluate the effects of twice-daily oral buspirone on the ADOS Composite calibrated severity score, social behavior, repetitive behavior, language, sensory dysfunction and anxiety.|To determine whether there are age group differences in the effects of buspirone on social interaction, repetitive behavior, language, sensory dysfunction and anxiety.|To determine whether there is a difference in the incidence of side effects and long term safety between the buspirone and placebo groups, and between the different dose groups.|To determine whether the whole brain PET measure of serotonin synthesis capacity is a predictor of buspirone effect.|To determine whether blood serotonin concentration is a predictor of buspirone effect.","Chugani, Diane C.|National Institute of Neurological Disorders and Stroke (NINDS)",All,2 Years to 6 Years   (Child),Phase 2|Phase 3,166.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",10888|5U01NS061264,2009-05-01,2015-01-01,2015-01-01,2009-04-01,,2016-07-26,"University California Davis M.I.N.D. Institute, Sacramento, California, United States|Children's Hospital of Michigan Wayne State University, Detroit, Michigan, United States|New York University Langone Medical Center, New York, New York, United States|Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States|University of Texas Southwestern, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT00873509
564,565,NCT00273650,Efficacy Study of Subcutaneous Methyl-B12 in Children With Autism,,Completed,No Results Available,Autistic Disorder,Drug: methylcobalamin|Other: saline placebo,"Primary measure is the Clinical Global Impression Scale -Improvement supplemented by videos taken at all visits and rated blindly to measure executive function, speech, and language, and socio-economic development.|Secondary measures:NEPSY, ABC, PPVT, SB:V, PDRF, MCDI, PIA-CV, and CARS.","University of California, San Francisco",All,3 Years to 8 Years   (Child),Phase 2|Phase 3,30.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",MB12-AUT,2005-07-01,2009-06-01,2009-08-01,2006-01-09,,2019-10-09,"UC Davis MIND Institute, Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT00273650
565,566,NCT04948814,Application of Fecal Microbiota Transplantation in Children With ASD,,Recruiting,No Results Available,Autism Spectrum Disorder,Biological: Fecal microbiota transplantation|Drug: Vancomycin,Change in Autism Diagnostic Observation Scale (ADOS) in ASD children|Changes in the Autism Behavior Checklist (ABC) in ASD children|Changes in the Childhood Autism Rating Scale (CARS) in ASD children|Change in Social Responsiveness Scale (SRS) in ASD children|Change in Autism Treatment Evaluation Checklist (ATEC) in ASD children|Change in gastrointestinal symptoms among children with ASD|Evaluate the difference of the gut microbe composition between children with ASD and healthy children by sequencing faecal metagenome.,Tongji Hospital,All,"3 Years to 18 Years   (Child, Adult)",Phase 1,100.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,F616|2018B030335001,2021-07-01,2023-09-01,2023-09-01,2021-07-02,,2021-07-02,"Tongji Hospital, Wuhan, Hubei, China|Tongji Hospital, Wuhan, Hubei, China",,https://ClinicalTrials.gov/show/NCT04948814
569,570,NCT00054730,Effects of CX516 on Functioning in Fragile X Syndrome and Autism,,Completed,No Results Available,Fragile X Syndrome|Autism,Drug: CX516 (Ampalex®),,RespireRx|FRAXA Research Foundation,All,18 Years to 50 Years   (Adult),Phase 2,,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CORX-CX516-013,2002-06-01,,,2003-02-11,,2005-06-24,"UC Davis-MIND Institute, Sacramento, California, United States|RUSH-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00054730
571,572,NCT00541346,A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms,,Completed,Has Results,Autism|Attention Deficit Hyperactivity Disorder,Drug: Methylphenidate Transdermal System,Change in Attention Deficit Hyperactivity Disorder Rating Scale - IV (ADHD-RS-IV) Total Score From Baseline to 8-week Follow-up Visit|Change in Aberrant Behavior Checklist (ABC) Hyperactivity Scores From Baseline to 8-week Follow-up Visit|Change in Aberrant Behavior Checklist (ABC) Irritability Scores From Baseline to 8-week Follow-up Visit|Change in Aberrant Behavior Checklist (ABC) Lethargy Scores From Baseline to 8-week Follow-up Visit|Change in Aberrant Behavior Checklist (ABC) Stereotypy Scores From Baseline to 8-week Follow-up Visit|Change in Aberrant Behavior Checklist (ABC) Inappropriate Speech Scores From Baseline to 8-week Follow-up Visit|Change in Lifetime Participation Scale (LPS) Total Scores From Baseline to 8-week Follow-up Visit|Change in Family III General Scale Summed Score From Baseline to 8-week Follow-up Visit|Change in Pediatric Evaluation Disability Inventory (PEDI) Caregiver Assistance: Self-Care From Baseline to 8-week Follow-up Visit|Change in Pediatric Evaluation Disability Inventory (PEDI) Social Function From Baseline to 8-week Follow-up Visit|Change in Attention Deficit Hyperactivity Disorder Rating Scale IV: Teacher Assessment Total Scores From Baseline to 8-week Follow-up Visit,"University of Oklahoma|Mark L. Wolraich, M.D.",All,6 Years to 11 Years   (Child),Phase 3,16.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SPD485-420-Lock,2007-09-01,2009-05-01,2010-02-01,2007-10-10,2014-02-06,2014-02-06,"OU Child Study Center, Oklahoma City, Oklahoma, United States",,https://ClinicalTrials.gov/show/NCT00541346
573,574,NCT00198120,Safety and Effectiveness of D-Cycloserine in Children With Autism,,Completed,No Results Available,Autistic Disorder,Drug: D-cycloserine|Drug: Placebo,Change in Clinical Global Impressions (CGI) Global Improvement|Change in Lethargy Subscale of the Aberrant Behavior Checklist (ABC),Indiana University|National Institute of Mental Health (NIMH)|National Alliance for Research on Schizophrenia and Depression|Indiana University School of Medicine,All,3 Years to 12 Years   (Child),Phase 3,80.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",K23MH068627|0305-30|DDTR BK-TKND,2004-02-01,2007-09-01,2010-08-01,2005-09-20,,2016-04-12,"Riley Hospital for Children, Christian Sarkine Autism Treatment Center, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT00198120
574,575,NCT02414451,Trial of Propranolol in Adults and Adolescents With ASD and Predictors of Response,,Withdrawn,No Results Available,Autism,Drug: Propranolol|Drug: Placebo,Change in General Social Outcome Measure (GSOM)|Change in Social Responsiveness Scale (SRS)|Change in Anagrams task|Change in Verbal fluency for categories task|Change in Spence Children's Anxiety Scale (SCAS)|Vertical attention task|Change in Clinical Global Impression of Change (CGIC) scale|Change in Autism Impact Measure (AIM)|Change in Vineland Adaptive Behavior Scales-II (VABS)|Change in Aberrant Behavior Checklist (ABC)|Change in Clinical Global Impression of Severity (CGIS) scale,University of Missouri-Columbia,All,"15 Years to 30 Years   (Child, Adult)",Not Applicable,0.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",200089,2016-09-01,2016-09-01,2016-09-01,2015-04-10,,2016-10-04,,,https://ClinicalTrials.gov/show/NCT02414451
575,576,NCT00676195,An Open-Label Study of N-Acetyl Cysteine in Children With Autism,,Completed,Has Results,Autistic Disorder,Drug: N-Acetyl Cysteine,Number of Participants With Adverse Events Reported on the Dosage Record and Treatment Emergent Symptom Scale (DOTES)|Social Responsiveness Scale (SRS)|Sensory Profile Questionnaire (SPQ)|Irritability Subscale of the Aberrant Behavior Checklist (ABC)|Glutathione Metabolism Intermediates in Peripheral Blood Measured by High-performance Liquid Chromatography,Stanford University,All,3 Years to 12 Years   (Child),Phase 2,24.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SU-05062008-1139,2008-06-01,2010-06-01,2010-06-01,2008-05-12,2017-03-29,2017-03-29,"Stanford University School of Medicine, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT00676195
577,578,NCT00943579,Open-Label Extension Study of Kuvan for Autism,,Completed,Has Results,Autistic Disorder,Drug: Kuvan®,"Clinical Global Impressions Scale|Vineland Adaptive Behavior Scale, 2nd Edition|Children's Yale Brown Obsessive Compulsive Scale|Parental Global Assessment|Preschool Language Scale, 4th Edition (PLS-4)|Connor's Preschool ADHD Questionnaire|Aberrant Behavior Checklist (ABC)|Adverse Events Reporting",The Children's Health Council|BioMarin Pharmaceutical,All,3 Years to 6 Years   (Child),Phase 2|Phase 3,41.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CHC-0902,2009-08-01,2011-12-01,2012-03-01,2009-07-22,2013-07-04,2018-05-02,"The Children's Health Council, Palo Alto, California, United States",,https://ClinicalTrials.gov/show/NCT00943579
580,581,NCT00065884,Valproate Response in Aggressive Autistic Adolescents,,Unknown status,No Results Available,Autism,Drug: Valproate,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Mental Health (NIMH),All,"6 Years to 21 Years   (Child, Adult)",Phase 3,30.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Treatment,P30HD002528|K08MH001516,,,,2003-08-05,,2005-06-24,"Outpatient MR/Autism Clinic, University of Kansas, Kansas City, Kansas, United States",,https://ClinicalTrials.gov/show/NCT00065884
581,582,NCT00627705,A Study of N-Acetyl Cysteine in Children With Autism,,Completed,Has Results,Autistic Disorder,Drug: N-Acetyl Cysteine|Other: Placebo - sugar pill,"Total Number of Subjects With Reported Side Effects as Assessed by Dosage Record and Treatment Emergent Symptom Scale (DOTES)|The Clinical Global Rating Scale (CGRS) Improvement Subscale Score|Glutathione (GSH) Levels in Peripheral Blood, Measured by State-of-the-art High-performance Liquid Chromatography (HPLC)|Irritability Subscale of the Aberrant Behavior Checklist (ABC)|The Aberrant Behavior Checklist Total Score (ABC)|Social Responsiveness Scale (SRS)|Sensory Profile Questionnaire (SPQ)|Glutathione (GSH) Metabolism Intermediates in Peripheral Blood",Stanford University,All,3 Years to 12 Years   (Child),Phase 2,43.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SU-02012008-995|10142,2008-02-01,2010-09-01,2010-09-01,2008-03-03,2017-05-18,2017-05-18,"Stanford University School of Medicine, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT00627705
582,583,NCT00086645,Citalopram for Children With Autism and Repetitive Behavior (STAART Study 1),,Completed,No Results Available,Autistic Disorder,Drug: citalopram hydrobromide|Other: placebo,Clinical Global Improvement|Safety Monitoring Uniform Research Form (SMURF)|Children's Yale-Brown Obsessive-Compulsive Scale (CYBOCS)|Repetitive Behavior Scale-Revised (RBS-R)|Parent Chief Complaint|Aberrant Behavior Checklist|Child and Adolescent Symptom Inventory: Anxiety and Depression scales|Behavioral Activation|Caregiver Strain Questionnaire|Vineland,Boston University|National Institute of Mental Health (NIMH),All,5 Years to 17 Years   (Child),Phase 2,149.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U54MH066398,2004-04-01,2006-10-01,2007-04-01,2004-07-13,,2017-03-10,"UCLA Neuropsychiatric Institute, Los Angeles, California, United States|Yale University, New Haven, Connecticut, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|North Shore - Long Island Jewish Hospital, Great Neck, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|University of North Carolina Chapel Hill, Chapel Hill, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00086645
584,585,NCT03487770,Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Autistic Disorder,,Completed,No Results Available,Autistic Disorder,Drug: Aripiprazole Oral Solution|Drug: Placebo Oral Solution,Changes from Baseline to Week 8 (or endpoint) in the ABC-I score|Clinician-rated CGI-I score at Week 8 (or endpoint)|Change in ABC subscale scores from Baseline to Week 8 (or endpoint)|Response Rate at Week 8 (or endpoint) (or endpoint),Otsuka Beijing Research Institute,All,6 Years to 17 Years   (Child),Phase 3,111.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",031-403-00106,2018-04-09,2020-04-21,2020-04-21,2018-04-04,,2020-12-29,"6th affiliated hospital, Peking University, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT03487770
585,586,NCT00692315,Treating Oxidative Stress in Children With Autism,,Completed,No Results Available,Autistic Disorder,Drug: Methylcobalamin (methylB12),Glutathione redox status (GSH/GSSG)|Vineland Adaptive Behavior Scales,Arkansas Children's Hospital Research Institute,All,3 Years to 7 Years   (Child),Not Applicable,40.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,28839,2006-09-01,2007-06-01,2007-12-01,2008-06-06,,2016-04-15,"Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States",,https://ClinicalTrials.gov/show/NCT00692315
587,588,NCT00787111,Extended Management and Measurement of Autism,EMMA,Terminated,No Results Available,Autistic Disorder,Drug: Fluoxetine (prozac),"Safety Outcomes: Laboratory determinations, Urine drugs of abuse tests,Vital Signs,Physical Examinations, Adverse Events/Serious Adverse Events, Clinical Global Impression of Severity (CGI-S AD)",Neuropharm|Autism Speaks,All,"5 Years to 18 Years   (Child, Adult)",Phase 3,128.0,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NPL-2008-4-AUTUS-005,2008-11-01,2009-04-01,2009-04-01,2008-11-07,,2010-02-23,"Southwest Autism Research and Resource Centre, Phoenix, Arizona, United States|University of California Davis, Sacramento, California, United States|Institute for Behavioral Medicine, Smyrna, Georgia, United States|University of Illinois, Chicago, Illinois, United States|AMR-Baber Research Inc., Naperville, Illinois, United States|Harvard Medical School, Medford, Massachusetts, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|CRCNJ, Voorhees, New Jersey, United States|Long Island Jewish Hospital, Bethpage, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|Seattle Children's Hosptial University of Washington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00787111
593,594,NCT01535508,Open Label Clinical Trial of Vitamin D in Children With Autism,,Completed,No Results Available,Autism|Vitamin D Deficiency,Drug: Liquid Vitamin D,Clinical Global Impression Scale - Improvement (CGI-I),"University of California, San Francisco",All,3 Years to 8 Years   (Child),Phase 2|Phase 3,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,VitD11-06899,2012-02-01,2015-09-01,2015-12-01,2012-02-17,,2019-10-09,"University of California, San Francisco, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT01535508
594,595,NCT00198107,Evaluating the Effectiveness of Aripiprazole and D-Cycloserine to Treat Symptoms Associated With Autism,,Completed,Has Results,Autistic Disorder,Drug: Aripiprazole|Drug: Placebo|Drug: D-cycloserine,"Mean Post-baseline Aberrant Behavior Checklist Irritability Score, Parent Report, Double-blind Phase|Odds of Improvement as Measured by the Clinical Global Impression-Global Improvement Scale (Improvement Defined as CGI-I=1 or CGI-I=2)|Mean Post-baseline Aberrant Behavior Checklist Hyperactivity Score, Parent Report, Double-blind Phase|Mean Post-baseline Aberrant Behavior Checklist Inappropriate Speech Score, Parent Report, Double-blind Phase|Mean Post-baseline Aberrant Behavior Checklist Social Withdrawal Score, Parent Report, Double-blind Phase|Mean Post-baseline Aberrant Behavior Checklist Stereotypy Score, Parent Report, Double-blind Phase|Mean Post-baseline Score on a Modified Version of the Compulsion Subscale of the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)|Mean Vineland Maladaptive Behavior Subscales Total Score, Week 8|Mean Autism Diagnostic Observation Schedule (ADOS) Social Affect and Restricted and Repetitive Behaviors Total Score, Week 8|Mean Social Reciprocity Scale (SRS) Total Score, Week 8",Indiana University|National Institute of Mental Health (NIMH),All,5 Years to 17 Years   (Child),Phase 3,81.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R01MH072961|DSIR 82-SEDR,2005-09-01,2011-09-01,2011-09-01,2005-09-20,2019-03-29,2019-04-09,"Riley Hospital for Children, Christian Sarkine Autism Treatment Center, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT00198107
604,605,NCT02903030,Probiotics for Quality of Life in Autism Spectrum Disorders,,Completed,Has Results,Autism Spectrum Disorders|Anxiety,Drug: Maltose (placebo)|Drug: Visbiome Extra Strength,Change in Gastrointestinal (GI) Module of the Pediatric Quality of Life Inventory (PedsQL) at From Baseline at Week 8|Change in Target Symptom Rating From Baseline at Week 8|Change in Parent Anxiety Checklist--ASD From Baseline at Week 8|Change in The Aberrant Behavior Checklist (ABC) From Baseline at Week 8|Change in Social Responsiveness Scale (SRS) From Baseline at Week 8|Children's Sleep Habits Questionnaire (CSHQ) at Week 8|Change in The Parenting Stress Index Short Form (PSI),Ohio State University|Autism Treatment Network|Autism Speaks,All,3 Years to 12 Years   (Child),Early Phase 1,13.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2016H0174,2016-08-01,2017-12-01,2017-12-01,2016-09-16,2020-02-05,2020-02-05,"Ohio State University Wexner Medical Center, Columbus, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT02903030/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02903030
606,607,NCT03279471,Specifying and Treating Anxiety in Autism Research,STAAR,Recruiting,No Results Available,Autism Spectrum Disorder|Anxiety,Drug: Sertraline|Behavioral: CBT/BIACA|Drug: Placebo,Change in Pediatric Anxiety Rating Scale,"University of California, Davis",All,8 Years to 14 Years   (Child),Phase 2,132.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",1097281,2017-10-01,2022-02-15,2022-09-14,2017-09-12,,2021-01-13,"UC Davis MIND Institute, Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT03279471
607,608,NCT00027404,Study of Fluoxetine in Adults With Autistic Disorder,,Completed,No Results Available,Autistic Disorder,Drug: Fluoxetine,,Icahn School of Medicine at Mount Sinai|FDA Office of Orphan Products Development,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,48.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,FD-R-2026-01|FD-R-002026-01,2001-09-01,,2005-08-01,2001-12-07,,2015-03-25,"Mount Sinai School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00027404
608,609,NCT03099239,hCT-MSCs for Children With Autism Spectrum Disorder (ASD),hCT-MSCs,Completed,No Results Available,Autism|Autism Spectrum Disorder|ASD,Biological: hCT-MSC infusion,Incidence of Infusion reactions|Incidence of Infections,"Joanne Kurtzberg, MD|The Marcus Foundation|Duke University",All,2 Years to 11 Years   (Child),Phase 1,12.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00079421,2017-06-06,2019-06-10,2019-06-10,2017-04-04,,2019-12-03,"Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT03099239
615,616,NCT01661855,A Pilot Study of Riluzole Versus Placebo in the Treatment of Children and Adolescents With ASD,RILISE,Completed,No Results Available,Autism Spectrum Disorders,Drug: Riluzole|Drug: Placebo,Efficacy of riluzole vs. placebo on measures of social function|Efficacy of riluzole vs. placebo on measures of repetitive behaviors|Safety and tolerability of riluzole in children and adolescents with ASD,"Evdokia Anagnostou|Holland Bloorview Kids Rehabilitation Hospital|McMaster University|The Hospital for Sick Children|University of Western Ontario, Canada|Unity Health Toronto|University of Toronto|Anagnostou, Evdokia, M.D.",All,6 Years to 17 Years   (Child),Phase 2,58.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RILISE-07-2013,2013-09-01,2015-09-01,2015-10-01,2012-08-10,,2017-03-20,"Offord Centre for Child Studies, Hamilton, Ontario, Canada|Lawson Health Research Institute, London, Ontario, Canada|Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01661855
618,619,NCT02278328,MEG Study of Acute STX209 Effects in ASD,,Completed,Has Results,Autism Disorder,Drug: STX209 (15mg)|Drug: placebo|Drug: STX209 (30mg),M50 Latency (Left Hemisphere)|M50 Latency (Right Hemisphere)|Steady State Inter Trial Coherence (Left Hemisphere)|Steady State Inter Trial Coherence (Right Hemisphere)|GABA (Left Hemisphere),"Timothy Roberts|Simons Foundation|Clinical Research Associates, LLC|Children's Hospital of Philadelphia",Male,14 Years to 17 Years   (Child),Early Phase 1,25.0,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,14-010857,2016-02-01,2018-07-30,2019-09-27,2014-10-30,2019-10-21,2019-10-21,"Children's Hospital of Phladelphia, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02278328/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02278328
624,625,NCT03337035,Probiotics and Oxytocin Nasal Spray on Social Behaviors of Autism Spectrum Disorder (ASD) Children,,Completed,No Results Available,Autism Spectrum Disorder,Drug: intranasal oxytocin|Dietary Supplement: oral probiotics|Dietary Supplement: oral placebo,Social Responsiveness Scale (SRS) Edition 2|Aberrant Behavior Checklist (ABC) Edition 2|Neuroinflammation and Oxytocin levels|structural MRI|Functional MRI (resting state)|Functional MRI (task based)|Autonomic indices 1|Autonomic indices 2|Autonomic indices 3|Autonomic indices 4|Autonomic indices 5|Microbiome|Eye tracking and Behavioral task (joint attention)|Eye tracking and behavioral task (emotion response)|Eye tracking and behavioral task (eye behavior),Massachusetts General Hospital,All,"3 Years to 25 Years   (Child, Adult)",Phase 1,35.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2017P001667,2018-12-01,2019-10-02,2019-10-02,2017-11-08,,2020-03-04,"Massachusetts General Hospital, Charlestown, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03337035
625,626,NCT02719951,Glutaminergic Transmission in Autism : Molecular Imaging Exploration,TANGAU,Completed,No Results Available,Autism|Fragile-X Syndrome (FXS)|Healthy Volunteers,Drug: [18F]FPEB PET imaging|Other: Biological samples|Other: MRI,cerebral glutaminergic activity assessed by binding potential of [18F]FPEB|distribution volume of [18F]FPEB,"University Hospital, Tours",Male,18 Years to 45 Years   (Adult),Phase 1,27.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,PRIA 14 FBB / TANGAU,2016-04-01,2018-11-15,2019-05-01,2016-03-25,,2019-06-11,"CHU Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT02719951
628,629,NCT02812368,Clonidine for Sleep Disturbances in Children With Autism Spectrum Disorder,,Withdrawn,No Results Available,Autism Spectrum Disorder,Drug: Clonidine|Drug: Placebo (for clonidine),Change in Children's Sleep Habits Questionnaire (CSHQ) Total Score,Ohio State University|Autism Treatment Network|Autism Intervention Research Network on Physical Health,All,6 Years to 14 Years   (Child),Phase 2,0.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2016H0181,2016-08-01,2017-01-01,2017-01-01,2016-06-24,,2017-02-02,"Ohio State University Nisonger Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02812368
632,633,NCT00325572,Evaluation and Treatment of Copper/Zinc Imbalance in Children With Autism,,Terminated,Has Results,Autism|Pervasive Developmental Disorder,Drug: oral zinc and vitamin C supplements|Other: oral Placebo,Copper/Zinc Ratio of Children With Autism Compared to Typically Developing Children Phase 2: Change in Copper/Zinc Ratio With Supplementation of Zinc and Vitamin C,Milton S. Hershey Medical Center|Thrasher Research Fund,All,3 Years to 8 Years   (Child),Phase 1,89.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",23275,2006-11-01,2010-12-01,2011-12-01,2006-05-15,2019-07-17,2019-07-17,"Penn State Children's Hospital, Hershey, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00325572
635,636,NCT01745497,Iron Treatment of Sleep Disorders in Children With Autism Spectrum Disorder,,Completed,No Results Available,Autism Spectrum Disorder|Insomnia,Drug: Ferrous sulfate|Drug: Placebo,Improvement in sleep onset|Changes inDay time behavior|Improvements in sleep maintenance insomnia,"University of Colorado, Denver|Autism Treatment Network|Massachusetts General Hospital|The Emmes Company, LLC|Health Resources and Services Administration (HRSA)",All,2 Years to 10 Years   (Child),Phase 2,24.0,Other|Industry|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",12-0466,2012-12-01,2015-08-01,2015-08-01,2012-12-10,,2020-08-03,"Childrens Hospital Colorado, Aurora, Colorado, United States|University of Rochester, Rochester, New York, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|The Hospital for Sick Children, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01745497
641,642,NCT04942522,Application of Probiotic PS128 in Children With ASD,,Enrolling by invitation,No Results Available,Autism Spectrum Disorder,Biological: probiotics PS128|Drug: placebo (Microcrystalline cellulose ),"change in Autism Diagnostic Observation Scale (ADOS)|change in Social Responsiveness Scale (SRS)|Change in Social Communication Questionnaire (SCQ)|Change in the Autism Behavior Checklist (ABC)|Change in the Childhood Autism Rating Scale (CARS)|Change in Gesell developmental scale|Change in frequency of child behavioral problems|Change in frequency of ASD symptoms|change in gastrointestinal symptoms among children with ASD|Cytokine Analysis|Evaluate changes of type, number and structural composition of gut microorganisms in children with ASD.",Yan Hao|Tongji Hospital,All,2 Years to 5 Years   (Child),Phase 1,80.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",S313,2021-06-06,2023-06-06,2023-10-06,2021-06-28,,2021-06-28,"Tongji Hospital, Wuhan, Hubei, China",,https://ClinicalTrials.gov/show/NCT04942522
642,643,NCT05015439,Cannabidiol (CBD) in Adults With ASD,,Not yet recruiting,No Results Available,Autism Spectrum Disorder,Drug: Cannabidiol|Drug: Placebo,Change in Aberrant Behaviors as assessed by the Aberrant Behavior Checklist|Change in Anxiety as assessed by the Hamilton Anxiety Rating Scale|Change in Yale-Brown Obsessive Compulsive Scale (Y-BOCS)|Change in Clinical Global Impression Scale-Improvement (CGI)|Change in neuropsychiatric symptomatology as assessed by the Neuropsychiatric Inventory Questionnaire (NPI-Q)|Change in Waisman Activities of Daily Living scale|Change in Social Communication Questionnaire|Change in Mini Mental State Examination (MMSE)|Change in Adverse Effects- Drug Effect Questionnaire (DEQ) Subjective|Change in Adverse Effects- Drug Effect Questionnaire (DEQ) Informant|Change in Adverse Effects- Medication Side-Effects Questionnaire,Johns Hopkins University|Canopy Growth Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 1,40.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IRB00267739,2021-12-01,2023-05-01,2023-08-01,2021-08-20,,2021-09-16,,,https://ClinicalTrials.gov/show/NCT05015439
646,647,NCT01078714,Efficiency of Bumetanide in Autistic Children,BUMEA,Completed,No Results Available,Autistics Children,Drug: bumetanide,Child Autism Rating Scale score|Clinical global impressions score|Repetitive end restricted behavior score|GRAM score,"University Hospital, Brest",All,3 Years to 10 Years   (Child),Phase 3,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RB09-017,2010-03-01,2011-06-01,2011-06-01,2010-03-02,,2011-12-21,"Lemonnier, Brest, France|Chevreuil, Rennes, France|DUPIN, Vannes, France",,https://ClinicalTrials.gov/show/NCT01078714
655,656,NCT04312932,Fatty Acid Supplementation in Children With ASD (Study 2),Omega Heroes,Not yet recruiting,No Results Available,Autism Spectrum Disorder,Drug: LCPUFA Oil Supplement|Dietary Supplement: Canola Oil Placebo,Pervasive Developmental Disorder Behavior Inventory (PDDBI) - Autism Composite|Vineland Adaptive Behavior Scales 2nd ed. (modified timeframe of 90 days)|Pervasive Developmental Disorder (PDD) Behavior Inventory (PDDBI) - Aggressiveness Problems|Preschool Language Scales - 5 (PLS-5)|Childhood Autism Rating Scale (CARS2) (2nd ed.)|Autism Impact Measure,Sarah Keim|National Center for Complementary and Integrative Health (NCCIH)|Nationwide Children's Hospital,All,2 Years to 6 Years   (Child),Phase 2,96.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IRB17-00517-2,2021-10-15,2023-10-31,2024-01-31,2020-03-18,,2021-09-09,"Nationwide Children's Hospital, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04312932
664,665,NCT03432065,A Pilot Study of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders,,Not yet recruiting,No Results Available,Autism Spectrum Disorder|Anxiety,Drug: Buspirone,Reduction in Child and Adolescent Symptom Inventory-5-Anxiety (CASI-Anx) Score,Massachusetts General Hospital,All,6 Years to 17 Years   (Child),Phase 2,15.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2017-P-002731,2021-12-01,2022-08-01,2023-08-01,2018-02-13,,2021-09-23,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03432065
665,666,NCT04233502,Efficacy and Safety of Slenyto for Insomnia in Children With ASD,ASD,Withdrawn,No Results Available,Autism Spectrum Disorder,Drug: Melatonin|Drug: Placebo,Total Sleep Time (TST)|Sleep Latency (SL)|Longest Sleep Episode (LSE),Neurim Pharmaceuticals Ltd.,All,"2 Years to 18 Years   (Child, Adult)",Phase 3,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NEU_CH_7913,2020-09-01,2022-09-01,2022-12-01,2020-01-18,,2021-03-12,,,https://ClinicalTrials.gov/show/NCT04233502
668,669,NCT04060030,Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism,,Recruiting,No Results Available,Autism Spectrum Disorder|Language Disorders,Drug: Levoleucovorin Calcium|Other: Placebo,Evaluate the change in social communication symptoms|Evaluate the safety and tolerability of L-leucovorin calcium in young children with ASD|Evaluate the safety of L-leucovorin calcium in young children with ASD|Examine the change in measures of Expressive and Receptive Language|Evaluate the change in effects of autism symptoms on family members|Evaluate the change in stereotypical autism symptoms|Evaluate change in overall autism severity|Evaluate the change in overall cognitive ability|Evaluate the change in adaptive functioning|Evaluate the overall change in core ASD symptoms of social communication,Phoenix Children's Hospital|Autism Speaks|State University of New York - Downstate Medical Center|University of Arizona|New York State Institute for Basic Research,All,30 Months to 60 Months   (Child),Phase 2,80.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AS Leucovorin,2020-10-08,2022-12-01,2022-12-01,2019-08-16,,2021-03-10,"Phoenix Children's Hospital, Phoenix, Arizona, United States|State University of New York, Downstate, Brooklyn, New York, United States",,https://ClinicalTrials.gov/show/NCT04060030
670,671,NCT01170325,A Study of Divalproex Sodium in Children With ASD and Epileptiform EEG,,Withdrawn,No Results Available,Autism|Autism Spectrum Disorders,Drug: Divalproex Sodium|Drug: Placebo Comparator,epileptiform EEG discharges|Improvement in behavior,National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC),All,3 Years to 10 Years   (Child),Phase 2,0.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,100157|10-M-0157,2010-06-30,2011-01-28,2011-01-28,2010-07-27,,2017-07-02,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01170325
671,672,NCT03550209,Fatty Acid Supplementation in Children With ASD,Omega Heroes,Completed,Has Results,Autism Spectrum Disorder,Drug: LCPUFA Oil Supplement|Dietary Supplement: Canola Oil Placebo,Bioavailability|Safety (Adverse Events)|Biological Signatures,Sarah Keim|National Center for Complementary and Integrative Health (NCCIH)|Nationwide Children's Hospital,All,2 Years to 6 Years   (Child),Phase 2,72.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IRB17-00517|R61AT009632,2018-06-28,2020-01-10,2020-01-10,2018-06-08,2021-04-02,2021-08-03,"Nationwide Children's Hospital, Columbus, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT03550209/Prot_SAP_002.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT03550209/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03550209
672,673,NCT04145076,Brain Response to Serotonergic Medications in ASD,,Unknown status,No Results Available,Autism Spectrum Disorder,Drug: Placebo|Drug: Citalopram|Drug: Tianeptine,Brain excitation and inhibition response to pharmacological stimulation as assessed by magnetic resonance spectroscopy|Brain activation response to pharmacological stimulation as assessed by functional magnetic resonance imaging|Brain connectivity response to pharmacological stimulation as assessed by resting-state functional magnetic resonance imaging,King's College London,Male,18 Years to 60 Years   (Adult),Not Applicable,100.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",14/LO/0663,2014-12-15,2020-06-01,2020-07-01,2019-10-30,,2019-10-30,"King's College London, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT04145076
676,677,NCT00178503,Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children,,Completed,Has Results,Autism|Attention Deficit Disorder With Hyperactivity,Drug: Methylphenidate-extended release|Drug: Methylphenidate-immediate release|Other: Placebo,Mean Conners' Teacher ADHD Index T Score by Dose|Mean Continuous Performance Test (CPT)-Commission Errors by Dose|Mean Conners' Parent ADHD Index T Score by Week,"The University of Texas Health Science Center, Houston|National Institute of Mental Health (NIMH)",All,7 Years to 12 Years   (Child),Phase 2|Phase 3,24.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R01MH072263|DDTR B2-NDA,2005-09-01,2011-05-01,2011-05-01,2005-09-15,2013-05-07,2013-05-09,"University of Texas Health Science Center at Houston, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00178503
691,692,NCT03682978,Arbaclofen in Children and Adolescents With ASD,AIMS2-CT1,Recruiting,No Results Available,Autism Spectrum Disorder,Drug: Arbaclofen|Drug: Placebo,Effect of Arbaclofen vs. placebo on social function|Effect of Arbaclofen vs. placebo on measures of global function|Effect of Arbaclofen vs. placebo on other adaptive domains|Effect of Arbaclofen on measures of social abilities and responsiveness|Effect of Arbaclofen on measures of social abilities and responsiveness through BOSCC|Effect of Arbaclofen on measures of social abilities and responsiveness through SRS-2-P|Effect of Arbaclofen on measures of social abilities and responsiveness through SRS-2-T|Effect of Arbaclofen on measures of problem behaviours|Effect of Arbaclofen on other measures of core symptoms|Safety and tolerability of Arbaclofen in children and adolescents with ASD as assessed with the SMURF|Safety and tolerability of Arbaclofen in children and adolescents with ASD as assessed with the ESS-CHAD|Safety and tolerability of Arbaclofen in children and adolescents with ASD as assessed with the C-SSRS|Safety and tolerability of Arbaclofen in children and adolescents with ASD as assessed with a pulse rate measurement|Safety and tolerability of Arbaclofen in children and adolescents with ASD as assessed with a body temperature measurement|Safety and tolerability of Arbaclofen in children and adolescents with ASD as assessed with a blood pressure measurement|Safety and tolerability of Arbaclofen in children and adolescents with ASD as assessed by measuring weight|Safety and tolerability of Arbaclofen in children and adolescents with ASD as assessed by measuring height|Safety and tolerability of Arbaclofen in children and adolescents with ASD as assessed with the Tanner scale|Safety and tolerability of Arbaclofen in children and adolescents with ASD as assessed with blood tests|To explore the use and feasibility of digital biomarkers,"Celso Arango, MD, PhD|UMC Utrecht",All,5 Years to 17 Years   (Child),Phase 2,130.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AIMS2-CT-01|2018-000942-21,2019-09-19,2022-08-31,2022-08-31,2018-09-25,,2021-09-28,"Robert Debré Hospital, Paris, France|Hospital Clínic de Barcelona, Barcelona, Spain|Servicio de Psiquiatría del Niño y del Adolescente, Hospital General Universitario Gregorio Marañón, SERMAS, Madrid, Spain|University of Salamanca & Complejo asistencial de Zamora, Salamanca, Spain|University of Glasgow, Glasgow, United Kingdom|King's College London, London, United Kingdom|University of Newcastle upon Tyne, Newcastle, United Kingdom",,https://ClinicalTrials.gov/show/NCT03682978
693,694,NCT00183339,Early Intervention With Fluoxetine in Autism,,Completed,Has Results,Autistic Disorder,Drug: Fluoxetine|Drug: Placebo,Rate of Recruitment|Rate of Attrition|Change From Baseline to 12 Months in Total Score on Caregiver Strain Questionnaire|Change From Baseline to Month 12 in Aberrant Behavior Checklist Irritability Subscale Score (ABC-I),"University of North Carolina, Chapel Hill|National Institute of Mental Health (NIMH)",All,30 Months to 58 Months   (Child),Phase 2,18.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U54MH066418,2005-07-01,2008-02-01,2008-02-01,2005-09-16,2014-03-26,2014-03-26,"Mount Sinai School of Medicine, New York, New York, United States|University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00183339
696,697,NCT03715166,Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder,,"Active, not recruiting",No Results Available,Autism Spectrum Disorder (ASD),Drug: Bumetanide Oral Solution|Drug: Placebo,"Childhood Autism Rating Scale, Second Edition (CARS2) total raw score|Social Responsiveness Scale, Second Edition (SRS-2) total raw score|Clinical Global Impression - Global Improvement (CGI-I) score|Vineland Adaptative Behaviour Sales, Second Edition (VABS II) subscores|Adverse events and Paediatric Adverse Event Rating Scale (PAERS)|Abnormalities in 12-leads electrocardiogram (ECG) parameters|Renal ultrasound|the Columbia Suicide Severity Rating Scale Children's version (C-SSRS-C)|Tanner stage|Acceptability and palatability questionnaire|Paediatric Quality of Life Inventory (PedsQL) questionnaire","Institut de Recherches Internationales Servier|ADIR, a Servier Group company|Servier",All,7 Years to 17 Years   (Child),Phase 3,211.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CL3-95008-001|2017-004419-38,2018-09-24,2021-12-08,2021-12-08,2018-10-23,,2021-01-20,"Trial Tech em Pesquisas com Medicamentos Ltda, Curitiba, Brazil|Hospital Universitário Walter Cantídio - Universidade Federal do Ceará, Fortaleza, Brazil|Hospital São Vicente de Paulo, Passo Fundo, Brazil|Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo, Brazil|Faculdade de Medicina da Universidade de São Paulo - Departamento de Psiquiatria, São Paulo, Brazil|GSC CHU-LENVAL Centre ressource autisme, Nice, Alpes-Maritimes, France|Hôpitaux Universitaires de Strasbourg Service de Psychiatrie de l'Enfant et de l'Adolescent, Strasbourg, Alsace-Champagne-Ardenne-Lorraine, France|Centre d'Investigation Clinique de Lyon, Bron, Auvergne Rhone Alpes, France|Hôpital Le Vinatier CRA Rhône-Alpes, Bat 211, Bron, Auvergne-Rhône-Alpes, France|Hôpital Robert Debré Service de Psychiatrie de l'enfant et de l'adolescent, Paris, Il De France, France|CHU Rouen, Rouen, Normandie, France|Centre Hospitalier du Rouvray Centre de Ressources pour l'Autisme, Sotteville-lès-Rouen, Normandie, France|Hôpital des Enfants-Pellegrin, Bordeaux, Nouvelle Aquitaine, France|Centre Hospitalier Charles Perrens CRA Aquitaine, Bordeaux, Nouvelle-Aquitaine, France|Universitätsklinikum Freiburg, Zentrum für Psychische Erkrankungen, Klinik für Psychiatrie, Psychotherapie und Psychosomatik im Kindes- und Jugendalter, Freiburg, Baden-Württemberg, Germany|Klinik für Psychiatrie und Psychotherapie des Kindes- und Jugendalters am Zentralinstitut für Seelische Gesundheit, Mannheim, Baden-Württemberg, Germany|Universitätsklinikum Carl Gustav Carus an der TU Dresden, Klinik und Poliklinik für Kinder- und Jugendpsychiatrie und, Dresden, Saxony (Sachsen), Germany|Vadaskert Korhaz es Szakambulancia, Budapest, Hungary|Servus Salvus Kft., Budapest, Hungary|Bekes Megyei Kozponti Korhaz Gyermek es ifjusagpszichiatriai osztaly, Gyula, Hungary|Szegedi Tudományegyetem Szent-Gyorgy Albert Klinikai Kozpont Gyermekgyógyászati Klinika Gyermek es Ifjusagpszichiátriai o, Szeged, Hungary|Unità Semplice di Psichiatria Infantile Policlinico Universitario di Napoli - Università Federico II, Napoli, Campania, Italy|Neuro Riabilitazione/Psicopatologia dell'età evolutiva Istituto Scientifico Medea - Bosisio Parini, Bosisio Parini, Lombardia, Italy|U.O. di Neuropsichiatria Infantile Fondazione Istituto Neurologico Nazionale Casimiro Mondino Istituto di Ricovero e Cura a Carattere Scientifico, Pavia, Lombardia, Italy|Clinica di Neuropsichiatria dell'Infanzia e dell'Adolescenza Ospedale Pediatrico-Microcitemico, Cagliari, Sardegna, Italy|Programma Interdipartimentale ""Autismo 0-90"" A.O.U. Policlinico ""Gaetano Martino"", Messina, Sicilia, Italy|U.O.C. Psichiatria dello Sviluppo IRCCS Fondazione Stella Maris, Calambrone, Toscana, Italy|U.O. di Neuropsichiatria Infantile Azienda Ospedaliera Universitaria Senese, Siena, Toscana, Italy|Accare Groningen, Groningen, Netherlands|NAVICULA Centrum Diagnozy i Terapii Autyzmu w Łodzi, Lodz, Wojewodztwo Lodzkie, Poland|Samodzielny Publiczny Dziecięcy Szpital Kliniczny w Warszawie Oddział Kliniczny Psychiatrii Wieku Rozwojowego, Warszawa, Wojewodztwo Mazowieckie, Poland|Niepubliczny Zakład Opieki Zdrowotnej Gdańskie Centrum Zdrowia Sp. z o.o., Gdansk, Wojewodztwo Pomorskie, Poland|Centrum Badań Klinicznych PI-House sp. z o.o, Gdansk, Poland|Fundacja SYNAPSIS ul., Warszawa, Poland|Centro Hospitalar e Universitario de Coimbra Hospital Pediatrico, Coimbra, Portugal|Hospita Mutua de Terrassa, Terrassa, Barcelona, Spain|Policlinica Guipuzcoa, San Sebastian, Guipuzcoa, Spain|Hospital Puerta de Hierro, Majadahonda, Madrid, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Niño Jesus, Madrid, Spain|Hospital Universitario Gregorio Marañon, Madrid, Spain|Forward Thinking Birmingham_Birmingham Women's and Children's NHS Foundation Trust, Birmingham, United Kingdom|ReCognition Health, London, United Kingdom|The Winnicott Centre, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT03715166
698,699,NCT01205282,Dose Finding Study of Pioglitazone in Children With Autism Spectrum Disorders (ASD) (PIO),,Completed,No Results Available,Autism Spectrum Disorders,Drug: Pioglitazone|Drug: Placebo,"Safety of pioglitazone in children with ASD ages 5-12 years|Efficacy of outcome measure to be used in a follow-up multisite randomized control trial of pioglitazone in children with ASD|Maximum tolerated dose to be used in the follow-up multisite randomized controlled trial|Efficacy of pioglitazone on markers of inflammation (cytokine levels) and oxidative stress (superoxide dismutase, malonyl aldehydes)|Relationship between different doses and response to treatment","Evdokia Anagnostou|Holland Bloorview Kids Rehabilitation Hospital|Anagnostou, Evdokia, M.D.",All,5 Years to 12 Years   (Child),Phase 2,28.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,10-002,2013-04-01,2015-09-01,2015-09-01,2010-09-20,,2017-03-20,"Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01205282
702,703,NCT03757585,Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD),,Recruiting,No Results Available,Non-verbal Learning Disorder|Autism Spectrum Disorder|Autism,Drug: Open-label Treatment with Omega-3 Fatty Acids + Inositol|Drug: Open-label Treatment with N-acetylcysteine,Mean Change in the Parent-Young Mania Rating Scale (P-YMRS) Score|Mean Change in the Parent-completed Children's Depression Inventory (CDI)|Mean Change in the NIMH Clinical Global Improvement scale (CGI),Massachusetts General Hospital|Demarest Lloyd Jr. Foundation,All,5 Years to 17 Years   (Child),Phase 4,60.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2018P002261,2019-05-20,2021-12-01,2021-12-01,2018-11-29,,2021-02-24,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03757585
705,706,NCT04944901,"28-Day Daily-dose Crossover Study of the Safety and Tolerability of SB-121 (Lactobacillus Reuteri With Sephadex® and Maltose) in Subjects, Ages 15 to 45 Years, Diagnosed With Autistic Disorder",,Recruiting,No Results Available,Autistic Disorder,Drug: SB-121|Drug: Placebo,"Incidence and severity of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), adverse event of special interest (AESIs), and adverse events (AEs) leading to discontinuation from the study|Incidence of presence of L. reuteri and Sephadex® microspheres in the stool|Incidence of symptomatic bacteremia with positive L. reuteri identification|Change from baseline in Clinical Global Impressions Severity (CGI-S) Subscales|Change from baseline in Clinical Global Impressions Improvement (CGI-I) Subscales|Change from baseline in Vineland Adaptive Behavior Scales (3rd edition)|Change from baseline in Aberrant Behavior Checklist (ABC)|Change from baseline in Woodcock Johnson 3rd Edition (WJ-III)|Change from baseline in Repeatable Battery for Assessment of Neuropsychological Status (RBANS)|Change from baseline in Test of Attentional Performance for Children (KiTap)|Change from baseline in Neurophysiology Measures: electroencephalogram (EEG) resting state|Change from baseline in Neurophysiology Measures: auditory habituation|Change from baseline in Neurophysiology Measures: chirp modulated sweep auditory evoked response|Change from baseline in eye tracking|Change from baseline in Biomarkers: plasma oxytocin|Change from baseline in Biomarkers: plasma vasopressin|Change from baseline in Biomarkers: serum high-sensitivity C-reactive protein (hs-CRP)|Change from baseline in Biomarkers: tumor necrosis factor-α|Change from baseline in Biomarkers: stool biomarkers","Scioto Biosciences, Inc.",All,"15 Years to 45 Years   (Child, Adult)",Phase 1,16.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",SBI-SB121-20-01,2021-08-03,2021-11-29,2021-11-29,2021-06-30,,2021-09-22,"Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04944901
712,713,NCT02348125,Does Clinical Treatment of Mitochondrial Dysfunction Impact Autism Spectrum Disorder (ASD)?,MitoASD,Unknown status,No Results Available,Autism Spectrum Disorders|Mitochondrial Diseases,Drug: Mitochondrial Cocktail,Change in features of Autistic behavior phenotype assessed using the Social Responsiveness Scale (SRS)|Change in Executive Function assessed using the Behavior Rating Inventory of Executive Function (BRIEF)|Changes in mitochondrial enzyme specific activities biochemically evaluated using buccal swab analysis|Change in buccal oxidative stress markers and mitochondrial DNA (mtDNA) damage,Drexel University,All,3 Years to 12 Years   (Child),Phase 1,50.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DrexelMitoApp,2016-03-01,2017-06-01,2017-06-01,2015-01-28,,2017-04-14,"St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02348125
721,722,NCT00927030,Melatonin for Sleep in Children With Autism,NICHD,Completed,No Results Available,Autistic Disorder|Insomnia,Drug: supplemental liquid melatonin|Drug: flavored liquid or liquid supplemental melatonin,"Determine dose-response, tolerability, and adverse effects of melatonin in 30 children with autism.|A sub-set of 12 children will be studied to characterize the pharmacokinetic profile of orally administered melatonin.|A group of behavioral and parental stress measures will be piloted for the participants in this study.",Vanderbilt University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),All,4 Years to 10 Years   (Child),Phase 1,17.0,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,071269,2008-01-01,2010-04-01,2010-10-01,2009-06-24,,2012-07-02,"Vanderbilt Medical Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00927030
722,723,NCT01734941,TSO in Pediatric Autistic Spectrum Disorders,TSO,Terminated,No Results Available,Autistic Spectrum Disorders,Drug: TSO|Drug: Placebo,"Aberrant Behavior Checklist (ABC) subscale scores|Secondary assessments of efficacy will be assessed via: The change from baseline in the CY-BOCS, CGI-I, SRS, SCQ.",Hadassah Medical Organization,All,6 Years to 17 Years   (Child),Phase 2,9.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",0522-12-HMO,2014-04-01,2015-05-01,2015-05-01,2012-11-28,,2016-02-02,"The Neuro-Cognitive Center, Pediatric Division, Hadassah-Hebrew University Medical Center, Jerusalem, Mount Scopus, Israel",,https://ClinicalTrials.gov/show/NCT01734941
724,725,NCT01929642,Rapalogues for Autism Phenotype in TSC: A Feasibility Study,RAPT,Completed,Has Results,Tuberous Sclerosis Complex|Self-injury|Autism,Drug: Sirolimus|Drug: Everolimus,Number of Participants With Compliance to the Treatment Protocol.|Caregiver Burden|Feasibility Measurements of Parental Stress|Total Number of Aggressions or Self-injuries|Cognitive Function as Assessed by the Capute Scale|Repetitive Behavior|Self-Injury Trauma Scale--SIT Scale|Frequency of Seizures Assessed by Total Number of Seizures,"Hugo W. Moser Research Institute at Kennedy Krieger, Inc.",All,"2 Years to 30 Years   (Child, Adult)",Phase 2,3.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AM00037881,2013-07-01,2016-07-01,2016-08-01,2013-08-28,2021-03-29,2021-03-29,"Kennedy Krieger Institute, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01929642
726,727,NCT01694667,Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder,,Completed,Has Results,Autism Spectrum Disorders|Hyperactivity,Drug: Omega-3 Fatty Acids|Other: Placebo,Change in Aberrant Behavior Checklist - Hyperactivity Subscale (ABC-H) Score|Change in Aberrant Behavior Checklist - Lethargy Subscale Score|Change in Aberrant Behavior Checklist - Stereotypy Subscale Score|Aberrant Behavior Checklist - Irritability Subscale Score|Aberrant Behavior Checklist - Inappropriate Speech Subscale Score|Change in Social Responsiveness Scale (SRS) Score|Change in Clinical Global Impression - Improvement (CGI-I) Score,"Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|University of California, San Francisco",All,5 Years to 8 Years   (Child),Phase 2,57.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NA_00068694,2012-09-01,2012-12-01,2013-05-01,2012-09-27,2014-06-16,2020-08-31,"This study is open to continental USA, Multiple Locations, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01694667
730,731,NCT04060017,Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium,,Recruiting,No Results Available,Autism Spectrum Disorder|Language Disorders,Drug: Levoleucovorin Calcium|Other: Placebo,Evaluate the change in measures of expressive language|Evaluate the change in measures of language|Evaluate the safety and tolerability of L-leucovorin calcium in young children with ASD|Evaluate the safety of L-leucovorin calcium in young children with ASD|Evaluate the overall change in core autism symptoms of social communication|Evaluate the change in stereotypical autism symptoms|Evaluate the change in social withdrawal autism symptoms|Evaluate the change in effects of autism symptoms most problematic to family members|Evaluate change in overall autism severity|Evaluate the change in overall cognitive ability|Evaluate the change in adaptive functioning,Phoenix Children's Hospital|State University of New York - Downstate Medical Center|United States Department of Defense|University of Arizona|New York State Institute for Basic Research,All,30 Months to 60 Months   (Child),Phase 2,80.0,Other|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DOD Leucovorin,2020-09-22,2022-12-01,2022-12-01,2019-08-16,,2021-03-10,"Phoenix Children's Hospital, Phoenix, Arizona, United States|State University of New York, Downstate, Brooklyn, New York, United States",,https://ClinicalTrials.gov/show/NCT04060017
733,734,NCT01850355,An Open-Label Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders,,"Active, not recruiting",No Results Available,Autism Spectrum Disorders|Anxiety,Drug: Buspirone,Reduction in Pediatric Anxiety Rating Scale (PARS) score|Clinical Global Impression-Anxiety (CGI-Anxiety) Improvement Score,Massachusetts General Hospital,All,6 Years to 17 Years   (Child),Not Applicable,9.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2013-P-000661,2013-07-01,2021-12-01,2021-12-01,2013-05-09,,2021-07-09,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01850355
735,736,NCT02008396,Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults,,Completed,Has Results,Social Anxiety in Autistic Adults,Drug: Placebo|Drug: 75 mg to 125 mg MDMA|Behavioral: Psychotherapy,Liebowitz Social Anxiety Scale (LSAS) Total Score at Baseline|Liebowitz Social Anxiety Scale (LSAS) Total Score 1-Month Post Experimental Session 2|Change in Leibowitz Social Anxiety Scale (LSAS) Total Score From Baseline to 1-Month Post Experimental Session 2,Multidisciplinary Association for Psychedelic Studies|Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center,All,"21 Years and older   (Adult, Older Adult)",Phase 2,12.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MAA-1,2014-02-01,2017-08-01,2017-08-01,2013-12-11,2020-10-14,2021-06-22,"Los Angeles Biomedical Research Institute, Torrance, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT02008396/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT02008396/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02008396
736,737,NCT02757066,Verification of the Efficacy of NPC-15 for Sleep Disorders of Children With Autism Spectrum Disorders,NPC-15-5,Completed,No Results Available,Sleep Disorders|Autism Spectrum Disorder,Drug: NPC-15 Granules Lower Dose|Drug: NPC-15 Granules Higher Dose|Drug: NPC-15 Placebo Granule,Sleep latency with electronic sleep diary|Sleep latency measured by actigraphy|Abnormal behavior checklist Japanese version|Adverse events|Electro cardiogram,Nobelpharma,All,6 Years to 15 Years   (Child),Phase 2|Phase 3,196.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NPC-15-5,2016-06-16,2018-09-01,2018-09-14,2016-04-29,,2019-04-16,,,https://ClinicalTrials.gov/show/NCT02757066
740,741,NCT01825798,Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD),MET,Completed,Has Results,Overweight|Autism Spectrum Disorder,Drug: Metformin|Drug: Placebo,Change in Body Mass Index Z-score|Changes in Additional Body Composition Parameters (Absolute Change in Weight)|Changes in Additional Body Composition Parameters (Relative Change in Weight)|Changes in Additional Body Composition Parameters (Absolute BMI)|Changes in Additional Body Composition Parameters (Abdominal Circumference)|Changes in Additional Body Composition Parameters (Hip Circumference)|Changes in Fasting Metabolic Parameters (Total Cholesterol)|Changes in Fasting Metabolic Parameters (LDL)|Changes in Fasting Metabolic Parameters (HDL)|Changes in Fasting Metabolic Parameters (Triglycerides)|Changes in Fasting Metabolic Parameters (Glucose)|Changes in Fasting Metabolic Parameters (Insulin),"Evdokia Anagnostou|Massachusetts General Hospital|Vanderbilt University|University of Pittsburgh|Nationwide Children's Hospital|Ohio State University|Anagnostou, Evdokia, M.D.",All,6 Years to 17 Years   (Child),Phase 3,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MET-10-2012,2013-04-01,2015-06-01,2015-10-01,2013-04-08,2018-02-22,2018-02-22,"Ohio State University/Nationwide Children's Hospital, Columbus, Ohio, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States|Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01825798
742,743,NCT00047697,Donepezil HCl & Cognitive Deficits in Autism,,Completed,Has Results,Autistic Disorder,Drug: Donepezil HCl|Drug: Placebo,Cognitive Assessment: TMT|Cognitive Assessment: EOWVT Standard Score|Cognitive Assessment: CVLT,University of Pittsburgh|National Institute of Mental Health (NIMH),All,8 Years to 17 Years   (Child),Phase 2,34.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R21MH064941|DSIR CT-M3,2002-10-01,2006-08-01,2006-08-01,2002-10-16,2017-10-05,2017-10-05,"Western Psychiatric Institute & Clinic, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00047697
746,747,NCT02874690,Eye Tracking as a Predictor of Methylphenidate Response in Autism With ADHD,SAT,Completed,No Results Available,Autism Spectrum Disorder|Attention Deficit Hyperactivity Disorder,Drug: Methylphenidate|Drug: Placebo,Change in Eye-Tracking: Microsaccades and pupil size using Tobii eye tracker|Change in Short Interval IntraCortical Inhibition (SICI) using Transcranial Magnetic Stimulation (TMS)|Change in Resting State Electroencephalogram (EEG),"Children's Hospital Medical Center, Cincinnati",All,"8 Years to 21 Years   (Child, Adult)",Early Phase 1,40.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",2015-4401,2016-02-19,2017-08-03,2017-08-03,2016-08-22,,2021-01-15,"Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT02874690/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02874690
750,751,NCT01474278,A Study of RO5028442 in Adult Male High-Functioning Autistic Patients,,Completed,No Results Available,Autistic Disorder,Drug: Placebo|Drug: RO5028442,Efficacy: Behavior assessments|Safety: Incidence of adverse events,Hoffmann-La Roche,Male,18 Years to 45 Years   (Adult),Phase 1,19.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)",BP27801,2011-12-01,2013-03-01,2013-03-01,2011-11-18,,2016-11-02,"Los Ageles, California, United States|New Haven, Connecticut, United States|Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT01474278
755,756,NCT03337646,Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism,,Recruiting,No Results Available,Attention Deficit Hyperactivity Disorder|Autism Spectrum Disorder,Drug: Lisdexamfetamine Dimesylate,ADHD Symptoms|Health Related Quality of Life|Executive Function|Severity of illness|Improvement of Subjects|Safety-Adverse events|Safety - suicidality,JPM van Stralen Medicine Professional|Shire,All,6 Years to 12 Years   (Child),Phase 4,40.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RES 16-002,2018-09-26,2021-10-01,2021-10-01,2017-11-09,,2021-05-21,"Center for Pediatric Excellence, Ottawa, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT03337646
757,758,NCT02918864,Oxytocin and Social Cognitive Skills Groups,ION-ASD,Completed,No Results Available,Autism Spectrum Disorder,Drug: Oxytocin and social cognitive skills group|Behavioral: Facilitated Play Therapy,Change from Baseline in Social Behavior Composite|Change from Baseline in Social Cognition Composite|Change from Baseline in Global Functioning|Change from Baseline in Social Functioning|Change from Baseline in Quality of Life,Rush University Medical Center|University of Illinois at Chicago|University of Chicago|Northwestern University|Eotvos Lorand University,All,8 Years to 11 Years   (Child),Phase 2,83.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,14062403,2016-06-15,2021-09-01,2021-09-01,2016-09-29,,2021-10-06,"Rush University Medical Center, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT02918864
761,762,NCT02552147,Nicotinic Cholinergic Modulation as a Novel Treatment Strategy for Aggression Associated With Autism,,Completed,Has Results,Autism Spectrum Disorder|Aggression|Irritability,Drug: Transdermal nicotine|Other: Transdermal placebo,Change From Baseline in Aberrant Behavior Checklist Irritability Subscale (ABC-I)|Change in Social Responsiveness Scale-Adults (SRS-A)|Change in Qualitative Description of Irritability and Aggression Symptoms|Change in Frustration and Irritability Ratings During Frustration-induction Go-NoGo Task|Change in State/Trait Anxiety Inventory (STAI) Score|Nightly Sleep Quality,Yale University|Autism Speaks,All,18 Years to 60 Years   (Adult),Phase 1,8.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1502015384,2015-09-01,2017-11-17,2017-11-17,2015-09-16,2019-03-14,2019-03-14,"Yale University, New Haven, Connecticut, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT02552147/ICF_001.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT02552147/Prot_SAP_002.pdf",https://ClinicalTrials.gov/show/NCT02552147
763,764,NCT02677051,Sulforaphane in a New Jersey (NJ) Population of Individuals With Autism,,Recruiting,No Results Available,Autism|Autistic Disorder|Autism Spectrum Disorder|Autistic Behavior,Drug: Sulforaphane|Drug: Placebo,Change in Aberrant Behavior Checklist (ABC) scores.|Change in Social Responsiveness Scale (SRS) scores.|Clinical Global Impression Severity Scale (CGI-S).|Clinical Global Impression Improvement Scale (CGI-I) to measure change from baseline CGI-S scores.|Liver Function Tests as a screen for entry into the study and a monitor of potential change/adverse events due to treatment.|Renal Function Tests as a screen for entry into the study and a monitor of potential change/adverse events due to treatment.|Thyroid Stimulating Hormone (TSH) as a screen for entry into the study and a monitor of potential change/adverse events due to treatment.,"Rutgers, The State University of New Jersey|Rowan University",Male,"13 Years to 30 Years   (Child, Adult)",Phase 2,40.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Pro20120001884|CAUT15APL013,2016-02-01,2021-12-01,2022-07-01,2016-02-09,,2021-07-14,"Rutgers University - Staged Research Building, Piscataway, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT02677051
765,766,NCT03408886,Microbiota Transfer Therapy for Adults With Autism Spectrum Disorder (ASD) Who Have Gastrointestinal Disorders,MTT-ASD,Recruiting,No Results Available,Autism Spectrum Disorder|Gastrointestinal Disorder,Drug: Vancomycin|Drug: MoviPrep|Biological: Full Spectrum Microbiota,Change in Childhood Autism Rating Scale (CARS) from baseline to 10 weeks|Change in Daily Stool Log (DSL) from baseline to 10 weeks|Change in Social Responsiveness Scale - 2 from baseline to 10 weeks of treatment|Change in Aberrant Behavior Checklist from baseline to 10 weeks,Arizona State University,All,18 Years to 60 Years   (Adult),Phase 2,84.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MTT-Adults-1|Wi1XWH-16-1-0492,2018-01-04,2022-10-04,2023-09-01,2018-01-24,,2020-09-02,"Arizona State University, Tempe, Arizona, United States",,https://ClinicalTrials.gov/show/NCT03408886
766,767,NCT01256060,Intranasal Oxytocin for the Treatment of Children and Adolescents With ASD (OXY),,Completed,Has Results,Autism Spectrum Disorder,Drug: Intranasal Oxytocin,Maximum Tolerated Dose (MTD)|Number of Participants With Serious Adverse Events|Baseline Levels of Oxytocin in Relation to Either Safety or Treatment Response|Blood Levels of Oxytocin During the Trial in Relation to Safety or Treatment Response,"Evdokia Anagnostou|Holland Bloorview Kids Rehabilitation Hospital|The Hospital for Sick Children|University of Illinois at Chicago|Anagnostou, Evdokia, M.D.",All,10 Years to 17 Years   (Child),Phase 2,15.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,10-001,2010-11-01,2013-03-01,2013-03-01,2010-12-08,2015-04-15,2016-08-12,"Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01256060
770,771,NCT01617460,"A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder",,Completed,Has Results,Autistic Disorder,Drug: Aripiprazole,Mean Change From Baseline at the Final Assessment in Aberrant Behavior Checklist Japanese Version (ABC-J) Irritability Subscale Score,"Otsuka Pharmaceutical Co., Ltd.",All,6 Years to 17 Years   (Child),Phase 3,86.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,031-11-003,2012-09-01,2016-10-01,2016-10-01,2012-06-12,2017-10-20,2017-10-20,"Chubu Region, Japan|Chugoku Region, Japan|Kanto Region, Japan|Kinki Region, Japan|Kyushu Region, Japan",,https://ClinicalTrials.gov/show/NCT01617460
772,773,NCT04243382,"Treatment of Children With Autistic Spectrum Disorder With Autologous Umbilical Cord Blood, a Pilot Study",,Recruiting,No Results Available,Autistic Spectrum Disorder,Biological: Autologous umbilical cord blood|Biological: Placebo,Improvement of social communication skills|Functional assessment,Sheba Medical Center,All,18 Months to 12 Years   (Child),Phase 2,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SHEBA-18-5105-OBY-CTIL,2020-02-27,2024-12-01,2024-12-01,2020-01-28,,2021-01-20,"Chaim Seba Medical Center, Ramat Gan, Israel",,https://ClinicalTrials.gov/show/NCT04243382
775,776,NCT00332241,Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD),,Completed,Has Results,Autistic Disorder,Drug: Aripiprazole|Drug: Placebo,Mean Change (Week 8 - Baseline) in the Autistic Behavior Checklist (ABC) Irritability Subscale Score|Mean Clinical Global Impressions Improvement Scale (CGI-I) Score|Number of Participants With Response at Week 8|Mean Change (Week 8 - Baseline) in the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS; Compulsion Scale Only)|Mean Change (Week 8 - Baseline) in the Other ABC Subscale Scores|Mean Change (Week 8 - Baseline) in CGI-Severity (CGI-S)|Summary of Safety|Change From Baseline in Body Weight,"Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka America Pharmaceutical",All,6 Years to 17 Years   (Child),Phase 3,98.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CN138-178,2006-06-01,2008-04-01,2008-04-01,2006-06-01,2009-07-23,2013-12-02,"Marsella, Gregory, Boca Raton, Florida, United States|Child Neurology Associates, Pc, Atlanta, Georgia, United States|University Of Louisville, Louisville, Kentucky, United States|Neurobehavioral Medicine Group, Bloomfield Hills, Michigan, United States|Center For Psychiatry And Behavioral Medicine, Las Vegas, Nevada, United States|Suny - Stony Brook School Of Medicine, Stony Brook, New York, United States|Univ Of Nc, Chapel Hill, North Carolina, United States|Ut Medical Group, Memphis, Tennessee, United States|Red Oak Psychiatry Associates, Pa, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00332241
776,777,NCT01617447,A Short Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder,,Completed,Has Results,Autistic Disorder,Drug: Placebo of Aripiprazole|Drug: Aripiprazole,Mean Change From Baseline in the Aberrant Behavior Checklist Japanese Version (ABC-J) Irritability Subscale Score,"Otsuka Pharmaceutical Co., Ltd.",All,6 Years to 17 Years   (Child),Phase 3,92.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",031-11-002,2012-07-01,2015-06-01,2015-06-01,2012-06-12,2017-04-11,2017-04-11,"Chubu Region, Japan|Chugoku Region, Japan|Kanto Region, Japan|Kinki Region, Japan|Kyushu Region, Japan",,https://ClinicalTrials.gov/show/NCT01617447
784,785,NCT02847182,Cord Blood Infusion for Children With Autism Spectrum Disorder,Duke ACT,Completed,Has Results,Autism Spectrum Disorder|ASD|Autism|PDD,Biological: Cord Blood Infusion|Biological: Placebo,"Change in Social Communication as Measured by the Vineland Adaptive Behavior Scales, Third Edition (VABS-3)|Change in Vineland Socialization Domain Raw Score|Change in Vineland Socialization Domain Age Equivalent|Change in Pervasive Developmental Disorder Behavior Inventory (PDD-BI) Composite Standard Score (Parent Questionnaire)|Change in Clinical Global Impressions - Severity of Illness (CGI-S) Score, Clinician Assessment|Clinical Global Impressions - Global Improvement (CGI-I) Score, Clinician Assessment|Change in Expressive One-Word Picture Vocabulary Test (Clinician Assessment)|Change in Vineland Adaptive Behavior Scales II (VABS-II) Communication Subscale Standard Score|Change in Vineland Adaptive Behavior Scales II (VABS-II) Daily Living Subscale Standard Score|Change in Vineland Adaptive Behavior Scales II (VABS-II) Composite Score|Change in Pervasive Developmental Disorder Behavior Inventory (PDD-BI) Repetitive, Ritualistic and Pragmatic Problems T-Score|Change in PDD-BI Approach/Withdrawal Problems T-Score|Change in PDD-BI Sensory/Perceptual Approach Behaviors T-Score|Change in PDD-BI Ritualisms/Resistance to Change T-Score|Change in PDD-BI Social Pragmatic Problems T-Score|Change in PDD-BI Semantic/Pragmatic Problems T-Score|Change in PDD-BI Arousal Regulation Problems T-Score|Change in PDD-BI Specific Fears T-Score|Change in PDD-BI Aggressiveness T-Score|Change in PDD-BI Expressive Social Communication Abilities T-Score|Change in PDD-BI Receptive/Expressive Social Communication Ability T-Score|Change in PDD-BI Social Approach Behaviors T-Score|Change in PDD-BI Expressive Language T-Score|Change in PDD-BI Learning, Memory, and Receptive Language T-Score|Number of Participants With Infusion Reactions|Severity of Infusion Reactions|Number of Participants With Product-related Infections|Severity of Product-related Infections|Evidence of Alloimmunization Via Anti-HLA (Human Leukocyte Antigen) and Anti-RBC (Red Blood Cell) Antibodies and Nonspecific Markers of Systemic Inflammation (ESR, CRP)|Incidence of Graft vs. Host Disease|Severity of Graft vs. Host Disease|Incidence of Unexpected Adverse Events, by Relation to Study Product|Severity of Unexpected Adverse Events, by Relation to Study Product","Joanne Kurtzberg, MD|Duke University",All,2 Years to 7 Years   (Child),Phase 2,180.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Pro00070514,2016-09-01,2018-08-19,2019-05-01,2016-07-28,2019-12-26,2020-06-09,"Duke University Medical Center, Durham, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT02847182/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02847182
787,788,NCT00619190,Study of Aripiprazole to Treat Children and Adolescents With Autism,PAIRS,Completed,Has Results,Autistic Disorder|Asperger Syndrome|Autism Spectrum Disorder,Drug: aripiprazole,Change From Baseline in Aberrant Behavior Checklist-Irritability at 12 Weeks|Clinical Global Impressions Scale - Severity Score (CGI-S)|Change From Baseline in the Aberrant Behavior Checklist -Lethargy/Social Withdrawal Subscale at 12 Weeks,"University of North Carolina, Chapel Hill|Bristol-Myers Squibb",All,30 Months to 17 Years   (Child),Phase 2,30.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,04-1792 GCRC-2491,2006-01-01,2012-06-01,2012-06-01,2008-02-20,2014-03-26,2014-03-26,"University of North Carolina, Department of Psychiatry, Chapel Hill, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00619190
790,791,NCT01227668,Phase IV Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder,,Completed,Has Results,Irritability Associated With Autistic Disorder,Drug: Aripiprazole|Drug: Placebo,"Percentage of Patients Relapsing by Week 16|Adjusted Mean Change From Baseline to Week 16 on the Aberrant Behavior Checklist Irritability (ABC-I) Subscale Score (Last Observation Carried Forward [LOCF])|Change From Baseline in Mean Clinical Global Impression Improvement (CGI-I) Scale Score at Week 16 (Last Observation Carried Forward [LOCF])|Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Discontinuation During Phase 1",Bristol-Myers Squibb,All,6 Years to 17 Years   (Child),Phase 4,215.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CN138-603,2011-03-01,2012-06-01,2012-06-01,2010-10-25,2014-05-02,2014-05-02,"Harmonex Neuroscience Research, Inc, Dothan, Alabama, United States|Southwest Autism Research And Resource Center, Phoenix, Arizona, United States|Clinical Innovations, Inc., Costa Mesa, California, United States|Behavioral Research Specialists, Llc, Glendale, California, United States|Abbey Neuropsychology Clinic, Palo Alto, California, United States|Ucsf - Lppi, San Francisco, California, United States|Stanford University School Of Medicine, Stanford, California, United States|Children'S National Medical Center, Washington, District of Columbia, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|Palm Springs Research Institute, Hialeah, Florida, United States|Florida Clinical Research Center, Llc, Maitland, Florida, United States|Miami Children'S Hospital, Miami, Florida, United States|University Of South Florida, Tampa, Florida, United States|Institute For Behavioral Medicine, Llc, Smyrna, Georgia, United States|Kootenai Behavioral Health Center, Coeur D'Alene, Idaho, United States|Kosair Charities Pediatric Clinical Research Unit, Louisville, Kentucky, United States|Lsu Health Sciences Center, Shreveport, Louisiana, United States|Neurocare, Inc., Newton, Massachusetts, United States|Neurobehavioral Medicine Group, Bloomfield Hills, Michigan, United States|Center For Psychiatry And Behavioral Medicine, Inc, Las Vegas, Nevada, United States|Clinical Research Center Of New Jersey, Gibbsboro, New Jersey, United States|Children'S Specialized Hosp, Toms River, New Jersey, United States|Stony Brook University School Of Medicine, Stony Brook, New York, United States|Unc Chapel Hill, Chapel Hill, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|The Ohio State University Nisonger Center, Columbus, Ohio, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Ou Physician'S Child Study Center, Oklahoma City, Oklahoma, United States|Tulsa Clinical Research, Llc, Tulsa, Oklahoma, United States|Cyn3rgy Research, Gresham, Oregon, United States|Drexel University College Of Medicine, Philadelphia, Pennsylvania, United States|Western Psychiatric Institute And Clinic, Pittsburgh, Pennsylvania, United States|Holston Medical Group, Kingsport, Tennessee, United States|Insite Clinical Research, Desoto, Texas, United States|Ericksen Research And Development, Clinton, Utah, United States|Childrens Specialty Gr., Pllc, Norfolk, Virginia, United States|Virginia Treatment Center For Children, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01227668
791,792,NCT03887676,Arbaclofen vs. Placebo in the Treatment of Children and Adolescents With ASD (ARBA),ARBA,Recruiting,No Results Available,Autism Spectrum Disorder,Drug: Arbaclofen|Other: Placebo,"Vineland Adaptive Behavior Scales, Third Edition (Vineland-3) - Social Domain|Clinical Global Impressions - Impression Scale - Improvement (CGI-I)|Aberrant Behavior Checklist (ABC) - Social Withdrawal Subscale|Vineland Adaptive Behavior Scales, Third Edition (Vineland-3) - Communication Domain|Safety Monitoring Uniform Report Form (SMURF)|Clinical Global Impressions - Impression Scale - Global (CGI-I-Global)|Epworth Sleepiness Scale for Children and Adolescents (ESS-CHAD)|Suicidality assessment using the Columbia-Suicide Severity Rating Scale (C-SSRS)","Evdokia Anagnostou|Holland Bloorview Kids Rehabilitation Hospital|McMaster University|University of Western Ontario, Canada|Queen's University|Unity Health Toronto|University of Toronto|Anagnostou, Evdokia, M.D.",All,5 Years to 17 Years   (Child),Phase 2,90.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ARB-05-2018,2019-03-18,2022-05-15,2022-05-15,2019-03-25,,2021-08-13,"McMaster University, Offord Centre for Child Studies, Hamilton, Ontario, Canada|Queen's Universtiy, Kingston, Ontario, Canada|University of Western Ontario, Lawson Health Research Institute, London, Ontario, Canada|Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT03887676
793,794,NCT01337700,Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism,,Completed,Has Results,Autism Spectrum Disorder|Asperger Syndrome|Aspergers Syndrome,Drug: Milnacipran|Drug: Placebo,Change in Score on Conners Adults Attention Deficit Hyperactivity Disorder (ADHD) Rating Scale|Change in Hyperactivity as Measured by Aberrant Behavior Checklist - Hyperactivity Scale|Change in Autism Severity Levels Based on the Clinical Global Impressions Scale|Change in Repetitive Behaviors Using YBOCS-Compulsion and Rigidity Subscale|Change in Diagnostic Analysis of Nonverbal Activity-2 ADULT FACIAL EXPRESSIONS: (DANVA2-AF),Montefiore Medical Center|Forest Laboratories,All,18 Years to 50 Years   (Adult),Phase 4,10.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",10-09-299,2011-02-01,2014-07-01,2014-07-01,2011-04-19,2020-02-27,2020-02-27,"Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT01337700
797,798,NCT00773812,Placebo-Controlled Pilot Trial of Mecamylamine for Treatment of Autism Spectrum Disorders,,Completed,No Results Available,Autistic Disorder|Pervasive Developmental Disorder,Drug: mecamylamine|Drug: placebo,"The primary measure will be a global composite derived by calculating the z scores on each measure other than CGI from published norms (or from the baseline descriptives, then averaging the z scores of the various outcome measures for each individual.|OSU Autism Rating Scale-DSM-IV|Repetitive Behavior Questionnaire|Aberrant Behavior Checklist|Ohio Autism Clinical Impressions Scale|Social Responsiveness Scale|Expressive Vocabulary test-Second Edition|Adverse Experience checklist and AE log|Cognitive Battery",Ohio State University|Autism Speaks,All,4 Years to 12 Years   (Child),Phase 1,20.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2007H0096,2007-07-01,2012-11-01,2012-11-01,2008-10-16,,2017-01-13,"Nisonger Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00773812
798,799,NCT01078844,Memantine in Adult Autism Spectrum Disorder,,Terminated,Has Results,Autism|Asperger's Disorder|Pervasive Developmental Disorder NOS,Drug: memantine|Drug: Placebo,Clinical Global Impression-Scale(CGI-S),Johns Hopkins University|Forest Laboratories,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,4.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NA_00015760,2010-02-01,2010-07-01,2010-07-01,2010-03-02,2017-07-26,2017-07-26,"Johns Hopkins Bayview, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01078844
801,802,NCT00308074,An Open-Label Trial of Aripiprazole in Autism Spectrum Disorders,,Completed,Has Results,Autism|Asperger's Disorder|Pervasive Developmental Disorder,Drug: Aripiprazole,Clinical Global Impressions-Improvement|Aberrant Behavior Checklist-Irritability Subscale|Yale-Brown Obsessive Compulsive Scale (Y-BOCS)|Brief Psychiatric Rating Scale for Children (BPRS-C),Cambridge Health Alliance|Bristol-Myers Squibb,All,6 Years to 17 Years   (Child),Phase 2,14.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CHA-IRB-0119/06/05,2006-02-01,2008-12-01,2009-02-01,2006-03-29,2017-01-02,2017-02-15,"Cambridge Health Alliance, Medford, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00308074
805,806,NCT04007224,Umbilical Cord Blood vs Personalized Treatments for Improving Autistic Disorder,,Recruiting,No Results Available,Autistic Spectrum Disorder,Drug: Intranasal oxytocin|Biological: Autologous umbilical cord blood,"Improvement in behaviour, interaction with family and peers|Improvement in behavior and social interaction|Improvement in overall functioning of the child",Fundatia Bio-Forum|Spitalul Angiomedica,All,3 Years to 7 Years   (Child),Phase 1,20.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CORDUS,2019-01-17,2021-11-30,2021-12-30,2019-07-05,,2021-06-24,"Spitalul Angiomedica, Bucharest, Bucuresti, Romania|Medicover Hospital, Bucharest, Romania|Ponderas Academic Hospital, Bucharest, Romania","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT04007224/Prot_SAP_ICF_001.pdf",https://ClinicalTrials.gov/show/NCT04007224
807,808,NCT01624675,A Study to Evaluate the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents With Irritability Associated With Autistic Disorder,,Completed,No Results Available,Autistic Disorder in Children and Adolescents,Drug: Risperidone|Drug: Placebo,The change from baseline in the Aberrant Behavior Checklist-Japanese Version (ABC-J) Irritability Subscale scores|The changes from baseline in the subscale scores of Aberrant Behavior Checklist-Japanese Version (ABC-J) at each evaluation of the double-blind phase|The changes from baseline in the subscale scores of Aberrant Behavior Checklist-Japanese Version (ABC-J) at each evaluation of the open-label phase|The changes from baseline in scores of the Clinical Global Impression - Severity (CGI-S) at each evaluation time point of the double-blind phase|The changes from baseline in scores of the Clinical Global Impression - Severity (CGI-S) at each evaluation time point of the open-label-phase|The changes from baseline in scores of the Children's Global Assessment Scale (C-GAS) at each evaluation time point of the double-blind phase and open-label-phase|The changes from baseline in scores of the Children's Global Assessment Scale (C-GAS) at each evaluation time point of open-label-phase|The Clinical Global Impression-Change (CGI-C) at each evaluation time point of the double-blind phase|The Clinical Global Impression-Change (CGI-C) at each evaluation time point of the open label-phase|The Parent Satisfaction Questionnaire (PSQ) at each evaluation time point of the double-blind phase|The Parent Satisfaction Questionnaire (PSQ) at each evaluation time point of the open label-phase,Janssen Pharmaceutical K.K.,All,5 Years to 17 Years   (Child),Phase 3,39.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CR100877|RIS-AUT-JPN-01,2012-09-01,2014-10-01,2014-10-01,2012-06-21,,2015-10-15,"Fuchu, Japan|Fukui, Japan|Hirakata, Japan|Ichikawa, Japan|Kanzaki, Japan|Kobe, Japan|Kodaira, Japan|Kurashiki, Japan|Neyagawa, Japan|Okayama, Japan|Sakai, Japan|Shimotsuke, Japan|Tokyo, Japan|Toyama, Japan|Tsuyama, Japan|Tsu, Japan|Yokohama, Japan",,https://ClinicalTrials.gov/show/NCT01624675
819,820,NCT00376194,Mercury Chelation to Treat Autism,,Withdrawn,No Results Available,"Autism|Asperger's Disorder|Child Development Disorders, Pervasive",Drug: DMSA,"Improvement in social reciprocity.|Improvement in language skills, decrease in blood mercury levels.",National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC),All,4 Years to 10 Years   (Child),Phase 2,0.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,060238|06-M-0238,2006-09-01,,2007-03-01,2006-09-14,,2013-09-18,"National Institute of Mental Health (NIMH), 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00376194
824,825,NCT03900923,Cannabidiol for ASD Open Trial,,Recruiting,No Results Available,ASD|Autism Spectrum Disorder,Drug: 98% pure CBD,"Clinical Global Impression Scale -Improvement (CGI-I)|Repetitive Behavior Scale-Revised (RBS-R)|Social Responsiveness Scale, 2nd Edition (SRS-2), School-Age Form|Aberrant Behavior Checklist (ABC) - Irritability and Social Withdrawal Subscales|Anxiety, Depression and Mood Scale (ADAMS)|Screen for Child Anxiety Related Disorders (SCARED), Parent Version|Sleep Disturbance Scale for Children (SDSC)|Vineland Adaptive Behavior Scales, Third Edition (Vineland-3) Parent/Caregiver Form|Clinical Global Impression-Severity (CGI-S):|Autism Family Experience Questionnaire (AFEQ)|Anxiety Scale for Children - Autism Spectrum Disorder - Parent Versions (ASC-ASD-P)|Anxiety Scale for Children - Autism Spectrum Disorder (ASC-ASD-C) - Child Versions|OSU Autism Clinical Global Impressions: Severity|OSU Autism Clinical Global Impressions: Improvement|Behavioral Inflexibility Scale (BIS)|Home Situations Questionnaire - Modified for ASD (HSQ-ASD)|16. Strengths and Weaknesses of Attention-Deficit/Hyperactivity Disorder Symptoms and Normal Behavior (SWAN)",NYU Langone Health,All,7 Years to 17 Years   (Child),Phase 2,30.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18-00250,2019-03-12,2022-12-31,2022-12-31,2019-04-03,,2021-09-27,"NYU Langone Health, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03900923
826,827,NCT02199925,An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum,,Unknown status,No Results Available,Autism|Autistic Disorder|Asperger's Disorder|PDD|Pervasive Developmental Disorder,Drug: Gammaplex 5%,The primary objective is to assess the efficacy of Gammaplex as an immunomodulatory therapy in autistic children with evidence of immune dysfunction.|The modulatory effect of IVIG on neuroinflammation will be assessed by laboratory measurements which we believe are indicative of immune dysregulation.,Isaac Melamed|Bio Products Laboratory|IMMUNOe Research Centers,All,4 Years to 12 Years   (Child),Phase 4,30.0,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GMXAUT01,2013-06-01,2015-04-01,2015-07-01,2014-07-25,,2015-04-16,"IMMUNOe International Research Centers, Centennial, Colorado, United States",,https://ClinicalTrials.gov/show/NCT02199925
828,829,NCT04768816,Clinical Effect and Safety of Autologous Umbilical Cord Blood Transfusion in the Treatment of Autism Spectrum Disorder,,Recruiting,No Results Available,Safety Issues;Effect of Drugs,Drug: 0.9% Sodium Chloride|Biological: Autologous Umbilical Cord Blood,ABC|CARS,Guangdong Women and Children Hospital,All,"2 Years and older   (Child, Adult, Older Adult)",Phase 1,25.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,GuangdongWCHASD,2019-07-01,2022-12-31,2024-12-31,2021-02-24,,2021-02-24,"Guangdong Women and Children's Hospital and Health Institute, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT04768816
829,830,NCT04903353,Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole,,Recruiting,No Results Available,Weight Gain|Autism Spectrum Disorder|Medication Side Effect,Drug: Comparison of Risperidone and Aripiprazole,weight gain,Vanderbilt University Medical Center,All,up to 17 Years   (Child),Phase 4,350.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,210757,2021-11-01,2024-07-01,2025-07-01,2021-05-26,,2021-09-21,"Division of Developmental Medicine, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT04903353
837,838,NCT04930471,Steroid and Behaviour Changes Under Metformin,,Not yet recruiting,No Results Available,Autistic Disorder,Drug: Metformin,"Changes in GC-MS measured urinary androgen metabolite levels.|Changes in GC-MS measured urinary oestrogen metabolite levels.|Changes in GC-MS measured urinary progesterone metabolite levels.|Changes in GC-MS measured urinary aldosterone metabolite levels.|Changes in GC-MS measured urinary corticosterone metabolite levels.|Changes in GC-MS measured urinary cortisone metabolite levels.|Changes in GC-MS measured urinary cortisol metabolite levels.|Behavioral Changes|Correlation between urinary steroid hormone level changes (metabolites of androgen, oestrogen, progesterone, aldosterone, corticosterone, cortisone and cortisol) and behavioral changes measured with pearson correlation coefficient.","University Hospital Inselspital, Berne|Lindenhofstiftung",All,"18 Years and older   (Adult, Older Adult)",,45.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Steroid Changes Metformin,2021-06-01,2023-08-01,2023-12-01,2021-06-18,,2021-06-18,"Lindenhofgruppe, Berne, Switzerland",,https://ClinicalTrials.gov/show/NCT04930471
844,845,NCT02383758,An Interdisciplinary Approach to the Treatment of Encopresis in Children With Autism Spectrum Disorders,,Completed,Has Results,Encopresis|Autistic Disorder,Drug: Glycerin Suppository|Drug: Bisacodyl suppository|Drug: Senna,Percent Continent|Percent Independence|Mean Clinical Global Impression for Severity (CGI-S) Score|Mean Clinical Global Impression for Improvement (CGI-I) Score,Emory University|Organization for Autism Research,All,"5 Years to 21 Years   (Child, Adult)",Not Applicable,22.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,IRB00076608,2015-02-01,2017-01-01,2017-01-01,2015-03-09,2018-01-11,2018-07-02,"Marcus Autism Center, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT02383758
849,850,NCT01352611,Open Label Treatment of Severe Tactile Defensiveness With Intrathecal Baclofen,,Withdrawn,No Results Available,Autism Spectrum Disorder,"Drug: baclofen, intrathecal",Modified Short Sensory Profile.|Clinical Global Impression of Change in Autism Symptoms,University of Missouri-Columbia,All,"10 Years to 65 Years   (Child, Adult, Older Adult)",Not Applicable,0.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1109397,2014-09-01,2015-04-01,2015-04-01,2011-05-12,,2016-10-06,"University Hospital/University of Missouri Health Care, Columbia, Missouri, United States",,https://ClinicalTrials.gov/show/NCT01352611
873,874,NCT01730209,Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex,RAPIT,Unknown status,No Results Available,Tuberous Sclerosis Complex|TSC Related Cognitive Disability|TSC Related Autism|TSC Related Learning Problems,Drug: Everolimus|Drug: Placebo,"Cognitive ability measured by IQ|Autistic features|Social and communicational skills|Working memory and attention, information processing|Visual-motor integration|Child behavior|Executive functioning|Sleeping problems|Child health|Sensory related difficulties|Epilepsy",Erasmus Medical Center|Utrecht University,All,4 Years to 15 Years   (Child),Phase 2|Phase 3,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NL38619.078.11,2012-11-01,2015-11-01,2016-11-01,2012-11-21,,2015-05-05,"Erasmus Medical Center, Rotterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT01730209
878,879,NCT00337571,Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD),,Completed,Has Results,Behavioral Symptoms|Autistic Disorder,Drug: Aripiprazole|Drug: Placebo,Mean Change (Week 8 - Baseline) in the Autistic Behavior Checklist (ABC) Irritability Subscale Score|Mean Clinical Global Impressions Improvement Scale (CGI-I) Score|Number of Participants With Response at Week 8|Mean Change (Week 8 - Baseline) in the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS; Compulsion Scale Only)|Mean Change (Week 8 - Baseline) in the Other ABC Subscale Scores|Mean Change (Week 8 - Baseline) in CGI-Severity (CGI-S)|Summary of Safety|Change From Baseline in Body Weight,"Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka America Pharmaceutical",All,6 Years to 17 Years   (Child),Phase 3,218.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CN138-179,2006-06-01,2008-06-01,2008-06-01,2006-06-16,2009-07-23,2013-12-02,"University Of Alabama At Birmingham, Birmingham, Alabama, United States|Harmonex Neuroscience, Dothan, Alabama, United States|Southwest Autism Research And Resource Center, Phoenix, Arizona, United States|Clinical Innovations, Inc., Huntington Beach, California, United States|University Of California-Davis Medical Center, Sacramento, California, United States|Stanford University School Of Medicine, Stanford, California, United States|The Children'S Hospital, Aurora, Colorado, United States|Marsella, Gregory, Boca Raton, Florida, United States|University Of Florida, Gainesville, Florida, United States|University Of South Florida, Tampa, Florida, United States|Institute For Behavioral Medicine, Smyrna, Georgia, United States|University Of Illinois At Chicago, Chicago, Illinois, United States|Cambridge Health Alliance, Medford, Massachusetts, United States|Ladders Clinic, Wellsley, Massachusetts, United States|Children'S Hospital Of Michigan, Detroit, Michigan, United States|Regions Hospital, St. Paul, Minnesota, United States|Children'S Mercy Hospital, Kansas City, Missouri, United States|Munroe-Meyer Institute, Omaha, Nebraska, United States|North Shore - Long Island Jewish Health System, Bethpage, New York, United States|Seaver And New York Autism Center Of Excellence, New York, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Mission Hospitals, Asheville, North Carolina, United States|Duke Child And Family Study Center, Durham, North Carolina, United States|The Nisonger Center, Columbus, Ohio, United States|Cutting Edge Research, Oklahoma City, Oklahoma, United States|Western Psychiatric Institute And Clinic, Pittsburgh, Pennsylvania, United States|Dallas Pediatric Neurology Associates, Dallas, Texas, United States|Bayou City Research, Ltd., Houston, Texas, United States|Children'S National Medical Center, Fairfax, Virginia, United States|Pacific Institute Of Medical Sciences, Bothell, Washington, United States|Children'S Hospital Of Wisconsin, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00337571
883,884,NCT04053036,Effects of Drugs on Responses to Brain and Emotional Processes,MAT,Completed,No Results Available,Autism Spectrum Disorder|Healthy,Drug: MDMA|Drug: Placebo oral tablet,Change in responses to affective touch,University of Chicago,All,21 Years to 40 Years   (Adult),Early Phase 1,24.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",IRB19-0174,2019-08-08,2021-04-12,2021-04-12,2019-08-12,,2021-06-09,"University of Chicago, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT04053036
885,886,NCT00380692,Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder,,Completed,Has Results,Autistic Disorder|Attention Deficit Disorder With Hyperactivity,Drug: Atomoxetine|Drug: Placebo,ADHD Rating Scale-IV-Parent Version: Investigator Scored - Total Score|Clinical Global Impressions-ADHD-Improvement (CGI-ADHD - I)|Conners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S)|ADHD Rating Scale-IV-Parent Version: Investigator Scored Total Score|Sleep Measure Scale|Aberrant Behavior Checklist (ABC)|Children's Social Behavior Questionnaire (CSBQ) Total Score|General Health Questionnaire (GHQ) Total Score|Nijmeegse Ouderlijke Stress Index (NOSI) Total Score|Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Error Rates|Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Reaction Times for Hits and Correct Rejections|Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Standard Deviation of Reaction Times for Hits and Correct Rejections|Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error Rates|Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct Rejections|Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct Rejections|Amsterdam Neuropsychological Tasks (ANT): Pursuit Motor Control Task - Accuracy|Amsterdam Neuropsychological Tasks (ANT): Pursuit Motor Control Task - Stability of Movement|Amsterdam Neuropsychological Tasks (ANT): Go/No-Go Response Inhibition Task - Error Rates|Amsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Error Rates|Amsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Reaction Times|Cytochrome P450 2D6 Genotype,Eli Lilly and Company,All,6 Years to 17 Years   (Child),Phase 4,97.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",10483|B4Z-UT-S017,2006-10-01,2008-05-01,2008-10-01,2006-09-26,2009-07-08,2010-05-11,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amsterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Den Haag, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Groningen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hoorn, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Maastricht, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nijmegen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oosterhout, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Utrecht, Netherlands",,https://ClinicalTrials.gov/show/NCT00380692
886,887,NCT02956226,Cannabinoids for Behavioral Problems in Children With ASD,CBA,Completed,No Results Available,Autistic Disorder,Drug: Cannabinoids - 99% pure cannabinoids mix|Drug: Placebo|Drug: Cannabinoids - whole plant extract,"Change from baseline Home Situations Questionnaire-Autism Spectrum Disorder (HSQ-ASD) score, at three months. Within subject difference between the placebo condition and the whole plant extract condition.|Clinical Global Impression-Improvement scores (CGI-I ) at three months. Within subject difference between the placebo condition and the whole plant extract condition.|Clinical Global Impression-Improvement scores (CGI-I ) at three months. Within subject differences between the placebo condition and the pure cannabinoids condition and between the whole plant extract condition and the pure cannabinoids condition.|Change in Social Responsiveness Scale scores-2 (SRS-2, parent and teacher rated) at three months|Change in Autism Parenting Stress Index (APSI) score, at three months|Change from baseline Home Situations Questionnaire-Autism Spectrum Disorder (HSQ-ASD) score, at three months.",Shaare Zedek Medical Center,All,"5 Years to 21 Years   (Child, Adult)",Phase 2,150.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CBA,2017-01-01,2018-10-01,2018-12-01,2016-11-06,,2018-12-27,"Shaare Zedek Medical Center, Jerusalem, Israel",,https://ClinicalTrials.gov/show/NCT02956226
888,889,NCT03225651,Autologous Bone Marrow Stem Cell Therapy Combined With Psychological Therapy and Rehabilitation for Autism,ASPRA,Completed,No Results Available,Stem Cell Transplantation,Biological: Stem cell transplantation|Behavioral: Psychological therapy and Rehabilitation,Assess the change in autism level by using tools|Evaluate the safety of therapy by record number of adverse events,Vinmec Research Institute of Stem Cell and Gene Technology,All,3 Years to 7 Years   (Child),Phase 2,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,VinmecRISCGT69,2017-07-18,2019-08-30,2019-08-30,2017-07-21,,2019-09-06,"Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi, Vietnam",,https://ClinicalTrials.gov/show/NCT03225651
892,893,NCT00844753,"Atomoxetine, Placebo and Parent Management Training in Autism",Strattera,Completed,Has Results,Autism|Pervasive Development Disorder|Asperger's Disorder|Attention Deficit Hyperactivity Disorder,Drug: atomoxetine|Drug: Placebo|Behavioral: Parent Management Training,Percentage of Participants Who Were Attention Deficit Hyperactivity Disorder (ADHD) Respondents|Percentage of Participants Who Were Autism Spectrum Disorder Respondents,University of Rochester|University of Pittsburgh|Ohio State University,All,5 Years to 14 Years   (Child),Phase 4,128.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",1R01MH079082-01A2,2008-10-01,2014-04-01,2014-04-01,2009-02-16,2016-02-04,2016-02-04,"University of Rochester Medical Center, Rochester, New York, United States|Ohio State University, Columbus, Ohio, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00844753
895,896,NCT02909959,Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder,,Completed,Has Results,"Autism Spectrum Disorder|Autistic Disorder|Neurodevelopmental Disorder|Childhood Developmental Disorders, Pervasive",Drug: Sulforaphane|Drug: Placebo,Social Responsiveness Scale-2 (SRS-2) Total Score at Baseline|Social Responsiveness Scale-2 (SRS-2) Total Score at Week 4|Social Responsiveness Scale-2 (SRS-2) Total Score at Week 8|Social Responsiveness Scale-2 (SRS-2) Total Score at Week 12|Social Responsiveness Scale-2 (SRS-2) Total Score at Week 16|Social Responsiveness Scale-2 (SRS-2) Subscale Score (Social Awareness)|Social Responsiveness Scale-2 (SRS-2) Subscale Score (Social Cognition)|Social Responsiveness Scale-2 (SRS-2) Subscale Score (Social Communication)|Social Responsiveness Scale-2 (SRS-2) Subscale Score (Social Motivation)|Social Responsiveness Scale-2 (SRS-2) Subscale Score (Restricted Interests/Repetitive Behaviors)|Aberrant Behavior Checklist (ABC) Subscale Score (Social Withdrawal)|Aberrant Behavior Checklist (ABC) Subscale Scores (Hyperactivity)|Aberrant Behavior Checklist (ABC) Subscale Score (Inappropriate Speech)|Aberrant Behavior Checklist (ABC) Subscale Score (Stereotypy)|Aberrant Behavior Checklist (ABC) Subscale Score (Irritability)|Clinical Global Impression-Severity (CGI-S) Score|Number of Participants With Clinical Global Impression-Improvement (CGI-I) Score of Much Improved or Very Much Improved|Repetitive Behavior Scale-Revised (RBSR) Total Score|Mean Red Blood Cell Value|Mean White Blood Cell Value|Mean Hemoglobin Value|Mean Hematocrit Value|Mean Corpuscular Volume Value|Mean Corpuscular Hemoglobin Value|Mean Corpuscular Hemoglobin Concentration Value|Mean Red Blood Cell Distribution Width Value|Mean Platelets Value|Mean Absolute Neutrophils Value|Mean Absolute Lymphocytes Value|Mean Absolute Monocytes Value|Mean Absolute Eosinophils Value|Mean Absolute Basophils Value|Mean Serum Chemistries (Sodium)|Mean Serum Chemistries (Potassium)|Mean Serum Chemistries (Chloride)|Mean Serum Chemistries (Bicarbonate)|Mean Serum Chemistries (Blood Urea Nitrogen)|Mean Serum Chemistries (Creatinine)|Mean Serum Chemistries (Glucose)|Mean Liver Function Tests Values (Alanine Transaminase)|Mean Liver Function Tests Values (Aspartate Transaminase)|Mean Liver Function Tests Values (Total Bilirubin)|Mean Value of Thyroid Stimulating Hormone (TSH)|Least Squares Mean of Vital Signs (Weight)|Least Squares Mean of Vital Signs (Height)|Least Squares Mean of Vital Signs (Blood Pressure)|Least Squares Mean of Vital Signs (Heart Rate),"University of North Carolina, Chapel Hill|North Carolina Translational and Clinical Sciences Institute",Male,"13 Years to 30 Years   (Child, Adult)",Phase 2,48.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",16-2059|5KL2TR001109-05,2017-03-01,2019-05-30,2019-05-30,2016-09-21,2020-05-15,2020-06-04,"Carolina Institute for Developmental Disabilities, University of North Carolina School of Medicine, Carrboro, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT02909959/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02909959
902,903,NCT04156646,A Study to Investigate the Effect of Esomeprazole and the Effect of Food on the Pharmacokinetics of Balovaptan in Healthy Volunteers,,Completed,Has Results,Autism Spectrum Disorder,Drug: Balovaptan|Drug: Esomeprazole,Maximum Plasma Concentration (Cmax) of Balovaptan|Mean Area Under the Concentration-Time Curve From Time Extrapolated to Infinity (AUC (0-inf)) of Balovaptan|Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC(0-24h)) of Balovaptan|Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Balovaptan|Time to Reach Cmax in Plasma (Tmax) of Balovaptan|Last Quantifiable Concentration (Clast) of Balovaptan|Time To the Last Quantifiable Concentration (Tlast) of Balovaptan|Time Between Dosing and Time of First Balovaptan Plasma Concentration (Tlag)|Apparent Clearance (Cl/F) of Balovaptan|Apparent Volume of Distribution (Vd/F) of Balovaptan|Terminal Elimination Phase Half-Life (T1/2) of Balovaptan|Terminal Phase Rate Constant (λz) of Balovaptan|Plasma Concentrations of Balovaptan|Maximum Plasma Concentration (Cmax) of M2 Metabolite|Maximum Plasma Concentration (Cmax) of M3 Metabolite|Maximum Plasma Concentration (Cmax) of Esomeprazole|Area Under the Concentration-Time Curve From Time Extrapolated to Infinity (AUC (0-inf)) of M2 Metabolite|Area Under the Concentration-Time Curve From Time Extrapolated to Infinity (AUC (0-inf)) of M3 Metabolite|Area Under the Concentration-Time Curve From Time Extrapolated to Infinity (AUC (0-inf)) of Esomeprazole|Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC(0-24h)) of M2 Metabolite|Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC(0-24h)) of M3 Metabolite|Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of M2 Metabolite|Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of M3 Metabolite|Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Esomeprazole|Time to Reach Cmax in Plasma (Tmax) of M2 Metabolite|Time to Reach Cmax in Plasma (Tmax) of M3 Metabolite|Time to Reach Cmax in Plasma (Tmax) of Esomeprazole|Last Quantifiable Concentration (Clast) of M2 Metabolite|Last Quantifiable Concentration (Clast) of M3 Metabolite|Last Quantifiable Concentration (Clast) of Esomeprazole|Time To the Last Quantifiable Concentration (Tlast) of M2 Metabolite|Time To the Last Quantifiable Concentration (Tlast) of M3 Metabolite|Time To the Last Quantifiable Concentration (Tlast) of Esomeprazole|Terminal Elimination Phase Half-Life (T1/2) of M2 Metabolite|Terminal Elimination Phase Half-Life (T1/2) of M3 Metabolite|Terminal Elimination Phase Half-Life (T1/2) of Esomeprazole|Percentage of Patricipants With Adverse Events (AEs)|Terminal Phase Rate Constant (λz) of M2 Metabolite|Terminal Phase Rate Constant (λz) of M3 Metabolite|Terminal Phase Rate Constant (λz) of Esomeprazole|Plasma Concentrations of M2 Analyte|Plasma Concentrations of M3 Analyte|Plasma Concentrations of Esomeprazole,Hoffmann-La Roche,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,16.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,WP41047,2019-11-19,2019-12-24,2020-01-06,2019-11-07,2021-03-16,2021-03-16,"PRA International Clinical Pharmacology Center (EDS US Clinic), Lenexa, Kansas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT04156646/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04156646
906,907,NCT03912350,The Effect of Hepatic Impairment on the Pharmacokinetics of Balovaptan,,Suspended,No Results Available,Autism Spectrum Disorder,Drug: Balovaptan,"Plasma concentration of balovaptan|Plasma concentration of M2 metabolite, as applicable|Plasma concentration of M3 metabolite|AUC during the dosing interval on Day 1 of balovaptan|AUC during the dosing interval on Day 1 of M2 metabolite|AUC during the dosing interval on Day 1 of M3 metabolite|AUC during the dosing interval at steady state on Day 14 of balovaptan|AUC during the dosing interval at steady state on Day 14 of M2 metabolite|AUC during the dosing interval at steady state on Day 14 of M3 metabolite|Maximum observed plasma concentration (Cmax) of balovaptan|Maximum observed plasma concentration (Cmax) of M2 metabolite|Maximum observed plasma concentration (Cmax) of M3 metabolite|Time of maximum observed plasma concentration (Tmax) of balovaptan|Time of maximum observed plasma concentration (Tmax) of M2 metabolite|Time of maximum observed plasma concentration (Tmax) of M3 metabolite|Metabolite:Parent ratio of area under the plasma (MRauc) of M2 metabolite|Metabolite:Parent ratio of area under the plasma (MRauc) of M3 metabolite|Metabolite:Parent ratio of maximum observed plasma (MRcmax) of M2 metabolite|Metabolite:Parent ratio of maximum observed plasma (MRcmax) of M3 metabolite|Apparent volume of distribution (V/F) of balovaptan|Apparent volume of distribution (V/F) of M2 metabolite|Apparent volume of distribution (V/F) of M3 metabolite|Terminal phase rate constant (λZ) of balovaptan, when possible|Terminal phase rate constant (λZ) of M2 metabolite, when possible|Terminal phase rate constant (λZ) of M3 metabolite, when possible|Apparent terminal elimination half-life (t½) of balovaptan, when possible|Apparent terminal elimination half-life (t½) of M2 metabolite, when possible|Apparent terminal elimination half-life (t½) of M3 metabolite, when possible|Apparent plasma clearance after oral administration (CLss/F) of balovaptan, when possible|Apparent plasma clearance after oral administration (CLss/F) of M2 metabolite, when possible|Apparent plasma clearance after oral administration (CLss/F) of M3 metabolite, when possible|Apparent volume of distribution based on the terminal phase after oral administration (Vz/F) of balovaptan, when possible|Apparent volume of distribution based on the terminal phase after oral administration (Vz/F) of M2 metabolite, when possible|Apparent volume of distribution based on the terminal phase after oral administration (Vz/F) of M3 metabolite, when possible|Percentage of participants with adverse events",Hoffmann-La Roche,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,16.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,WP41045,2022-06-26,2022-09-24,2022-10-13,2019-04-11,,2021-05-18,"Clinical Pharmacology of Miami, Inc., Miami, Florida, United States|Orlando Clinical Research Center, Orlando, Florida, United States",,https://ClinicalTrials.gov/show/NCT03912350
914,915,NCT02985749,A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder,,"Active, not recruiting",No Results Available,Autism Spectrum Disorder|Pervasive Developmental Disorder|ASD|PDD,Drug: Intranasal Oxytocin,Social Responsiveness Scale (SRS-2 School Age form and SRS-2 Adult Self-Report)|Quality of Life Enjoyment and Satisfaction (PQ-LES-Q and Q-LES-Q),Massachusetts General Hospital,All,"12 Years to 55 Years   (Child, Adult)",Phase 3,60.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2016P002148,2017-10-09,2022-09-01,2022-09-01,2016-12-07,,2021-06-25,"Massachusetts General Hospital, Cambridge, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02985749
917,918,NCT03507569,"Open Label, Adaptive, Parallel Group PET Study Using RO7017773 And [11C] RO15-4513",,Completed,Has Results,Autism Spectrum Disorder,Drug: RO7017773|Other: [11C] Ro15-4513,Percentage of Brain Alpha5-Containing GABA-A Receptors Occupied by RO7017773|Plasma Concentrations of RO7017773|Number of Participants With Adverse Events (AEs),Hoffmann-La Roche,All,23 Years to 55 Years   (Adult),Phase 1,6.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BP40257,2018-04-24,2018-06-22,2018-06-22,2018-04-25,2019-09-30,2019-09-30,"Hammersmith Medicines Research; Central Middlesex Hospital, London, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT03507569/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03507569
918,919,NCT01931033,An Open-Label Trial of Oxytocin in Adolescents With Autism Spectrum Disorders,,"Active, not recruiting",No Results Available,Autism Spectrum Disorders|Pervasive Developmental Disorders|ASD|PDD,Drug: Intranasal Oxytocin,Social Responsiveness Scale (SRS-2)|Clinical Global Impression of PDD - Improvement (CGI-I),Massachusetts General Hospital,All,11 Years to 17 Years   (Child),Not Applicable,40.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2013-P-001548,2013-10-01,2022-06-01,2022-06-01,2013-08-29,,2021-07-09,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01931033
923,924,NCT03370510,Translating Neuroprediction Into Precision Medicine Via Brain Priming,,Recruiting,No Results Available,Autism Spectrum Disorder,Drug: Oxytocin|Behavioral: Pivotal Response Treatment|Drug: Placebo,"Social Responsiveness Scale, 2nd edition (SRS-2)|Vineland Adaptive Behavior Scale, 3rd edition (Vineland-III)",Yale University,All,5 Years to 9 Years   (Child),Phase 2,80.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2000021581,2018-12-07,2022-01-01,2022-06-01,2017-12-12,,2021-09-05,"Yale School of Medicine, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT03370510
926,927,NCT00365859,Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD),,Completed,Has Results,Autistic Disorder|Behavioral Symptoms,Drug: Aripiprazole,"Number of Participants With Serious Adverse Events (SAEs), Treatment-Emergent Adverse Events (AEs), Deaths, AEs Leading to Discontinuation, Extra Pyramidal Syndrome (EPS)-Related AEs|Mean Change From Baseline in Total Simpson-Angus Scale (SAS) At Week 8, Week 26, and Week 52|Mean Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) At Week 8, Week 26, and Week 52|Mean Change From Baseline in Barnes Akathisia Global Clinical Assessment at Week 8, Week 26, Week 52, and Endpoint|Number of Participants With Potentially Clinically Relevant Laboratory Metabolic Abnormalities|Number of Participants With Potentially Clinically Relevant Laboratory Hematology Abnormalities|Number of Participants With Potentially Clinically Relevant Laboratory Chemistry Abnormalities|Number of Participants With Potentially Clinically Relevant Eletrocardiograph (ECG) Abnormalities|Number of Potentially Clinically Relevant Vital Sign Abnormalities|Mean Change From Baseline in Patient Weight|Mean Change From Baseline by Time Period in Body Weight Z-Score|Mean Change From Baseline in Patient Body Mass Index (BMI)|Mean Change From Baseline By Time Period in BMI Z-Score|Mean Change From Baseline in Clinical Global Impression (CGI)-Severity Score at Week 52 (Endpoint, LOCF)|CGI-Improvement Score at Week 52 (Endpoint, LOCF)|Mean Change From Baseline in Aberrant Behavior Checklist (ABC) Irritability Score at Week 52 (Endpoint, LOCF)|Mean Change From Baseline in ABC Hyperactivity Subscale Score at Week 52 (Endpoint, LOCF)|Change From Baseline in ABC Stereotypy Subscale Score at Week 52 (Endpoint, LOCF)|Mean Change From Baseline in ABC Social Withdrawal Scale At Week 52 (Endpoint, LOCF)|Mean Change From Baseline in ABC Inappropriate Speech Subscale Score at Week 52 (Endpoint, LOCF)|Change From Baseline in Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) Score at Week 52 (Endpoint, LOCF)","Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka America Pharmaceutical",All,6 Years to 17 Years   (Child),Phase 3,330.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CN138-180,2006-09-01,2009-06-01,2009-06-01,2006-08-18,2010-01-25,2013-12-02,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Harmonex Neuroscience, Dothan, Alabama, United States|Southwest Autism Research and Resource Center, Phoenix, Arizona, United States|Univ of Arizona, Tuscon, Arizona, United States|Clinical Innovations, Inc, Costa Mesa, California, United States|Peninsula Research Assoc, Rolling Hills Estate, California, United States|University Of California-Davis Health Science Center, Sacramento, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|Stanford University School Of Medicine, Stanford, California, United States|The Children's Hospital, Aurora, Colorado, United States|Offices of Gregory Marsella, MD, PA, Boca Raton, Florida, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|University of Florida, Gainesville, Florida, United States|Miami Children's Hospital, Miami, Florida, United States|University of South Florida, Tampa, Florida, United States|Children's Developmental Center, Winter Park, Florida, United States|Child Neurology Associates, PC, Atlanta, Georgia, United States|Institute For Behavioral Medicine, Smyrna, Georgia, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Kansas University Medical Center, Kansas City, Kansas, United States|University of Louisville, Louisville, Kentucky, United States|Massachusetts General Hospital, Cambridge, Massachusetts, United States|Cambridge Health Alliance, Cambridge, Massachusetts, United States|Ladders Clinic, Wellsley, Massachusetts, United States|Neurobehavioral Medicine Group, Bloomfield Hills, Michigan, United States|Children's Hospital Of Michigan, Detroit, Michigan, United States|Regions Hospital, St. Paul, Minnesota, United States|Children's Mercy Hospital and Clinics, Kansas City, Missouri, United States|Munroe-Meyer Institute Diagnostic Center, Omaha, Nebraska, United States|Center for Psychiatry and Behavioral Medicine, Las Vegas, Nevada, United States|Children's Specialized Hospital, Toms River, New Jersey, United States|North Shore - Long Island Jewish Health System, Bethpage, New York, United States|Seaver and New York Autism Center of Excellence, New York, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|SUNY at Stony Brook - School of Medicine, Stony Brook, New York, United States|Mission Hospitals - Mission Children's Clinics, Asheville, North Carolina, United States|University of NC, Chapel Hill, North Carolina, United States|Duke Child and Family Study Center, Durham, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|The Nisonger Center, Columbus, Ohio, United States|Cutting Edge Research, Oklahoma City, Oklahoma, United States|Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States|UT Medical Group, Department Of Psychiatry, Memphis, Tennessee, United States|Dallas Pediatric Neurology Associates, Dallas, Texas, United States|Bayou City Research, Ltd., Houston, Texas, United States|Red Oak Psychiatry Associates, PA, Houston, Texas, United States|North San Antonio Healthcare Associates, San Antonio, Texas, United States|Children's National Medical Center, Fairfax, Virginia, United States|Neuroscience, Inc, Herndon, Virginia, United States|Monarch Research Associates, Norfolk, Virginia, United States|Virginia Treatment Center For Children, Richmond, Virginia, United States|Pacific Institute of Medical Sciences, Bothell, Washington, United States|Autism Spectrum Treatment and Research Center, Seattle, Washington, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00365859
936,937,NCT02574741,Combination Treatment for Augmenting Language in Children With ASD,PIII,Completed,No Results Available,Autism Spectrum Disorder,Behavioral: Behavioral Therapy|Drug: Aripiprazole|Drug: Placebo,Number of words as assessed in a naturalistic language assessment,"University of California, Los Angeles",All,5 Years to 11 Years   (Child),Phase 2,58.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",12-000726,2012-06-01,2019-12-01,2019-12-01,2015-10-14,,2020-04-29,"University of California, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT02574741
946,947,NCT03829878,"Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Autism Spectrum Disorder and Associated GI Symptoms (SPROUT)",SPROUT,Withdrawn,No Results Available,Autism Spectrum Disorder|Autism|ASD|Autistic Thinking|Autistic Behavior|Finch|FMT|Fecal Microbiota Transplant|CP101|SPROUT|Fecal Transplant,Drug: CP101|Drug: Placebo,Childhoood Autism Rating Scales-2 (CARS-2)|Aberrant Behavior Checklist-2 (ABC-2)|Social Responsiveness Scale-2 (SRS-2)|Parent Global Impressions-III (PGI-III)|Gastrointestinal Symptom Rating Scale (GSRS)|Gastrointestinal Stool & Symptom Questionnaire for Autism (GSSQA)|Reynolds Intellectual Assessment Scales-2-Nonverbal (RIAS-2-NV)|Autism Diagnostic Interview-Revised (ADI-R),Finch Research and Development LLC.,All,5 Years to 17 Years   (Child),Phase 2,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CP101-ASD-203,2020-05-01,2020-05-01,2021-12-01,2019-02-04,,2021-04-08,,,https://ClinicalTrials.gov/show/NCT03829878
949,950,NCT00453180,A Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders,,Completed,Has Results,"Autistic Disorder|Asperger Syndrome|Child Development Disorders, Pervasive",Drug: N-acetylcysteine|Drug: Placebo,Clinical Global Impression - Severity|Clinical Global Impression - Improvement|Aberrant Behavior Checklist|Social Responsiveness Scale|Pervasive Developmental Disorder Behavior Index|Vineland Adaptive Behavior Scales-II (VABS-II),Indiana University School of Medicine|National Alliance for Autism Research|Indiana University,All,4 Years to 12 Years   (Child),Phase 2,31.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",0611-10,2007-03-01,2009-08-01,2009-11-01,2007-03-28,2017-06-14,2017-06-14,"Riley Hospital, Riley Child and Adolescent Psychiatry Clinic, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT00453180
963,964,NCT00374764,Comparison of Applied Behavioral Analysis (ABA) Versus ABA and Risperidone,,Completed,No Results Available,Autistic Disorder,Drug: Risperidone|Behavioral: ABA,,Washington University School of Medicine,All,30 Months to 5 Years   (Child),Not Applicable,60.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,IND #58033,2000-07-01,,2002-06-01,2006-09-11,,2007-02-16,"Early Emotional Development Program, St. Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT00374764
973,974,NCT03826940,From Molecules to Cognition: Inhibitory Mechanisms in ASD and NF1,ASD/NF1inhib,Completed,No Results Available,Autism Spectrum Disorder|Neurofibromatosis 1,Drug: Lovastatin 60 MG|Drug: Placebos,Neurochemical response changes to GABAergic stimulation|Motor evoked potentials changes under motor cortical stimulation|Cortical excitability changes under motor cortical stimulation|Brain oscillations changes under sensory stimulation|Event-related potentials changes under sensory stimulation,University of Coimbra,All,"16 Years to 65 Years   (Child, Adult, Older Adult)",Not Applicable,16.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",CRU2C-ICNAS-001|FLAD Life Science 2020,2019-02-19,2020-03-31,2020-08-31,2019-02-01,,2021-04-02,"ICNAS, Coimbra, Portugal",,https://ClinicalTrials.gov/show/NCT03826940
975,976,NCT00110708,Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism,,Unknown status,No Results Available,"Autism|Autistic Disorder|Child Development Disorders, Pervasive|Gastrointestinal Diseases|Signs and Symptoms, Digestive",Drug: Oralgam (human immunoglobulin),Global improvement in gastrointestinal function|Assessment of behavior (improvement and severity); additional assessments of gastrointestinal conditions,PediaMed Pharmaceuticals,All,"2 Years to 18 Years   (Child, Adult)",Phase 2,120.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,Protocol 004,2005-04-01,,2006-06-01,2005-05-13,,2006-02-22,"Southwest Autism Research and Resource Center, Phoenix, Arizona, United States|Center for Autism Research and Education, Phoenix, Arizona, United States|University of California Davis, MIND Institute, Sacramento, California, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|University of Florida HSC, Gainesville, Florida, United States|International Child Development Resource Center, Melbourne, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|University of Kansas Medical Center, Developmental Disabilities Center, Kansas City, Kansas, United States|Bluegrass Clinical Research, Louisville, Kentucky, United States|Gulf Coast Research, LLC, Baton Rouge, Louisiana, United States|Hardy Health Associates, Hingham, Massachusetts, United States|Pivotal Research Centers - Detroit, Royal Oak, Michigan, United States|Mercy Health Research, St. Louis, Missouri, United States|Robert Wood Johnson Medical School, Piscataway, New Jersey, United States|Strong Center for Developmental Disabilities, University of Rochester Medical Center, Rochester, New York, United States|Children's Hospital Medical Center of Akron, Akron, Ohio, United States|Cincinnati Children's Hospital, Cincinnati, Ohio, United States|Nisonger Center Ohio State University, Columbus, Ohio, United States|Merck Child Outpatient Clinic, Pittsburgh, Pennsylvania, United States|North San Antonio Healthcare Associates, San Antonio, Texas, United States|Autism Spectrum Treatment and Research Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00110708
976,977,NCT04509401,Effects of High Dose of Vitamin B6 With Magnesium in Children With Autism Spectrum Disorder,,Recruiting,No Results Available,ASD,Drug: Vitamin B 6 with Magnesium|Drug: placebo of vitamin B6 and magnesium,To measure the urinary homovanillic acid Conc in µgm/mg of creatinine in Vitamin B6 with magnesium treated autistic children pre and post supplementation of Vitamin B6 and Magnesium.,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",All,2 Years to 8 Years   (Child),Not Applicable,66.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BSMMU/2019/12342,2020-01-11,2020-11-15,2020-11-15,2020-08-12,,2020-10-06,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",,https://ClinicalTrials.gov/show/NCT04509401
980,981,NCT04047355,Propranolol for Challenging Behaviors in Autism,,Recruiting,No Results Available,Autism Spectrum Disorder|Developmental Disability|Aggression|Self-Injurious Behavior|Challenging Behavior,Drug: Propranolol,Change in Aberrant Behavior Checklist (ABC-C)|Change in Clinical Global Impression Scale (CGI)|Change in Modified Overt Aggression Scale (IBR-MOAS)|Change in Questions About Behavior Function (QABF)|Change in Side Effects Survey,"Rutgers, The State University of New Jersey|New Jersey Governor's Council for Medical Research and Treatment of Autism|New York State Institute for Basic Research",All,"12 Years to 30 Years   (Child, Adult)",Phase 2,24.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Pro20170001942|CAUT17 APL025,2021-01-01,2023-01-01,2023-07-01,2019-08-06,,2021-03-16,"Department of Pediatrics, Division of Pediatric Neurology, Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT04047355
984,985,NCT01141595,Tetrahydrobiopterin Treatment in Children With Idiopathic Cognitive Developmental Disorders,,Completed,Has Results,Autism Spectrum Disorder,Drug: sapropterin dihydrochloride,Preschool Language Scales,"The University of Texas Health Science Center, Houston|BioMarin Pharmaceutical",All,2 Years to 6 Years   (Child),Not Applicable,10.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HSC-MS-09-0578,2010-07-01,2011-09-01,2011-09-01,2010-06-10,2014-02-24,2014-04-01,"Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States",,https://ClinicalTrials.gov/show/NCT01141595
988,989,NCT03426826,The Gut-Brain Study,,Recruiting,No Results Available,Autism Spectrum Disorder (ASD)|Gastro-Intestinal Disorder,Biological: FMT versus placebo,"Primary Outcome Measures, safety and tolerability|Secondary Outcome Measures, symptom improvement",Children's Hospital Los Angeles,All,5 Years to 17 Years   (Child),Phase 1,10.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",APP-18-00409,2019-08-15,2022-03-01,2022-06-01,2018-02-08,,2020-01-27,"Children's Hospital Los Angles, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT03426826
989,990,NCT01592773,"Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)",,Terminated,Has Results,Autism Spectrum Disorder (ASD)|Autism|Autistic Disorder|Asperger's Disorder|Asperger's|Pediatric Autism|Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS),Drug: Memantine Hydrochloride (HCl),Patients With Any Treatment-emergent Adverse Event,Forest Laboratories,All,6 Years to 12 Years   (Child),Phase 2,747.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MEM-MD-69,2012-10-01,2014-01-01,2014-03-01,2012-05-07,2015-02-16,2015-02-16,"Forest Investigative Site 068, Dothan, Alabama, United States|Forest Investigative Site 005, Phoenix, Arizona, United States|Forest Investigative Site 055, Tucson, Arizona, United States|Forest Investigative Site 077, Little Rock, Arkansas, United States|Forest Investigative Site 054, Glendale, California, United States|Forest Investigative Site 109, Imperial, California, United States|Forest Investigative Site 066, Irvine, California, United States|Forest Investigative Site 096, Los Angeles, California, United States|Forest Investigative Site 021, San Francisco, California, United States|Forest Investigative Site 026, Santa Ana, California, United States|Forest Investigative Site 002, Stanford, California, United States|Forest Investigative Site 078, Boulder, Colorado, United States|Forest Investigative Site 073, Centennial, Colorado, United States|Forest Investigative Site 052, Washington, District of Columbia, United States|Forest Investigative Site 075, Bradenton, Florida, United States|Forest Investigative Site 080, Gainesville, Florida, United States|Forest Investigative Site 117, Jacksonville, Florida, United States|Forest Investigative Site 065, Maitland, Florida, United States|Forest Investigative Site 118, Miami, Florida, United States|Forest Investigative Site 085, Oakland Park, Florida, United States|Forest Investigative Site 115, Orange City, Florida, United States|Forest Investigative Site 125, Orlando, Florida, United States|Forest Investigative Site 062, Orlando, Florida, United States|Forest Investigative Site 067, Tampa, Florida, United States|Forest Investigative Site 101, Wellington, Florida, United States|Forest Investigative Site 102, Libertyville, Illinois, United States|Forest Investigative Site 023, Naperville, Illinois, United States|Forest Investigative Site 082, Evansville, Indiana, United States|Forest Investigative Site 123, Fort Wayne, Indiana, United States|Forest Investigative Site 056, Indianapolis, Indiana, United States|Forest Investigative Site 061, Louisville, Kentucky, United States|Forest Investigative Site 095, Lake Charles, Louisiana, United States|Forest Investigative Site 091, New Orleans, Louisiana, United States|Forest Investigative Site 086, Rockville, Maryland, United States|Forest Investigative Site 059, Newton, Massachusetts, United States|Forest Investigative Site 108, Springfield, Massachusetts, United States|Forest Investigative Site 116, Lincoln, Nebraska, United States|Forest Investigative Site 097, Lincoln, Nebraska, United States|Forest Investigative Site 130, Henderson, Nevada, United States|Forest Investigative Site 104, Las Vegas, Nevada, United States|Forest Investigative Site 136, Neptune, New Jersey, United States|Forest Investigative Site 127, Toms River, New Jersey, United States|Forest Investigative Site 081, Albuquerque, New Mexico, United States|Forest Investigative Site 107, Albuquerque, New Mexico, United States|Forest Investigative Site 098, Bronx, New York, United States|Forest Investigative Site 072, Chapel Hill, North Carolina, United States|Forest Investigative Site 069, Avon Lake, Ohio, United States|Forest Investigative Site 001, Columbus, Ohio, United States|Forest Investigative Site 019, Oklahoma City, Oklahoma, United States|Forest Investigative Site 092, Tulsa, Oklahoma, United States|Forest Investigative Site 053, Gresham, Oregon, United States|Forest Investigative Site 132, Johnstown, Pennsylvania, United States|Forest Investigative Site 131, McMurray, Pennsylvania, United States|Forest Investigative Site 100, Media, Pennsylvania, United States|Forest Investigative Site 105, Charleston, South Carolina, United States|Forest Investigative Site 090, Memphis, Tennessee, United States|Forest Investigative Site 057, Nashville, Tennessee, United States|Forest Investigative Site 051, Houston, Texas, United States|Forest Investigative Site 070, The Woodlands, Texas, United States|Forest Investigative Site 028, Clinton, Utah, United States|Forest Investigative Site 141, Ogden, Utah, United States|Forest Investigative Site 029, Salt Lake City, Utah, United States|Forest Investigative Site 064, Charlottesville, Virginia, United States|Forest Investigative Site 113, Norfolk, Virginia, United States|Forest Investigative Site 124, Roanoke, Virginia, United States|Forest Investigative Site 071, Bothell, Washington, United States|Forest Investigative Site 119, Charleston, West Virginia, United States|Forest Investigative Site 063, Middleton, Wisconsin, United States|Forest Investigative Site 204, Brussels, Belgium|Forest Investigative Site 203, Jette, Belgium|Forest Investigative Site 155, Toronto, Ontario, Canada|Forest Investigative Site 228, Antioquia, Bello, Colombia|Forest Investigative Site 227, Barranquilla, Colombia|Forest Investigative Site 226, Bogota, Colombia|Forest Investigative Site 276, Tallinn, Estonia|Forest Investigative Site 329, Bron Cedex, Rhone, France|Forest Investigative Site 381, Budapest, Hungary|Forest Investigative Site 376, Budapest, Hungary|Forest Investigative Site 378, Budapest, Hungary|Forest Investigative Site 382, Gyula, Hungary|Forest Investigative Site 401, Kopavogur, Iceland|Forest Investigative Site 453, Roma, Italy|Forest Investigative Site 452, Siena, Italy|Forest Investigative Site 704, Yangsan-si, Gyeongsangnam-do, Korea, Republic of|Forest Investigative Site 702, Seoul, Korea, Republic of|Forest Investigative Site 703, Seoul, Korea, Republic of|Forest Investigative Site 701, Seoul, Korea, Republic of|Forest Investigative Site 526, Wellington, New Zealand|Forest Investigative Site 579, Gdansk, Poland|Forest Investigative Site 578, Gdansk, Poland|Forest Investigative Site 580, Kielce, Poland|Forest Investigative Site 576, Tyniec Maly, Poland|Forest Investigative Site 577, Warsaw, Poland|Forest Investigative Site 626, Belgrade, Serbia|Forest Investigative Site 627, Belgrade, Serbia|Forest Investigative Site 629, Nis, Serbia|Forest Investigative Site 628, Novi Sad, Serbia|Forest Investigative Site 676, Bellville Cape Town, South Africa|Forest Investigative Site 729, Barcelona, Spain|Forest Investigative Site 728, Sabadell, Spain|Forest Investigative Site 730, Torremolinos, Spain|Forest Investigative Site 803, Donetsk, Ukraine|Forest Investigative Site 807, Kharkiv, Ukraine|Forest Investigative Site 802, Kherson, Ukraine|Forest Investigative Site 804, Kyiv, Ukraine|Forest Investigative Site 801, Odessa, Ukraine",,https://ClinicalTrials.gov/show/NCT01592773
990,991,NCT01592786,"An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)",,Completed,Has Results,Autism Spectrum Disorder (ASD)|Autism|Autistic Disorder|Asperger's Disorder|Asperger's|Pediatric Autism|Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS),Drug: Memantine Hydrochloride (HCl),Number of Confirmed Social Responsiveness Scale (SRS) Responders,Forest Laboratories,All,6 Years to 12 Years   (Child),Phase 2,906.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MEM-MD-91,2012-06-01,2013-07-01,2013-08-01,2012-05-07,2014-08-07,2014-08-07,"Forest Investigative Site 068, Dothan, Alabama, United States|Forest Investigative Site 005, Phoenix, Arizona, United States|Forest Investigative Site 055, Tucson, Arizona, United States|Forest Investigative Site 077, Little Rock, Arkansas, United States|Forest Investigative Site 054, Glendale, California, United States|Forest Investigative Site 109, Imperial, California, United States|Forest Investigative Site 066, Irvine, California, United States|Forest Investigative Site 096, Los Angeles, California, United States|Forest Investigative Site 021, San Francisco, California, United States|Forest Investigative Site 026, Santa Ana, California, United States|Forest Investigative Site 002, Stanford, California, United States|Forest Investigative Site 078, Boulder, Colorado, United States|Forest Investigative Site 073, Centennial, Colorado, United States|Forest Investigative Site 052, Washington, District of Columbia, United States|Forest Investigative Site 075, Bradenton, Florida, United States|Forest Investigative Site 080, Gainesville, Florida, United States|Forest Investigative Site 117, Jacksonville, Florida, United States|Forest Investigative Site 065, Maitland, Florida, United States|Forest Investigative Site 118, Miami, Florida, United States|Forest Investigative Site 085, Oakland Park, Florida, United States|Forest Investigative Site 115, Orange City, Florida, United States|Forest Investigative Site 124, Orlando, Florida, United States|Forest Investigative Site 125, Orlando, Florida, United States|Forest Investigative Site 062, Orlando, Florida, United States|Forest Investigative Site 114, Orlando, Florida, United States|Forest Investigative Site 067, Tampa, Florida, United States|Forest Investigative Site 101, Wellington, Florida, United States|Forest Investigative Site 102, Libertyville, Illinois, United States|Forest Investigative Site 023, Naperville, Illinois, United States|Forest Investigative Site 082, Evansville, Indiana, United States|Forest Investigative Site 123, Fort Wayne, Indiana, United States|Forest Investigative Site 056, Indianapolis, Indiana, United States|Forest Investigative Site 084, Indianapolis, Indiana, United States|Forest Investigative Site 106, Wichita, Kansas, United States|Forest Investigative Site 061, Louisville, Kentucky, United States|Forest Investigative Site 074, Owensboro, Kentucky, United States|Forest Investigative Site 095, Lake Charles, Louisiana, United States|Forest Investigative Site 091, New Orleans, Louisiana, United States|Forest Investigative Site 086, Rockville, Maryland, United States|Forest Investigative Site 059, Newton, Massachusetts, United States|Forest Investigative Site 108, Springfield, Massachusetts, United States|Forest Investigative Site 116, Lincoln, Nebraska, United States|Forest Investigative Site 097, Lincoln, Nebraska, United States|Forest Investigative Site 130, Henderson, Nevada, United States|Forest Investigative Site 104, Las Vegas, Nevada, United States|Forest Investigative Site 136, Neptune, New Jersey, United States|Forest Investigative Site 127, Toms River, New Jersey, United States|Forest Investigative Site 081, Albuquerque, New Mexico, United States|Forest Investigative Site 107, Albuquerque, New Mexico, United States|Forest Investigative Site 098, Bronx, New York, United States|Forest Investigative Site 072, Chapel Hill, North Carolina, United States|Forest Investigative Site 069, Avon Lake, Ohio, United States|Forest Investigative Site 001, Columbus, Ohio, United States|Forest Investigative Site 019, Oklahoma City, Oklahoma, United States|Forest Investigative Site 092, Tulsa, Oklahoma, United States|Forest Investigative Site 053, Gresham, Oregon, United States|Forest Investigative Site 132, Johnstown, Pennsylvania, United States|Forest Investigative Site 131, McMurray, Pennsylvania, United States|Forest Investigative Site 100, Media, Pennsylvania, United States|Forest Investigative Site 105, Charleston, South Carolina, United States|Forest Investigative Site 090, Memphis, Tennessee, United States|Forest Investigative Site 057, Nashville, Tennessee, United States|Forest Investigative Site 051, Houston, Texas, United States|Forest Investigative Site 070, The Woodlands, Texas, United States|Forest Investigative Site 028, Clinton, Utah, United States|Forest Investigative Site 141, Ogden, Utah, United States|Forest Investigative Site 029, Salt Lake City, Utah, United States|Forest Investigative Site 064, Charlottesville, Virginia, United States|Forest Investigative Site 113, Norfolk, Virginia, United States|Forest Investigative Site 071, Bothell, Washington, United States|Forest Investigative Site 119, Charleston, West Virginia, United States|Forest Investigative Site 063, Middleton, Wisconsin, United States|Forest Investigative Site 177, Camperdown, New South Wales, Australia|Forest Investigative Site 204, Brussel, Belgium|Forest Investigative Site 203, Bruxelles, Belgium|Forest Investigative Site 202, Hoboken, Belgium|Forest Investigative Site 201, Leuven, Belgium|Forest Investigative Site 155, Toronto, Ontario, Canada|Forest Investigative Site 227, Barranquilla, Colombia|Forest Investigative Site 228, Bello, Colombia|Forest Investigative Site 226, Bogota, Colombia|Forest Investigative Site 276, Tallinn, Estonia|Forest Investigative Site 329, Bron, Rhone, France|Forest Investigative Site 326, Paris, France|Forest Investigative Site 379, Budapest, Hungary|Forest Investigative Site 381, Budapest, Hungary|Forest Investigative Site 376, Budapest, Hungary|Forest Investigative Site 378, Budapest, Hungary|Forest Investigative Site 382, Gyula, Hungary|Forest Investigative Site 380, Szeged, Hungary|Forest Investigative Site 401, Kopavogur, Iceland|Forest Investigative Site 453, Roma, Italy|Forest Investigative Site 452, Siena, Italy|Forest Investigative Site 704, Yangsan-si, Gyeongsangnam-do, Korea, Republic of|Forest Investigative Site 702, Seoul, Korea, Republic of|Forest Investigative Site 703, Seoul, Korea, Republic of|Forest Investigative Site 701, Seoul, Korea, Republic of|Forest Investigative Site 526, Wellington, New Zealand|Forest Investigative Site 579, Gdansk, Poland|Forest Investigative Site 578, Gdansk, Poland|Forest Investigative Site 580, Kielce, Poland|Forest Investigative Site 576, Kobierzyce, Poland|Forest Investigative Site 577, Warszawa, Poland|Forest Investigative Site 626, Belgrade, Serbia|Forest Investigative Site 627, Belgrade, Serbia|Forest Investigative Site 629, Nis, Serbia|Forest Investigative Site 628, Novi Sad, Serbia|Forest Investigative Site 651, Singapore, Singapore|Forest Investigative Site 676, Cape Town, Western Cape, South Africa|Forest Investigative Site 728, Sabadell, Barcelona, Spain|Forest Investigative Site 730, Torremolinos, Málaga, Spain|Forest Investigative Site 729, Barcelona, Spain|Forest Investigative Site 727, Madrid, Spain|Forest Investigative Site 802, Kherson, Vil. Stepanivka, Ukraine|Forest Investigative Site 803, Donetsk, Ukraine|Forest Investigative Site 807, Kharkiv, Ukraine|Forest Investigative Site 804, Kyiv, Ukraine|Forest Investigative Site 801, Odesa, Ukraine",,https://ClinicalTrials.gov/show/NCT01592786
991,992,NCT02096952,Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD,,Completed,Has Results,Attention-deficit/Hyperactivity Disorder|Autism Spectrum Disorder,Drug: Methylphenidate extended-release liquid formulation,Change in Adult ADHD Investigator Symptom Report Scale (AISRS) Score,Massachusetts General Hospital,All,18 Years to 40 Years   (Adult),Phase 4,15.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2014P000501,2014-05-01,2018-01-01,2018-01-01,2014-03-26,2018-02-23,2018-02-23,"Massachusetts General Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT02096952/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT02096952/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02096952
995,996,NCT01302964,Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders,,Completed,Has Results,Autism Spectrum Disorders,Drug: Placebo|Drug: Mirtazapine,"Mean 10-Week Change in Pediatric Anxiety Rating Scale 5-Item Total Score, Double-blind Phase|Proportion of Participants Who Responded to Treatment at 10 Weeks According to the Improvement Item of the Clinical Global Impression-Scale (Response Defined as CGI-I=1 or CGI-I=2)",Massachusetts General Hospital|Autism Speaks,All,5 Years to 17 Years   (Child),Phase 3,30.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2012P001009,2010-08-01,2017-10-10,2017-10-10,2011-02-24,2018-11-07,2018-11-07,"Riley Child and Adolescent Psychiatry Clinic Riley Hospital, Indianapolis, Indiana, United States|Lurie Center -MassGeneral Hospital, Lexington, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT01302964/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01302964
1006,1007,NCT01592747,"Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine",,Completed,Has Results,Autistic Disorder|Autism|Asperger's Disorder|Asperger Syndrome|Autism Spectrum Disorders|Pervasive Developmental Disorder - Not Otherwise Specified (PDD-NOS),Drug: Memantine Hydrochloride (HCl)|Drug: Placebo capsules,Proportion of Patients Meeting the Criterion for Loss of Therapeutic Response (LTR) by the End of the Study (Based on Observed Cases)|Time to First Loss of Therapeutic (LTR) Response|Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Speech Subscale at Week 12|Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Syntax Subscale at Week 12|Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Semantics Subscale at Week 12|Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Coherence Subscale at Week 12|Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Initiation Subscale at Week 12|Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Scripted Language Subscale at Week 12|Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Context Subscale at Week 12|Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Nonverbal Communication Subscale at Week 12|Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Social Relations Subscale at Week 12|Change From Baseline in Children's Communication Checklist-2 (CCC-2) - Interests Subscale at Week 12,Forest Laboratories,All,6 Years to 12 Years   (Child),Phase 2,479.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MEM-MD-68,2012-09-01,2013-09-01,2013-10-01,2012-05-07,2019-04-24,2019-04-24,"Forest Investigative Site 068, Dothan, Alabama, United States|Forest Investigative Site 005, Phoenix, Arizona, United States|Forest Investigative Site 055, Tucson, Arizona, United States|Forest Investigative Site 077, Little Rock, Arkansas, United States|Forest Investigative Site 054, Glendale, California, United States|Forest Investigative Site 109, Imperial, California, United States|Forest Investigative Site 096, Los Angeles, California, United States|Forest Investigative Site 021, San Francisco, California, United States|Forest Investigative Site 026, Santa Ana, California, United States|Forest Investigative Site 002, Stanford, California, United States|Forest Investigative Site 078, Boulder, Colorado, United States|Forest Investigative Site 073, Centennial, Colorado, United States|Forest Investigative Site 052, Washington, District of Columbia, United States|Forest Investigative Site 075, Bradenton, Florida, United States|Forest Investigative Site 080, Gainesville, Florida, United States|Forest Investigative Site 117, Jacksonville, Florida, United States|Forest Investigative Site 065, Maitland, Florida, United States|Forest Investigative Site 118, Miami, Florida, United States|Forest Investigative Site 085, Oakland Park, Florida, United States|Forest Investigative Site 115, Orange City, Florida, United States|Forest Investigative Site 125, Orlando, Florida, United States|Forest Investigative Site 062, Orlando, Florida, United States|Forest Investigative Site 067, Tampa, Florida, United States|Forest Investigative Site 101, Wellington, Florida, United States|Forest Investigative Site 102, Libertyville, Illinois, United States|Forest Investigative Site 023, Naperville, Illinois, United States|Forest Investigative Site 082, Evansville, Indiana, United States|Forest Investigative Site 056, Indianapolis, Indiana, United States|Forest Investigative Site 106, Wichita, Kansas, United States|Forest Investigative Site 061, Louisville, Kentucky, United States|Forest Investigative Site 095, Lake Charles, Louisiana, United States|Forest Investigative Site 086, Rockville, Maryland, United States|Forest Investigative Site 059, Newton, Massachusetts, United States|Forest Investigative Site 108, Springfield, Massachusetts, United States|Forest Investigative Site 116, Lincoln, Nebraska, United States|Forest Investigative Site 097, Lincoln, Nebraska, United States|Forest Investigative Site 130, Henderson, Nevada, United States|Forest Investigative Site 104, Las Vegas, Nevada, United States|Forest Investigative Site 136, Neptune, New Jersey, United States|Forest Investigative Site 127, Toms River, New Jersey, United States|Forest Investigative Site 081, Albuquerque, New Mexico, United States|Forest Investigative Site 107, Albuquerque, New Mexico, United States|Forest Investigative Site 072, Chapel Hill, North Carolina, United States|Forest Investigative Site 069, Avon Lake, Ohio, United States|Forest Investigative Site 001, Columbus, Ohio, United States|Forest Investigative Site 019, Oklahoma City, Oklahoma, United States|Forest Investigative Site 092, Tulsa, Oklahoma, United States|Forest Investigative Site 053, Gresham, Oregon, United States|Forest Investigative Site 132, Johnstown, Pennsylvania, United States|Forest Investigative Site 131, McMurray, Pennsylvania, United States|Forest Investigative Site 100, Media, Pennsylvania, United States|Forest Investigative Site 105, Charleston, South Carolina, United States|Forest Investigative Site 090, Memphis, Tennessee, United States|Forest Investigative Site 057, Nashville, Tennessee, United States|Forest Investigative Site 051, Houston, Texas, United States|Forest Investigative Site 070, The Woodlands, Texas, United States|Forest Investigative Site 028, Clinton, Utah, United States|Forest Investigative Site 141, Ogden, Utah, United States|Forest Investigative Site 029, Salt Lake City, Utah, United States|Forest Investigative Site 064, Charlottesville, Virginia, United States|Forest Investigative Site 113, Norfolk, Virginia, United States|Forest Investigative Site 071, Bothell, Washington, United States|Forest Investigative Site 119, Charleston, West Virginia, United States|Forest Investigative Site 063, Middleton, Wisconsin, United States|Forest Investigative Site 204, Brussel, Belgium|Forest Investigative Site 203, Bruxelles, Belgium|Forest Investigative Site 228, Bello, Colombia|Forest Investigative Site 226, Bogotá, Colombia|Forest Investigative Site 276, Tallinn, Estonia|Forest Investigative Site 329, Bron Cedex, France|Forest Investigative Site 381, Budapest, Hungary|Forest Investigative Site 376, Budapest, Hungary|Forest Investigative Site 378, Budapest, Hungary|Forest Investigative Site 401, Kopavogur, Iceland|Forest Investigative Site 453, Roma, Italy|Forest Investigative Site 452, Siena, Italy|Forest Investigative Site 704, Yangsan-si, Gyeongsangnam-do, Korea, Republic of|Forest Investigative Site 702, Seoul, Korea, Republic of|Forest Investigative Site 703, Seoul, Korea, Republic of|Forest Investigative Site 701, Seoul, Korea, Republic of|Forest Investigative Site 526, Wellington, New Zealand|Forest Investigative Site 579, Gdansk, Poland|Forest Investigative Site 578, Gdansk, Poland|Forest Investigative Site 576, Kobierzyce, Poland|Forest Investigative Site 577, Warszawa, Poland|Forest Investigative Site 626, Belgrade, Serbia|Forest Investigative Site 627, Belgrade, Serbia|Forest Investigative Site 629, Nis, Serbia|Forest Investigative Site 628, Novi Sad, Serbia|Forest Investigative Site 676, Cape Town, Western Cape, South Africa|Forest Investigative Site 728, Sabadell, Barcelona, Spain|Forest Investigative Site 807, Kharkiv, Ukraine|Forest Investigative Site 802, Kherson,Vil. Stepanivka, Ukraine|Forest Investigative Site 804, Kyiv, Ukraine",,https://ClinicalTrials.gov/show/NCT01592747
1010,1011,NCT01033565,Melatonin CR for the Treatment of Impaired Sleep Maintenance in 4-8 Year Old Children With Autism Spectrum Disorders,,Terminated,Has Results,Sleep Disorder,Drug: Natrol,Clinical Global Impression-Improvement,University of Nebraska,All,4 Years to 8 Years   (Child),Phase 4,1.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,401-09,2009-12-01,2010-10-01,2010-10-01,2009-12-16,2013-09-09,2013-09-09,"University of Nebraska Medical Center Munroe Meyer Institute, Omaha, Nebraska, United States",,https://ClinicalTrials.gov/show/NCT01033565
1017,1018,NCT02543203,Essential Oils for Enhancing QOL in ASD,,Completed,Has Results,Autism Spectrum Disorder|Quality of Life|Sleep|Anxiety,Biological: Reconnect|Biological: Coconut oil Comparator,Pediatric Quality of Life Inventory|Children's Sleep Habits Questionnaire|Parent-rated Anxiety Scale for Autism Spectrum Disorder PRAS-ASD,Jill Hollway|Young Living Essential Oils|Ohio State University,All,3 Years to 9 Years   (Child),Phase 2,28.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",2015H0005,2015-07-01,2018-03-16,2018-03-16,2015-09-07,2021-04-01,2021-04-01,"Ohio State University Nisonger Center, Columbus, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT02543203/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02543203
1023,1024,NCT02302209,Dyad Oxytocin Study (DOS),DOS,Completed,No Results Available,Schizophrenia|Autism Spectrum Disorder,Drug: Oxytocin|Other: Placebo Comparator,Change in Negative Expressed Emotion,"University of California, San Francisco",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,104.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other",10-04286,2011-04-01,2017-10-01,2017-10-01,2014-11-26,,2019-05-21,"University of California, San Francisco, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT02302209
1026,1027,NCT04535817,Xolair Interventional Study in ASD Patients With Comorbid Atopy,,Withdrawn,No Results Available,Autism Spectrum Disorder|Atopy,Drug: Omalizumab Injection [Xolair],Change from Baseline to Week 12 in Social Responsiveness Scale (SRS) Edition 2|Change from Baseline to Week 24 in Social Responsiveness Scale (SRS) Edition 2|Change from Baseline to Week 48 in Social Responsiveness Scale (SRS) Edition 2|Change from Week 24 to Week 48 in Social Responsiveness Scale (SRS) Edition 2|Change from Baseline to Week 12 in Aberrant Behavior Checklist (ABC)|Change from Baseline to Week 24 in Aberrant Behavior Checklist (ABC)|Change from Baseline to Week 48 in Aberrant Behavior Checklist (ABC)|Change from Week 24 to Week 48 in Aberrant Behavior Checklist (ABC)|Change from Baseline to Week 1 in Autism Treatment Evaluation Checklist (ATEC)|Change from Baseline to Week 4 in Autism Treatment Evaluation Checklist (ATEC)|Change from Baseline to Week 8 in Autism Treatment Evaluation Checklist (ATEC)|Change from Baseline to Week 12 in Autism Treatment Evaluation Checklist (ATEC)|Change from Baseline to Week 16 in Autism Treatment Evaluation Checklist (ATEC)|Change from Baseline to Week 20 in Autism Treatment Evaluation Checklist (ATEC)|Change from Baseline to Week 24 in Autism Treatment Evaluation Checklist (ATEC)|Change from Baseline to Week 48 in Autism Treatment Evaluation Checklist (ATEC)|Change from Week 24 to Week 48 in Autism Treatment Evaluation Checklist (ATEC)|Inflammatory Marker Levels|Structural MRI|Functional MRI (resting state)|Generalized Anxiety Disorder 7-item (GAD-7)|Epworth Sleepiness Scale (ESS)|Pittsburgh Sleep Quality Index (PSQI)|Asthma Control Test (ACT)|Rhinitis Control Assessment Test (RCAT)|Validated Investigator Global Assessment of Atopic Dermatitis (vIGA-AD),Beth Israel Deaconess Medical Center|Novartis,All,18 Years to 30 Years   (Adult),Phase 1,0.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020P000753,2021-01-01,2022-01-01,2022-01-01,2020-09-02,,2021-08-18,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT04535817
1027,1028,NCT03553875,Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions,,Recruiting,No Results Available,Autism|Autism Spectrum Disorder|Nonverbal Learning Disability,Drug: Memantine Hydrochloride|Drug: Placebo,Clinical Global Impression-Improvement Scale (CGI-I),Massachusetts General Hospital,All,"8 Years to 18 Years   (Child, Adult)",Phase 3,100.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2018P001082,2018-11-13,2022-06-01,2022-06-01,2018-06-12,,2021-07-09,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03553875
1033,1034,NCT00324909,Effects of Hyperbaric Oxygen Therapy in Autistic Children: A Pilot Study,,Completed,No Results Available,Autism|Oxidative Stress|Inflammation,Drug: Hyperbaric Oxygen Therapy,Scores on autism rating scales before and after HBOT|Measure of inflammation before and after HBOT|Measures of oxidative stress before and after HBOT,International Hyperbarics Association,All,"2 Years to 18 Years   (Child, Adult)",Not Applicable,18.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HBA-1,,,,2006-05-11,,2007-04-10,"Blue Ridge Medical Center, Arrington, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00324909
1034,1035,NCT01620060,Lurasidone Pediatric Pharmacokinetics Study,,Completed,Has Results,Schizophrenia|Autism,Drug: Lurasidone,Lurasidone Primary Pharmacokinetic Parameters|Lurasidone Peak Serum Concentration (Cmax)|Number of Participants With Serious Adverse Events and Non-serious Adverse Events,Sunovion,All,6 Years to 17 Years   (Child),Phase 1,105.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D1050300,2012-06-01,2013-05-01,2013-05-01,2012-06-15,2014-07-31,2016-04-08,"Woodland International Research Group, Inc., Little Rock, Arkansas, United States|Woodland Northwest Research, LLC, Springdale, Arkansas, United States|World Wide Research Centers Inc., Murrietta, California, United States|Segal Institute for Clinical Research, Ft. Lauderdale, Florida, United States|Miami Children's Hospital, South Miami, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|University of Cincinnati, Dept. of Psychiatry & Behavioral Neuroscience, Cincinnati, Ohio, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|CRI Worldwide, LLC, Philadelphia, Pennsylvania, United States|Aspen Clinical Research, Orem, Utah, United States",,https://ClinicalTrials.gov/show/NCT01620060
1036,1037,NCT01172509,TMS Measures of Plasticity and Excitatory/Inhibitory Ratio as Biomarkers: R-baclofen Effects in Normal Volunteers,,Terminated,No Results Available,Autism,Drug: R-baclofen,percent of baseline TMS-induced measures of (1) human synaptic plasticity (LTD),"Gonzalez-Heydrich, Joseph, M.D.|Boston Children's Hospital|Seaside Therapeutics, Inc.",All,18 Years to 30 Years   (Adult),Phase 1,6.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",TMS_biomarker_Rbac_normals1,2010-10-01,2012-07-01,2012-07-01,2010-07-29,,2015-08-21,"Berenson-Allen Center for Noninvansive Brain Stimulation Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01172509
1044,1045,NCT02428205,Combined Effects of Early Behavioral Intervention and Propranolol on ASD,,Recruiting,No Results Available,Autism,Drug: Propranolol|Drug: Placebo,Change in General Social Outcome Measure (GSOM)|Change in Social Responsiveness Scale (SRS)|Change in Preschool Anxiety Scale (PAS)|Change in Clinical Global Impression of Change (CGIC) scale|Change in Clinical Global Impression of Severity (CGIS) scale|Change in Aberrant Behavior Checklist (ABC)|Change in Vineland Adaptive Behavior Scales-II (VABS)|Change in Autism Impact Measure (AIM)|Change in Preschool Language Scale (PLS):,University of Missouri-Columbia|Autism Science Foundation,All,3 Years to 10 Years   (Child),Not Applicable,30.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2001935,2015-04-01,2022-12-01,2022-12-01,2015-04-28,,2021-04-12,"Thompson Center for Autism & Neurodevelopmental Disorders, Columbia, Missouri, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT02428205/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02428205
1047,1048,NCT01086475,D-Cycloserine and Social Skills Training in Autism Spectrum Disorders,,Completed,Has Results,Autistic Disorder|Asperger's Disorder|Pervasive Developmental Disorder NOS,Drug: D-cycloserine|Drug: Placebo,Social Responsiveness Scale (SRS) Change|Social Responsiveness Scale (SRS) at Follow-Up|Clinical Global Impressions Improvement Scale Responder Analysis,Indiana University|United States Department of Defense,All,5 Years to 11 Years   (Child),Phase 3,68.0,Other|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",0906-09,2010-03-01,2014-01-01,2014-01-01,2010-03-15,2016-04-14,2016-04-14,"Riley Hospital for Children, Indianapolis, Indiana, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01086475
1056,1057,NCT02054949,Treatment Resistant Epilepsy and N-Acetyl Cysteine,TRE-NAC,Withdrawn,No Results Available,Autistic Disorder|Seizures|Irritability,Drug: N-Acetyl Cysteine (NAC),Recruitment rate|seizure frequency,Nationwide Children's Hospital,All,"6 Years to 21 Years   (Child, Adult)",Not Applicable,0.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB12-00325,2013-04-01,2015-01-01,2015-01-01,2014-02-04,,2015-10-09,"Nationwide Children's Hospital, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02054949
1058,1059,NCT01602016,A Folinic Acid Intervention for Autism Spectrum Disorders,,Terminated,Has Results,Autism Spectrum Disorder|Autistic Disorder|Autism|Asperger's Syndrome|Pervasive Development Disorders,Drug: Folinic Acid and placebo|Drug: Folinic Acid,Language Improvement|Improved Stereotyped Behavior and Improved Social Skills,University of Arkansas|Arkansas Children's Hospital Research Institute,All,3 Years to 14 Years   (Child),Phase 2,99.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",136002,2012-05-01,2015-11-01,2015-11-01,2012-05-18,2016-11-06,2017-10-17,"Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States",,https://ClinicalTrials.gov/show/NCT01602016
1065,1066,NCT03242772,Impact of Combined Medication and Behavioral Treatment for ASD & ADHD,,Terminated,No Results Available,Autism Spectrum Disorder|Attention Deficit Hyperactivity Disorder,Drug: Amphetamine|Behavioral: ESDM informed parent coaching|Drug: Placebo Oral Tablet,"Change in amount and quality of joint engagement between the child and parent during a semi-structured 6 minute parent child interaction task|Change in Mean Socialization and Communication Subscales Standard Scores of the Vineland Adaptive Behavior Scale - 3rd edition, Interview Version (VABS-3)|Change in ADHD Symptoms using Preschool or School age ADHD Rating Scale (ADHD-RS)",Duke University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),All,36 Months to 131 Months   (Child),Phase 2,18.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Pro00085179|1P50HD093074-01,2018-12-14,2020-12-28,2021-04-19,2017-08-08,,2021-08-23,"Duke Center for Autism and Brain Development, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT03242772
1074,1075,NCT01300923,Acamprosate in Youth With Fragile X Syndrome,,Completed,Has Results,Fragile X Syndrome|Autism Spectrum Disorders,Drug: Acamprosate,Clinical Global Impression- Severity Scale (CGI-S)|The Aberrant Behavior Checklist (ABC)|Social Responsiveness Scale|Children's Yale-Brown Obsessive Compulsive Scale Modified for PDD|ADHD Rating Scale 4th Edition|Vineland Adaptive Behavior Scales-II (VABS-II) Communication Domain|Peabody Picture Vocabulary|Brain-derived Neurotrophic Factor (BDNF),Indiana University,All,5 Years to 17 Years   (Child),Phase 2,14.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1003-26,2010-08-01,2011-09-01,2011-09-01,2011-02-23,2017-04-28,2019-07-30,"Riley Child and Adolescent Psychiatry Clinic - Riley Hospital for Children, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT01300923
1077,1078,NCT00261508,A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Children With Autistic Disorder and Other Pervasive Developmental Disorders (PDD),,Completed,No Results Available,"DCild Development Disorders, Pervasive|Autistic Disorder|Developmental Disabilities|Asperger Syndrome|Rett Syndrome",Drug: risperidone,"Change in the Irritability Subscale of the Aberrant Behavior Checklist (ABC) and other ABC subscales at end of treatment compared with baseline|Change from baseline to end of treatment in Nisonger Child Behavior Rating Form (N-CBRF), Visual Analogue Scale (VAS), and Clinical Global Impression (CGI); incidence of adverse events throughout study.","Janssen-Ortho Inc., Canada",All,5 Years to 12 Years   (Child),Phase 3,80.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CR006106,1999-08-01,,2001-12-01,2005-12-05,,2011-01-24,,,https://ClinicalTrials.gov/show/NCT00261508
1084,1085,NCT00251303,Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders,,Completed,Has Results,Obsessive-Compulsive Disorder|Autism Spectrum Disorder|Autism|Asperger Disorder|Developmental Disorder,Drug: Riluzole|Drug: Placebo,Much/Very Much Improved on Clinical Global Impressions - Improvement Score (CGI-I)|Children's Yale-Brown Obsessive-Compulsive Scale Scores (CY-BOCS),National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC),All,7 Years to 17 Years   (Child),Phase 2,78.0,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",050225|05-M-0225,2005-08-01,2012-02-01,2012-02-01,2005-11-09,2014-07-15,2014-07-15,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00251303
1085,1086,NCT01993251,Does Melatonin Restore Sleep Architecture in Autistic Children,SOMELIA,Completed,No Results Available,Sleep Disorders,Drug: melatonin|Drug: Melatonin|Drug: placebo,To determine the most effective dose of melatonin to improve sleep quality in autistic children.|To assess in autistic children the melatonin effects on sleep characteristics|To assess the effectiveness of treatment on sleep disorders.|To assess the effectiveness of melatonin on daytime autistic behavior|To assess the melatonin safety in autistic children.|Establish whether there is a correlation between sleep quality and melatonin secretion.|To assess in autistic children the melatonin effects on sleep characteristics.,Hospices Civils de Lyon,All,3 Years to 12 Years   (Child),Phase 2,26.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2012-732|2013-001230-17,2014-06-01,2018-06-12,2018-06-12,2013-11-25,,2019-01-28,"Hôpital Femme Mere Enfant, Bron, France|CHU de Caen, Caen, France|Centre Hospitalier du Chinonais, Chinon, France|CHRU de Strasbourg, Strasbourg, France|CHU de Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT01993251
1101,1102,NCT00080145,RUPP PI PDD: Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders,,Completed,No Results Available,"Child Development Disorders, Pervasive",Drug: Risperidone|Behavioral: Behavior Therapy,Home Situations Questionnaire|Vineland Daily Living Skills Scale|Irritability subscale-Aberrant Behavioral Checklist|Clinical Global Impressions-Improvement (CGI-I),Yale University|National Institute of Mental Health (NIMH),All,4 Years to 13 Years   (Child),Not Applicable,124.0,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U10MH066764|U10MH066766|U10MH066768|DDTR BD-DD,2004-02-01,2007-09-01,2007-09-01,2004-03-25,,2013-08-16,"Yale University, New Haven, Connecticut, United States|Indiana University, Indianapolis, Indiana, United States|Ohio State University, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00080145
1104,1105,NCT03776656,Evaluation of a Treatment With Allopurinol in Adenylosuccinate Lyase Deficiency,ADSL,"Active, not recruiting",No Results Available,Adenylosuccinate Lyase Deficiency,Drug: Allopurinol,Measurement of adaptive functional improvement : composite total score for Vineland II adaptive behaviour Scale|Evolution of the Scores of different subdomains Vineland II scale from baseline|Evolution of the Psycho-Educative Profile (PEP III/R) from baseline|Evolution of the Score ADI-R (Autism Diagnostic Interview-Revised) from baseline|Evolution of the Score ADOS-2 (Autism Diagnostic Observation Schedule 2) from baseline|Evolution of the Score on Conners hyperactivity Scale|Evolution of the Score on ABC scale (Aberrant Behaviour Checklist)|Evolution of SAICAr levels in the urine|Evolution of S-Ado levels in the urine|Evolution of SAICAr levels in the blood|Evolution of S-Ado levels in the blood|Evolution of the number of seizures from Baseline for epileptic patients|Evolution of antiepileptic treatments from Baseline for epileptic patients|Evolution of electroencephalogram tracing from Baseline for epileptic patients,Assistance Publique - Hôpitaux de Paris|URC-CIC Paris Descartes Necker Cochin,All,"18 Months and older   (Child, Adult, Older Adult)",Phase 2,8.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P160902J|2017-002155-28,2019-10-14,2022-04-01,2022-04-01,2018-12-17,,2021-08-31,"LA PITIE-SALPETRIERE Hospital, AP-HP, Paris, France|Department of Pediatry. Reference centre of Hereditary diseases of the metabolism of child and adult. Necker - Enfants malades Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT03776656
1106,1107,NCT04475848,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants",,Recruiting,No Results Available,"Autistic Disorder|Autism Spectrum Disorder|Child Development Disorders, Pervasive|Mental Disorders|Neurodevelopmental Disorders",Drug: RO6953958|Drug: Placebo,Percentage of Participants with Adverse Events in Part 1|Percentage of Participants with Adverse Events in Part 2|Part 2: Change in suicide risk assessed using the Columbia Suicide Severity Rating Scale (C-SSRS)|Part 1: Maximum Observed Plasma Concentration (Cmax) of RO6953958 and its Metabolites RO7021594 and RO7045755 in Fasted and Fed state|Part 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) of RO6953958 and its Metabolites RO7021594 and RO7045755 in Fasted and Fed state|Part 1: Last Quantifiable Concentration (Clast) of RO6953958 and its Metabolites RO7021594 and RO7045755 in Fasted and Fed state|Part 1: Time To the Last Quantifiable Concentration (Tlast) of RO6953958 and its Metabolites RO7021594 and RO7045755 in Fasted and Fed state|Part 1: Terminal Elimination Phase Half-Life (T1/2) of RO6953958 and its Metabolites RO7021594 and RO7045755 in Fasted and Fed state|Part 1: Area Under the Concentration-Time Curve from Time 0 to 12 hours (AUC(0-12h)) of RO6953958 and its Metabolites RO7021594 and RO7045755 in Fasted and Fed state|Part 1: Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of RO6953958 and its Metabolites RO7021594 and RO7045755 in Fasted and Fed state|Part 1: Area Under the Concentration-Time Curve from Time Extrapolated to Infinity (AUC (0-inf)) of RO6953958 and its Metabolites RO7021594 and RO7045755 in Fasted and Fed state|Part 1: Apparent Clearance (CL/F) of RO6953958 in Fasted and Fed state|Part 1: Apparent Volume of Distribution (V/F) of RO6953958 in Fasted and Fed state|Part 1: Cumulative Amount of Unchanged Drug Excreted into the Urine (Ae) of RO6953958 and its Metabolites RO7021594 and RO7045755 in Fasted and Fed state|Part 1: Fraction of the Administered Drug Excreted into the Urine (Fe) of RO6953958 in Fasted and Fed state|Part 1: Renal Clearance of the Drug from Urine (CLR) of RO6953958 in Fasted and Fed state|Parts 2: Cmax of RO6953958 and its Metabolites RO7021594 and RO7045755|Parts 2: Molecular Weight Adjusted Metabolite-to-Parent Ratio for Cmax of RO6953958 and its Metabolites RO7021594 and RO7045755|Parts 2: Average Plasma Concentration (Cavg) of RO6953958 and its Metabolites RO7021594 and RO7045755|Part 2: Tmax of RO6953958 and its Metabolites RO7021594 and RO7045755|Part 2: Area Under the Concentration-Time Curve (AUC(0-t)) of RO6953958 and its Metabolites RO7021594 and RO7045755|Part 2: Molecular Weight Adjusted Metabolite-to-Parent Ratio for Area Under the Concentration-Time Curve (AUC(0-t)) of RO6953958 and its Metabolites RO7021594 and RO7045755|Part 2: T1/2 of RO6953958 and its Metabolites RO7021594 and RO7045755|Part 2: CL/F of RO6953958|Part 2: V/F of RO6953958|Part 2: Ae of RO6953958|Part 2: Fe of RO6953958|Part 2: CLR of RO6953958|Part 2: Trough Plasma Concentration (Ctrough) of RO6953958 and its Metabolites RO7021594 and RO7045755|Part 2: Accumulation Ratio based on AUC (Rauc) of RO6953958 and its Metabolites RO7021594 and RO7045755|Part 2: Accumulation Ratio Based on Cmax (RCmax) of RO6953958 and its Metabolites RO7021594 and RO7045755|Part 2: Accumulation Ratio based on Ctrough (RCtrough) of RO6953958 and its Metabolites RO7021594 and RO7045755,Hoffmann-La Roche,Male,18 Years to 55 Years   (Adult),Phase 1,80.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP41695|2019-004486-41,2020-07-15,2021-11-08,2021-11-08,2020-07-17,,2021-09-17,"Hammersmith Medicines Research; Central Middlesex Hospital, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT04475848
1109,1110,NCT01914393,Pediatric Open-Label Extension Study,,Completed,Has Results,Schizophrenia|Autism|Bipolar Depression,"Drug: Lurasidone 20, 40, 60, 80 mg, flexibly dosed","Number of Subjects With Adverse Events (AEs), Discontinuations Due to AEs and Serious AEs (SAEs)|Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score|Change From Baseline in PANSS Positive Subscale Score|Change From Baseline in PANSS Negative Subscale Score|Change From Baseline in PANSS General Psychopathology Subscale Score|Change From Baseline in PANSS Excitability Subscale Score|Change From Baseline in the Clinical Global Impression -Severity Score|Change From Baseline in Clinician-Rated Children's Global Assessment Score (CGAS) Score|Change From Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Percentage Maximum Possible Score|Change From Baseline in Aberrant Behavior Checklist (ABC) Irritability Subscale Score|Change From Baseline in Aberrant Behavior Checklist (ABC) Lethargy and Social Withdrawal Subscale Score|Change From Baseline in Aberrant Behavior Checklist (ABC) Stereotypic Behavior Subscale Score|Change From Baseline in Aberrant Behavior Checklist (ABC) Hyperactivity and Noncompliance Subscale Score|Change From Baseline in Aberrant Behavior Checklist (ABC) Inappropriate Speech Subscale Score|Change From Baseline in Clinical Global Impression (CGI) - Severity Score|Change From Baseline in Children's Yale-Brown Obsessive Compulsive Score (CY-BOCS)|Change From Baseline in Caregiver Strain Questionnaire (CGSQ) Global Strain Score|Change From Baseline in Children's Depression Rating Scale, Revised (CDRS-R) Total Score|Change From Baseline in Clinical Global Impression Bipolar Version (CGI-BP-S) Depression Score|Change From Baseline in Clinician-rated Children's Global Assessment Scale (CGAS) Score|Change From Baseline in Pediatric Anxiety Rating Scale (PAR) Total Score|Change From Baseline in Attention-Deficity/Hyperactivity Disorder Rating Scale (ADHD-RS) Total Score",Sunovion,All,6 Years to 17 Years   (Child),Phase 3,702.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D1050302|2013-001694-24,2013-09-30,2018-10-17,2018-10-17,2013-08-02,2019-12-19,2019-12-19,"Harmonex Neuroscience Research, Dothan, Alabama, United States|Diligent Clinical Trials, Inc, Downey, California, United States|University of California San Francisco Medical Center, San Francisco, California, United States|Neuropsychiatric Research Center of Orange County, Santa Ana, California, United States|Sarkis Clinical Trials - Parent, Gainesville, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|APG Research, LLC, Orlando, Florida, United States|University of South Florida, Saint Petersburg, Florida, United States|Medical Research Group of Central Florida, Sanford, Florida, United States|University of South Florida Rothman Center of Neuropychiatry, Tampa, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Attalla Consultants, LLC, Smyrna, Georgia, United States|Psychiatric Associates, Overland Park, Kansas, United States|University Of Kentucky, Lexington, Kentucky, United States|Lake Charles Clinical Trials LLC,2770 3rd Avenue,Suite 340, Lake Charles, Louisiana, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|Neurobehavioral medicine Group, LLC, Bloomfield Hills, Michigan, United States|St. Charles Psychiatric Associates, Saint Charles, Missouri, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|North Shore/Long Island Jewish PRIME, Glen Oaks, New York, United States|Dr. Jeanette Cueva, Mount Kisco, New York, United States|Montefiore Medical Center PRIME, New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|The Ohio State University Nisonger Center, Columbus, Ohio, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Pillar Clinical Research, LLC, Dallas, Texas, United States|Family Psychiatry of The Woodlands, P.A., The Woodlands, Texas, United States|Ericksen Research & Development, LLC, Clinton, Utah, United States|University of Virginia, Charlottesville, Virginia, United States|Neuroscience, Inc., Herndon, Virginia, United States|Clinical Research Partners, LLC, Petersburg, Virginia, United States|Carilion Clinic, Roanoke, Virginia, United States|MHC - Ruse, EOOD, Ruse, Bulgaria|UMHAT ""Alexandrovska"" EAD, Sofia, Bulgaria|MHAT-Targovishte, AD, Targovishte, Bulgaria|DCC ""Mladost M"" - Varna, OOD, Varna, Bulgaria|Centro de Investigaciones y Proyectos en Neurociencias CIPNA, Barranquilla, Colombia|E.S.E. Hospital Mental de Antioquia, Bello, Colombia|Centro de Investigaciones del Sistema Nervioso Limitada - Grupo CISNE Ltda, Bogota, Colombia|CHU Nantes - Hôpital Mère-Enfant, Nantes Cedex 1, France|Vadaskert Alapitvany a Gyermekek Lelki Egeszsegeert, Budapest, Hungary|Bekes Megyei Pandy Kalman Korhaz, Gyula, Hungary|Seoul National University Hospital, Seoul, Gyeonggi-do, Korea, Republic of|Chonnam National University Hospital, Gwangju, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Chonbuk National University Hospital, Jeonju, Korea, Republic of|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Centro para el Desarrollo de la Medicina y de Asistencia Medica Especializada S.C., Culiacan, Sinaloa, Mexico|Dr. Jessica Rosas Escobar, Durango, Mexico|Instituto de Investigaciones Aplicadas a la Neurociencia A.C., Durango, Mexico|Accelerium S. de R.L. de C.V., Monterrey, Mexico|Instituto de Informacion de Investigacion en Salud Mental, Monterrey, Mexico|Av Modesto Arreola #917 Ote. Col Centro, Nuevo León, Mexico|Alexian Brothers Health and Wellness Center, Davao City, Philippines|West Visayas State University Medical Center, Iloilo, Philippines|National Center for Mental Health, Mandaluyong City, Philippines|Veterans Memorial Medical Center, Quezon City, Philippines|NZOZ Poradnia Zdrowia Psychicznego, Kobierzyce, Poland|Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu, Oddzial Kliniczmy VI Psychiatrii Mlodziezy, Toruń, Poland|Centro de Investigacion Clinica Psiquiatrica, Caguas, Puerto Rico|Spitalul Clinic de Psihiatrie Prof. Dr. Alexandru Obregia, Bucuresti, Romania|Spitalul Clinic de Psihiatrie Socola, Iasi, Romania|Spitalul Clinic de Urgenta pentru Copii ""Louis Turcanu"" Timisoara, Timisoara, Romania|Sverdiovsk Regional Clinical Psychiatric Hospital, Ekaterinburg, Russian Federation|GUZ Lipetsk Regional psychoneurological Hospital #1, Lipetsk, Russian Federation|Closed corporation ""Scientific Center of Personalized Psychiatry"", Moscow, Russian Federation|Scientific Center of Personalized Psychiatry, Moscow, Russian Federation|State Healthcare Institution of Nizhniy Novgordo region ""Clinical Psychiatric Hospital #1 of City of Nizhniy Novgorod"", Nizhny Novgorod, Russian Federation|SHI ""City Psychoneurological dispensary #7 (with Hospital)"", Saint Petersburg, Russian Federation|Center of Recovery Treatment ""Pediatric Psychiatry"" named after S.S. Mnukhin, Saint Petersburg, Russian Federation|Bekhterev Institute, Saint Petersburg, Russian Federation|Regional Clinical Mental Hospital of Saint Sofiya, Saratow, Russian Federation|FSBSI ""Scientific Research Institute of Mental Health"", Tomsk, Russian Federation|State Healthcare Institution of Yaroslavl Rgion ""Yaroslavl Regional clinical Mental Hospital"", Yaroslavl, Russian Federation|Hospital Marítimo de Torremolinos, Torremolinos, Málaga, Spain|RPsH #3 Сhildren Dept SHEI Ivano-Frankivsk SMU, Ivano Frankivsk, Ukraine|SI Institute of Neurology, Psychiatry and Narcology of NAMSU, Kharkiv, Ukraine|SI Institute of Children and Adolescents Healthcare of NAMSU, Kharkiv, Ukraine|TMA Psychiatry in Kyiv Center of NT & Rehabilitation of Psychotic Conditions, Kyiv, Ukraine|CI Lviv Regional Clinical Psychiatric Hospital, Lviv, Ukraine|Odesa Regional Psychoneurological Dispensary, Outpatient Dept., Odesa, Ukraine|O.F. Maltcev Poltava RCPsH Children Dept Ukrainian Medical Stomatological Academy, Poltava, Ukraine|CI Kherson Regional Psychiatric Hospital of Kherson RC, Stepanivka, Ukraine|Ternopil RCCPH Dept of Psychiatry #9 (adolescent)& #8 (pediatric) Ternopil I.Ya. Gorbachevskyi SMU, Ternopil, Ukraine|Reg. Psych. Hosp.n.a. O.Yuschenko, Dept. #121 VNMI, Vinnitsia, Ukraine","""Study Protocol: Final Protocol"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT01914393/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT01914393/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01914393
1112,1113,NCT04878198,Treatment of Sleep Disturbance in Children With ASD,,Not yet recruiting,No Results Available,Physical Exercise|Sleep Disturbance|Autism Spectrum Disorder|Melatonin Deficiency,Behavioral: Jogging program|Drug: Melatonin supplement intervention,Sleep onset latency|Sleep efficiency|Wake after sleep onset|Sleep duration|Parental-assessed sleep quality|24-h melatonin level|First morning void melatonin level,Education University of Hong Kong|Chinese University of Hong Kong|Castle Peak Hospital|University of Leicester|United Christian Hospital,All,8 Years to 12 Years   (Child),Not Applicable,100.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RG 21/2019-2020R,2021-09-01,2023-06-30,2023-06-30,2021-05-07,,2021-05-11,,,https://ClinicalTrials.gov/show/NCT04878198
1121,1122,NCT03282162,The Effects of Oxytocin on Affective Touch,,Completed,No Results Available,Healthy,Drug: intranasal oxytocin|Drug: intranasal placebo,brain function: neural activity during affective touch as assessed via BOLD fMRI|Brain function: functional connectivity during affective touch as assessed via BOLD fMRI|Perceived affective quality of the touch|Associations with trait autism as assessed via the Autism-Spectrum Quotient (AQ) - brain function: activity|Associations with trait autism as assessed via the Autism-Spectrum Quotient (AQ) - brain function: functional connectivity|Associations with trait autism as assessed via the Autism-Spectrum Quotient (AQ) - behaviour: pleasantness experience|Associations with Sensory Responsivity as assessed via the Sensory Responsivity Scale - brain function: activity|Associations with Sensory Responsivity as assessed via the Sensory Responsivity Scale - brain function: functional connectivity|Associations with Sensory Responsivity as assessed via the Sensory Responsivity Scale - behaviour: pleasantness experience,University of Electronic Science and Technology of China,Male,18 Years to 30 Years   (Adult),Not Applicable,50.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",UESTC-neuSCAN-40,2017-08-28,2018-01-31,2018-07-12,2017-09-13,,2018-10-29,"University of Electronic Science and Technology of China(UESTC), Chengdu, Sichuan, China",,https://ClinicalTrials.gov/show/NCT03282162
1127,1128,NCT01184235,Multidimensional Measurement of Psychopharmacological Treatment Response,,Completed,No Results Available,Autism Spectrum Disorders|Mood Disorders|Sleep Disorders|Attention Deficit Disorders,Drug: Pharmacological Intervention,Actigraphic Measurement|Operationally Defined Observations,Child Psychopharmacology Institute,All,"6 Months and older   (Child, Adult, Older Adult)",,44.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Act3,2010-08-01,2011-08-01,2011-08-01,2010-08-18,,2014-01-06,"Child Psychopharmacology Institute, Fargo, North Dakota, United States",,https://ClinicalTrials.gov/show/NCT01184235
1128,1129,NCT03293511,Oxytocin Modulates Eye Gaze Behavior During Social Processing,,Unknown status,No Results Available,Healthy,Drug: intranasal oxytocin|Drug: intranasal placebo,Global eye gaze characteristic: differences between oxytocin and placebo treatment|Feature-specific eye gaze characteristics: differences between oxytocin and placebo treatment|Global eye gaze characteristic - associations with autism traits|Feature-specific eye gaze characteristics - associations with trait autism,University of Electronic Science and Technology of China,Male,18 Years to 30 Years   (Adult),Not Applicable,40.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",UESCT_neuSCAN_42,2017-06-09,2019-07-01,2019-07-01,2017-09-26,,2018-10-29,"school of life science and technology, University of Electronic Science and Technology of China, Chengdu, Sichuan, China|University of Electronic Science and Technology of China, Chengdu, Sichuan, China",,https://ClinicalTrials.gov/show/NCT03293511
1131,1132,NCT03610919,Effects of Oxytocin Dose Frequency on Behavioral and Neural Responses,,Unknown status,No Results Available,Healthy,Drug: Nasal Sprays,Between group differences in the changes between acute and chronic administration effects of oxytocin on amygdala reactivity towards fearful faces as assessed by fMRI.|Between group differences in the changes between acute and chronic administration effects of oxytocin on amygdala resting state connectivity as assessed by fMRI.|Association between trait autism with acute and chronic treatment effects on amygdala activity in response to fearful faces|Association between trait autism with acute and chronic treatment effects on amygdala resting state connectivity|Interaction of acute and chronic treatment effects on amygdala activity with oxytocin receptor genotype.|Interaction of acute and chronic treatment effects on amygdala connectivity with oxytocin receptor genotype.|Treatment effects on arousal will be assessed by subjects rating their arousal on a 9-point Likert scale in response to the face pictures presented again after their fMRI scans on day 1 and day 5|Treatment effects on valence will be assessed by subjects rating their valence on a 9 point Likert scale in response to the face pictures presented again after their fMRI scans on day 1 and day 5|Treatment effects on intensity will be assessed by subjects rating their intensity on a 9 point Likert scale in response to the face pictures presented again after their fMRI scans on day 1 and day 5,University of Electronic Science and Technology of China,Male,"17 Years to 30 Years   (Child, Adult)",Phase 1,150.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",UESTC-neuSCAN-57,2018-03-01,2018-09-01,2018-12-01,2018-08-01,,2018-10-29,"school of life science and technology, University of Electronic Science and Technology of China, Chengdu, Sichuan, China",,https://ClinicalTrials.gov/show/NCT03610919
1132,1133,NCT02342366,Characterization of the Prosocial and Prosexual Effects of GHB,,Completed,No Results Available,"Depressive Disorder, Major|Bipolar Disorder|Autistic Disorder",Drug: GHB 35 mg/kg p.o.|Drug: GHB 20 mg/kg p.o.,Sexual Arousal|Social Cognition and Behavior|Composite measure of Neuroendocrine Parameters|electroencephalography (EEG) activity|fMRI activity,University of Zurich|University of Regensburg|University of Salerno|University of Vienna|University of Freiburg,Male,18 Years to 40 Years   (Adult),Not Applicable,19.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other",PUK-GHB01,2012-02-01,2014-11-01,2014-12-01,2015-01-19,,2019-07-29,"Hospital for Psychiatry, University of Zurich, Zurich, Switzerland","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT02342366/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02342366
1135,1136,NCT01731119,Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents,,Completed,Has Results,"Schizophrenia|Schizoaffective Disorder|Schizophreniform Disorder|Psychosis NOS|Autistic Disorder|Asperger Syndrome|Child Development Disorders, Pervasive|Bipolar I Disorder|Bipolar II Disorder|Mood Disorder NOS|Severe Major Depression With Psychotic Features|Single Episode Major Depression Without Psychotic Symptoms|Severe Mood Disorder With Psychotic Features",Drug: Latuda©,Change in Weight|Proportion of Participants Completing Treatment|Changes in Efficacy Measures|Number of Participants Experiencing Side Effects|Overall Clinical Improvement,"University of North Carolina, Chapel Hill|Foundation of Hope, North Carolina",All,"6 Years to 19 Years   (Child, Adult)",Phase 2,9.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12-2302,2012-12-01,2014-08-01,2014-08-01,2012-11-21,2017-05-17,2017-06-14,"University of North Carolina, Chapel Hill, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01731119
1136,1137,NCT02741063,Oxytocin Effect on Attentional Bias Towards Emotional Expression Faces in Individuals With High and Low Autistic Traits: A Functional Magnetic Resonance Imaging (fMRI) Study,,Unknown status,No Results Available,Healthy,Behavioral: screen low autistic subjects|Behavioral: screen high autistic subjects|Drug: oxytocin|Drug: placebo,attentional bias toward emotional expression faces|brain activity during RSVP task,University of Electronic Science and Technology of China,Male,18 Years to 30 Years   (Adult),Early Phase 1,120.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",UESTC-neuSCAN-19,2016-05-01,2019-06-01,2019-09-01,2016-04-18,,2018-10-29,"China, Sichuan, Chengdu, Sichuan, China",,https://ClinicalTrials.gov/show/NCT02741063
1142,1143,NCT02776215,Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents,,Unknown status,No Results Available,Circadian Rhythm Sleep Disorders|Non-24 Hour Sleep-Wake Disorder|Autism Spectrum Disorder|Smith-Magenis Syndrome,Drug: tasimelteon,Area under the curver (AUC) of tasimelteon and its metabolites|Maximum concetration (Cmax) of tasimelteon and its metabolites|Steady-state concentration (Css) of tasimelteon and its metabolites|Half-life of tasimelteon and its metabolites|Trough concentration (Ctrough) of tasimelteon and its metabolites|Safety and tolerability of tasimelteon as measured by spontaneous reporting of adverse events (AEs)|Safety and tolerability of tasimelteon as measured by Pediatric Adverse Event Reporting System (PAERS),Vanda Pharmaceuticals,All,3 Years to 17 Years   (Child),Phase 1,24.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,VP-VEC-162-4201,2016-09-01,2018-12-01,,2016-05-18,,2017-03-01,"Parexel Early Phase Clinical Unit, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02776215
1143,1144,NCT00025779,Methylphenidate in Children and Adolescents With Pervasive Developmental Disorders,,Completed,No Results Available,Attention Deficit Disorder With Hyperactivity|Autistic Disorder|Pervasive Development Disorders,Drug: methylphenidate|Drug: guanfacine,"hyperactivity, impulsiveness, and distractibility",National Institute of Mental Health (NIMH),All,5 Years to 14 Years   (Child),Not Applicable,60.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,N01 MH70009|N01 MH80011|N01 MH70010|N01 MH70001|DSIR CT,2001-10-01,2003-11-01,,2001-10-24,,2009-07-28,"UCLA Neuropsychiatric Institute, Los Angeles, California, United States|Yale Child Study Center, New Haven, Connecticut, United States|Indiana University-Riley Hospital for Children, Indianapolis, Indiana, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|Ohio State University, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00025779
1147,1148,NCT03826498,Allogenic Cord Blood Transfusion in Patients With Cerebral Palsy,,"Active, not recruiting",No Results Available,Cerebral Palsy,Biological: CP CB-MNC injection|Other: Standard therapy,Number of participants with non-serious and serious adverse events|Changes in Standardized Gross Motor Function 66 (GMFM-66) Score for all child.|Changes in Cognitive Neurodevelopmental Outcome for child before 3yrs|Changes in The Infant Toddler Quality of Life Questionnaire for child above 3yrs.|Changes in Ashworth scale score for all child.|Number of Participants with Chimerism (longevity) of infused cell,"State-Financed Health Facility ""Samara Regional Medical Center Dinasty""",All,1 Year to 10 Years   (Child),Phase 2,40.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12102017,2018-01-12,2021-12-26,2022-01-26,2019-02-01,,2021-03-17,"Medical Centre Dinasty, Samara, Russian Federation",,https://ClinicalTrials.gov/show/NCT03826498
1152,1153,NCT01050582,A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children,,Completed,Has Results,Schizophrenia|Bipolar Disorder|Autistic Disorder|Conduct and Other Disruptive Behavior Disorders,Drug: Risperidone|Drug: Other atypical antipsychotic drugs,Height (cm) Z-score at Study Visit|Age (Years) at Current Tanner Stage|Number of Participants With Retrospectively Reported Potentially Prolactin-Related Adverse Events,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",All,8 Years to 16 Years   (Child),Phase 4,244.0,Industry,Interventional,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR016687|RISNAP4022,2009-10-01,2011-07-01,2011-07-01,2010-01-15,2012-11-27,2012-11-27,"San Francisco, California, United States|Aurora, Colorado, United States|Altamonte Springs, Florida, United States|Gainesville, Florida, United States|Smyrna, Georgia, United States|Naperville, Illinois, United States|Indianapolis, Indiana, United States|Valparaiso, Indiana, United States|Boston, Massachusetts, United States|Cambridge, Massachusetts, United States|Glen Oaks, New York, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Antwerpen, Belgium|Freiburg, Germany|Jena, Germany|Mannheim, Germany|München, Germany|Tübingen, Germany|Ulm, Germany|Würzburg, Germany|Athens, Greece|Nijmegen, Netherlands|Gdansk, Poland|Kielce, Poland|Lódź, Poland|Sosnowiec, Poland|Warszawa N/A, Poland|Warszawa, Poland",,https://ClinicalTrials.gov/show/NCT01050582
1153,1154,NCT00198055,A Study of Aripiprazole in Children and Adolescents With Aspergers and Pervasive Developmental Disorder.,,Completed,No Results Available,Asperger's Disorder|Pervasive Developmental Disorder,Drug: aripiprazole,The Clinical Global Impression(CGI)Improvement Scale.|The Irritability subscale of the Aberrant Behavior Checklist (ABC)|The Clinical Global Impression Severity Scale.|The Compulsion subscale of the Children's Yale-Brown Obsessive-Compulsive(CY-BOCS).|The Vineland Maladaptive Behavior Subscale.,Indiana University School of Medicine|Bristol-Myers Squibb|Indiana University,All,4 Years to 17 Years   (Child),Phase 2,25.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0302-24,2005-01-01,2007-09-01,2007-09-01,2005-09-20,,2014-06-04,"Riley Hospital, Riley Child and Adolescent Psychiatry Clinic, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT00198055
1154,1155,NCT01712464,Modulation of Reinforcement Learning,,Completed,No Results Available,Impact of Oxytocin on Social Learning,Drug: Oxytocin vs. Placebo,Bold Signal in nucleus accumbens|Bold signal in ventral tegmental areal,RWTH Aachen University,Male,18 Years to 26 Years   (Adult),Not Applicable,60.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic",12-033,2013-10-18,2016-08-07,2016-08-07,2012-10-23,,2018-05-01,"Universtiy Hospital Aachen, Aachen, Northrhine-Westfalia, Germany",,https://ClinicalTrials.gov/show/NCT01712464
1155,1156,NCT00892580,Biomarker and DNA Collection in Subjects Participating in Protocol 22003,,Completed,No Results Available,Fragile X Syndrome,Drug: STX209,Biomarker,"Seaside Therapeutics, Inc.",All,6 Years to 17 Years   (Child),,32.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,22003A,2009-05-01,2010-06-01,,2009-05-04,,2013-07-31,"Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|University of California-Los Angeles Neuropsychiatric Institute, Los Angeles, California, United States|Yale Child Study Center, New Haven, Connecticut, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|University of North Carolina Neurosciences Hospital, Chapel Hill, North Carolina, United States|Vanderbilt Kennedy Center, Nashville, Tennessee, United States|Red Oaks Psychiatry Associates, PA, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00892580
1159,1160,NCT01431326,Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care,PTN_POPS,Completed,No Results Available,Adenovirus|Anesthesia|Anxiety|Anxiolysis|Autism|Autistic Disorder|Bacterial Meningitis|Bacterial Septicemia|Benzodiazepine|Bipolar Disorder|Bone and Joint Infections|Central Nervous System Infections|Convulsions|Cytomegalovirus Retinitis|Early-onset Schizophrenia Spectrum Disorders|Epilepsy|General Anesthesia|Gynecologic Infections|Herpes Simplex Virus|Infantile Hemangioma|Infection|Inflammation|Inflammatory Conditions|Intra-abdominal Infections|Lower Respiratory Tract Infections|Migraines|Pain|Pneumonia|Schizophrenia|Sedation|Seizures|Skeletal Muscle Spasms|Skin and Skin-structure Infections|Treatment-resistant Schizophrenia|Urinary Tract Infections|Withdrawal|Sepsis|Gram-negative Infection|Bradycardia|Cardiac Arrest|Cardiac Arrhythmia|Staphylococcal Infections|Nosocomial Pneumonia|Neuromuscular Blockade|Methicillin Resistant Staphylococcus Aureus|Endocarditis|Neutropenia|Headache|Fibrinolytic Bleeding|Pulmonary Arterial Hypertension|CMV Retinitis|Hypertension|Chronic Kidney Diseases|Hyperaldosteronism|Hypokalemia|Heart Failure|Hemophilia|Heavy Menstrual Bleeding|Insomnia,Drug: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:,Composite of pharmacokinetic outcomes for understudied drugs in children|Composite pharmacodynamic outcomes of understudied drugs in children|Biomarkers associated with understudied drugs in children,"Daniel Benjamin|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|The Emmes Company, LLC|Duke University",All,"up to 21 Years   (Child, Adult)",,3520.0,Other|NIH|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,Pro00029638|IND 113645|IND 114369|IND 114531|IND 118358|HHSN20100006|HHSN27500020|HHSN27500027|HHSN27500043|HHSN27500049,2011-11-01,2019-11-01,2019-11-01,2011-09-09,,2019-12-20,"Alaska Native Medical Center, Anchorage, Alaska, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|University of California at San Diego Medical Center, La Jolla, California, United States|Axis Clinical Trials, Los Angeles, California, United States|University of California, Los Angeles Medical Center, Los Angeles, California, United States|The Children's Hospital Colorado, Aurora, Colorado, United States|Yale New Haven Children's Hospital, New Haven, Connecticut, United States|Alfred I. DuPont Hospital for Children, Wilmington, Delaware, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida Jacksonville Shands Medical Center, Jacksonville, Florida, United States|Kapiolani Womens and Childrens Medical Center, Honolulu, Hawaii, United States|Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Riley Hospital for Children at Indiana University, Indianapolis, Indiana, United States|University of Kansas Medical Center, Fairway, Kansas, United States|Children's Mercy Hospital and Clinics, Kansas City, Kansas, United States|Wesley Medical Center, Wichita, Kansas, United States|Norton Children's Hospital, Louisville, Kentucky, United States|Tulane University Health Science Center, New Orleans, Louisiana, United States|Ochsner Baptist Clinical Trials Unit, New Orleans, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States|University of Montana, Missoula, Montana, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|University of New Mexico, Health Sciences Center, Albuquerque, New Mexico, United States|UNC Hospital Neonatal-Perinatal Medicine, Chapel Hill, North Carolina, United States|Duke University Medical Center (PICU / NICU), Durham, North Carolina, United States|Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States|Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Akron Children's Hospital, Cleveland, Ohio, United States|Board of Regents of the University of Oklahoma, Oklahoma City, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of South Carolina, Columbia, South Carolina, United States|University of Utah Hospitals and Clinics, Salt Lake City, Utah, United States|University of Vermont Medical Center, Burlington, Vermont, United States|University of Virginia Children's Hospital, Charlottesville, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|West Virginia University Hospital, Morgantown, West Virginia, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Manitoba Institute of Child Health, Winnipeg, Manitoba, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|The Hospital for Sick Children, Toronto, Ontario, Canada|Hospital Sainte-Justine, Montreal, Quebec, Canada|Assaf Harofeh Medical Center, Zerifin, Tel Aviv, Israel|Schneider Children's Medical Center of Israel, Petah Tikva, Israel|KK Women's and Children's Hospital Pte Ltd, Singapore, Singapore|Southampton General Hospital, Southampton, Hampshire, United Kingdom|Alder Hey Children's Hospital, Liverpool, Merseyside, United Kingdom",,https://ClinicalTrials.gov/show/NCT01431326
1164,1165,NCT00391261,An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.,,Completed,No Results Available,Schizophrenia|Schizoaffective Disorder|Schizophreniform Disorder|Bipolar Disorder|Autism Spectrum Disorders,Drug: Metformin,BMI|MOSES,Cambridge Health Alliance|American Psychiatric Association,All,"10 Years to 18 Years   (Child, Adult)",Phase 4,11.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CHA-IRB-0143/12/05,2006-07-01,2007-10-01,2007-10-01,2006-10-23,,2010-03-25,"Cambridge Health Alliance, Medford, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00391261
1165,1166,NCT00318162,Trial of Low-Dose Naltrexone for Children With Pervasive Developmental Disorder (PDD),,Unknown status,No Results Available,Pervasive Developmental Disorder,Drug: low dose naltrexone,play observation|Autism Behavior Checklist (ABC) questionnaire,Hadassah Medical Organization|Jerusalem Institute for Child Development,All,3 Years to 6 Years   (Child),Phase 1|Phase 2,50.0,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,PDDLDN-HMO-CTIL,,,,2006-04-26,,2006-05-03,"Jerusalem Institute for Child Development, Jerusalem, Israel",,https://ClinicalTrials.gov/show/NCT00318162
1167,1168,NCT00166595,Pharmacogenetics of Risperidone in Children With Pervasive Developmental Disorder (PDD),,Completed,No Results Available,"Child Development Disorders, Pervasive",Drug: Risperidone,,"Children's Hospital Medical Center, Cincinnati|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",All,"4 Years to 21 Years   (Child, Adult)",Phase 1|Phase 2,100.0,Other|NIH,Interventional,Primary Purpose: Treatment,PPRU 10545s,2003-02-01,,2005-03-01,2005-09-14,,2014-01-28,"Children's Hospital of Michigan/Wayne State University, Detroit, Michigan, United States|Duke University Medical Center, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00166595
1169,1170,NCT03327467,Expanded Access Protocol: Umbilical Cord Blood Infusions for Children With Brain Injuries,,Available,No Results Available,"Autism Spectrum Disorder|Autism|Cerebral Palsy|Hydrocephalus|Apraxia of Speech|Hypoxia Ischemia, Cerebral|Drowning; Anoxia",Biological: Cord Blood Infusion,,"Joanne Kurtzberg, MD|Duke University",All,"up to 26 Years   (Child, Adult)",,,Other,Expanded Access:Treatment IND/Protocol,,Pro00083888,,,,2017-10-31,,2020-11-24,"Duke University Medical Center, Durham, North Carolina, United States|MD Anderson, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03327467
1172,1173,NCT00485849,A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASD,,Completed,No Results Available,Attention Deficit Hyperactivity Disorder,Drug: Atomoxetine Hydrochloride,"Test whether atomoxetine is effective in reducing symptoms of inattention and overactivity/impulsivity as measured by the AHDHRS-IV-Parent:Inv scale in pediatric outpatients with ASD accompanied by ADHD behavior problems|To assess whether atomoxetine will be effective in reducing symptoms of inattention and overactivity/impulsivity|To assess whether atomoxetine will be effective for improving social functioning and personal sufficiency in children and adolescents with ASD+ADHD|To assess whether atomoxetine has a positive or negative effect on frequently associated symptoms as impulsive aggression, agitation, self-injurious behavior, troublesome repetitive behavior and poor motor coordination|To assess whether atomoxetine has a positive or negative effect on neuropsychological functioning|To assess the overall influence on functioning and burden on the family|To monitor clinical safety and side effects as assessed by adverse events elicited during open-ended questioning",Eli Lilly and Company,All,6 Years to 17 Years   (Child),Phase 4,12.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,6639|B4Z-UT-S003,2004-02-01,,2004-10-01,2007-06-13,,2007-06-13,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Groningen, Netherlands",,https://ClinicalTrials.gov/show/NCT00485849
1174,1175,NCT00147394,Risperidone Pharmacokinetics in Children With Pervasive Developmental Disorder (PDD),,Completed,No Results Available,"Child Development Disorders, Pervasive",Drug: Risperidone,"Quantify the variability of clearance and volume of distribution among AE rating, weight gain and ABC responder status.|Exploratory analysis will be performed to examine the relationship of other factors to risperidone and metabolite concentrations for PK/PD assessment.","Children's Hospital Medical Center, Cincinnati",All,5 Years to 16 Years   (Child),Phase 1,100.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PPRU 10544,2001-12-01,,2004-06-01,2005-09-07,,2012-10-29,"Children's Hospital of Michigan/Wayne State University, Detroit, Michigan, United States|Duke University Medical Center, Durham, North Carolina, United States|Cincinnati Children's Hospital, Cincinnati, Ohio, United States|Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00147394
1177,1178,NCT03292848,"Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders",,Completed,No Results Available,ADHD|Autism|Bipolar I Disorder|Conduct Disorder|Oppositional Defiant Disorder,Drug: Brexpiprazole,"Maximum Plasma Concentration (Cmax) [PK]|Area under concentration-time curve (AUC) calculated from time zero to time t (AUCt) [PK]|AUC from time zero to infinity [PK]|Time of maximum plasma concentration (tmax) [PK]|Terminal-phase elimination half-life (t½,z) [PK]|Apparent clearance of drug from plasma after extravascular administration (CL/F) [PK]|Treatment-Emergent Adverse Events (TEAES) [Safety]|Clinical laboratory tests [Safety]|Vital signs observed and change from baseline data (systolic and diastolic blood pressure) [Safety]|Vital signs observed and change from baseline data (heart rate) [Safety]|Vital signs observed and change from baseline data (respiratory rate) [Safety]|Vital signs observed and change from baseline data (body temperature) [Safety]|12-lead electrocardiogram (ECGs) [Safety]|Physical examinations (height) [Safety]|Physical examinations (weight) [Safety]|Physical examinations- Body Mass Index (BMI) [Safety]|Physical examinations- review of body systems [Safety]|Simpson-Angus Scale (SAS) rating scale [Safety]|Abnormal Involuntary Movement Scale (AIMS) [Safety]|Barnes Akathisia Rating Scale (BARS) [Safety]|Columbia-Suicide Severity Rating Scale (C-SSRS) [Safety]","Otsuka Pharmaceutical Development & Commercialization, Inc.|H. Lundbeck A/S",All,6 Years to 12 Years   (Child),Phase 1,24.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,331-201-00103,2017-10-10,2018-05-21,2018-05-21,2017-09-26,,2018-06-12,"Woodland International Research Group, Little Rock, Arkansas, United States|Woodland Research Northwest, LLC, Rogers, Arkansas, United States|Alliance for Wellness dba Alliance for Research, Long Beach, California, United States|New Hope Clinical Research, Charlotte, North Carolina, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Road Runner Research Ltd., San Antonio, Texas, United States|Aspen Clinical Research, Orem, Utah, United States",,https://ClinicalTrials.gov/show/NCT03292848
1178,1179,NCT04689282,Intranasal Inhalations of M2 Macrophage Soluble Factors in Children With Developmental Speech Disorders,,Recruiting,No Results Available,"Language Delay|Language; Developmental Disorder, Expressive|Language; Developmental Disorder, Receptive|Autism Spectrum Disorder|Attention Deficit-Hyperactivity Disorder|Speech Disorders in Children","Biological: Bioactive Factors, Produced by M2 Type Macrophages (M2-BFs).",Change in the severity of speech disorders according to Speech Assessment Scale (SAS)|The number of patients with adverse events,Russian Academy of Medical Sciences,All,"3 Years to 18 Years   (Child, Adult)",Phase 1|Phase 2,30.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IFCI-23/06/2017,2020-02-01,2021-12-01,2022-07-01,2020-12-30,,2020-12-30,"Institute of Fundamental and Clinical Immunology, Novosibirsk, Russian Federation",,https://ClinicalTrials.gov/show/NCT04689282
1181,1182,NCT02149823,Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations,,Suspended,No Results Available,Borderline Personality Disorder|BPD|Schizotypal Personality Disorder|SPD|Autism Spectrum Disorder|Schizophrenia|Schizoaffective Disorder|Bipolar Disorder,Drug: Syntocinon 24 Intranasal Units (IU)|Drug: Syntocinon 40 Intranasal Units (IU)|Drug: Intranasal Placebo,Movie for the Assessment of Social Cognition (MASC)|Reading of the Mind in the Eyes|Resting-state functional connectivity,"Maria de las Mercedes Perez Rodriguez|James J. Peters Veterans Affairs Medical Center|VISN 3 Mental Illness Research, Education and Clinical Center|Icahn School of Medicine at Mount Sinai",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,165.0,Other|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",GCO 13-0340|UL1TR000067,2013-09-01,2021-08-01,2021-08-01,2014-05-29,,2020-10-08,"James J Peters VA Medical Center, Bronx, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02149823
1182,1183,NCT00870974,A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions,FPEB,Completed,No Results Available,Parkinson Disease|Huntington Disease|Autistic Spectrum Disorders|Fragile X Syndrome|Alzheimer Disease|Mild Cognitive Impairment,Drug: [18F]FPEB,Does FPEB reliably represent the known distribution of MGLUR5 in the brain?,Institute for Neurodegenerative Disorders,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,48.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label),FPEB,2009-03-01,2016-10-01,2016-11-01,2009-03-27,,2017-01-06,"Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00870974
1189,1190,NCT00870727,Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders,,Completed,Has Results,Pervasive Developmental Disorder,Drug: Aripiprazole oral product|Drug: Placebo oral capsule,"Number of Participants Improved as Measured by the Clinical Global Impression-Global Improvement Scale (Improvement Defined as CGI-I=1 or CGI-I=2)|Mean Post-baseline Aberrant Behavior Checklist Irritability Subscale Score, Parent Report, Double-blind Phase|Mean Post-baseline Aberrant Behavior Checklist Hyperactivity Subscale Score, Parent Report, Double-blind Phase|Mean Post-baseline Aberrant Behavior Checklist Inappropriate Speech Subscale Score, Parent Report, Double-blind Phase|Mean Post-baseline Aberrant Behavior Checklist Social Withdrawal Subscale Score, Parent Report, Double-blind Phase|Mean Post-baseline Aberrant Behavior Checklist Stereotypy Subscale Score, Parent Report, Double-blind Phase",Indiana University|National Institute of Mental Health (NIMH)|Bristol-Myers Squibb,All,5 Years to 17 Years   (Child),Phase 3,33.0,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0805-26|MH 082119,2009-02-01,2015-03-01,2015-05-01,2009-03-27,2018-11-28,2019-01-02,"Riley Hospital for Children, Christian Sarkine Autism Treatment Center, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT00870727
1190,1191,NCT00709202,Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain,,Completed,Has Results,Schizophrenia|Schizoaffective Disorder|Schizophreniform Disorder|Bipolar I Disorder|Bipolar II|Bipolar NOS(Not Otherwise Specified)|Psychotic Disorder Not Otherwise Specified|Autism Spectrum Disorder,Drug: Betahistine|Drug: Placebo Oral Tablet,Change in Weight|Change in Body Mass Index (BMI)|Change in Waist Circumference|Change in Hip Circumference|Change in Glucose|Change in Cholesterol|Change in LDL|Change in HDL|Change in Triglycerides|Change in Appetite Hunger|Change in Appetite Fullness,Nathan Kline Institute for Psychiatric Research|Stanley Medical Research Institute,All,18 Years to 59 Years   (Adult),Phase 2,48.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07TGF-1112,2008-07-01,2016-05-01,2016-12-01,2008-07-03,2019-01-25,2019-01-25,"Nathan Kline Insitute for Psychiatric Research, Orangeburg, New York, United States",,https://ClinicalTrials.gov/show/NCT00709202
1196,1197,NCT01894958,A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome,,Completed,No Results Available,Fragile X Syndrome,Drug: NNZ-2566|Drug: Placebo,Adverse events|Physiological changes|Behavior|Global and Functional outcome Measures,Neuren Pharmaceuticals Limited,Male,"12 Years to 45 Years   (Child, Adult)",Phase 2,72.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Neu-2566-FXS-001,2014-01-01,2015-09-01,2015-10-01,2013-07-10,,2018-02-05,"UC Davis MIND Institute, Sacramento, California, United States|Children's Hospital Colorado, Denver, Colorado, United States|Children's National Hospital, Washington, District of Columbia, United States|Emory University, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Nebraska, Omaha, Nebraska, United States|Mount Sinai School of Medicine, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Autism & Developmental Medicine Institute Geisinger Health System, Lewisburg, Pennsylvania, United States|Suburban Research Associates, Media, Pennsylvania, United States|Greenwood Genetic Center, Greenwood, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Children's Hospital, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01894958
1200,1201,NCT01282268,Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome,Harbor-A,Completed,No Results Available,Fragile X Syndrome,Drug: arbaclofen|Drug: placebo,Aberrant Behavior Checklist - FXS Social Avoidance Subscale,"Seaside Therapeutics, Inc.",All,"12 Years to 50 Years   (Child, Adult)",Phase 3,125.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",209FX301,2011-05-01,2012-12-01,,2011-01-24,,2013-07-31,"Southwest Autism Research & Resource Center, Phoenix, Arizona, United States|Miller Children's Hospital Research Administration, Long Beach, California, United States|University of California-Davis, M.I.N.D. Institute, Sacramento, California, United States|Psychiatric Centers at San Diego, San Diego, California, United States|University of Colorado Denver, Children's Hospital, Aurora, Colorado, United States|University of Miami, Mailman Center for Child Development, Miami, Florida, United States|Lake Mary Pediatrics, Orange City, Florida, United States|Emory University School of Medicine, Decatur, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|University of Massachusetts, Worcester, Massachusetts, United States|University of Missouri, Thompson Research Center for Autism & Neurodevelpmental Disorders, Columbia, Missouri, United States|Seaver Autism Center, Mount Sinai Medical Center, New York, New York, United States|New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York, United States|Duke University Clinical Research Unit, Durham, North Carolina, United States|Akron Children's Hospital, Akron, Ohio, United States|University of Oklahoma, Physician's Child Study Center, Oklahoma City, Oklahoma, United States|Suburban Research Associates/Elwyn Genetics, Media, Pennsylvania, United States|Vanderbilt Kennedy Center, Nashville, Tennessee, United States|Texas Children's Hospital, Houston, Texas, United States|Red Oaks Psychiatry Associates, P.A., Houston, Texas, United States|Road Runner Research, San Antonio, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01282268
1203,1204,NCT01238575,Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder,,Completed,Has Results,Pervasive Development Disorders,Other: placebo|Drug: extended-release guanfacine,Aberrant Behavior Checklist Hyperactivity Subscale|ADHD Rating Scale - Total|Aberrant Behavior Checklist Irritability Subscale|Aberrant Behavior Checklist Social Withdrawal Subscale|Aberrant Behavior Checklist Sterotypy Subscale|Aberrant Behavior Checklist Inappropriate Speech Subscale|ADHD Rating Scale - Inattention Subscale|ADHD Rating Scale - Hyperactivity Subscale,"Yale University|Emory University|Massachusetts General Hospital|Seattle Children's Hospital|University of California, Los Angeles|National Institute of Mental Health (NIMH)",All,5 Years to 14 Years   (Child),Phase 4,62.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1001006172|R01MH083707,2011-12-01,2014-03-01,2014-03-01,2010-11-10,2015-12-07,2020-03-31,"University of California, Los Angeles, Los Angeles, California, United States|Yale University, New Haven, Connecticut, United States|Emory University, Atlanta, Georgia, United States|Massachusetts General Hospital, Lexington, Massachusetts, United States|Seattle Children's Hospital, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01238575
1204,1205,NCT01903681,Assessment of the Pharmacokinetics of Circadin® in Children With Neurodevelopmental Disorders and Sleep Disturbances,,Completed,No Results Available,Sleep Problems,Drug: Circadin 2 mg|Drug: Circadin 10 mg,baseline profile of endogenous saliva melatonin concentrations and urine 6-SMT excretion|concentration-time profile of saliva melatonin concentrations and 24 hour 6-SMT urine excretion after 2 and 10 mg Circadin® mini-tablets single dose administration|adverse event profile after a single dose of 2 or 10 mg Circadin® mini-tablets,Neurim Pharmaceuticals Ltd.,All,2 Years to 17 Years   (Child),Phase 1,16.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,CHDR1219,2013-03-01,2014-02-01,2014-04-01,2013-07-19,,2014-04-04,"Centre for Human Drug Research, Leiden, Netherlands",,https://ClinicalTrials.gov/show/NCT01903681
1206,1207,NCT01525901,Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome),,Recruiting,No Results Available,22q13 Deletion Syndrome|Phelan-McDermid Syndrome,Drug: Insulin-Like Growth Factor-1 (IGF-1)|Drug: Normal saline,Aberrant Behavior Checklist - Social Withdrawal (ABC-SW) subscale|Repetitive Behavior Scale|CGI-Improvement and Severity Scales|Caregiver Strain Index|Exploratory outcomes,Icahn School of Medicine at Mount Sinai|National Institute of Mental Health (NIMH),All,5 Years to 12 Years   (Child),Phase 2,35.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GCO 12-0929|IF# 1358648|1R34MH100276-01|GCO 11-1555|R34MH100276,2012-02-01,2023-04-01,2023-04-01,2012-02-03,,2021-03-15,"Seaver Austin Center, Icahn School of Medicine at Mount Sinai, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01525901
1208,1209,NCT03944447,Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19,OMNI-Can,Recruiting,No Results Available,Chronic Pain|Chronic Pain Syndrome|Chronic Pain Due to Injury|Chronic Pain Due to Trauma|Fibromyalgia|Seizures|Hepatitis C|Cancer|Crohn Disease|HIV/AIDS|Multiple Sclerosis|Traumatic Brain Injury|Sickle Cell Disease|Post Traumatic Stress Disorder|Tourette Syndrome|Ulcerative Colitis|Glaucoma|Epilepsy|Inflammatory Bowel Diseases|Parkinson Disease|Amyotrophic Lateral Sclerosis|Chronic Traumatic Encephalopathy|Anxiety|Depression|Insomnia|Autism|Opioid-use Disorder|Bipolar Disorder|Covid19|SARS-CoV Infection|COVID-19|Corona Virus Infection|Coronavirus,"Drug: Cannabis, Medical",Prevention of COVID-19|Treatment of COVID-19|Treatment of Symptoms|Cannabis Impact on Quality of Life|Cannabis Route and Dosing|Monitoring Adverse Events,"OMNI Medical Services, LLC|OMNI Medical Services Inc",All,"7 Years and older   (Child, Adult, Older Adult)",Phase 2,200000.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00033337,2018-12-01,2025-12-31,2025-12-31,2019-05-09,,2020-12-09,"OMNI Medical Services, Boca Raton, Florida, United States|OMNI Medical Services, Bradenton, Florida, United States|OMNI Medical Services, Fort Lauderdale, Florida, United States|OMNI Medical Services, Fort Myers, Florida, United States|OMNI Medical Services, Gainesville, Florida, United States|OMNI Medical Services, Merritt Island, Florida, United States|OMNI Medical Services, Miami, Florida, United States|OMNI Medical Services, Ocoee, Florida, United States|OMNI Medical Services, Pensacola, Florida, United States|OMNI Medical Services, Pompano Beach, Florida, United States|OMNI Medical Services, Tampa, Florida, United States|OMNI Medical Services, Wesley Chapel, Florida, United States|OMNI Medical Services, Beechwood, Ohio, United States|OMNI Medical Services, Bowling Green, Ohio, United States|OMNI Medical Services, Sandusky, Ohio, United States|OMNI Medical Services, Toledo, Ohio, United States|OMNI Medical Services, Toledo, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03944447
1212,1213,NCT00352196,Janssen Asperger's MRS (Magnetic Resonance Spectroscopy Risperidone Study,,Completed,No Results Available,Asperger's Disorder,Drug: Risperidone|Other: Magnetic Resonance Spectroscopy,Chang in the Scale for the Assessment of Negative Symptoms (SANS)|Change in Positive and Negative Symptom Scale (PANNS)|Change in Brief Psychiatric Rating Scale (BPRS)|Change in Montgomery Asberg Rating Scale (MADRS)|Change in Global Assessment Scale (GAS)|Change in Abnormal Involuntary Movement Scale (AIMS)|Change in Neurocognitive test battery,"Augusta University|Ortho-McNeil Janssen Scientific Affairs, LLC",All,"6 Years and older   (Child, Adult, Older Adult)",Phase 4,23.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RIS-EMR-4026|MCG HAC File #01-09-063,2001-11-01,2007-05-01,2007-05-01,2006-07-14,,2015-01-14,"Medical College of Georgia, Dept. of Psychiatry, Augusta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT00352196
1216,1217,NCT02680379,Combined Treatment of Minocycline and Lovastatin to Treat Individuals With Fragile X Syndrome,LovaMiX,Completed,No Results Available,Fragile X Syndrome,"Drug: Minocycline, then Minocycline/Lovastatin|Drug: Lovastatin, then Minocycline/Lovastatin","Change from baseline Aberrant Behavior Checklist-Community (ABC-C) total score at 8,12 and 20 weeks|Clinical Global Impression Scale improvement (CGI-I)|Change from baseline Social Responsiveness Scale (SRS) at 8 and 20 weeks|Anxiety, depression and mood scale (ADAMS), change from baseline to 8 and 20 weeks|Behavior Rating Inventory of Executive Function (BRIEF)|Change from baseline Vineland II; adaptive behaviour scale at 20 weeks",Université de Sherbrooke|FRAXA Research Foundation,All,"8 Years to 45 Years   (Child, Adult)",Phase 2,22.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2016-1177,2016-03-01,2017-10-01,2017-11-01,2016-02-11,,2018-10-15,"Centre de Recherche du CHUS, Sherbrooke, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02680379
1218,1219,NCT01474746,Trial of Sertraline to Treat Children With Fragile X Syndrome,,Completed,Has Results,Fragile X Syndrome,Drug: Sertraline|Drug: Placebo,"Change in Mullen Scales of Early Learning - Expressive Language Raw Score|Clinical Global Impression - Improvement|Change in Mullen Scales of Early Learning - Expressive Language Standard T Score|Autism Diagnostic Observation Schedule|Visual Analog Scale|Eye Tracking|Preschool Language Scale-fifth Edition (PLS-5): AC+EC Total Raw Score|Sensory Processing Measure - Preschool (SPM-P) Social Participation: Raw Score|Sensory Profile - Sensation Seeking Subscale Raw Score|Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) - Adaptive Behavior Composite Standard Score|Mullen Scales of Early Learning - Visual Reception Raw Score|Mullen Scales of Early Learning - Fine Motor Raw Score|The Autism Diagnostic Observation Schedule (ADOS-2)|The Visual Analog Scale|Sensory Processing Measure-Preschool (SPM-P) Social Participation: Raw Score|Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) Adaptive Behavior Composite Standard Score|Mullen Scales of Early Learning - Visual Reception Age-equivalent Score|Mullen Scales of Early Learning - Fine Motor Age-equivalent Score|Mullen Scales of Early Learning - Cognitive T Score Sum|Mullen Scales of Early Learning - Summary Age-equivalent Score","Randi J. Hagerman, MD|University of California, Davis",All,24 Months to 68 Months   (Child),Phase 2,57.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",271070|R40MC22641,2012-01-01,2015-08-01,2015-09-01,2011-11-18,2017-09-25,2017-09-25,"UC Davis M.I.N.D. Institute, Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT01474746
1220,1221,NCT01777542,Treatment of Rett Syndrome With Recombinant Human IGF-1,,Completed,Has Results,Rett Syndrome,Drug: Recombinant Human Insulin Growth Factor 1 (rhIGF-1)|Drug: Placebo,"Rett Syndrome Behavior Questionnaire (RSBQ) - Fear/Anxiety Subscale|Anxiety, Depression, and Mood Scale (ADAMS) - Social Avoidance Subscale|Clinical Global Impression - Severity (CGI-S)|Clinical Global Impression - Improvement (CGI-I)|Parental Global Impression - Severity (PGI-S)|Parental Global Impression - Improvement (PGI-I)|Parent Targeted Visual Analog Scale (PTSVAS) - Scale 1|Parent Targeted Visual Analog Scale (PTSVAS) - Scale 2|Parent Targeted Visual Analog Scale (PTSVAS) - Scale 3|Kerr Clinical Severity Scale|Rett Syndrome Behavior Questionnaire (RSBQ)|Anxiety, Depression, and Mood Scale (ADAMS)|Mullen Scales of Early Learning (MSEL)|Vineland Adaptive Behavior Scales, Second Edition (VABS-II)|Communication and Symbolic Behavior Scales - Developmental Profile (CSBS-DP)|Aberrant Behavior Checklist - Community Edition (ABC-C)|Quantitative Measures of Respiration: Apnea Index",Boston Children's Hospital|International Rett Syndrome Foundation,Female,2 Years to 10 Years   (Child),Phase 2,30.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",IRB-P00005610,2013-01-01,2016-07-01,2016-11-01,2013-01-29,2018-03-26,2018-03-26,"Boston Children's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01777542
1222,1223,NCT02715115,A Safety Study of NNZ-2566 in Pediatric Rett Syndrome,,Completed,No Results Available,Rett Syndrome,Drug: NNZ-2566|Drug: Placebo,Adverse events|Motor Behaviour Assessment Scale (MBA)|Clinical Global Impression of Improvement (CGI-I)|Caregiver Top 3 Concerns via a Visual Analogue Scale (VAS),Neuren Pharmaceuticals Limited|rettsyndrome.org,Female,5 Years to 15 Years   (Child),Phase 2,82.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Neu-2566-RETT-002,2016-03-01,2017-01-05,2017-01-05,2016-03-22,,2020-08-14,"University of Alabama, Birmingham, Alabama, United States|UCSF Benioff Children's Hospital Oakland, Oakland, California, United States|University of California, San Diego, San Diego, California, United States|Children's Hosptial Colorado, Aurora, Colorado, United States|Rush University Medical Center, Chicago, Illinois, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Gillette Children's Specialty Healthcare, Saint Paul, Minnesota, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Greenwood Genetic Center, Greenwood, South Carolina, United States|Vanderbilt University, Nashville, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02715115
1223,1224,NCT00205699,Metabolic Effects of Antipsychotics in Children,MEAC,Completed,Has Results,Aggression|Attention Deficit-Hyperactivity|Oppositional Defiant Disorder|Pervasive Development Disorders|Bipolar Disorder,Drug: risperidone|Drug: olanzapine|Drug: aripiprazole,Change in DEXA % Body Fat|Change in Insulin-stimulated Glucose Rate of Disappearance (Glucose Rd)|Change in Insulin-stimulated Glycerol Rate of Appearance (Glycerol Ra)|Change in Insulin-stimulated Glucose Rate of Appearance (Glucose Ra)|Change in MRI-measured Visceral Abdominal Fat|Change in MRI-measured Subcutaneous Abdominal Fat,Washington University School of Medicine|National Institute of Mental Health (NIMH),All,"6 Years to 18 Years   (Child, Adult)",Phase 4,144.0,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,NIMH|R01MH072912,2006-04-01,2011-03-01,2011-07-01,2005-09-20,2018-06-15,2018-06-15,"Washington University School of Medicine, Psychiatry Dept., Saint Louis, Missouri, United States","""Informed Consent Form: Child and Adult Consent"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT00205699/ICF_000.pdf|""Informed Consent Form: Genetics Consent"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT00205699/ICF_001.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT00205699/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT00205699/SAP_003.pdf",https://ClinicalTrials.gov/show/NCT00205699
1224,1225,NCT01703533,A Safety Study of NNZ-2566 in Patients With Rett Syndrome,,Completed,No Results Available,Rett Syndrome,Drug: NNZ-2566|Drug: Placebo,Adverse events|Change in EEG activity|Behavior|Physiological changes|Global and Functional outcome Measures,Neuren Pharmaceuticals Limited|Baylor College of Medicine|International Rett Syndrome Foundation,Female,"16 Years to 45 Years   (Child, Adult)",Phase 2,67.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Neu-2566-RETT-001,2013-03-01,2014-09-01,2014-09-01,2012-10-10,,2018-02-05,"University of Alabama, Birmingham, Alabama, United States|Gillette Children's Specialty Healthcare, Saint Paul, Minnesota, United States|Baylor School of Medicine, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01703533
1225,1226,NCT04003207,Growth Hormone Treatment in Children With Phelan McDermid Syndrome,,Completed,No Results Available,Phelan McDermid Syndrome,Drug: Recombinant human Growth hormone,ABC - Social Withdrawal subscale|Repetitive Behavior Scale-Revised (RBS-R)|The Sensory Profile|The Sensory Assessment for Neurodevelopmental Disorders (SAND)|Visual evoked potentials (VEP)|Change in Auditory event related potentials (AERP),Swathi Sethuram|Icahn School of Medicine at Mount Sinai,All,2 Years to 12 Years   (Child),Phase 2,6.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GCO 18-2549,2019-09-13,2020-06-05,2020-06-05,2019-07-01,,2020-06-12,"Seaver Autism Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT04003207
1231,1232,NCT00399698,Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone.,,Completed,No Results Available,Oppositional Defiant Disorder|Conduct Disorder|Attention Deficit/Hyperactivity Disorder (ADHD)|Intermittent Explosive Disorder|Impulse-Control Disorders|Adjustment Disorder|Bipolar Disorder|Pervasive Developmental Disorder,Drug: Risperdal,Short Term Recognition Memory task (accuracy)|Titrated Delayed Matching-to-Sample task (accuracy)|Continuous Performance task (omission errors)|Seat Activity|Graduated Holes task (errors and error times),Ohio State University,All,4 Years to 14 Years   (Child),Phase 3,30.0,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Diagnostic,1998H0298,1999-05-01,,2005-06-01,2006-11-15,,2016-06-23,"Ohio State University Nisonger Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00399698
1234,1235,NCT03569631,A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome,,Completed,No Results Available,Fragile X Syndrome|FXS|Fra(X) Syndrome,Drug: BPN14770|Drug: Placebo,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],Tetra Discovery Partners,Male,18 Years to 45 Years   (Adult),Phase 2,30.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BPN14770-CNS-203,2018-07-09,2020-07-31,2020-07-31,2018-06-26,,2020-12-03,"Rush University Medical Center, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT03569631
1239,1240,NCT01289912,Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC),TSC,Completed,Has Results,Tuberous Sclerosis Complex,Drug: RAD001|Drug: Placebo,Evaluation of the Safety of RAD001 on Neurocognition in Patients With TSC Compared With Placebo in Patients With TSC.|Evaluation of the Efficacy of RAD001 on Neurocognition in Patients With TSC Compared With Placebo.|Evaluation of the Efficacy of RAD001 on Neurocognition (Cambridge Neuropsychological Test Automated Battery) in Patients With TSC Compared With Placebo.|Comparison of Absolute Change From Baseline in Frequency of Epileptiform Events Between Patients Taking RAD001 vs. Placebo|Comparison of Sleep Disturbances Between Patients Taking RAD001 vs. Placebo|Comparison of Autism Spectrum Disorders Features Between Patients Taking RAD001 vs. Placebo|Comparison of Academic Skills Between Patients Taking RAD001 vs. Placebo|Comparison of Behavioral Problems Between Patients Taking RAD001 vs Placebo,Mustafa Sahin|Tuberous Sclerosis Alliance|Autism Speaks|Novartis Pharmaceuticals|Seizure Tracker LLC|Boston Children's Hospital,All,"6 Years to 21 Years   (Child, Adult)",Phase 2,52.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",10-06-0247,2011-01-01,2014-12-01,2014-12-01,2011-02-04,2018-01-25,2018-01-25,"Boston Children's Hospital, Boston, Massachusetts, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01289912
1241,1242,NCT02991807,RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome,,"Active, not recruiting",No Results Available,PTEN Gene Mutation|PTEN Hamartoma Tumor Syndrome,Drug: RAD001|Drug: Placebo,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Change in Working Memory at 6 Months|Change in Processing Speed at 6 Months|Change in Fine Motor Skills at 6 Months|Change in Attention at 6 Months|Change in Impulsivity at 6 Months|Change in Global Cognitive Ability at 6 Months|Change in Motor Functioning at 6 Months|Change in Communication Ability at 6 Months,Boston Children's Hospital|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS)|Office of Rare Diseases (ORD)|National Center for Advancing Translational Science (NCATS)|Novartis Pharmaceuticals|PTEN Research|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),All,"5 Years to 45 Years   (Child, Adult)",Phase 1|Phase 2,40.0,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",IRB-P00020332|1U54NS092090,2017-06-12,2021-09-01,2021-12-01,2016-12-14,,2021-02-04,"Stanford University, Palo Alto, California, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Cleveland Clinic, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02991807
1243,1244,NCT03694275,"A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY)",,Completed,Has Results,15q Duplication Syndrome|CDKL5 Deficiency Disease,Drug: Soticlestat,Percent Change From Baseline in Motor Seizure Frequency Per 28 Days During the Maintenance Period|Percent Change From Baseline in Motor Seizure Frequency Per 28 Days During the Treatment Period|Percentage of Participants Considered as Treatment Responders During the Maintenance Period|Percent Change From Baseline in Frequency of Motor Seizures Longer Than 5 Minutes in Participants With CDD|Proportion of Motor Seizure-free Days in Participants During the Maintenance Period|Change From Baseline in Clinician's Global Impression of Severity (CGI-S) Responses of Investigator|Percentage of Participants With Clinical Global Impression of Change (CGI-C) Responses as Per the Investigator Reported Impression|Percentage of Participants With Care Clinical Global Impression of Change (CGI-C) Responses of Parent/Family|Change From Baseline of Plasma 24S-hydroxycholesterol (24HC) Levels|Change From Baseline in Seizure Frequency in Participants Treated With TAK-935 as an Adjunctive Therapy,Takeda|Ovid Therapeutics Inc.,All,"2 Years to 55 Years   (Child, Adult)",Phase 2,20.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TAK-935-18-002 (OV935)|U1111-1219-5787,2018-09-10,2020-07-13,2020-07-31,2018-10-03,2021-04-20,2021-04-20,"UCLA, Los Angeles, California, United States|Research Institute Children's Hospital Colorado, Aurora, Colorado, United States|Center for Rare Neurological Diseases, Norcross, Georgia, United States|Center for Rare Neurological Diseases (CRND)--Massachusetts General Hospital, Boston, Massachusetts, United States|Boston Children's Hospital Translational Neuroscience Center, Boston, Massachusetts, United States|Minnesota Epilepsy Group, P.A., Saint Paul, Minnesota, United States|New York University (NYU), New York, New York, United States|Columbia University Medical Center, New York, New York, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03694275/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03694275/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03694275
1249,1250,NCT04665453,Dexmedetomidine and Melatonin for Sleep Induction for EEG in Children,MeloDex,Recruiting,No Results Available,Electroencephalography|Child|Dexmedetomidine|Melatonin|Sleep|Epilepsy,"Diagnostic Test: Electroencephalography|Diagnostic Test: Monitoring of vital functions|Drug: Melatonin 0,1mg/kg oral syrup|Drug: Dexmedetomidine 3 mcg/kg sublingually|Drug: Dexmedetomidine 3 mcg/kg intranasally",Comparison of the three medical interventions on sleep initiation|Comparison of the three medical interventions on the depth of sleep and the most prominent sleep stage on EEG|Comparison of the three medical interventions on respiratory rate|Comparison of the three medical interventions on heart rate|Comparison of the three medical interventions on oxygene saturation|Comparison of the three medical interventions on blood pressure,University Medical Centre Ljubljana,All,"1 Year to 20 Years   (Child, Adult)",Not Applicable,150.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,0120-597/2019/16,2020-09-01,2021-12-31,2021-12-31,2020-12-11,,2020-12-16,"University Medical Centre Ljubljana, Ljubljana, Slovenia",,https://ClinicalTrials.gov/show/NCT04665453
1251,1252,NCT01906866,Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities,,Completed,Has Results,Sleep Disorders,Drug: Circadin 2/5/10 mg|Drug: Placebo,"The Total Sleep Time Will be Measured for the Circadin 2/5 mg and Placebo by a Sleep and Nap Diary Questionnaire After the 13 Week, Double-blind Treatment Period.|Sleep Latency Will be Measured for the Circadin 2/5 mg and Placebo by a Sleep and Nap Diary After 13 Weeks of Double-blind Treatment.|The Duration of Wake After Sleep Onset Period Will be Measured for the Circadin 2/5 mg and Placebo by a Sleep and Nap Diary After 13 Weeks of Double-blind Treatment.|The Number of Awakenings During the Night Will be Measured for the Circadin 2/5 mg and Placebo by a Sleep and Nap Diary After 13 Weeks of Double-blind Treatment.|The Duration of the Longest Sleep Period Will be Measured for the Circadin 2/5 mg and Placebo by a Sleep and Nap Diary After 13 Weeks of Double-blind Treatment.|The Children's Social Functioning at Home, in School, and Community Settings Will be Measured for the Circadin 2/5 mg and Placebo by the Children Global Assessment Scale (CGAS) Questionnaire After 13 Weeks of Double-blind Treatment.|The Children's Behavior at Home, in School, and Community Will be Measured for the Circadin 2/5 mg and Placebo by the Strength of Difficulties Questionnaire (SDQ) Questionnaire Filled Out by the Parents After 13 Weeks of Double-blind Treatment.|The Number of Dropouts Between Circadin 2/5 mg to That of Placebo Will be Compared During the 13 Weeks of Double-blind Treatment.|Sleep Parameters (Rest/Activity Cycles) Will be Measured for the Circadin 2/5 mg and Placebo as Measured by Actigraphy After 13 Weeks of Double-blind Treatment.|Safety and Tolerability Throughout the Study Will be Measured for the Circadin 2/5 mg and Placebo Throughout the Study Using AE Eliciting Method Treatment Emergent Signs and Symptoms (TESS)|The Following Vital Signs Will be Measured: Blood Pressure, Pulse, Breathing and Body Temperature. They Will be Compared Between the Circadin and Placebo Groups.",Neurim Pharmaceuticals Ltd.,All,2 Years to 17 Years   (Child),Phase 3,125.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NEU_CH_7911,2013-10-01,2018-03-27,2018-03-27,2013-07-24,2018-10-30,2019-05-21,"Southwest Autism Research and Resource Center (SARRC), Phoenix, Arizona, United States|Crystal BioMedical Research, LLC, Miami Lakes, Florida, United States|Lake Mary Pediatrics, Orange City, Florida, United States|Mate Lazlo, West Palm Beach, Florida, United States|Attalla Consultants LLC, dba Institue for Behabiovral medicine, Smyrna, Georgia, United States|AMR Baber research INC, Naperville, Illinois, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|Child Neurology Specialists/ CRCN, Henderson, Nevada, United States|Clinical research center of New Jersey, LLC, Voorhees, New Jersey, United States|Geinsinger Clinic, Danville, Pennsylvania, United States|The children's hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States|INSITE Clinical Research, DeSoto, Texas, United States|Red Oak Psychiatry Associates, Houston, Texas, United States|Sleep Therapy & Research Center, San Antonio, Texas, United States|Road Runner Research, Ltd, San Antonio, Texas, United States|Ericksen Research & Development, Clinton, Utah, United States|Pacific institute of medical science, Bothell, Washington, United States|Helsinki Sleep Clinic Vitalmed OY, Helsinki, Finland|Hospital Raymond Poincare, Garches, France|Strasbourg University Hospital Depatment of Child Psychiatry & Neurology, Strasbourg,, France|Yulius Mental Health Organization, Dordrecht, Netherlands|Hospital Gelderse Vallei, Ede, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Birmingham Childrens Hospital NHS FOUNDATION TRUST, Birmingham, United Kingdom|Blackpool Victoria Teaching Hospitals NHS Foundation Trust, Blackpool, United Kingdom|Guy's & St. Thomas's NHS Foundation Trust of St Thomas's Hospital, London, United Kingdom|University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT01906866/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT01906866/SAP_003.pdf",https://ClinicalTrials.gov/show/NCT01906866
